


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A2	(11) International Publication Number:	WO 99/28342
C07K 14/00		(43) International Publication Date:	10 June 1999 (10.06.99)
(21) International Application Number:		PCT/US98/25671	
(22) International Filing Date:		3 December 1998 (03.12.98)	
(30) Priority Data:			
08/984,709	3 December 1997 (03.12.97)	US	HANS, Michael [DE/US]; 2635 San Clemente Terrace, San Diego, CA 92122 (US). URRUTIA, Arturo [US/US]; 778 Beech Avenue, Chula Vista, CA 91910 (US). WASHBURN, Mark, S. [US/US]; 1535 Kings Cross Drive, Cardiff, CA 92007 (US).
09/188,932	10 November 1998 (10.11.98)	US	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications			
US Filed on	08/984,709 (CON)	(74) Agent: SEIDMAN, Stephanie, L.; Heller Ehrman White & McAuliffe, Suite 700, 4250 Executive Square, La Jolla, CA 92037 (US).	
US Filed on	3 December 1997 (03.12.97)		
US Filed on	09/188,932 (CON)		
US Filed on	10 November 1998 (10.11.98)		
(71) Applicant (for all designated States except US): SIBIA NEUROSCIENCES, INC. [US/US]; Suite 300, 505 Coast Boulevard South, La Jolla, CA 92037-4641 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): WILLIAMS, Mark [US/US]; 946 Jasmine Court, Carlsbad, CA 92009 (US). STAUDERMAN, Kenneth [US/US]; 3615 Lotus Drive, San Diego, CA 92106 (US). HARPOLD, Michael [US/US]; 1462 Encina Road, Santa Fe, NM 87505-4726 (US).			
(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).			
Published <i>Without international search report and to be republished upon receipt of that report.</i>			

(54) Title: LOW-VOLTAGE ACTIVATED CALCIUM CHANNEL COMPOSITIONS AND METHODS

Steady-state activation and inactivation

(57) Abstract

Isolated nucleic acid encoding low voltage activated calcium channel subunits, including subunits encoded by nucleic acid that arises as splice variants of primary transcripts, is provided. Cells and vectors containing the nucleic acid and methods for identifying compounds that modulate the activity of calcium channels that contain these subunits are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

LOW-VOLTAGE ACTIVATED CALCIUM CHANNEL COMPOSITIONS AND METHODS

RELATED APPLICATIONS

- Benefit of priority to U.S. application Serial No. 08/984,709, to
- 5 Williams *et al.*, entitled, "CALCIUM CHANNEL COMPOSITIONS AND METHODS" filed December 3, 1997, and to U.S. application Serial No. 09/188,932, to Williams *et al.*, entitled, "CALCIUM CHANNEL COMPOSITIONS AND METHODS" filed November 10, 1998 is claimed herein.
- 10 This application is related to U.S. application Serial No. 08/450,272, filed May 25, 1995, U.S. application Serial No. 08/450,273, filed May 25, 1995, U.S. application Serial No. 08/450,562, filed May 25, 1995. Each of these applications is a continuation-in-part of U.S. application Serial No. 08/290,012. This
- 15 application is also related to International PCT application No. PCT/US94/09230, filed August 11, 1994, which claims priority to U.S. application Serial Nos. 08/105,536 and 08/149,097. This application is also related to U.S. application Serial No. 08/404,354, filed February 15, 1995, now U.S. Patent No. 5,618,720, which is a
- 20 continuation of U.S. application Serial No. 07/914,231, filed July 13, 1992, now U.S. Patent No. 5,407,820, and also U.S. application Serial No. 08/314,083, filed September 28, 1994, now U.S. Patent No. 5,686,241, U.S. application Serial No. 08/435,675, filed May 5, 1995, now U.S. Patent No. 5,710,250, each of which is a divisional of U.S.
- 25 application Serial No. 07/914,231. U.S. application Serial No. 07/914,231 is a continuation of U.S. application Serial No. 07/603,751, filed November 8, 1990, now abandoned, which is the national stage of International PCT Application PCT/US89/01408, filed April 4, 1989,

-2-

which is a continuation-in-part of U.S. application Serial No. 07/176,899, filed April 4, 1988, now abandoned.

This application is also related to U.S. application Serial No. 08/884,599, filed June 27, 1997, which is a continuation of U.S. 5 application Serial No. 08/314,083.

This application is also related to U.S. application Serial No. 08/290,012, filed August 11, 1994, now abandoned, which corresponds to published International PCT application No. WO95/04822, which is a continuation-in-part of allowed U.S. application Serial No. 08/149,097, 10 filed November 5, 1993, and a continuation-in-part of United States Application Serial No. 08/105,536, filed August 11, 1993. United States Application Serial No. 08/149,097 is a continuation-in-part of United States Application Serial No. 08/105,536, which is a continuation-in-part of the above-mentioned United States Application Serial No. 07/603,751, 15 filed November 8, 1990.

This application is also related to allowed U.S. application Serial No. 08/223,305, filed April 4, 1994, now U.S. Patent No. 5,851,824, which is a continuation of U.S. application Serial No. 07/868,354, now abandoned, which is a continuation-in-part of U.S. application Serial No. 20 07/745,206, filed August 15, 1991, now U.S. Patent No. 5,429,921, which is a continuation-in-part of the above-mentioned United States Application Serial No. 07/603,751, filed November 8, 1990, and a continuation-in-part of U.S. application Serial No. 07/620,250, filed November 30, 1990, now abandoned. This application is also related to 25 allowed application U.S. application Serial No. 08/455,543, filed May 31, 1995, now U.S. Patent No. 5,792,846, which is a continuation of U.S. application Serial No. 07/868,354, filed April 10, 1992.

-3-

This application is also related to U.S. application Serial No. 08/311,363, filed September 23, 1994, which is a continuation of allowed U.S. application Serial No. 07/745,206, filed August 15, 1991.

- This application is also related to allowed U.S. application Serial
- 5 No. 08/193,078, now U.S. Patent No. 5,846,756, filed February 7, 1994, which is the National Stage of International PCT Application No. PCT/US92/06903, published as International PCT application No. WO93/04083, filed August 14, 1992 and which is a continuation-in-part of U.S. application Serial Nos. 07/868,354, 07/745,206, 07/603,751,
- 10 07/176,899, 07/620,250, filed November 30, 1990, now abandoned, and 07/482,384, now U.S. Patent No. 5,386,025, filed February 2, 1990.

- This application is also related to allowed U.S. application Serial No. 08/336,257, now U.S. Patent No. 5,726,035, filed November 7, 15 1994, which is a continuation of 07/482,384, now U.S. Patent No. 5,386,025, filed February 2, 1990.

Where permitted, the subject matter of each of the above-noted U.S. applications, patents and International PCT applications is incorporated herein in its entirety.

20 TECHNICAL FIELD

The present invention relates to molecular biology and pharmacology. More particularly, the invention relates to calcium channel compositions and methods of making and using the same.

BACKGROUND OF THE INVENTION

- 25 Calcium channels are membrane-spanning, multi-subunit proteins that allow controlled entry of Ca^{2+} ions into cells from the extracellular fluid. Cells throughout the animal kingdom, and at least some bacterial, fungal and plant cells, possess one or more types of calcium channel.

-4-

- The most common type of calcium channel is voltage dependent. All "excitable" cells in animals, such as neurons of the central nervous system (CNS), peripheral nerve cells and muscle cells, including those of skeletal muscles, cardiac muscles, and venous and arterial smooth
- 5 muscles, have voltage-dependent calcium channels (VGCCs). "Opening" of a voltage-dependent channel to allow an influx of Ca^{2+} ions into the cells requires a depolarization to a certain level of the potential difference between the inside of the cell bearing the channel and the extracellular environment bathing the cell. The rate of influx of Ca^{2+} into the cell
- 10 depends on this potential difference.

Calcium channels are multisubunit proteins that contain two large subunits, designated α_1 and α_2 , which have molecular weights between about 130 and about 200 kilodaltons ("kD"), and one to three different smaller subunits of less than about 60 kD in molecular weight. At least

15 one of the larger subunits and possibly some of the smaller subunits are glycosylated. Some of the subunits are capable of being phosphorylated. The α_1 subunit has a molecular weight of about 150 to about 170 kD when analyzed by sodium dodecylsulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) after isolation from mammalian muscle tissue and

20 has specific binding sites for various 1,4-dihydropyridines (DHPs) and phenylalkylamines. Under non-reducing conditions (in the presence of N-ethylmaleimide), the α_2 subunit migrates in SDS-PAGE as a band corresponding to a molecular weight of about 160-190 kD. Upon reduction, a large fragment and smaller fragments are released. The β

25 subunit of the rabbit skeletal muscle calcium channel is a phosphorylated protein that has a molecular weight of 52-65 kD as determined by SDS-PAGE analysis. This subunit is insensitive to reducing conditions. The γ subunit of the calcium channel appears to be a glycoprotein with an

-5-

apparent molecular weight of 30-33 kD, as determined by SDS-PAGE analysis.

In order to study calcium channel structure and function, large amounts of pure channel protein are needed. Because of the complex nature of these multisubunit proteins, the varying concentrations of calcium channels in tissue sources of the protein, the presence of mixed populations of calcium channels in tissues, difficulties in obtaining tissues of interest, and the modifications of the native protein that can occur during the isolation procedure, it is extremely difficult to obtain large amounts of highly purified, completely intact calcium channel protein.

Because calcium channels are present in various tissues and have a central role in regulating intracellular calcium ion concentrations, they are implicated in a number of vital processes in animals, including neurotransmitter release, muscle contraction, pacemaker activity, and secretion of hormones and other substances. These processes appear to be involved in numerous human disorders, such as central nervous system disorders and cardiovascular diseases. Calcium channels, thus, are also implicated in numerous disorders. A number of compounds useful for treating various cardiovascular diseases in animals, including humans, are thought to exert their beneficial effects by modulating functions of voltage-dependent calcium channels present in cardiac and/or vascular smooth muscle. Many of these compounds bind to calcium channels and block, or reduce the rate of, influx of Ca^{2+} into the cells in response to depolarization of the cell membrane.

The results of studies of recombinant expression of rabbit calcium channel α_1 subunit-encoding cDNA clones and transcripts of the cDNA clones indicate that the α_1 subunit forms the pore through which calcium enters cells. The relevance of the barium currents generated in these recombinant cells to the actual current generated by calcium channels

-6-

containing as one component the respective α_1 subunits *in vivo* is unclear. In order to completely and accurately characterize and evaluate different calcium channel types, however, it is essential to examine the functional properties of recombinant channels containing all of the subunits as found

5 *in vivo*.

In order to conduct this examination and to fully understand calcium channel structure and function, it is critical to identify and characterize as many calcium channel subunits as possible. Also in order to prepare recombinant cells for use in identifying compounds that

10 interact with calcium channels, it is necessary to be able to produce cells that express uniform populations of calcium channels containing defined subunits.

An understanding of the pharmacology of compounds that interact with calcium channels in other organ systems, such as the CNS, may aid

15 in the rational design of compounds that specifically interact with subtypes of human calcium channels to have desired therapeutic effects, such as in the treatment of neurodegenerative and cardiovascular disorders. Such understanding and the ability to rationally design therapeutically effective compounds, however, have been hampered by

20 an inability to independently determine the types of human calcium channels and the molecular nature of individual subtypes, particularly in the CNS, and by the unavailability of pure preparations of specific channel subtypes to use for evaluation of the specificity of calcium channel-effecting compounds. Thus, identification of DNA encoding human

25 calcium channel subunits and the use of such DNA for expression of calcium channel subunits and functional calcium channels would aid in screening and designing therapeutically effective compounds.

Multiple types of calcium channels have been identified in mammalian cells from various tissues, including skeletal muscle, cardiac

-7-

- muscle, lung, smooth muscle and brain, (see, e.g., Bean, B.P.(1989) *Ann. Rev. Physiol.* 51:367-384 and Hess, P. (1990) *Ann. Rev. Neurosci.* 56:337). The different types of calcium channels have been broadly categorized into four classes, L-, T-, N-, P-, Q and R-type, distinguished
- 5 by current kinetics, holding potential sensitivity and sensitivity to calcium channel agonists and antagonists. The primary determinant of diversity among calcium channels is the nature of the pore-forming α_1 subunit. Nucleic acid encoding numerous α_1 subunits has been cloned and the encoded subunits expressed. Correlations between α_1 subunits and the
- 10 operationally defined Ca^{2+} currents have been established. Six gene products α_{1A} - α_{1E} and α_{1S} participate in the formation of high-voltage activated channels, which include the L, N, P, Q and R-type channels.
- DNA encoding human α_1 -subunits, including α_{1A} , α_{1B} , α_{1C} , α_{1D} and α_{1E} subunits and splice variants thereof has been described (see, e.g.,
- 15 U.S. Patent No. 5,429,921, U.S. Patent No. 5,846,756, U.S. Patent No. 5,851,824, published International PCT application No. PCT/US92/06903, and published International PCT application No. PCT/US94/09230). These subunits appear to participate in formation of high voltage calcium (HVA) channels, which in addition to one of these
- 20 α_1 -subunits, includes a β subunit and an α_2 -subunit, including δ , which is linked to α_2 by a disulfide bridge and arises from the same precursor. The distinct biophysical and pharmacological properties of each channel derive primarily from the α_1 -subunit, but are modulated by the ancillary subunits, principally the β subunits associated with the channel. β -subunits have
- 25 been shown to increase the peak current amplitude, to shift activation/inactivation curves toward more hyperpolarized potentials and to alter kinetics of activation and inactivation (see, e.g., Lambert *et al.* (1997) *J. Neurosci.* 17:6621-6625). The $\alpha_2\delta$ subunit, which is tissue-

-8-

specific, increases the current generated by any α_1 subunit and potentiates the stimulatory response of β subunits.

T-type or LVA channels

- Little is known about the channels that have been designated T-
5 channels or LVA (low voltage activated) channels. Low-voltage activated (LVA), i.e., T-type, calcium channels are reportedly found in a variety of cell types. Low-voltage activated (LVA) or T-type calcium channels are also widely distributed in the central and peripheral nervous system and apparently involved in an extensive array of different neuronal processes.
10 In general it is believed that T-type currents do not differ fundamentally from other Ca^{2+} currents. Like HVA channels, T-type channels are selectively permeable to divalent cations, as long as a minimal concentration of divalent cations is present in the external medium. For LVA (or T-type) currents, this minimal Ca^{2+} concentration is
15 about $25 \mu\text{M}$, and for HVA currents it is about $1 \mu\text{M}$. T-type current is reported to saturate with a K_d of about 10 mM Ca^{2+} , which is similar to that reported for HVA currents. The channels, however, appear to exhibit certain differences. They differ in their relative permeability to divalent cations. In general, HVA channels are more permeable to Ba^{2+} than to
20 Ca^{2+} ; T-type are equally or slightly less permeable to Ba^{2+} than to Ca^{2+} . T-type channels also are believed to exhibit slower activation/inactivation and deactivation kinetics and have been reported to exhibit relatively higher sensitivity to Ni^{2+} . This type of channel is activated near the resting potential of the membrane, and is believed to be responsible for
25 the generation of repetitive firing activity or intrinsic neuronal oscillations and for Ca^{2+} entry accompanying the spike activity (see, e.g., Huguenard (1996) Annual Rev. Physiol. **58**:329-348). Recent data suggests that β -subunits identified to date may not be a constitutive T-type channel subunit (see, Lambert et al. (1997) J. Neurosci. **17**:6621-6625). The

-9-

structure of calcium channels that generate the various LVA currents is unknown. None of the α_1 subunits previously cloned appear to have all properties that have been ascribed to the low voltage-activated T-type (or LVA) channels.

- 5 Therefore, it is an object herein, to provide nucleic acid encoding specific calcium channel subunits that have structural and functional properties that differ from the HVA type channels. It is also an object herein to provide nucleic acid encoding channels that have activities that have been ascribed to T-type channels and to provide eukaryotic cells
- 10 bearing recombinant tissue-specific or subtype-specific calcium channels. It is also an object to provide assays for identification of potentially therapeutic compounds that act as modulators of calcium channel activity, particularly those specific for channels that exhibit properties of human T-type channels and other types of channels.

15 **SUMMARY OF THE INVENTION**

- Isolated and purified nucleic acid fragments that encode calcium channel subunits are provided. The subunits form low-voltage activated (LVA) channels, particularly channels that have properties associated with T-type channels. The subunits and results provided herein, provide a
- 20 family of α_1 subunits corresponding to LVA, or T-type, channels. Channels that contain these subunits have ability to open at low potential difference, but stay open for only moderate time periods. These channels are located in critical physiologic locations, including neurons in the thalamus, hypothalamus, and brain stem, and consequently may be
- 25 involved in autonomic nervous functions, perhaps involved in regulation of cardiovascular activities such as heart rate, arterial and venous smooth muscle innervation and tone, pulmonary rate and other critical physiologic activities.

-10-

- DNA encoding these α_1 subunits of a animal channels, and RNA, encoding such subunits, made upon transcription of such DNA are provided. In particular, nucleic acid that encodes T-type calcium channels, designated α_{1H} -subunits (designated α_{1F} in the priority document
- 5 U.S. application Serial No. 08/984,709) of a calcium channel, particularly an animal calcium channel and more particularly a mammalian calcium channel is provided.

Of particular interest herein is the nucleic acid that encodes the α_{1H} subunits of calcium channels, particularly mammalian calcium channels.

- 10 Nucleic acid encoding exemplary α_{1H} subunits are provided. Nucleic acid encoding two splice variants, designated α_{1H-1} and α_{1H-2} , from human calcium channels is provided. The nucleic acid sequences and encoded amino acids of the exemplified subunits are set forth in SEQ ID Nos. 12 (α_{1H-1}), 15 (α_{1H-1}) and 16 (α_{1H-2}). SEQ ID NOs. 12 and 15 differ only in that
- 15 in amino acid 2230 (bases 6983-6985) is Asp (GAC) in the SEQ ID No. 15 and Glu (GAA) in SEQ ID No. 12.

- This nucleic acid can be used to isolate variants, including additional splice variants of the nucleic acid encoding α_{1H} subunits, allelic variants and α_{1H} subunits from other animals, particularly mammals. Such
- 20 nucleic acid includes DNA encoding an α_{1H-1} subunit that has substantially the same sequence of amino acids as encoded by the DNA set forth in SEQ ID Nos. 12 and 15. This nucleic acid can also be used to isolate DNA encoding α_{1H} subunits from other species, particularly other mammals.
- 25 Also provided is nucleic acid that encodes a second splice variant, designated α_{1H-2} , is provided. The nucleic acid sequence of this variant, differs from α_{1H-1} in having a 957 nucleotide deletion, resulting in loss of 319 amino acids (corresponding to amino acids 470-788 of α_{1H-1}).

-11-

- Also included are any subunits that are encoded by nucleic acid containing nucleotides nt 1506 to nt 2627 of SEQ ID No. 12 or 15 or subunits that are encoded by nucleic acid that hybridizes, preferably under conditions of high stringency, to a probe derived from this region
- 5 and that encodes a T-channel, which can be identified using methods herein.

The α_{1H} subunit differs from the α_{1A} - α_{1E} calcium channel subunits in a number of aspects. First, the intracellular loop positioned between transmembrane Domains I and II is considerably longer than HVA calcium

10 channels. For instance, as exemplified in SEQ ID Nos. 12 and 15 and described below, the intracellular loop between Domains I and II is greater than 1,100 nt (1122 nt), whereas the corresponding region in HVA calcium channels ranges from 351 to 381 nt in length. Thus, the

15 intracellular loop of α_{1H} contains approximately 370 additional amino acid residues (aa 420 to aa 794 of SEQ ID No. 12) not found in HVA calcium channel α_1 subunits. In addition, the encoded amino acid sequence of this loop region is highly proline rich and contains a poly-HIS region of 9 consecutive histidine residues.

Other distinguishing features of the α_{1H} subunit, include the

20 absence of amino acid residues in the intracellular loop between transmembrane Domains I and II that are known to be critical (e.g., see De Waard *et al.* (1996) FEBS Letters **380**:272-276; Pragnell *et al.* (1994) Nature **368**:67-70) for the interaction between an α_1 subunit and a β subunit. The α_{1H} subunit also contains a notably large extracellular loop in

25 Domain I between IS5 and IS6. The HVA α_1 calcium channel subunits provided herein contain 249-270 nucleotide residues in this loop. In contrast, the human α_{1H} subunit contains 426 nucleotide residues in this loop. The intracellular loop between transmembrane Domains III and IV is

-12-

also slightly larger than the HVA α_1 subunits (186 nt compared to 159-165 nt).

- Nucleic acid probes, which can be labeled for detection, containing at least about 14, preferably 16, or, if desired, 20 or 30 or more, 5 contiguous nucleotides of α_{1H} -encoding nucleic acid are provided.
- Methods using the probes for the isolation and cloning of calcium channel subunit-encoding DNA, including splice variants within tissues and inter-tissue variants are also provided. Particularly preferred regions from which to construct probes for the isolation of DNA encoding a human α_{1H} 10 subunit include the nucleic acid sequence encoding the notably long intracellular loop located between transmembrane Domains I and II (e.g., nt 1506 to nt 2627 of SEQ ID Nos. 12 and 15). Probes for isolating DNA encoding a human α_{1H} subunit are preferably 14 or 16 contiguous nucleotides in length. In some instances, probes of 30 or 50 nucleotides 15 are used and in other instances probes between 50 to 100 nucleotides are used.

- Eukaryotic cells containing heterologous DNA encoding one or more calcium channel subunits, particularly human calcium channel subunits, or containing RNA transcripts of DNA clones encoding one or 20 more of the subunits are provided. A single α_{1H} subunit can form a channel. The requisite combination of subunits for formation of active channels in selected cells, however, can be determined empirically using the methods herein. For example, if a selected α_1 subtype or variant does not form an active channel in a selected cell line, an additional subunit or 25 subunits can be added until an active channel is formed. Other subunits can be added to assess the effects of such addition.

In preferred embodiments, the cells contain DNA or RNA encoding an α_1 subunit, preferably an α_{1H} subunit of an animal, preferably of a mammalian calcium channel. Embodiments in which the cells contain

-13-

nucleic acid encoding an α_{1H} are of particular interest herein. In other embodiments, the cells contain DNA or RNA encoding additional heterologous subunits, including an $\alpha_2\delta$. The cells may also include nucleic acid encoding a β subunit and/or a γ subunit. In such

5 embodiments, eukaryotic cells stably or transiently transfected with any combination of one, two, three or four of the subunit-encoding DNA clones, such as DNA encoding any of α_1 , $\alpha_1 + \beta$, $\alpha_1 + \beta + \alpha_2$, are provided. The eukaryotic cells provided herein contain heterologous nucleic acid that encodes an α_1 subunit and optionally a heterologous α_2 -

10 subunit and/or a β subunit and/or γ subunit.

In preferred embodiments, the cells express such heterologous calcium channel subunits and include one or more of the subunits in membrane-spanning heterologous calcium channels. In more preferred embodiments, the eukaryotic cells express functional, heterologous

15 calcium channels that are capable of gating the passage of calcium channel-selective ions and/or binding compounds that, at physiological concentrations, modulate the activity of the heterologous calcium channel. In certain embodiments, the heterologous calcium channels include at least one heterologous calcium channel subunit. In most

20 preferred embodiments, the calcium channels that are expressed on the surface of the eukaryotic cells are composed substantially or entirely of subunits encoded by the heterologous DNA or RNA. In preferred embodiments, the heterologous calcium channels of such cells are distinguishable from any endogenous calcium channels of the host cell.

25 Such cells provide a means to obtain homogeneous populations of calcium channels. Typically, the cells contain the selected calcium channel as the only heterologous ion channel expressed by the cell.

In certain embodiments the recombinant eukaryotic cells that contain the heterologous DNA encoding the calcium channel subunits are

-14-

produced by transfection with DNA encoding one or more of the subunits or are injected with RNA transcripts of DNA encoding one or more of the calcium channel subunits. The DNA may be introduced as a linear DNA fragment or may be included in an expression vector for stable or

- 5 transient expression of the subunit-encoding DNA. Vectors containing DNA encoding human calcium channel subunits are also provided.

The eukaryotic cells that express heterologous calcium channels may be used in assays for calcium channel function or, in the case of cells transformed with fewer subunit-encoding nucleic acids than

- 10 necessary to constitute a functional recombinant human calcium channel, such cells may be used to assess the effects of additional subunits on calcium channel activity. The additional subunits can be provided by subsequently transfecting such a cell with one or more DNA clones or RNA transcripts encoding human calcium channel subunits.

- 15 The recombinant eukaryotic cells that express membrane spanning heterologous calcium channels may be used in methods for identifying compounds that modulate calcium channel activity. In particular, the cells are used in assays that identify agonists and antagonists of calcium channel activity in humans and/or assessing the contribution of the
- 20 various calcium channel subunits to the transport and regulation of transport of calcium ions. Because the cells constitute homogeneous populations of calcium channels, they provide a means to identify agonists or antagonists of calcium channel activity that are specific for each such population.

- 25 The cells provided herein may be used to assess T-type channel function and tissue distribution and to identify compounds that modulate the activity of T-type channels. Because T-type channels are operative in neurons in the thalamus, hypothalamus, and brain stem, and may be involved in autonomic nervous functions, in regulation of cardiovascular

-15-

activities such as heart rate, arterial and venous smooth muscle innervation and tone, pulmonary rate and other fundamental processes, assays designed to assess such activities and assays the identify modulators of these activities provide a means to understand fundamental 5 physiological processes and also a means to identify new drug candidates for an array of disorders.

Assays that use the eukaryotic cells for identifying compounds that modulate calcium channel activity are also provided. In practicing these assays the eukaryotic cell that expresses a heterologous calcium channel, 10 containing at least one subunit encoded by the DNA provided herein, is in a solution containing a test compound and a calcium channel selective ion, the cell membrane is depolarized, and current flowing into the cell is detected. If the test compound is one that modulates calcium channel activity, the current that is detected is different from that produced by 15 depolarizing the same or a substantially identical cell in the presence of the same calcium channel-selective ion but in the absence of the compound. In preferred embodiments, prior to the depolarization step, the cell is maintained at a holding potential which substantially inactivates calcium channels which are endogenous to the cell. Also in preferred 20 embodiments, the cells are mammalian cells, most preferably HEK cells, or amphibian oocytes.

Cells that express T-channels or LVA channels may be used in assays that screen for compounds that have activity as modulators, particularly antagonists, of the activity of these channels.

25 Transcription based assays for identifying compounds that modulate the activity of calcium channels (see, U.S. Patent Nos. 5,436,128 and 5,401,629), particularly calcium channels that contain an α_{1H} subunit are provided. These assays use cells that express calcium channels, particularly calcium channels containing an α_{1H} -subunit, and

-16-

- more preferably an α_{1H} -subunit encoded by heterologous DNA, and also contain nucleic acid encoding a reporter gene construct containing a reporter gene in operative linkage with one or more transcriptional control elements that is regulated by a calcium channel. The assays are effected
- 5 by comparing the difference in the amount of transcription of a the reporter gene in the cells provided herein in the presence of the compound with the amount of transcription in the absence of the compound, or with the amount of transcription in the absence of the heterologous calcium channel, whereby compounds that modulate the
- 10 activity of the heterologous calcium channel in the cell are identified. The reporter gene is any such gene known to those of skill in the art, including, but not limited to the gene encoding bacterial chloramphenicol acetyltransferase, the gene encoding firefly luciferase, the gene encoding bacterial luciferase, the gene encoding β -galactosidase or the gene
- 15 encoding alkaline phosphatase, and the transcriptional control element is any such element known to those of skill in the art, including, but not limited to serum responsive elements, cyclic adenosine monophosphate responsive elements, the *c-fos* gene promoter, the vasoactive intestinal peptide gene promoter, the somatostatin gene promoter, the
- 20 proenkephalin promoter, the phosphoenolpyruvate carboxykinase gene promoter or the nerve growth factor-1 A gene promoter and elements responsive to intracellular calcium ion levels.

Other assays in which receptor activity in response to test compounds is measured may also be practiced with the cells provided

25 herein (see, e.g., U.S. Patent No. 5,670,113).

Because T-type channels appear to be associated with a variety of K^+ functions, cells that express T-channels and assays using such cells will be useful for identification of compounds for treatment of a variety of

-17-

disorders, disease and conditions. Identified compounds will be candidates for use in the treatment of disorders and conditions associated with T-channel activity. Such activities include, but are not limited to, those involving role in muscle excitability, secretion and pacemaker

5 activity, Ca^{2+} dependent burst firing, neuronal oscillations, and potentiation of synaptic signals, for improving arterial compliance in systolic hypertension, or improving vascular tone, such as by decreasing vascular welling, in peripheral circulatory disease, and others. Other disorders include, but are not limited to hypertension, cardiovascular

10 disorders, including but not limited to: myocardial infarct, cardiac arrhythmia, heart failure and angina pectoris; neurological disorders, such as schizophrenia, epilepsy and depression, peripheral muscle disorders, respiratory disorders and endocrine disorders.

In particular, cells that express LVA channels, such as the α_{1H} subunits, are useful for identifying compounds that are candidates for treatment of disorders associated with conduction tissues, such as atrial pacemaker cells, Purkinje fibers, and also coronary smooth muscles. Such disorders include, but are not limited to, compounds useful for treatment of cardiovascular, such as angina, vascular, such as

15 hypertension, and urologic, hepatic, reproductive, adjunctive therapies for reestablishing normal heart rate and cardiac output following traumatic injury, heart attack and other cardiac injuries; treatments of myocardial infarct (MI), post-MI and in an acute setting. Other compounds that interact with LVA, particularly T-type, calcium channels, may be effective

20 for increasing cardiac contractile force, such as measured by left ventricular end diastolic pressure, and without changing blood pressure or heart rate. In an acute other compounds may be effective to decrease formation of scar tissue, such as that measured by collagen deposition or septal thickness, and without cardiodepressant effects. The assays may

25

-18-

- identify compounds useful in regulating vascular smooth muscle tone, either vasodilating or vasoconstricting in: (a) treatments for reestablishing blood pressure control, e.g., following traumatic injury, surgery or cardiopulmonary bypass, and in prophylactic treatments designed to
- 5 minimize cardiovascular effects of anaesthetic drugs; (b) treatments for improving vascular reflexes and blood pressure control by the autonomic nervous system; for identifying compounds useful in treating urological disorders: (a) treating and restoring renal function following surgery, traumatic injury, uremia and adverse drug reactions; (b) treating bladder
- 10 dysfunctions; and (c) uremic neuronal toxicity and hypotension in patients on hemodialysis; reproductive disorders, for identifying compounds useful in treating: (a) disorders of sexual function including impotence; (b) alcoholic impotence (under autonomic control that may be subject to T-channel controls); hepatic disorders for identifying compounds useful in
- 15 treating and reducing neuronal toxicity and autonomic nervous system damage resulting from acute over-consumption of alcohol; neurologic disorders for identifying compounds useful in treating: (a) epilepsy and diencephalic epilepsy; (b) Parkinson's disease; (c) aberrant temperature control, such as, abnormalities of shivering and sweat gland secretion and
- 20 peripheral vascular blood supply; (d) aberrant pituitary and hypothalamic functions including abnormal secretion of noradrenaline, dopamine and other hormones; for respiratory such as in treating abnormal respiration, e.g., post-surgical complications of anesthetics; and endocrine disorders, for identifying compounds useful in treating aberrant secretion of
- 25 hormones including e.g., possible treatments for overproduction of insulin, thyroxin, adrenalin, and other hormonal imbalances.

Purified human α_{1H} calcium channel subunits and purified human calcium channels containing such subunits are provided. The subunits

-19-

and channels can be isolated from a eukaryotic cell transfected with nucleic acid that encodes the subunit.

- In another embodiment, immunoglobulins or antibodies obtained from the serum of an animal immunized with a substantially pure
- 5 preparation of a human calcium channel, human calcium channel subunit or epitope-containing fragment of a human calcium subunit are provided. Monoclonal antibodies produced using a human calcium channel, human calcium channel subunit or epitope-containing fragment thereof as an immunogen are also provided. *E. coli* fusion proteins including a fragment
- 10 of a human calcium channel subunit may also be used as immunogen. Such fusion proteins may contain a bacterial protein or portion thereof, such as the *E. coli* TrpE protein, fused to a calcium channel subunit peptide. The immunoglobulins that are produced using the calcium channel subunits or purified calcium channels as immunogens have,
- 15 among other properties, the ability to specifically and preferentially bind to and/or cause the immunoprecipitation of a human calcium channel or a subunit thereof which may be present in a biological sample or a solution derived from such a biological sample. Such antibodies may also be used to selectively isolate cells that express calcium channels that contain
- 20 the subunit for which the antibodies are specific.

Methods for modulating the activity of ion channels by contacting the calcium channels with an effective amount of the above-described antibodies are also provided.

- Thus, assays for identifying compounds that modulate the activity
- 25 of LVA calcium channels, particularly T-type channels are provided as well as compounds identified by the methods.

Also provided are methods for diagnosing LVA calcium channel-mediated, particularly T-type channel-mediated, disorders. Methods of diagnosis will involve detection of aberrant channel expression or

-20-

function, such altered amino acid sequences, altered pharmacological profiles and altered electrophysiological profiles compared to normal or wild-type channels. Such methods typically can employ antibodies specific for the altered channel or nucleic acid probes to detect altered genes or transcripts.

DESCRIPTION OF THE FIGURES

FIGURE 1 shows the voltage-dependence of activation ($m\infty$) and steady-state inactivation (h) of human α_{1H} calcium channels expressed transiently in HEK cells. Voltage-dependence of activation ($m\infty$) was determined from tail current analysis. Tail currents were normalized with respect to the maximum peak tail current obtained at +60 mV and were plotted (open symbols, mean \pm SEM; n = 11) vs. test potential. Data were fitted by the sum of two Boltzman function $m\infty = F_A * [1 + \exp(-(V_{test} - V_{1/2,A})/k_A)]^{-1} + F_B * [1 + \exp(-(V_{test} - V_{1/2,B})/k_B)]^{-1}$, $F_A = 0.67$, $V_{1/2,A} = -5$ 10 21.5 mV, $k_A = 7.5$, $F_B = 0.33$, $V_{1/2,B} = 25.5$ mV, $k_B = 14.7$. Steady-state inactivation ($h\infty$) was determined from a holding potential of -100 mV by a test pulse to -20 mV (p1), followed by a 20 second prepulse from -100 mV to -10 mV in 5 mV decrements (pHold) preceding a second test pulse to -20 mV (p2). Normalized current amplitudes were plotted (closed symbols, mean \pm SEM; n = 9) vs. holding potential. Data were fitted by a Boltzman function $h\infty = [1 + \exp((V_{hold} - V_{1/2})/k)]^{-1}$, $V_{1/2} = -63.9$ mV, $k = 3$. 15 20 25 9 mV.

FIGURE 2 shows the kinetics of activation (FIGURE 2A) and inactivation (FIGURE 2B) of human α_{1H} (α_{1H-1}) calcium channels; kinetics of activation and inactivation were determined from current traces by fitting an exponential function to rising (FIG. 2A) or declining (FIG. 2B) phase of the current (the voltage-dependence for activation and inactivation follows approximately an exponential function).

-21-

FIGURE 3 schematically depicts features of the $\alpha_{1H.1}$ subunit and shows amino acid sequence alignment of human α_{1H} with α_{1D} and α_{1E} in each of the four pore regions; *indicates residues involved in ion selectivity in each of the four pore regions; the unusually large loop in the
5 LVA-associated α_{1H} subunits between transmembrane domains I and II.

FIGURE 4A shows the tail currents elicited by repolarization to -90 mV following 10 ms step depolarizations between -80 and -10 mV. For tail current measurements the digitization/filter rates were 50/16 kHz. Tail current decay was fitted to a bi-exponential function of the form
10 $I = A_0 + A_1 \exp(-t/\tau_1) + A_2 \exp(-t/\tau_2)$. The bi-exponential decay profile of the tail current was observed in every cell examined ($n = 12$). FIGURES 4B and 4C show the voltage-dependence of the time constants τ_1 and τ_2 for current deactivation (FIGURE 4B) and the current fractions A_1 and A_2 (FIGURE 4C).

15 DETAILED DESCRIPTION OF THE INVENTION

Definitions:

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents and publications
20 referred to herein are incorporated by reference herein.

Reference to each of the calcium channel subunits includes the subunits that are specifically disclosed herein and human calcium channel subunits encoded by nucleic acid that can be isolated by using the nucleic acid disclosed as probes and screening an appropriate human cDNA or
25 genomic library under at least low stringency, preferably high stringency. Such DNA also includes DNA that encodes proteins that have about 40% homology, typically at least about 90% sequence identity taking into account gaps) to any of the subunits proteins described herein or DNA or RNA that hybridizes under conditions of at least low stringency to the

-22-

- DNA provided herein and the protein encoded by such DNA exhibits additional identifying characteristics, such as function or molecular weight. In particular, reference to an α_{1H} subunit refers to subunits that can be isolated from nucleic acid libraries from any desired source using
- 5 the nucleic acid disclosed herein as a probe. The encoded subunit is characterized by the presence of the notably long intracellular loop between transmembrane domains I and II, and/or properties ascribed to T-type or LVA type channels.

It is understood that subunits that are encoded by transcripts that

10 represent splice variants of the disclosed subunits or other such subunits may exhibit less than 40% overall homology to any single subunit, but will include regions of such homology to one or more such subunits. It is also understood that 40% homology refers to proteins that share approximately 40% of their amino acids in common or that share

15 somewhat less, but include conservative amino acid substitutions, whereby the activity of the protein is not substantially altered.

The subunits and DNA fragments encoding such subunits are provided herein or known to those of skill in the art (see, published International PCT application Nos. WO89/09834, WO93/04083,

20 WO95/04822, U.S. Patent Nos. 5,792,846, 5,726,035, 5,407,820, 5,686,241, 5,618,720, 5,710,250, 5,429,921, 5,429,921 and 5,386,025) include any α_1 , α_2 , β or γ subunits of a human calcium channel.

Nucleic acid encoding LVA subunits, particularly α_{1H} subunits of

25 human and other animal calcium channels, are provided herein. In particular, such DNA fragments include any isolated DNA fragment that (encodes a subunit of a human calcium channel, that (1) contains a sequence of nucleotides that encodes the subunit, and (2) is selected from among:

-23-

- (a) a sequence of nucleotides that encodes a human calcium α_{1H} channel subunit and includes a sequence of nucleotides set forth in any of the SEQ ID's herein (i.e., SEQ ID Nos. 12, 15 and 16) that encodes such subunit;
- 5 (b) a sequence of nucleotides that encodes the subunit and hybridizes under conditions of high stringency to DNA that is complementary to an mRNA transcript present in a human cell that encodes a LVA subunit, particularly an α_{1H} -subunit;
- (c) a sequence of nucleotides that encodes the subunit that includes a sequence of amino acids encoded by any of SEQ 10 ID Nos. 12-16; and
- (d) a sequence of nucleotides that encodes a subunit that includes a sequence of amino acids encoded by a sequence of nucleotides that encodes such subunit and hybridizes under conditions of high stringency to DNA that is complementary to an mRNA transcript present in a human cell that encodes the subunit that includes a sequence of 15 nucleotides set forth in any of SEQ ID Nos. 12-16.

As used herein, the α , subunit types, encoded by different genes, 20 are designated as type α_{1A} , α_{1B} , α_{1C} , α_{1D} , α_{1E} and α_{1H} . These types have also been referred to as VDCC IV for α_{1B} , VDCC II for α_{1C} and VDCC III for α_{1D} . Subunit subtypes, which are splice variants, are referred to, for example as α_{1H-1} , α_{1H-2} , α_{1B-1} , α_{1B-2} , α_{1C-1} etc.

Thus, as used herein, nucleic acid (DNA or RNA) encoding the α , 25 subunit refers to nucleic acid that hybridizes to the DNA provided herein under conditions of at least low stringency, typically high stringency, or encodes a subunit that has at least about 40% homology to protein encoded by DNA disclosed herein that encodes the specified α , subunit of a human calcium channel. In the case of LVA channels, nucleic acid that

-24-

- encodes a subunit that hybridizes under at least low stringency, preferably high stringency, to nucleic acid that encodes an α_{1H} subunit, and that encodes a subunit having the requisite LVA properties in assays for such activity, as those described herein. Splice variants will have
- 5 varying percentages of overall homology (or identity), but will be derived from the same gene and will include regions of 100% identity.

In particular, a splice variant of any of the α_1 subunits (or any of the subunits particularly disclosed herein) will contain regions (at least one exon) of divergence and one or more regions (at least one exon,

10 typically more than about 16 nucleotides, and generally substantially more) that have 100% homology with one or more of the α_1 subunit subtypes provided herein, and will also contain a region that has substantially less homology, since it is derived from a different exon. It is well within the skill of those in this art to identify exons and splice

15 variants. Thus, for example, an α_{1H} subunit will be readily identifiable, because it will share at least about 40% protein homology with one of the α_{1H} subunits disclosed herein, and will include at least one region (one exon) that is 100% homologous. It will also have activity, as discussed below, that indicates that it is an LVA α_1 subunit.

20 It is noted herein, that identity and homology refer to the percentage of amino acids when proteins are compared or nucleotides when nucleic acids are compared that are shared. Numerous computer programs for determining identity are available. In all instances, intended gap penalties and other parameters are the defaults set by the

25 manufacturer. Although not really needed when there is a high (90% or greater) degree of identity between sequences such programs include, but are not limited to commercially available sequence alignment programs, such as the DNAStar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program

-25-

(Madison WI), to determine a percentage of sequence identity (see, also, von Heijne, entitled "Sequence Analysis in Molecular Biology: Treasure Trove of Trivial Pursuit" Academic Press (1987) Appendix 2 (citing to UWG and DNASTar among seven commercially available software programs)).

An α_1 subunit may be identified by its ability to form a calcium channel. Typically, α_1 subunits have molecular masses greater than at least about 120 kD. Also, hydropathy plots of deduced α_1 subunit amino acid sequences indicate that the α_1 subunits contain four internal repeats, each containing six transmembrane domains. An α_{1H} -subunit is identified by its pore-forming ability and also the low-voltage activation of the resulting channel.

The activity of a calcium channel may be assessed *in vitro* by methods known to those of skill in the art, including the electrophysiological and other methods described herein. Typically, α_1 subunits include regions with which one or more modulators of calcium channel activity, such as a 1,4-DHP or ω -CgTx, interact directly or indirectly. Types of α_1 subunits may be distinguished by any method known to those of skill in the art, including on the basis of binding specificity. For example, it has been found herein that α_{1B} subunits participate in the formation of channels that have previously been referred to as N-type channels, α_{1D} subunits participate in the formation of channels that had previously been referred to as L-type channels, α_{1A} subunits appear to participate in the formation of channels that exhibit characteristics typical of channels that had previously been designated P-type channels, and α_{1H} subunits appear to participate in channels that exhibit activities associated with T-type channels. Thus, for example, the activity of channels that contain the α_{1B} subunit are insensitive to 1,4-DHPs; whereas the activity of channels that contain the α_{1D} subunit are

-26-

modulated or altered by a 1,4-DHP. It is presently preferable to refer to calcium channels based on pharmacological characteristics and current kinetics and to avoid historical designations. Types and subtypes of α_1 subunits may be characterized on the basis of the effects of such modula-

- 5 tors on the subunit or a channel containing the subunit as well as differences in currents and current kinetics produced by calcium channels containing the subunit. The α_{1H} subunits may be further identified by the presence the notably long intracellular loop regions, such as between transmembrane domains I and II (e.g., nt 1506 to nt 2627 of SEQ ID No.
- 10 12), and also the loop in domain I.

In particular, nucleic acid that encodes an α_{1H} subunit as used herein, will hybridize under conditions of high stringency to the nucleic acid disclosed herein as SEQ ID Nos. 12, 15 and 16, and will form a channel in a mammalian cell, such as an HEK cell, that exhibits

- 15 electrophysiological and/or pharmacological properties of a LVA or T-channel. The electrophysiological properties include one or more of the following electrophysiological properties a relative conductance of Ba^{2+} of about 5 pS (picoseconds) to about 9 pS, an activation time of about 2 to about 8 milliseconds, a kinetics of activation $V_{1/2}$ value of about -60
- 20 millivolts to about 26 millivolts, an inactivation time of about 10 to about 30 milliseconds, a kinetics of inactivation $V_{1/2}$ value of about -100 millivolts to about -500 millivolts, and a tail deactivation time of about 2 to about 12 milliseconds.

- In addition, the resulting channel may have pharmacological properties, such as a relatively high degree of sensitivity to mibepradil, (1S,2S)-2-[2-[(3-(1H-benzimidazol-2-yl)propyl)methyl-amino]ethyl]-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate (Hoffman-LaRoche, Inc.) and/or a relatively high degree of resistance to the Conus

-27-

snail toxins GVIA and MVIIC as well as the arachnid toxins AgallIA and AgalVA compared to HVA calcium channels.

- As used herein, an α_2 subunit is encoded by nucleic acid (DNA or RNA) disclosed, for example, in U.S. Patent No. 5,407,820, U.S. Patent No. 5,792,846 and International PCT application No. WO95/04822 that encodes an α_2 subunit of a mammalian calcium channel or that hybridizes to DNA under conditions of low stringency, preferably high stringency, or encodes a protein that has at least about 40% homology, typically at least about 90% identity, taking into account gaps, with that disclosed therein. Such DNA encodes a protein that typically has a molecular mass greater than about 120 kD, but does not form a calcium channel in the absence of an α_1 subunit, and may alter the activity of a calcium channel that contains an α_1 subunit. Subtypes of the α_2 subunit that arise as splice variants are designated by lower case letter, such as α_{2a} , . . . α_{2e} .
- In addition, the α_2 subunit and the large fragment produced when the protein is subjected to reducing conditions appear to be glycosylated with at least N-linked sugars and do not specifically bind to the 1,4-DHPs and phenylalkylamines that specifically bind to the α_1 subunit. The smaller fragment, the C-terminal fragment, is referred to as the δ subunit and includes amino acids from about 946 (as numbered in International PCT application No. WO95/04822, e.g., SEQ ID No. 11 therein) through about the C-terminus. This fragment may dissociate from the remaining portion of α_2 when the α_2 subunit is exposed to reducing conditions. For purposes herein α_2 is also referred to as $\alpha_2\delta$. Thus, reference to $\alpha_2\delta$ means the α_2 subunit, including the C-terminal δ portion.

As used herein, a β subunit is encoded by DNA disclosed, for example, in U.S. Patent No. 5,407,820, U.S. Patent No. 5,792,846 and International PCT application No. WO95/04822 or that hybridizes to the DNA provided ther in under conditions of low stringency, preferably high

-28-

- stringency, or encodes a protein that has at least about 40% homology, typically about at least about 90% homology) with that disclosed therein and is a protein that typically has a molecular mass lower than the α subunits and on the order of about 50-80 kD, does not form a detectable
- 5 calcium channel in the absence of an α_1 subunit, but may alter the activity of a calcium channel that contains an α_1 subunit or that contains an α_1 and α_2 subunit.

Types of the β subunit that are encoded by different genes are designated with subscripts, such as β_1 , β_2 , β_3 and β_4 . Subtypes of β

10 subunits that arise as splice variants of a particular type are designated with a numerical subscript referring to the type and to the variant. Such subtypes include, but are not limited to the β_1 splice variants, including β_{1-1} - β_{1-5} and β_2 variants, including β_{2C} - β_{2E} .

As used herein, a γ subunit is a subunit of calcium channel

15 encoded by DNA disclosed for example in U.S. Patent Nos. 5,726,035 and 5,386,025; see, also Jay *et al.* (1990) Science **248**:490-492 and Lett *et al.* (*1998) Nature Genetics **19**:340-347) and may be isolated and identified using the nucleic acid disclosed therein as a probe by hybridization or other such method known to those of skill in the art, whereby full-length clones encoding a γ subunit may be isolated or constructed. A γ subunit will be encoded by nucleic acid that hybridizes to the DNA provided therein under conditions of low stringency, preferably high stringency, exhibits sufficient sequence homology to encode a protein that has at least about 40% homology with the γ subunit described

20

25 herein.

-29-

Thus, one of skill in the art, in light of the disclosure herein, can identify DNA encoding α_1 , α_2 , β , δ and γ calcium channel subunits, including types encoded by different genes and subtypes that represent splice variants. For example, DNA or RNA probes based on the DNA disclosed herein may be used to screen an appropriate library, including a genomic or cDNA library, for hybridization to the probe and obtain DNA in one or more clones that includes an open reading fragment that encodes an entire protein. Subsequent to screening an appropriate library with the DNA disclosed herein, the isolated DNA can be examined for the presence of an open reading frame from which the sequence of the encoded protein may be deduced. Determination of the molecular weight and comparison with the sequences herein should reveal the identity of the subunit as an α_1 , α_2 etc. subunit. Functional assays may, if necessary, be used to determine whether the subunit is an α_1 , α_2 subunit or β subunit.

For example, DNA encoding an α_{1A} subunit may be isolated by screening an appropriate library with DNA, encoding all or a portion of the human α_{1A} subunit. Such DNA includes the DNA in the phage deposited under ATCC Accession No. 75293 that encodes a portion of an α_1 subunit. DNA encoding an α_{1A} subunit may be obtained from an appropriate library by screening with an oligonucleotide having all or a portion of the sequence of an α_{1A} subunit (see, e.g., published International PCT application No. WO95/04822, particularly SEQ ID Nos. 21, 22 and/or 23 or with the DNA in the deposited phage therein). Alternatively, such DNA may have the coding sequence that encodes an α_{1A} subunit. Any method known to those of skill in the art for isolation and identification of DNA and preparation of full-length genomic or cDNA clones, including methods exemplified herein, may be used.

DNA encoding α_{1H} can be isolated by screening a human medullary thyroid carcinoma cell line (TT cells) or other suitable library human cDNA

-30-

library with DNA probes prepared from nucleic acid provided herein. Full-length clones are constructed and expressed as described and exemplified herein and the resulting channels tested to verify that the encoding nucleic acid encodes a LVA channel.

- 5 The subunit encoded by isolated DNA may be identified by comparison with the DNA and amino acid sequences of the subunits provided herein. Splice variants share extensive regions of homology, but include non-homologous regions, subunits encoded by different genes share a uniform distribution of non-homologous sequences.
- 10 As used herein, a splice variant refers to a variant produced by differential processing of a primary transcript of genomic DNA that results in more than one type of mRNA. Splice variants may occur within a single tissue type or among tissues (tissue-specific variants). Thus, cDNA clones that encode calcium channel subunit subtypes that have 15 regions of identical amino acids and regions of different amino acid sequences are referred to herein as "splice variants".

- As used herein, a "calcium channel-selective ion" is an ion that is capable of flowing through, or being blocked from flowing through, a calcium channel which spans a cellular membrane under conditions which 20 would substantially similarly permit or block the flow of Ca^{2+} . Ba^{2+} is an example of an ion which is a calcium channel-selective ion.

- As used herein, a compound that modulates calcium channel activity is one that affects the ability of the calcium channel to pass calcium channel-selective ions or affects other detectable calcium channel 25 features, such as current kinetics. Such compounds include calcium channel antagonists and agonists and compounds that exert their effect on the activity of the calcium channel directly or indirectly.

As used herein, a "substantially pure" subunit or protein is a subunit or protein that is sufficiently free of other polypeptide

-31-

contaminants to appear homogeneous by SDS-PAGE or to be unambiguously sequenced.

As used herein, selectively hybridize means that a DNA fragment hybridizes to a second fragment with sufficient specificity to permit the 5 second fragment to be identified or isolated from among a plurality of fragments. In general, selective hybridization occurs at conditions of high stringency.

As used herein, heterologous or foreign DNA and RNA are used interchangeably and refer to DNA or RNA that does not occur naturally as 10 part of the genome in which it is present or which is found in a location or locations in the genome that differ from that in which it occurs in nature. It is DNA or RNA that is not endogenous to the cell and has been artificially introduced into the cell. Examples of heterologous DNA include, but are not limited to, DNA that encodes a calcium channel 15 subunit and DNA that encodes RNA or proteins that mediate or alter expression of endogenous DNA by affecting transcription, translation, or other regulatable biochemical processes. The cell that expresses the heterologous DNA, such as DNA encoding a calcium channel subunit, may contain DNA encoding the same or different calcium channel 20 subunits. The heterologous DNA need not be expressed and may be introduced in a manner such that it is integrated into the host cell genome or is maintained episomally.

As used herein, operative linkage of heterologous DNA to regulatory and effector sequences of nucleotides, such as promoters, 25 enhancers, transcriptional and translational stop sites, and other signal sequences, refers to the functional relationship between such DNA and such sequences of nucleotides. For example, operative linkage of heterologous DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that th

-32-

transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA in reading frame.

As used herein, isolated, substantially pure DNA refers to DNA 5 fragments purified according to standard techniques employed by those skilled in the art (see, e.g., Maniatis *et al.* (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

As used herein, expression refers to the process by which nucleic 10 acid is transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the nucleic acid is derived from genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA.

As used herein, vector or plasmid refers to discrete elements that 15 are used to introduce heterologous DNA into cells for either expression of the heterologous DNA or for replication of the cloned heterologous DNA. Selection and use of such vectors and plasmids are well within the level of skill of the art.

As used herein, expression vector includes vectors capable of 20 expressing DNA fragments that are in operative linkage with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an 25 appropriate host cell, results in expression of the cloned DNA.

Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or may integrate into the host cell genome.

-33-

As used herein, a promoter region refers to the portion of DNA of a gene that controls transcription of the DNA to which it is operatively linked. The promoter region includes specific sequences of DNA that are sufficient for RNA polymerase recognition, binding and transcription initiation. This portion of the promoter region is referred to as the promoter. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of the RNA polymerase. These sequences may be *cis* acting or may be responsive to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated.

As used herein, a recombinant eukaryotic cell is a eukaryotic cell that contains heterologous DNA or RNA.

As used herein, a recombinant or heterologous calcium channel refers to a calcium channel that contains one or more subunits that are encoded by heterologous DNA that has been introduced into and expressed in a eukaryotic cell that expresses the recombinant calcium channel. A recombinant calcium channel may also include subunits that are produced by DNA endogenous to the cell. In certain embodiments, the recombinant or heterologous calcium channel may contain only subunits that are encoded by heterologous DNA.

As used herein, "functional" with respect to a recombinant or heterologous calcium channel means that the channel is able to provide for and regulate entry of calcium channel-selective ions, including, but not limited to, Ca^{2+} or Ba^{2+} , in response to a stimulus and/or bind ligands with affinity for the channel. Preferably such calcium channel activity is distinguishable, such as by electrophysiological, pharmacological and other means known to those of skill in the art, from any endogenous calcium channel activity that is in the host cell.

-34-

As used herein, a T-type channel or LVA type channel typically refers to a calcium channel that exhibits a low-threshold calcium current that is activated and inactivated at low voltages compared to calcium channels (such as those that include an α_{1D} subunit) referred to as high voltage activated (HVA) channels. In addition or alternatively, a T-type channel may be characterized by distinct biophysical features, such as slow deactivation rates, very low conductances (5-9 pS) and voltage-dependent inactivation. T channels may exhibit a relatively high degree of sensitivity to mibepradil (Hoffman-LaRoche, Inc.) and/or a relatively high degree of resistance to the Conus snail toxins GVIA and MVIIIC as well as the arachnid toxins AgallIA and AgalVA compared to HVA calcium channels. These channels also typically exhibit reduced affinity for cadmium. T-type channels or LVA type channels may also be characterized at the nucleic acid level by the presence of one or more extended intracellular loops (see, e.g., SEQ ID NO. 12, 15 and 16) between transmembrane domains, such as between transmembrane domains I and II.

As used herein, a polypeptide having an amino acid sequence substantially as set forth in a particular SEQ ID No. includes protein that may have the same function but may include minor variations in sequence, such as conservative amino acid changes or minor deletions or insertions that do not alter the activity of the protein. The activity of a calcium channel receptor subunit protein, particularly a LVA or T-type channel, refers to its ability to form a functional calcium channel alone or with other subunits. A T-type channel will have the distinguishing properties defined herein.

As used herein, a physiological concentration of a compound is that which is necessary and sufficient for a biological process to occur. For example, a physiological concentration of a calcium channel-selective

-35-

ion is a concentration of the calcium channel-selective ion necessary and sufficient to provide an inward current when the channels open.

As used herein, activity of a calcium channel refers to the movement of a calcium channel-selective ion through a calcium channel.

- 5 Such activity may be measured by any method known to those of skill in the art, including, but not limited to, measurement of the amount of current which flows through the recombinant channel in response to a stimulus.

- As used herein, a "functional assay" refers to an assay that
10 identifies functional calcium channels. A functional assay, thus, is an assay to assess function.

- As understood by those skilled in the art, assay methods for identifying compounds, such as antagonists and agonists, that modulate calcium channel activity, generally require comparison to a control. One
15 type of a "control" cell or "control" culture is a cell or culture that is treated substantially the same as the cell or culture exposed to the test compound except that the control culture is not exposed to the test compound. Another type of a "control" cell or "control" culture may be a cell or a culture of cells which are identical to the transfected cells except
20 the cells employed for the control culture do not express functional calcium channels. In this situation, the response of test cell to the test compound is compared to the response (or lack of response) of the calcium channel-negative cell to the test compound, when cells or cultures of each type of cell are exposed to substantially the same
25 reaction conditions in the presence of the compound being assayed. For example, in methods that use patch clamp electrophysiological procedures, the same cell can be tested in the presence and absence of the test compound, by changing the external solution bathing the cell as known in the art.

-36-

- It is also understood that each of the subunits disclosed herein may be modified by making conservative amino acid substitutions and the resulting modified subunits are contemplated herein. Suitable conservative substitutions of amino acids are known to those of skill in this art and may be made generally without altering the biological activity of the resulting molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al. *Molecular Biology of the Gene*, 4th Edition, 1987, The Benjamin/Cummings Pub. Co., p.224). Such substitutions are preferably, although not exclusively, made in accordance with those set forth in TABLE 1 as follows:

TABLE 1

	Original residue	Conservative substitution
15	Ala (A)	Gly; Ser
	Arg (R)	Lys
	Asn (N)	Gln; His
	Cys (C)	Ser
20	Gln (Q)	Asn
	Glu (E)	Asp
	Gly (G)	Ala; Pro
	His (H)	Asn; Gln
25	Ile (I)	Leu; Val
	Leu (L)	Ile; Val
	Lys (K)	Arg; Gln; Glu
	Met (M)	Leu; Tyr; Ile
30	Phe (F)	Met; Leu; Tyr
	Ser (S)	Thr
	Thr (T)	Ser
	Trp (W)	Tyr
	Tyr (Y)	Trp; Phe
	Val (V)	Ile; Leu

- Other substitutions are also permissible and may be determined empirically or in accord with known conservative substitutions. Any such modification of the polypeptide may be effected by any means known to those of skill in this art. Mutation may be effected by any method known to those of skill in the art, including site-specific or site-

-37-

directed mutagenesis of DNA encoding the protein and the use of DNA amplification methods using primers to introduce and amplify alterations in the DNA template.

As used herein, treatment means any manner in which the
5 symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein, such as use as contraceptive agents.

As used herein, a LVA-activated calcium channel-mediated disorder
10 refers to disorders that are associated with LVA channel activities. A T-type calcium channel-mediated disorders LVA-activated channel-mediated disorders that are associated with T-type channels. Such disorders include, but are not limited to: cardiovascular, hepatic, endocrine, urologic, reproductive, muscular, neurological and other disorders in
15 which LVA channels, particular T-type channels, play a role either in mediating the disorder in some manner contributing to it.

As used herein, amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or
20 transient that can be attributed to or associated with administration of the composition.

As used herein, substantially pure means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel
25 electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce

substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound may, however, be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.

- 5 As used herein, biological activity refers to the in vivo activities of a compound or physiological responses that result upon in vivo administration of a compound, composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures.
- 10 **Identification and isolation of DNA encoding human calcium channel subunits**

Methods for identifying and isolating nucleic acid (DNA and RNA) encoding α_1 , α_2 , β and γ , particularly nucleic acid encoding LVA α_1 subunits of human calcium channels are provided.

- 15 Identification and isolation of such nucleic acid may be accomplished by hybridizing, under appropriate conditions, at least low stringency, preferably high stringency, to restriction enzyme-digested human DNA with a labeled probe having at least 14, preferably 16 or more nucleotides (25, 30 or longer) and derived from any contiguous portion of DNA having a sequence of nucleotides set forth herein by sequence identification number. Once a hybridizing fragment is identified in the hybridization reaction, it can be cloned employing standard cloning techniques known to those of skill in the art. Full-length clones may be identified by the presence of a complete open reading frame and the
- 20 portion of DNA having a sequence of nucleotides set forth herein by sequence identification number. Once a hybridizing fragment is identified in the hybridization reaction, it can be cloned employing standard cloning techniques known to those of skill in the art. Full-length clones may be identified by the presence of a complete open reading frame and the
- 25 identity of the encoded protein verified by sequence comparison with the subunits provided herein and by functional assays to assess calcium channel-forming ability or other function. This method can be used to identify genomic DNA encoding the subunit or cDNA encoding splice variants of human calcium channel subunits generated by alternative

-39-

splicing of the primary transcript of genomic subunit DNA. For instance, DNA, cDNA or genomic DNA, encoding a calcium channel subunit may be identified by hybridization to a DNA probe and characterized by methods known to those of skill in the art, such as restriction mapping and DNA sequencing, and compared to the DNA provided herein in order to identify heterogeneity or divergence in the sequences of the DNA. Such sequence differences may indicate that the transcripts from which the cDNA was produced result from alternative splicing of a primary transcript, if the non-homologous and homologous regions are clustered, or from a different gene if the non-homologous regions are distributed throughout the cloned DNA. Splice variants share regions of 100% homology. As noted herein, the resulting nucleic acid may be expressed in cells and the resulting cells tested to verify or ascertain that expressed calcium channels exhibit pharmacological and/or electrophysiological properties of LVA or T-channels.

Any suitable method for isolating genes using the DNA provided herein may be used. For example, oligonucleotides corresponding to regions of sequence differences have been used to isolate, by hybridization, DNA encoding the full-length splice variant and can be used to isolate genomic clones. A probe, based on a nucleotide sequence disclosed herein, which encodes at least a portion of a subunit of a human calcium channel, such as a tissue-specific exon, may be used as a probe to clone related DNA, to clone a full-length cDNA clone or genomic clone encoding the human calcium channel subunit.

Labeled, including, but not limited to, radioactively or enzymatically labeled, RNA or single-stranded DNA of at least 14 substantially contiguous bases, preferably 16 or more, generally at least 30 contiguous bases of a nucleic acid which encodes at least a portion of a human calcium channel subunit, the sequence of which nucleic acid corresponds

-40-

to a segment of a nucleic acid sequence disclosed herein by reference to a SEQ ID No. are provided. Such nucleic acid segments may be used as probes in the methods provided herein for cloning DNA encoding calcium channel subunits. See, generally, Sambrook *et al.* (1989) *Molecular*

- 5 *Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Laboratory Press.

In addition, nucleic acid amplification techniques, which are well known in the art, can be used to locate splice variants of calcium channel subunits by employing oligonucleotides based on DNA sequences

- 10 surrounding the divergent sequence primers for amplifying human RNA or genomic DNA. Size and sequence determinations of the amplification products can reveal splice variants. Furthermore, isolation of human genomic DNA sequences by hybridization can yield DNA containing multiple exons, separated by introns, that correspond to different splice
15 variants of transcripts encoding human calcium channel subunits.

DNA encoding types and subtypes of each of the α_1 , α_2 , β and γ subunits of voltage-dependent human calcium channels has been cloned by nucleic acid amplification of cDNA from selected tissues or by screening human cDNA libraries prepared from isolated poly A + mRNA
20 from cell lines or tissue of human origin having such calcium channels. Among the sources of such cells or tissue for obtaining mRNA are human brain tissue or a human cell line of neural origin, such as a neuroblastoma cell line, human skeletal muscle or smooth muscle cells, and the like. Methods of preparing cDNA libraries are well known in the art (see
25 generally Ausubel *et al.* (1987) *Current Protocols in Molecular Biology*, Wiley-Interscience, New York; and Davis *et al.* (1986) *Basic Methods in Molecular Biology*, Elsevier Science Publishing Co., New York).

Prefixed regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode transmembrane

-41-

- domains, sequences predicted to encode cytoplasmic loops, signal sequences, ligand-binding sites, and other functionally significant sequences (see Table, below). Either the full-length subunit-encoding DNA or fragments thereof can be used as probes, preferably labeled with
- 5 suitable label means for ready detection. When fragments are used as probes, preferably the DNA sequences will be typically from the carboxyl-end-encoding portion of the DNA, and most preferably will include predicted transmembrane domain-encoding portions based on hydropathy analysis of the deduced amino acid sequence (see, e.g., Kyte and
- 10 Doolittle ((1982) *J. Mol. Biol.* 167:105).

Riboprobes that are specific for human calcium channel subunit types or subtypes have been prepared. These probes are useful for identifying expression of particular subunits in selected tissues and cells. The regions from which the probes were prepared were identified by

15 comparing the DNA and amino acid sequences of all known α or β subunit subtypes. Regions of least homology, preferably human-derived sequences, and generally about 250 to about 600 nucleotides were selected. Numerous riboprobes for α and β subunits have been prepared (see, e.g., Table 2 in International PCT application No. WO95/04822),

20 which is repeated in part in the following Table.

TABLE 2
SUMMARY OF RNA PROBES

	SUBUNIT SPECIFICITY	NUCLEOTIDE POSITION	PROBE NAME	PROBE TYPE	ORIENTATION
25	$\alpha 1A$ generic	3357-3840	pGEM7Z $\alpha 1A^*$	riboprobe	n/a
		761-790	SE700	oligo	antisense
		3440-3464	SE718	oligo	antisense
		3542-3565	SE724	oligo	sense
30	$\alpha 1B$ generic	3091-3463	pGEM7Z $\alpha 1B_{cyt}$	riboprobe	n/a
		6635-6858	pGEM7Z $\alpha 1B_{cooh}$	riboprobe	n/a

-42-

$\alpha 1B-1$ specific	6490-6676	pCRII $\alpha 1B-1/187$	riboprobe	n/a
$\alpha 1E$ generic	3114-3462	pGEM7Z $\alpha 1E$	riboprobe	n/a

5 * The pGEM series are available from Promega, Madison WI; see also,
U.S. Patent No. 4,766,072.

For the α_{1H} -specific probes (and also antibodies), regions unique to the α_{1H} subunits, such as the extended intracellular loops present in these channels may be used. For α_{1H-1} specific antibodies the region present in α_{1H-1} and absent from α_{1H-2} may be useful for preparation of subunit-specific probes.

10 purpose.

The DNA clones and fragments thereof provided herein thus can be used to isolate genomic clones encoding each subunit and to isolate any splice variants by hybridization screening of libraries prepared from different human tissues. Nucleic acid amplification techniques, which are well known in the art, can also be used to locate DNA encoding splice variants of human calcium channel subunits. This is accomplished by employing oligonucleotides based on DNA sequences surrounding divergent sequence(s) as primers for amplifying human RNA or genomic DNA. Size and sequence determinations of the amplification products can reveal the existence of splice variants. Furthermore, isolation of human genomic DNA sequences by hybridization can yield DNA containing multiple exons, separated by introns, that correspond to different splice variants of transcripts encoding human calcium channel subunits.

Once DNA encoding a calcium channel subunit is isolated, 25 ribonuclease (RNase) protection assays can be employed to determine which tissues express mRNA encoding a particular calcium channel subunit or variant. These assays provide a sensitive means for detecting and quantitating an RNA species in a complex mixture of total cellular RNA. The subunit DNA is labeled and hybridized with cellular RNA. If 30 complementary mRNA is present in the cellular RNA, a DNA-RNA hybrid results. The RNA sample is then treated with RNase, which degrades

-43-

single-stranded RNA. Any RNA-DNA hybrids are protected from RNase degradation and can be visualized by gel electrophoresis and autoradiography. *In situ* hybridization techniques can also be used to determine which tissues express mRNA encoding a particular calcium channel subunit. The labeled subunit-encoding DNA clones are hybridized to different tissue slices to visualize subunit mRNA expression.

With respect to each of the respective subunits (α_1 , α_2 , β or γ) of human calcium channels, once the DNA encoding the channel subunit was identified by a nucleic acid screening method, the isolated clone was used for further screening to identify overlapping clones. Some of the cloned DNA fragments can and have been subcloned into an appropriate vector such as pIBI24/25 (IBI, New Haven, CT), M13mp18/19, pGEM4, pGEM3, pGEM7Z, pSP72 and other such vectors known to those of skill in this art, and characterized by DNA sequencing and restriction enzyme mapping. A sequential series of overlapping clones may thus be generated for each of the subunits until a full-length clone can be prepared by methods, known to those of skill in the art, that include identification of translation initiation (start) and translation termination (stop) codons. For expression of the cloned DNA, the 5' noncoding region and other transcriptional and translational control regions of such a clone may be replaced with an efficient ribosome binding site and other regulatory regions as known in the art. Other modifications of the 5' end, known to those of skill in the art, that may be required to optimize translation and/or transcription efficiency may also be effected, if deemed necessary.

Examples 1-3 below, describe in detail the cloning DNA encoding α_{1H} splice variants and electrophysiological and pharmacological properties thereof. Except where noted, the methods of expression and other data is described with reference to the α_{1H} encoding nucleic acid. It is

-44-

understood that the exemplified methods may be used to isolate additional splice variants and related subunits from humans and other mammals and animals and may also be used to express such nucleic acid to produce cells for use in screening assays to identify compounds that

- 5 modulate the activity of LVA activated channels, particularly T-type channels. The nucleic acid may also be used in diagnostic assays to identify mutations and to produce proteins and then antibodies for use as reagents in diagnostic assays for disorders associated with T-type calcium channel activities.

10 α_1 subunits of LVA channels

Nucleic acid encoding α_1 subunits that form LVA channels is provided herein. The nucleic acid provided herein may also be used to isolate related channels from other tissues, and other mammals and animals.

**15 Identification and isolation of DNA encoding the
 α_{1H} human calcium channel subunits**

- Calcium channels that contain α_{1H} should exhibit properties that differ from known HVA channels, formed from the α_{1A} - α_{1E} calcium channel subunits. Such differences may include low voltage activation, voltage-dependent inactivation, relatively high sensitivity to mibepradil and relatively high resistance to snail and arachnid toxins that inhibit most HVA channels (e.g., spider venom toxins ω -AgallIA and ω -AgalVA and the Conus snail toxin GVIA). In addition α_{1H} -subunits may be identified by homology with other α_1 -subunits and additionally by presence of an extended intracellular loop in the encoded subunit (see, e.g., SEQ No. 49, nucleotides 1506-2627) located between transmembrane domains I and II. This region in α_{1H} is extended compared to other calcium channel α_1 subunits, such as α_{1A} - α_{1E} .

-45-

DNA encoding an α_{1H} -subunit may be isolated using the DNA provided herein. In particular, probes of at least about 16 nucleotides or 30 nucleotides or other suitable length, such 14, 30, 100 etc. bases, may be used to screen selected libraries, including mammalian DNA libraries.

- 5 The selected libraries are preferably prepared from mammalian tissue or cell sources known to express T-type channels. The sequence of the probe is preferably based on the sequence of the intracellular loop located between transmembrane domains I and II (see, e.g., SEQ ID Nos. 12 and 15).
- 10 DNA encoding the α_{1H} subunit was isolated by amplifying a region of genes encoding an α_1 subunit expressed in a human thyroid carcinoma cell line (TT cells) using degenerate oligonucleotide primers. The TT cell line is derived from a human medullary thyroid carcinoma and has been used to study calcitonin secretion and gene expression
- 15 (deBustros et al. (1986) J. Biol. Chem. 261:8036-8041; deBustros et al. 1990 Mol. Cell. Biol. 10:1773-1778). Whole-cell recordings from these cells reveal that the only voltage gated calcium channels expressed by these cells are low-voltage activated, rapidly inactivating and slowly deactivating, which are biophysical properties consistent with a T-type
- 20 channel.

- A portion of one of the positive clones was used to further screen a human thyroid carcinoma cDNA library to identify overlapping clones that span the entire length of the nucleotide sequence encoding the human α_{1H} subunit. A full-length α_{1H} DNA clone can be constructed by ligating
- 25 portions of the partial cDNA clones as described in Example 1. SEQ ID No. 15 sets forth the nucleotide sequence of a clone encoding an α_{1H-1} subunit as well as the deduced amino acid sequence.

Two splice variants, α_{1H-1} and α_{1H-2} , were detected by RT-PCR (reverse transcriptase-amplification) using RNA from multiple tissues. The

-46-

α_{1H-2} isoform (SEQ ID No. 16) contains a 957 nucleotide deletion, relative to α_{1H-1} (SEQ ID Nos. 12 and 15) in the I-II intracellular loop, i.e., (e.g., nt 1506 to nt 2627 of SEQ ID No. 12).

The α_{1H-1} subunit exhibits marked sequence differences, as well as 5 certain structural similarities to previously cloned α_1 subunits. Notably, the deduced amino acid sequence of α_{1H-1} shares less than 30% overall sequence identity with human α_{1A} - α_{1E} -encoding nucleic acids, which encode high-voltage activated calcium channels. Northern blot analysis indicates that mRNA transcripts for α_{1H} are expressed in the brain, 10 primarily in the amygdala, caudate nucleus and putamen, and in peripheral tissues, primarily in the liver, kidney and heart.

Specifically, a comparison of the nucleic acid and deduced amino acid sequences of this α_{1H} calcium channel subunit with other human α_1 subunits reveals several distinct features. There are notable differences 15 between α_{1H} and the HVA α_1 sequences. First, the intracellular loop between transmembrane Domains I and II is notably long. As exemplified in SEQ ID No. 49, the intracellular loop of human α_{1H} subunit is 1,122 nt in length whereas the corresponding intracellular loops in the other human α_1 subunits described herein range from 351 to 381 nt in length. Thus, 20 the intracellular loop of human α_{1H} is nearly 250 amino acids longer than human α_1 subunits found in HVA calcium channels. The deduced amino acid sequence of this region (aa 420 to aa 794 of SEQ ID No. 12) contains a large number of proline residues and includes a poly-HIS region of 9 contiguous histidine residues (aa 52 to aa 528 of SEQ ID No. 12) 25 and a region where 8 of 10 residues are alanine. The large intracellular loop located between transmembrane Domains I and II resembles the large intracellular loops found in a corresponding location in sodium channel α subunits some of which may function as homomers. It has been proposed that T-type channels have an activity that is a hybrid.

-47-

between HVA calcium channels and sodium channel. The α_{1H} subunits provided herein may also function as sodium channels.

Second, the isolated human α_{1H} subunit lacks amino acid residues that are generally known to be critical (e.g., see De Waard *et al.* (1996)

- 5 FEBS Letters 380:272-276; Pragnell *et al.* (1994) Nature 368:67-70) for the interaction between α_1 subunits and the β subunits. There are at least thirteen residues located in this intracellular loop between transmembrane Domains I and II that form a motif that is highly conserved among α_1 subunits, such as α_{1A} - α_{1E} described herein (see, also Pragnell *et al.* (1994)
- 10 Nature 368:67-70). In particular, this loop lacks the α_1 interaction domain (AID) involved in binding the β subunit. Also absent from this region is the G $\beta\gamma$ binding motif, GlnXXGluArg, originally identified in adenylyl cyclase 2 and found in the non-L-type, HVA α_1 subunits. An identical sequence occurs, however, within the II-III intracellular loop of the α_{1H}
- 15 sequence, suggesting a possible interaction of G $\beta\gamma$ in this region. The α_{1H} subunit also contains differences in the determinants of ion selectivity found in the S5-S6 linkers of HVA channels. In the S5-S6 pore loops of domain III and IV, the glutamate residues that play a critical role in Ca²⁺ selectivity and ion permeation are replaced by aspartate residues.

- 20 Third, the human α_{1H} subunit has another notably long extracellular loop in Domain I located between IS5 and IS6. This extracellular loop ranges from 249 to 270 nucleotide residues in other human α_1 subunits whereas the human α_{1H} subunit has 426 nucleotide residues. Other distinguishing features may be ascertained and have been ascertained by
- 25 expressing the subunit in cells as described herein.

-48-

The nucleic acid encoding an α_{1H} subunit can be used to screen appropriate libraries, particularly mammalian libraries, and more particularly mammalian libraries from tissues or cells that exhibit T-type channel activity. The encoded subunit can be identified by the above-
5 noted distinguishing properties. Nucleic acid probes from the α_{1H-1} -encoding clone was used to identify and isolate clones encoding a second variant, designated α_{1H-2} , which has a 957 bp deletion relative to α_{1H-1} .

The α_{1H} subunit forms a functional channel in two different expression systems without the addition of exogenous $\alpha_2\delta$ and β subunits. The absence of a β subunit interaction site within the I-II loop of the α_{1H} sequence is consistent with the report that β subunit depletion with antisense oligonucleotides in nodosus ganglia has no effect on T-type currents in that region. In addition, none of the known β subunits in HEK293 cells were detected by western analysis using β subunit-specific
10 antisera, indicating that the previously cloned β subunits may not play a role in the formation of LVA Ca^{2+} channels containing α_{1H} . Oocytes and HEK293 cells express an endogenous $\alpha_2\delta$ subunit and that TT cells, the source of the α_{1H} subunits described here, express relatively high amounts
15 of $\alpha_2\delta$ protein. Consequently, it is possible that α_{1H} -containing channels expressed, contain $\alpha_2\delta$ subunit, and that the $\alpha_2\delta$ subunit is a component
20 of native α_{1H} -containing channels.

Distribution of α_{1H} transcripts

Northern blots containing human mRNA from several neuronal and nonneuronal tissues were probed with labeled fragments generated from
25 the full-length α_{1H} cDNA. A single transcript of ~8.5 kb is present in all tissues examined, which included heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas. Neuronal tissues included, cerebellum, cerebral cortex, medulla, spinal cord, occipital lobe, frontal lobe, temporal lobe, putamen, amygdala, caudate nucleus, corpus callosum,

-49-

hippocampus, substantia nigra, subthalamic nucleus and thalamus. In nonneuronal tissues, the highest expression levels are found in the kidney, liver, and heart. In the brain, the α_{1H} transcript is most abundant in the amygdala, caudate nucleus, and putamen.

5 **Identification and isolation of DNA encoding other α_1 human calcium channel subunit types and subtypes**

DNA encoding additional α_1 subunits can be isolated and identified using the DNA provided herein as described for the α_{1A} , α_{1B} , α_{1C} , α_{1D} , α_{1E} and α_{1H} subunits or using other methods known to those of skill in the art.

10 In particular, the DNA provided herein may be used to screen appropriate libraries to isolate related DNA. Full-length clones can be constructed using methods, such as those described herein, and the resulting subunits characterized by comparison of their sequences and electrophysiological and pharmacological properties with the subunits exemplified herein.

15 A number of voltage-dependent calcium channel α_1 subunit genes, which are expressed in the human CNS and in other tissues, have been identified and have been designated as α_{1A} , α_{1B} (or VDCC IV), α_{1C} (or VDCC II), α_{1D} (or VDCC III), α_{1E} and α_{1H} . DNA, isolated from a human DNA libraries that encodes each of the subunit types has been isolated.

20 DNA encoding subtypes of each of the types, which arise as splice variants are also provided. Subtypes are herein designated, for example, as α_{1B-1} , α_{1B-2} . The α_{1H} subunit is of particular interest herein

The α_1 subunit types A, B, C, D, E and F of voltage-dependent calcium channels, and subtypes thereof, differ with respect to sensitivity

25 to known classes of calcium channel agonists and antagonists, such as DHPs, phenylalkylamines, omega conotoxins (ω -CgTx), the funnel web spider toxin ω -Aga-IV, pyrazonoylguanidines and/or in other physical and structural properties. These subunit types also appear to differ in the holding potential and in the kinetics of currents produced upon

-50-

depolarization of cell membranes containing calcium channels that include different types of α_1 subunits.

DNA that encodes an α_1 subunit that binds to at least one compound selected from among dihydropyridines, phenylalkylamines, ω -

- 5 CgTx, components of funnel web spider toxin, and pyrazonoylguanidines is provided. For example, the α_{1B} subunit provided herein appears to specifically interact with ω -CgTx in N-type channels, and the α_{1D} subunit provided herein specifically interacts with DHPs in L-type channels.

Antibodies

- 10 Antibodies, monoclonal or polyclonal, specific for calcium channel subunit subtypes or for calcium channel types can be prepared employing standard techniques, known to those of skill in the art, using the subunit proteins or portions thereof as antigens. Anti-peptide and anti-fusion protein antibodies can be used (see, for example, Bahouth et al. (1991) *Trends Pharmacol. Sci.* 12:338-343; *Current Protocols in Molecular Biology* (Ausubel et al., eds.) John Wiley and Sons, New York (1984)) Factors to consider in selecting portions of the calcium channel subunits for use as immunogens (as either a synthetic peptide or a recombinantly produced bacterial fusion protein) include antigenicity accessibility (i.e.,
- 15 20 extracellular and cytoplasmic domains), uniqueness to the particular subunit, and other factors known to those of skill in this art. Antibodies have therapeutic uses and also use in diagnostic assays.

The availability of subunit-specific antibodies makes possible the application of the technique of immunohistochemistry to monitor the

- 25 distribution and expression density of various subunits (e.g., in normal vs diseased brain tissue). Such antibodies could also be employed in diagnostic, such as LES diagnosis, and therapeutic applications, such as using antibodies that modulate activities of calcium channels.

-51-

- The antibodies can be administered to a subject employing standard methods, such as, for example, by intraperitoneal, intramuscular, intravenous, or subcutaneous injection, implant or transdermal modes of administration. One of skill in the art can 5 empirically determine dosage forms, treatment regiments, and other parameters, depending on the mode of administration employed.

Subunit-specific monoclonal antibodies and polyclonal antisera have been prepared. The regions from which the antigens were derived were identified by comparing the DNA and amino acid sequences of all known 10 α or β subunit subtypes. Regions of least homology, preferably human-derived sequences were selected. The selected regions or fusion proteins containing the selected regions are used as immunogens. Hydrophobicity analyses of residues in selected protein regions and fusion proteins are also performed; regions of high hydrophobicity are avoided. 15 Also, and more importantly, when preparing fusion proteins in bacterial hosts, rare codons are avoided. In particular, inclusion of 3 or more successive rare codons in a selected host is avoided. Numerous antibodies, polyclonal and monoclonal, specific for α or β subunit types or subtypes have been prepared; some of these are listed in the following 20 Table. Exemplary antibodies and peptide antigens that have been used to prepare the antibodies are set forth Table 3:

TABLE 3

SPECIFICITY	AMINO ACID NUMBER	ANTIGEN NAME	ANTIBODY TYPE
$\alpha 1$ generic	112-140	peptide 1A#1	polyclonal
$\alpha 1$ generic	1420-1447	peptide 1A#2	polyclonal
$\alpha 1A$ generic	1048-1208	$\alpha 1A\#2(b)$ GST fusion	polyclonal
			monoclonal
$\alpha 1B$ generic	983-1106	$\alpha 1B\#2(b)$ GST fusion	polyclonal
			monoclonal

$\alpha 1B$ -1	2164-2339	$\alpha 1B$ -1#3 GST fusion	polyclonal
$\alpha 1B$ -2	2164-2237	$\alpha 1B$ -2#4 GST fusion	polyclonal
$\alpha 1E$ generic	985-1004 ($\alpha 1E$ -3)	$\alpha 1E$ #2(a) GST fusion	polyclonal

5 * GST gene fusion system is available from Pharmacia; see also, Smith et al. (1988) *Gene* 67:31. The system provides pGEX plasmids that are designed for inducible, high-level expression of genes or gene fragments as fusions with *Schistosoma japonicum* GST. Upon expression in a bacterial host, the resulting fusion proteins are purified from bacterial lysates by affinity chromatography.

10 The GST fusion proteins are each specific for the cytoplasmic loop region IIS6-IIS1, which is a region of low subtype homology for all subtypes, including α_{1C} and α_{1D} , for which similar fusions and antisera can be prepared.

15 Using similar methods, antibodies specific for LVA subunits, particularly the α_{1H} subunits provided herein, using, for example, the extended intracellular loops, can be prepared. Such antibodies will have use in diagnostic assays for disorders in which LVA calcium channels are implicated.

20 **Preparation of recombinant eukaryotic cells containing DNA encoding heterologous calcium channel subunits**

25 DNA encoding one or more of the calcium channel subunits or a portion of a calcium channel subunit may be introduced into a host cell for expression or replication of the DNA. Such DNA may be introduced using methods described in the following examples or using other procedures well known to those skilled in the art. Incorporation of cloned DNA into a suitable expression vector, transfection of eukaryotic cells with a plasmid vector or a combination of plasmid vectors, each encoding one or more distinct genes or with linear DNA, and selection of transfected cells are also well known in the art (see, e.g., Sambrook et al.

30 (1989) *Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor Laboratory Press).

-53-

Cloned full-length nucleic acid encoding any of the subunits of a calcium channel may be introduced into a plasmid vector for expression in a eukaryotic cell. Such nucleic acid may be genomic DNA or cDNA or RNA. Presently preferred cells are those containing heterologous DNA 5 encoding an α_{1H} subunit. Host cells may be transfected with one or a combination of the plasmids, each of which encodes at least one calcium channel subunit. Alternatively, host cells may be transfected with linear DNA using methods well known to those of skill in the art.

While the DNA provided herein may be expressed in any eukaryotic 10 cell, including yeast cells such as *P. pastoris* (see, e.g., Cregg *et al.* (1987) *Bio/Technology* 5:479), mammalian expression systems for expression of the DNA encoding the human calcium channel subunits provided herein are preferred.

The heterologous DNA may be introduced by any method known to 15 those of skill in the art, such as transfection with a vector encoding the heterologous DNA. Particularly preferred vectors for transfection of mammalian cells are the pSV2dhfr expression vectors, which contain the SV40 early promoter, mouse dhfr gene, SV40 polyadenylation and splice sites and sequences necessary for maintaining the vector in bacteria, 20 cytomegalovirus (CMV) promoter-based vectors such as pCDNA1, or pcDNA-amp and MMTV promoter-based vectors. The vector pCDNA1 is a eukaryotic expression vector containing a cytomegalovirus (CMV) promoter which is a constitutive promoter recognized by mammalian host cell RNA polymerase II. DNA encoding the human calcium channel 25 subunits has been inserted in the vector pCDNA1 at a position immediately following the CMV promoter. The vector pCDNA1 is presently preferred and has been used to express the α_{1H} subunits in mammalian cells.

-54-

- Stably or transiently transfected mammalian cells may be prepared by methods known in the art by transfecting cells with an expression vector having a selectable marker gene such as the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance or the like, and, for
- 5 transient transfection, growing the transfected cells under conditions selective for cells expressing the marker gene. Functional voltage-dependent calcium channels have been produced in HEK 293 cells transfected with a derivative of the vector pCDNA1 that contains DNA encoding a human calcium channel subunit.
- 10 The heterologous DNA may be maintained in the cell as an episomal element or may be integrated into chromosomal DNA of the cell. The resulting recombinant cells may then be cultured or subcultured (or passaged, in the case of mammalian cells) from such a culture or a subculture thereof. Methods for transfection, injection and culturing
- 15 recombinant cells are known to the skilled artisan. Eukaryotic cells in which DNA or RNA may be introduced, include any cells that are transfectable by such DNA or RNA or into which such DNA may be injected. Virtually any eukaryotic cell can serve as a vehicle for heterologous DNA. Preferred cells are those that can also express the
- 20 DNA and RNA and most preferred cells are those that can form recombinant or heterologous calcium channels that include one or more subunits encoded by the heterologous DNA. Such cells may be identified empirically or selected from among those known to be readily transfected or injected. Preferred cells for introducing DNA include those that can
- 25 be transiently or stably transfected and include, but are not limited to, cells of mammalian origin, such as COS cells, mouse L cells, CHO cells, human embryonic kidney cells, African green monkey cells and other such cells known to those of skill in the art, amphibian cells, such as *Xenopus laevis* oocytes, or those of yeast such as *Saccharomyces cerevisiae* or

-55-

- Pichia pastoris.* Preferred cells for expressing injected RNA transcripts or cDNA include *Xenopus laevis* oocytes. Cells that are preferred for transfection of DNA are those that can be readily and efficiently transfected. Such cells are known to those of skill in the art or may be empirically identified. Preferred cells include DG44 cells and HEK 293 cells, particularly HEK 293 cells that can be frozen in liquid nitrogen and then thawed and regrown. Such HEK 293 cells are described, for example in U.S. Patent No. 5,024,939 to Gorman (see, also Stillman *et al.* (1985) *Mol. Cell. Biol.* 5:2051-2060).
- 10 The cells may be used as vehicles for replicating heterologous DNA introduced therein or for expressing the heterologous DNA introduced therein. In certain embodiments, the cells are used as vehicles for expressing the heterologous DNA as a means to produce substantially pure human calcium channel subunits or heterologous calcium channels.
- 15 Host cells containing the heterologous DNA may be cultured under conditions whereby the calcium channels are expressed. The calcium channel subunits may be purified using protein purification methods known to those of skill in the art. For example, antibodies, such as those provided herein, that specifically bind to one or more of the subunits may
- 20 be used for affinity purification of the subunit or calcium channels containing the subunits.

Substantially pure subunits of a human calcium channel α_1 subunits of a human calcium channel, α_2 subunits of a human calcium channel, β subunits of a human calcium channel and γ subunits of a human calcium channel are provided. Substantially pure isolated calcium channels that contain at least one of the human calcium channel subunits are also provided. Substantially pure calcium channels that contain a mixture of one or more subunits encoded by the host cell and one or more subunits encoded by heterologous DNA or RNA that has been introduced into the

-56-

cell are also provided. Substantially pure subtype- or tissue-type specific calcium channels are also provided.

In one embodiment, eukaryotic cells that contain heterologous DNA encoding at least one of α_1 subunit of a calcium channel, preferably an α_{1H} subunit, that express the α_{1H} subunit and form functional homomeric human α_{1H} -containing calcium channels are provided. These cells may be used to screen for compounds that modulate the activity of T-type channels and LVA type calcium channels.

In other embodiments, eukaryotic cells that contain heterologous DNA encoding at least one of an α_1 subunit of a human calcium channel, an α_2 subunit of a human calcium channel, a β subunit of a human calcium channel and a γ subunit of a human calcium channel are provided. In accordance with one preferred embodiment, the heterologous DNA is expressed in the eukaryotic cell and preferably encodes a human calcium channel α_1 subunit.

Expression of heterologous calcium channels: electrophysiology and pharmacology

The α_{1H-1} subunit-encoding DNA was transiently expressed in HEK203 cells and associated with expression of an α_{1H-1} protein of approximately 260kDa α_{1H-1} , as identified by SDS-PAGE/Western blot analysis.

Ba²⁺ or Ca²⁺ currents recorded from HEK293 cells transiently expressing α_{1H-1} channels, and found to exhibit biophysical and pharmacological properties characteristic of low-voltage activated, i.e., T-type, calcium channel currents. Similar results were obtained in *Xenopus* oocytes expressing α_{1H-1} .

Electrophysiological methods for measuring calcium channel activity are known to those of skill in the art and are exemplified herein. Any such methods may be used in order to detect the formation of

-57-

functional calcium channels and to characterize the kinetics and other characteristics of the resulting currents. Pharmacological studies may be combined with the electrophysiological measurements in order to further characterize the calcium channels.

- 5 With respect to measurement of the activity of functional heterologous calcium channels, preferably, endogenous ion channel activity and, if desired, heterologous channel activity of channels that do not contain the desired subunits, of a host cell can be inhibited to a significant extent by chemical, pharmacological and electrophysiological means, including
10 the use of differential holding potential, to increase the S/N ratio of the measured heterologous calcium channel activity.

Thus, various combinations of subunits encoded by the DNA provided herein are introduced into eukaryotic cells. The resulting cells can be examined to ascertain whether functional channels are expressed
15 and to determine the properties of the channels. In particularly preferred aspects, the eukaryotic cell which contains the heterologous DNA expresses it and forms a recombinant functional calcium channel activity. In more preferred aspects, the recombinant calcium channel activity is readily detectable because it is a type that is absent from the
20 untransfected host cell or is of a magnitude and/or pharmacological properties or exhibits biophysical properties not exhibited in the untransfected cell.

The eukaryotic cells can be transfected with various combinations of the subunit subtypes provided herein. The resulting cells will provide a
25 uniform population of calcium channels for study of calcium channel activity and for use in the drug screening assays provided herein. Experiments that have been performed have demonstrated the inadequacy of prior classification schemes.

-58-

Preferred among transfected cells is a recombinant eukaryotic cell with a functional heterologous calcium channel. The recombinant cell can be produced by introduction of and expression of heterologous DNA or RNA transcripts encoding an α_1 subunit of a human calcium channel as a homomer, more preferably also expressing, a heterologous DNA encoding a β subunit of a human calcium channel and/or heterologous DNA encoding an α_2 subunit of a human calcium channel. Especially preferred is the expression in such a recombinant cell of each of the α_1 , β and α_2 subunits encoded by such heterologous DNA or RNA transcripts, and optionally expression of heterologous DNA or an RNA transcript encoding a γ subunit of a human calcium channel. The functional calcium channels may preferably include at least an α_1 subunit and a β subunit of a human calcium channel. Eukaryotic cells expressing these two subunits and also cells expressing additional subunits, have been prepared by transfection of DNA and by injection of RNA transcripts. Such cells have exhibited voltage-dependent calcium channel activity attributable to calcium channels that contain one or more of the heterologous human calcium channel subunits. For example, eukaryotic cells expressing heterologous calcium channels containing an α_2 subunit in addition to the α_1 subunit and a β subunit have been shown to exhibit increased calcium selective ion flow across the cellular membrane in response to depolarization, indicating that the α_2 subunit may potentiate calcium channel function. Cells that have been co-transfected with increasing ratios of α_2 to α_1 and the activity of the resulting calcium channels has been measured. The results indicate that increasing the amount of α_2 -encoding DNA relative to the other transfected subunits increases calcium channel activity.

Eukaryotic cells that express heterologous calcium channels containing a human α_1 subunit as a homomer, particularly the α_{1H} subunit,

-59-

or at least a human α_1 subunit and optionally an $\alpha_2\delta$ subunit and/or a human β subunit are preferred. Eukaryotic cells transformed with a composition containing DNA or an RNA transcript that encodes an α_1 subunit alone or in combination with a β and/or an α_2 subunit may be
5 used to produce cells that express functional calcium channels. Since recombinant cells expressing human calcium channels containing all of the human subunits encoded by the heterologous DNA or RNA are especially preferred, it is desirable to inject or transfect such host cells with a sufficient concentration of the subunit-encoding nucleic acids to
10 form calcium channels that contain the human subunits encoded by heterologous DNA or RNA. The precise amounts and ratios of DNA or RNA encoding the subunits may be empirically determined and optimized for a particular combination of subunits, cells and assay conditions.

In particular, mammalian cells have been transiently and stably
15 transfected with DNA encoding one or more human calcium channel subunits. Such cells express heterologous calcium channels that exhibit pharmacological and electrophysiological properties that can be ascribed to human calcium channels. Such cells, however, represent homogeneous populations and the pharmacological and
20 electrophysiological data provides insights into human calcium channel activity heretofore unattainable. For example, HEK cells that have been transiently transfected with DNA encoding the α_{1E-1} , α_{2b} , and β_{1-3} subunits. The resulting cells transiently express these subunits, which form calcium channels that have properties that appear to be a pharmacologically
25 distinct class of voltage-activated calcium channels distinct from those of L-, N-, T- and P-type channels. The observed α_{1E} currents were insensitive to drugs and toxins previously used to define other classes of voltage-activated calcium channels.

-60-

HEK cells that have been transiently transfected with DNA encoding α_{1B-1} , α_{2b} , and β_{1-2} express heterologous calcium channels that exhibit sensitivity to ω -conotoxin and currents typical of N-type channels. It has been found that alteration of the molar ratios of α_{1B-1} , α_{2b} and β_{1-2} introduced into the cells to achieve equivalent mRNA levels significantly increased the number of receptors per cell, the current density, and affected the K_d for ω -conotoxin.

The electrophysiological properties of these channels produced from α_{1B-1} , α_{2b} , and β_{1-2} was compared with those of channels produced by 10 transiently transfecting HEK cells with DNA encoding α_{1B-1} , α_{2b} and β_{1-3} . The channels exhibited similar voltage dependence of activation, substantially identical voltage dependence, similar kinetics of activation and tail currents that could be fit by a single exponential. The voltage dependence of the kinetics of inactivation was significantly different at all 15 voltages examined.

In certain embodiments, the eukaryotic cell with a heterologous calcium channel is produced by introducing into the cell a first composition, which contains at least one RNA transcript that is translated in the cell into a subunit of a human calcium channel. In preferred 20 embodiments, the subunits that are translated include an α_1 subunit of a human calcium channel. More preferably, the composition that is introduced contains an RNA transcript which encodes an α_1 subunit of a human calcium channel and also contains (1) an RNA transcript which encodes a β subunit of a human calcium channel and/or (2) an RNA 25 transcript which encodes an α_2 subunit of a human calcium channel. Especially preferred is the introduction of RNA encoding an α_1 , a β and an α_2 human calcium channel subunit, and, optionally, a γ subunit of a human calcium channel. Methods for *in vitro* transcription of a cloned DNA and injection of the resulting RNA into eukaryotic cells are

-61-

well known in the art. Transcripts of any of the full-length DNA encoding any of the subunits of a human calcium channel may be injected alone or in combination with other transcripts into eukaryotic cells for expression in the cells. Amphibian oocytes are particularly preferred for expression 5 of *in vitro* transcripts of the human calcium channel subunit cDNA clones provided herein. Amphibian oocytes that express functional heterologous calcium channels have been produced by this method.

Pharmacological and electrophysiological properties

As described in the examples, nucleic acid encoding α_{1H-1} and 10 nucleic acid encoding α_{1H-2} has been expressed in mammalian cells and in amphibian oocytes. Electrophysiological and pharmacological properties have been studied.

The biophysical properties of recombinant human α_{1H}^{2+} channels expressed in HEK293 cells and *Xenopus* oocytes are in good 15 agreement, indicating that the biophysical properties of recombinant human α_{1H} channels are independent of the expression system. Several biophysical characteristics support the conclusion that the human α_{1H} subunit is the pore-forming α_1 subunit of a T-type channel. The rates of activation, inactivation, and deactivation and the single-channel 20 conductance of α_{1H} -containing channels are within the ranges described for T-type channels. The conductance value of 9 pS measured in this study is near the value determined for rat α_{1G} -containing channels and is significantly lower than those determined for recombinant HVA channels. In addition, α_{1H} -containing channels conduct Ba²⁺ and Ca²⁺ equally well, 25 consistent with the finding that the conductance of T-type channels for Ba²⁺ and Ca²⁺ is nearly equivalent in most cell types.

α_{1H} -containing Ca²⁺ channels display a pharmacological profile differing from those of HVA channels. α_{1H} -mediated currents are inhibited by Ni²⁺, amiloride, and mibepradil (Ro 40-5967), agents shown to reduce

-62-

LVA currents in a number of cell types. In contrast, ethosuximide, an antiepileptic agent that inhibits LVA currents in some cell types, had no effect on α_{1H} -mediated currents. Although the L-type Ca^{2+} -channel modulators nimodipine and (-)-Bay K 8644 had little effect at a 5 concentration of $1\mu\text{M}$ on α_{1H} -containing channels, both compounds produced a marked inhibition at a concentration of $10\ \mu\text{M}$, consistent with their effects on T-type channels in rat hypothalamic neurons (Akaike et al., 1989). In summary, the pharmacological properties of α_{1H} -containing channels described here have many similarities to native T-type channels 10 studied in a variety of cell types. The pharmacological profiles of T-type channels vary considerably between cell types, and no hallmark pharmacological feature of T-type channels has been identified. These results are consistent with the finding herein that multiple α , subunits are responsible for the pharmacological profiles of a family of LVA, or T-type, 15 channels.

Assays and Clinical uses of the cells and calcium channels

Assays

Assays for identifying compounds that modulate calcium channel activity

20 Among the uses for eukaryotic cells which recombinantly express one or more subunits are assays for determining whether a test compound has calcium channel agonist or antagonist activity. These eukaryotic cells may also be used to select from among known calcium channel agonists and antagonists those exhibiting a particular calcium 25 channel subtype specificity and to thereby select compounds that have potential as disease- or tissue-specific therapeutic agents.

In vitro methods for identifying compounds, such as calcium channel agonist and antagonists, that modulate the activity of calcium

-63-

channels using eukaryotic cells that express heterologous human calcium channels are provided.

- In particular, the assays use eukaryotic cells that express homomeric or heteromeric human calcium channel subunits encoded by 5 heterologous DNA provided herein, for screening potential calcium channel agonists and antagonists which are specific for human calcium channels and particularly for screening for compounds that are specific for particular human calcium channel subtypes. Such assays may be used in conjunction with methods of rational drug design to select among 10 agonists and antagonists, which differ slightly in structure, those particularly useful for modulating the activity of human calcium channels, and to design or select compounds that exhibit subtype- or tissue-specific calcium channel antagonist and agonist activities. These assays should accurately predict the relative therapeutic efficacy of a 15 compound for the treatment of certain disorders in humans. In addition, since subtype-and tissue-specific calcium channel subunits are provided, cells with tissue- specific or subtype-specific recombinant calcium channels may be prepared and used in assays for identification of human calcium channel tissue- or subtype-specific drugs.
- 20 Desirably, the host cell for the expression of calcium channel subunits does not produce endogenous calcium channel subunits of the type or in an amount that substantially interferes with the detection of heterologous calcium channel subunits in ligand binding assays or detection of heterologous calcium channel function, such as generation of 25 calcium current, in functional assays. Also, the host cells preferably should not produce endogenous calcium channels which detectably interact with compounds having, at physiological concentrations (generally nanomolar or picomolar concentrations), affinity for calcium

-64-

channels that contain one or all of the human calcium channel subunits provided herein.

- With respect to ligand binding assays for identifying a compound which has affinity for calcium channels, cells are employed which
- 5 express, preferably, at least a heterologous α_1 subunit. Transfected eukaryotic cells which express at least an α_1 subunit may be used to determine the ability of a test compound to specifically bind to heterologous calcium channels by, for example, evaluating the ability of the test compound to inhibit the interaction of a labeled compound known
- 10 to specifically interact with calcium channels. Such ligand binding assays may be performed on intact transfected cells or membranes prepared therefrom.

- The capacity of a test compound to bind to or otherwise interact with membranes that contain heterologous calcium channels or subunits
- 15 thereof, preferably α_{1H} subunit-containing calcium channels, may be determined by using any appropriate method, such as competitive binding analysis, such as Scatchard plots, in which the binding capacity of such membranes is determined in the presence and absence of one or more concentrations of a compound having known affinity for the calcium
- 20 channel. Where necessary, the results may be compared to a control experiment designed in accordance with methods known to those of skill in the art. For example, as a negative control, the results may be compared to those of assays of an identically treated membrane preparation from host cells which have not been transfected with one or
- 25 more subunit-encoding nucleic acids.

The assays involve contacting the cell membrane of a recombinant eukaryotic cell which expresses at least one subunit of a human calcium channel, preferably at least an α_1 subunit of a human calcium channel, with a test compound and measuring the ability of the test compound to

-65-

specifically bind to the membrane or alter or modulate the activity of a heterologous calcium channel on the membrane.

In preferred embodiments, the assay uses a recombinant cell that has a calcium channel containing an α_1 subunit of a human calcium channel. In other preferred embodiments, the assay uses a recombinant cell that has a calcium channel containing an α_1 subunit of a human calcium channel in combination with a β subunit of a human calcium channel and/or an α_2 subunit of a human calcium channel. Recombinant cells expressing heterologous calcium channels containing each of the α_1 , 10 and optionally a β and/or α_2 human subunits, and, optionally, a γ subunit of a human calcium channel are especially preferred for use in such assays.

In certain embodiments, the assays for identifying compounds that modulate calcium channel activity are practiced by measuring the calcium channel activity of a eukaryotic cell having a heterologous, functional calcium channel when such cell is exposed to a solution containing the test compound and a calcium channel-selective ion and comparing the measured calcium channel activity to the calcium channel activity of the same cell or a substantially identical control cell in a solution not containing the test compound. The cell is maintained in a solution having a concentration of calcium channel-selective ions sufficient to provide an inward current when the channels open. Recombinant cells expressing calcium channels that include each of the α_1 , β and α_2 human subunits, and, optionally, a γ subunit of a human calcium channel, are especially preferred for use in such assays. Methods for practicing such assays are known to those of skill in the art. For example, for similar methods applied with *Xenopus laevis* oocytes and acetylcholine receptors, see, Mishina *et al.* ((1985) *Nature* 313:364) and, with such oocytes and sodium channels (see, Noda *et al.* (1986) *Nature* 322:826-828). For

-66-

similar studies which have been carried out with the acetylcholine receptor, see, e.g., Claudio *et al.* ((1987) *Science* 238:1688-1694). Transcription based assays are also contemplated herein.

- Functional recombinant or heterologous calcium channels may be identified by any method known to those of skill in the art. For example, electrophysiological procedures for measuring the current across an ion-selective membrane of a cell, which are well known, may be used. The amount and duration of the flow of calcium-selective ions through heterologous calcium channels of a recombinant cell containing DNA encoding one or more of the subunits provided herein has been measured using electrophysiological recordings using a two electrode and the whole-cell patch clamp techniques. In order to improve the sensitivity of the assays, known methods can be used to eliminate or reduce non-calcium currents and calcium currents resulting from endogenous calcium channels, when measuring calcium currents through recombinant channels. For example, the DHP Bay K 8644 specifically enhances L-type calcium channel function by increasing the duration of the open state of the channels (see, e.g., Hess, J.B., *et al.* (1984) *Nature* 311:538-544). Prolonged opening of the channels results in calcium currents of increased magnitude and duration. Tail currents can be observed upon repolarization of the cell membrane after activation of ion channels by a depolarizing voltage command. The opened channels require a finite time to close or "deactivate" upon repolarization, and the current that flows through the channels during this period is referred to as a tail current. Because Bay K 8644 prolongs opening events in calcium channels, it tends to prolong these tail currents and make them more pronounced.

In practicing these assays, stably or transiently transfected cells or injected cells that express voltage-dependent human calcium channels containing one or more of the subunits of a human calcium channel

-67-

desirably may be used in assays to identify agents, such as calcium channel agonists and antagonists, that modulate calcium channel activity. Functionally testing the activity of test compounds, including compounds having unknown activity, for calcium channel agonist or antagonist

- 5 activity to determine if the test compound potentiates, inhibits or otherwise alters the flow of calcium ions or other ions through a human calcium channel can be accomplished by (a) maintaining a eukaryotic cell which is transfected or injected to express a heterologous functional calcium channel capable of regulating the flow of calcium channel-
- 10 10 selective ions into the cell in a medium containing calcium channel-selective ions (i) in the presence of and (ii) in the absence of a test compound; (b) maintaining the cell under conditions such that the heterologous calcium channels are substantially closed and endogenous calcium channels of the cell are substantially inhibited (c) depolarizing the
- 15 15 membrane of the cell maintained in step (b) to an extent and for an amount of time sufficient to cause (preferably, substantially only) the heterologous calcium channels to become permeable to the calcium channel-selective ions; and (d) comparing the amount and duration of current flow into the cell in the presence of the test compound to that of
- 20 20 the current flow into the cell, or a substantially similar cell, in the absence of the test compound.

The assays thus use cells, provided herein, that express heterologous functional calcium channels and measure functionally, such as electrophysiologically, the ability of a test compound to potentiate, antagonize or otherwise modulate the magnitude and duration of the flow of calcium channel-selective ions, such as Ca^{2+} or Ba^{2+} , through the heterologous functional channel. The amount of current which flows through the recombinant calcium channels of a cell may be determined directly, such as electrophysiologically, or by monitoring an independent

-68-

reaction which occurs intracellularly and which is directly influenced in a calcium (or other) ion dependent manner. Any method for assessing the activity of a calcium channel may be used in conjunction with the cells and assays provided herein. For example, in one embodiment of 5 the method for testing a compound for its ability to modulate calcium channel activity, the amount of current is measured by its modulation of a reaction which is sensitive to calcium channel-selective ions and uses a eukaryotic cell which expresses a heterologous calcium channel and also contains a transcriptional control element operatively linked for expression 10 to a structural gene that encodes an indicator protein. The transcriptional control element used for transcription of the indicator gene is responsive in the cell to a calcium channel-selective ion, such as Ca^{2+} and Ba^{2+} . The details of such transcriptional based assays are described in commonly owned PCT International Patent Application No. PCT/US91/5625, filed 15 August 7, 1991, which claims priority to copending commonly owned allowed U.S. Application Serial No. 07/563,751, filed August 7, 1990; see also, commonly owned published PCT International Patent Application PCT US92/11090, which corresponds to co-pending U.S. Applications Serial Nos. 08/229,150 and 08/244,985. The contents of these 20 applications are herein incorporated by reference thereto.

Biophysical and pharmacological properties of α_{1H} subunits

HEK cells were transfected with DNA and oocytes injected with nucleic acid provided herein. The cell expressed calcium channels, which were then characterized electrophysiologically and pharmacologically.

25 These results are described in the examples. Both splice variants formed calcium channels that exhibit properties associated with T-type channels. Variant-specific properties were observed.

These observed differences in the amino acid sequences of α_{1H-1} and α_{1H-2} will result in marked differences in susceptibility of these

-69-

- receptors to cellular regulation, particularly since the observed region of sequence divergence resides in the cytosolic linker region between domains I and II and the analogous sequence region in high-voltage activated calcium channels has been implicated in binding of cytosolic regulatory proteins. Observed differences in biophysical properties of α_{1H} -₁ and α_{1H-2} are also likely indicative of differences in the sensitivity of these two different channel subunits to pharmaceutical compounds.
- Thus, it seems likely that low-voltage activated calcium channels containing either the α_{1H-1} or the α_{1H-2} subunit will be subject to different regulatory controls, and different profiles of susceptibility to pharmaceutical compounds. For example, amiloride blocks the T-type current in neuroblastoma cells with an IC₅₀ of ~ 50 μ M, whereas in hippocampal neurons 300 μ M amiloride reduces the T-type current by only 40%.
- In this respect, each a different α_{1H} channel is a separate screening target for development of pharmaceutical drug compounds. Differential effects of drugs on different neural cells and in different neural tissues can be understood based on different patterns of expression of α_{1H-1} and/or α_{1H-2} *in vivo* and will provide a means to identify drugs specific for each subtype and associated disorders or conditions. The observed sequence variation in α_{1H} subunits explains observed pharmacological variability of T-type calcium channels in different native tissues, providing a useful tool to identify where the respective α_{1H-1} and α_{1H-2} subunit is expressed to use screening assays to identify targeted therapeutic drug candidates.

Differences in α_{1H-1} and α_{1H-2} functionality and expression in different tissues provides basis for using recombinant cells expressing calcium channels having either the α_{1H-1} or α_{1H-2} subunit. Agonists and antagonists capable of differentially affecting calcium channels containing

-70-

- these two different subunits should be useful for targeting therapeutic intervention into selected neural locations, e.g., to cardiovascular neurons and cardiac pacemaker neurons expressing α_{1H-2} . Calcium channels formed from α_{1H} subunits open at small changes in membrane potential, but only
- 5 allow moderate Ca^{2+} influx before closing. By allowing moderate influx of divalent ions the α_{1H} containing channels are likely to:
- (i) participate in pathways triggering changes in gene expression in response to subtle change in membrane potential difference, i.e., in neuronal and non-neuronal cell types (e.g., in activation
- 10 of immune cells such as T-cells, in activation of kidney and liver cells in response to metabolic changes;
- (ii) exert subtle controls over the overall excitability or accessibility of neurons to synaptic transmission, such as in determining which neurons will respond to stimuli, and to what extent, such as in
- 15 peripheral neurons and ganglia;
- (iii) determine the extent of neural responses to stimuli such as chronic pain;
- (iv) regulate the sensitivity of neurons in critical neural centers so that neuronal cells in these centers are protected from the adverse effects
- 20 associated with excessive bursts of firing (e.g., in the cardiac pacemaker);
- (v) act to set the steady state pattern of inactivation of neurons in different regions of the brain, (e.g., in response to sleep, sex, emotion, depression, fatigue and the other stimuli or conditions).

25 **Electrophysiology of cells that express channels containing the α_{1H-1} subunit**

Expression of recombinant α_{1H-1} channels

Following transient transfection of HEK293 cells with a DNA encoding the α_{1H} subunit, Ba^{2+} currents that were rapidly activating and inactivating were observed. Ba^{2+} currents (15 mM) elicited by step

-71-

depolarizations to various test potentials from a holding potential of -90-mV were measured. Currents were activated at a test potential of -50 mV, peaked between -20 and -10 mV, and reversed at a membrane potential more positive than +60 mV. Similar results were obtained with

5 Ca^{2+} (15 mM) as the charge carrier.

One hallmark of LVA channels is their slow rate of deactivation, which is reflected in a slow decay of tail currents. The time constant of this decay is ~10-fold slower for LVA channels (2-12 ms) than for HVA channels <300 μs . A slow decay of $\alpha_{1\text{H}-1}$ mediated tail currents over a

10 period of ~15 ms was observed. In contrast to the monoexponential decay of the tail currents reported for many native T-type Ca^{2+} channels, tail currents from $\alpha_{1\text{H}-1}$ channels showed a biexponential decay. At a test potential of -20 mV, the decay rate of the slow component, comprising 88.1 \pm 33.8% of the total current, was 2.1 ± 1.06 ms ($n = 6$), which is

15 similar to those observed in native T-type Ca^{2+} channels. The decay rate of the faster component was 0.64 ± 0.21 ms ($n = 6$).

Whole-cell patch clamp recordings were performed on HEK293 cells transiently expressing the human $\alpha_{1\text{H}-1}$ subunit. Step-depolarizations elicited inward Ba^{2+} currents that activate slowly and inactivate rapidly

20 (2.8 \pm 0.6 and 16.9 \pm 5.3 ms, at -20 mV). The activation curve of $\alpha_{1\text{H}-1}$ is shifted to the left ($V_{1/2}:-29.5$ mV) compared to HVA Ca^{2+} channels. The tails currents of $\alpha_{1\text{H}-1}$ -containing channels decay slowly ($\tau_1, \tau_2 \pm 1.0, 0.6, \pm 0.2$ ms). The permeability for Ba^{2+} and Ca^{2+} was virtually identical. The single channel conductance, determined with 110 mM Ba^{2+}

25 as charge carrier, is 9 pS.

The voltage dependence of activation of $\alpha_{1\text{H}-1}$ containing Ca^{2+} channels was determined from tail-current analysis. Normalized tail-current amplitudes were plotted as a function of test potential and revealed a biphasic activation curve that was well fitted by the sum of

-72-

two Boltzmann functions (Figure 1). The potentials for half-maximal activation of the individual Boltzmann terms were as follows: $V_{1/2,A}$: -25.1 ± 3.3 mV; and $V_{1/2,B}$: +25.5 ± 3.9 mV (n = 11). A value similar to $V_{1/2,A}$ has been reported previously for voltage dependence of activation of

- 5 T-type Ca^{2+} channels in the human TT cell line (-27 mV). The value of the second Boltzmann term $V_{1/2,B}$ is somewhat similar to that reported for HVA Ca^{2+} channels. Using a similar protocol, tail currents of HVA Ca^{2+} channels decay with time constants of <300 μs , whereas with α_{1H} the most prominent at test potentials close to $V_{1/2,B}$. The availability of α_{1H} 10 containing Ca^{2+} channels for opening was dependent on the membrane for potential as shown in Fig. 1. The potential for half-maximal steady-state inactivation ($V_{1/2}$) was -63.2 ± 2.0 mV (n = 9).

The rapid inactivation of α_{1H} Ca^{2+} channels was strongly voltage-dependent. The current decay was best described with an exponential function with time constants ranging from 42.2 ± 7.8 to 8.8 ± 3.8 ms at membrane potentials between -50 and +30 mV (n = 6; data not shown). Activation kinetics of α_{1H} Ca^{2+} channels were also voltage-dependent with time constants ranging from 9.9 ± 4.7 to 0.9 ± 0.3 ms for membrane potentials between -50 and +30 mV (n = 8; data not shown). α_{1H} Ca^{2+} channels inactivated completely during the 150-ms depolarization. Recovery from inactivation occurred within a period of ~3 s with a fast component ($\tau = 37 \pm 9 \text{ ms}$; 16.5 ± 4.6% of all channels) and a slow component ($\tau = 37 \pm 61 \text{ ms}$; 78 ± 8.5% of all channels; n = 3; data not shown). To confirm the biophysical properties 25 of recombinant α_{1H} channels observed in whole-cell recordings from HEK293 cells, the functional expression of α_{1H} in *Xenopus* oocytes was tested. Substantial currents (<1 μA) after injection of α_{1H} transcripts alone was observed. The activation and inactivation kinetics, as well as

-73-

the steady-state inactivation properties, were similar to those obtained in HEK293 cells (see EXAMPLES).

- Single-channel properties of $\alpha_{1H}Ca^{2+}$ channels in HEK293 cells were determined in cell-attached recordings with 110 mM Ba²⁺ as the charge carrier. Single-channel recordings at a test potential of -30 mV from a patch that contains at least three α_{1H} showed that channel openings occurred in bursts and were clustered mainly in the first third of the 100-ms depolarizing pulse, especially with stronger depolarizations.
- Occasionally, channel activity was spread throughout the entire sweep.
- 10 The time course of the ensemble-averaged current recorded at -30mV in 110 mM Ba²⁺ was similar to the α_{1H} whole-cell Ba²⁺ current recorded at -40 mV in 15 mM Ba²⁺. The currents were compared at different potentials to compensate for the shift in the activation curve to more positive potentials due to the increase in divalent concentration. The
- 15 unitary current-voltage relationship yielded a unitary slope conductance of 9.06 ± 0.22 pS (n=4).

Summary of Electrophysiologic Characteristics

- The biophysical properties of calcium channels containing the human α_{1H} subunit were evaluated. Whole cell recordings from transiently transfected HEK293 cells indicate that the current-voltage relationship, permeability to Ca²⁺ and Ba²⁺, kinetics of activation, and single channel conductance of calcium channels containing α_{1H} subunits were similar to those of native T-type calcium channels in tissues. Tail currents from A_{1H} channels showed a bi-exponential decay, exhibiting a fast and a slower component. At very negative membrane potentials (-150 to -100 mV) the fast component (τ : 200-450 μ s) dominated the inactivation process, while at depolarizing potentials >-50 mV the slower component (2-3 ms) dominates. At the resting membrane potential, i.e., ≤-80 mV, both components contribute equally.

-74-

Pharmacological properties

The pharmacological properties of α_{1H} -containing calcium channels were also consistent with those observed for native T-type calcium channels. Interestingly, the sensitivity of α_{1H-1} -containing calcium 5 channels to Cd^{2+} or Amiloride was about 10-fold lower when expressed in HEK293 cells than when expressed in *Xenopus* oocytes.

The data indicate that human α_{1H} calcium channel subunits have properties consistent with that of native T-type calcium channels and, as such, α_{1H} represent a member in the rapidly growing family of low-voltage 10 activated calcium channels.

Assays for diagnosis of LVA-calcium channel mediated disorders and clinical applications

Clinical applications

In relation to therapeutic treatment of various disease states, the 15 availability of DNA encoding human calcium channel subunits permits identification of any alterations in such genes (e.g., mutations) which may correlate with the occurrence of certain disease states. In addition, the creation of animal models of such disease states becomes possible, by specifically introducing such mutations into synthetic DNA fragments that 20 can then be introduced into laboratory animals or *in vitro* assay systems to determine the effects thereof.

Also, genetic screening can be carried out using the nucleotide sequences as probes. Thus, nucleic acid samples from subjects having pathological conditions suspected of involving alteration/modification of 25 any one or more of the calcium channel subunits can be screened with appropriate probes to determine if any abnormalities exist with respect to any of the endogenous calcium channels. Similarly, subjects having a family history of disease states related to calcium channel dysfunction

-75-

can be screened to determine if they are also predisposed to such disease states.

Disorders and for which screening assays can be developed and also for which candidate compounds for treatment of the disorders include, but are not limited to: cardiac treatments, such as myocardial infarct, cardiac arrhythmia, heart failure, and angina pectoris. Identified compounds will be useful in: (a) adjunctive therapies for reestablishing normal heart rate and cardiac output following traumatic injury, heart attack and other heart injuries; (b) treatments of myocardial infarct (MI), post-MI and in an acute setting. The compounds may be effective to increase cardiac contractile force, such as that measured by left ventricular enddiastolic pressure, and without changing blood pressure or heart rate. In an acute setting the compounds may be effective to decrease formation of scar tissue, such as that measured by collagen deposition or septal thickness, and without cardiodepressant effects. The identified compounds will be useful for and assays for diagnosis and compound screening will be useful in connection with vascular treatments and hypertension, for identifying compounds useful in regulating vascular smooth muscle tone, including vasodilating or vasoconstricting. Such compounds can be used in (a) treatments for reestablishing blood pressure control, e.g., following traumatic injury, surgery or cardiopulmonary bypass, and in prophylactic treatments designed to minimizing cardiovascular effects of anaesthetic drugs; (b) treatments for improving vascular reflexes and blood pressure control by the autonomic nervous system. Other conditions include urologic, for identifying compounds useful in: (a) treating and restoring renal function following surgery, traumatic injury, uremia and adverse drug reactions; (b) treating bladder dysfunctions; and (c) uremic neuronal toxicity and hypotension in patients on hemodialysis; reproductive conditions, for

-76-

- identifying compounds useful in treating: (a) disorders of sexual function including impotence; and (b) alcoholic impotence (under autonomic control that may be subject to T-channel controls); hepatic, for identifying compounds useful in treating and reducing neuronal toxicity and
- 5 autonomic nervous system damage resulting from acute over-consumption of alcohol; neurological conditions for identifying compounds useful in treating: (a) epilepsy and diencephalic epilepsy; (b) Parkinson disease; (c) aberrant temperature control, such as abnormalities of shivering and sweat gland secretion and peripheral
- 10 vascular blood supply;
- (d) aberrant pituitary and hypothalamic functions including abnormal secretion of noradrenaline, dopamine and other hormones; respiratory conditions, for identifying compounds useful in treating abnormal respiration, such as, post-surgical complications of anesthetics; endocrine
- 15 disorders for identifying compounds useful in treating aberrant secretion of hormones such as treatments for overproduction of hormones including insulin, thyroxin, and adrenalin.

EXAMPLES

The following examples are included for illustrative purposes only
20 and are not intended to limit the scope of the invention.

EXAMPLE 1: ISOLATION OF DNA ENCODING THE HUMAN CALCIUM CHANNEL α_{1H-1} SUBUNIT

Using mRNA and TT cells, a degenerate PCR approach was used to isolate nucleic acid encoding an α_1 subunit. Nucleic acid encoding an α_{1H-1} subunit and nucleic acid encoding a subunit designated as α_{1H-2} was isolated. The nucleic acid was introduced into HEK293 cells and *Xenopus* oocytes and voltage gated calcium channels were expressed. These channels exhibit pharmacological and electrophysiological properties consistent with native LVA, T-type, channels.

-77-

A. Materials and Methods

Nucleic acid amplification:

- The following sense strand 20-mer PCR primer, corresponding to nucleotides 1945-1964 of DNA encoding a human α_{1E} subunit, was synthesized:
- 5 AC(A/C/G/T)GTGTT(C/T)CAGATCCTGAC (Primer-1) SEQ ID NO. 4
- An antisense 22-nucleotide PCR primer, corresponding to nucleotides 3919 through 3940 of human α_{1E} , was also synthesized:
- T(C/T)CCCTTGAAGAGCTG(A/C/G/T)ACCCC (Primer-2) SEQ ID NO. 1
- 10 The sense and the antisense primers were used in amplification reactions with cDNA prepared from TT cells and Pfu DNA polymerase (Stratagene Inc., San Diego, CA).

Reaction conditions: 95°C for 5 minutes followed by 5 cycles of 20 seconds each at 95°C; then 20 seconds at 42°C; 2.5 minutes at 15 72°C; and, 30 cycles of 20 seconds each at 95°C followed by 20 seconds at 50°C and finally 2.5 minutes at 72°C. The product of the reaction is referred to herein (below) as "the original PCR products."

- A second 5' degenerate oligonucleotide primer was designed corresponding to a portion of the sequence reported for *C. elegans*, 20 cosmid C54D2 (Genebank accession #U37548), as a portion of that sense strand sequence which aligns with a portion of the human α_{1E} subunit DNA sequence between nucleotide 3598 and 3614. This primer had the following sequence:
- GA(A/G)ATGATGATGAA(A/G)GT (Primer-3) SEQ ID NO. 10
- 25 Primer-3 was used in a nested amplification reaction with the original PCR products and the Primer-2.

-78-

Isolation and Characterization of the clones: A recombinant cDNA library was constructed in phage vector λ gt10 using poly(A)⁺-selected RNA from the TT cell line. Approximately 1.5×10^6 were screened with the PCR fragment under high stringency (hybridization: 50% formamide, 5 5X SSPE, 5X Denhardts, 0.2% SDS, 200 μ g/ml herring sperm DNA for 16-18 hrs. at 42°C; wash: 6 washes of 30 minutes each in 0.1X SSPE, 0.1% SDS at 65°C).

Northern blot analysis: Multiple tissues were screened in Northern blots using 2 μ g of poly(A)⁺ RNA per lane (Clontech, Palo Alto, CA). Blots 10 were probed at high stringency, as described above, with labeled fragments generated from the full-length α_{1H} cDNA, i.e., nucleotide -6 to 7390.

Western blot analysis: Cellular membranes (total) were isolated from HEK293 cells expressing different α_{1H} subunits; membrane proteins 15 were separated by SDS-PAGE; transferred to nitrocellulose; and, blotted using a polyclonal anti- α_{1H} antisera and TBS-T buffer. Blotted proteins were visualized using the Lumiglo reagent kit (KPL, Gaithersburg, MD) according to the manufacturer's instructions.

B. RNA isolation

20 Human medullary thyroid carcinoma cells (TT cells; ATCC Accession No. CRL1803) were grown in DMEM medium supplemented with 10 % fetal calf serum at 37 °C in 5% CO₂ atmosphere and total cytoplasmic RNA was isolated from forty 10 cm plates using a "midi-prep" RNA isolation kit (Qiagen) as per the manufacturer's instructions. 25 The protocol entails the use of the detergent NP40 which lyses the cell membrane under mild conditions such that the nuclear membrane remains intact thereby eliminating incompletely spliced RNA transcripts from the preparation.

-79-

PolyA + RNA was isolated from total cytoplasmic RNA using two passes over an oligo(dT)-cellulose column. Briefly, 2-3 mg of total cytoplasmic RNA was resuspended in NETS buffer (500 mM NaCl 10 mM EDTA, 10 mM Tris, pH 7.4, 0.2% SDS) and passed slowly over a column 5 containing 0.5 g of oligo(dT)-cellulose (Collaborative Research) equilibrated in NETS buffer. The column was washed with 30 mls of NETS buffer and polyA + RNA was eluted using about 3 mls of ETS buffer (10 mM EDTA, 10 mM Tris, pH 7.4, 0.2% SDS). The ionic strength of the polyA + RNA-containing buffer was adjusted to 500 mM 10 NaCl and passed over a second oligo(dT)-cellulose column essentially as described above. Following elution from the second column, the polyA + RNA was precipitated twice in ethanol and resuspended in H₂O.

C. Library construction

Double stranded cDNA (dscDNA) was synthesized according to 15 standard methods (see, e.g., Gubler *et al.* (1985) *Gene* 25:263-269; Lapeyre *et al.* (1985) *Gene* 37:215-220). Briefly, first strand cDNA synthesis was initiated using TT cell polyA + RNA as a template and using random primers and Moloney Murine Leukemia Virus reverse transcriptase (MMLV-RT). The second strand was synthesized using a 20 combination of *E. coli* DNA polymerase, *E. coli* DNA ligase and RNase H.

Regions of single stranded DNA were converted to double-stranded DNA using T4 DNA polymerase generating blunt-ended double stranded fragments. EcoRI restriction endonuclease site adapters:

25 5' CGTGCACGTCACGCTAG 3' (SEQ ID NO. 2)
3' GCACGTGCAGT GCGATCTTAA 5' (SEQ ID NO. 3)
were ligated to the double-stranded cDNA using a standard protocol (see, e.g., Sambrook *et al.* (1989) IN: *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Chapter 8). The double-stranded DNA with the *Eco*RI adapters ligated was purified away from the free or

-80-

unligated adapters by column chromatography using Sepharose CL-4B resin followed by size selection of the cDNA on a 1.2% agarose gel. After visualizing the resolved DNA using ethidium bromide, two fractions of cDNA, >3.5 kb and 1.0-3.5 kb, were isolated from the gel and
5 inserted into the vector λgt10.

The ligated λgt10 containing the cDNA insert was packaged into λ phage virions *in vitro* using the Gigapack III Gold packaging (Stratagene, La Jolla, CA) kit. Using this method, phage libraries of ~1.5 × 10⁶ recombinants for cDNA >3.5 kb fraction and ~10 × 10⁶ recombinants
10 for DNA fraction between 1.0 and 3.5 kB were obtained.

D. **Isolation of DNA encoding a portion of human α₁ calcium channel subunits**

DNA encoding a small region of human α₁ subunits encoded in TT cells was isolated using degenerate PCR-based amplification (e.g., see
15 Williams *et al.* (1994) J. Biol. Chem. **269**:22347-22357). These amplified fragments were used to generate DNA probes for the isolation of DNA encoding a full-length human α_{1H} calcium channel subunit.

As noted above, two sets of degenerate oligonucleotides were synthesized based on the flanking regions of the II-III loop known to share
20 a high degree of sequence identity amongst known human α₁ calcium channel subunits: 1) two degenerate oligonucleotides complementary to the regions of the IIS5-IIS6 loop were synthesized as 5' upstream primers (SEQ ID NOs. 4 and 5); and 2) two degenerate oligonucleotides complementary to a portion of the IIS5 transmembrane segment were
25 synthesized as 3' downstream primers (SEQ ID NOs. 6 and 7).

These degenerate oligonucleotides were used as primer pairs in nested PCR amplification reactions using Pfu DNA polymerase (Stratagene, La Jolla, CA) and reactions were performed according to the manufacturer's instructions. Samples were placed in a commercially

-81-

available thermocycler (Perkin-Elmer) and the amplification reactions were set as follows: 1 cycle, 5 min @ 95 °C; 5 cycles, 20 sec @ 95 °C/20 sec @ 42 °C/2.5 min @ 72 °C; 30 cycles, 20 sec @ 95 °C/20 sec @ 50 °C/2.5 min @ 72 °C; and 1 cycle, 7 min @ 72 °C. Amplified DNA products were subjected to electrophoresis on an agarose gel and gel purified using standard methods.

E. Amplification of DNA encoding a portion of human α_{1H} calcium channel subunit

To amplify DNA encoding a portion of the human α_{1H} calcium channel subunit, three degenerate oligonucleotides (SEQ ID NOs. 8-10) that share partial complementarity to a region of Domain III were synthesized as 5' primers. This region is encompassed within all of the amplified α_1 -encoding fragments of Section C above. Two oligonucleotides based on sequences in IIIS2 (SEQ ID NOs. 8 and 10) were used as 5' primers in conjunction with the 3'IIIS5 transmembrane primers used in the initial PCR reactions (SEQ ID NOs. 6 and 7 to amplify DNA encoding a portion of the human α_{1H} subunit using the amplified products as templates.

The amplified DNA products were subcloned into the pCR-Blunt vector (Invitrogen), plasmid DNA was purified from isolated transformants and the DNA sequence of each insert was determined. A 340 bp fragment (SEQ ID NO. 48; nt 4271 to 4610 of SEQ ID NO. 49) that shares approximately 55-60% sequence identity to known human α_1 calcium channel subunits was identified. This DNA fragment, designated PCR1, was used as a DNA probe to isolate DNA encoding a human α_{1H} calcium channels subunit.

-82-

F. Isolation and characterization of individual clones

Hybridization and Washing Conditions

Hybridization of radiolabelled nucleic acids to immobilized DNA for the purpose of screening cDNA libraries, DNA Southern transfers, or 5 northern transfers was routinely performed in standard hybridization conditions (hybridization: 50% deionized formamide, 200 µg/ml sonicated herring sperm DNA (Cat #223646, Boehringer Mannheim Biochemicals, Indianapolis, IN), 5 x SSPE, 5 x Denhardt's, 42° C.; wash :0.2 x SSPE, 0.1% SDS, 65° C). The recipes for SSPE and Denhardt's 10 and the preparation of deionized formamide are described, for example, in Sambrook *et al.* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Chapter 8). In some hybridizations, lower stringency conditions were used in that 10% deionized formamide replaced 50% deionized formamide described for the standard 15 hybridization conditions.

The washing conditions for removing the non-specific probe from the filters was either high, medium, or low stringency as described below:

- 1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C
- 2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C
- 20 3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C.

It is understood that equivalent stringencies may be achieved using alternative buffers, salts and temperatures.

Approximately 1.5×10^5 recombinants of the TT cell phage library containing inserts > 3.5 kb were plated and duplicate lifts prepared from 25 each plate. The lifts were probed with radiolabelled PCR1 using standard hybridization conditions, the filters were washed and approximately 100 positive plaques were identified. Initially, 5 positives, λ1.201-λ1.205, were selected for plaque purification and characterization.

-83-

Restriction endonuclease digestion of purified DNA isolated from 11.201-11.205 with EcoRI indicated that clone 1.201 contains the original insert of ~350 bp PCR1 fragment, whereas clones 1.202, 1.203, 1.204 and 1.205 contain inserts of ~1100, ~4000, ~2600 and ~2200 5 nt, respectively.

F. Isolation of DNA encoding a human α_{1H} calcium channel subunit and construction of DNA encoding a full-length α_{1H} subunit

1. Reference list of partial human α_{1H} clones

The full-length α_{1H} cDNA sequence is set forth in SEQ ID NO. 49. A 10 list of partial cDNA clones used to characterize the α_{1H} sequence and the nucleotide position of each clone relative to the full-length α_{1H} cDNA sequence is shown below. The isolation and characterization of these clones are described below.

1.305	nt 1 to 3530 of SEQ ID No. 49
15 1.205	nt 2432 to 4658 of SEQ ID No. 49
1.204	nt 3154 to 5699 of SEQ ID NO. 49
PCR1	nt 4271 to 4610 of SEQ ID NO. 49
1.202	nt 4372 to 5476 of SEQ ID No. 49
1.203	nt 3891 to 7898 of SEQ ID No. 49

20 2. Characterization of the clones

DNA sequencing of each insert revealed that clone 1.202 contains 1,105 bp insert corresponding to nt 4372 to 5476 of SEQ ID No. 49; clone 1.203 contains 4,008 bp insert corresponding to nt 3891 to 7898 of SEQ ID No. 49; clone 1.204 contains 2,546 bp insert corresponding to 25 nt 3154 to 5699 of SEQ ID NO. 49; and clone 1.205 contains 2,227 bp insert corresponding to nt 2432 to 4658 of SEQ ID No. 49. These four DNA clones contain overlapping sequences that encode an open reading frame of approximately 6.6 kb that encodes a majority of the α_{1H} subunit,

-84-

including the entire carboxy terminus and the in-frame translational stop codon.

DNA encoding the 5'-end of the human α_{1H} calcium channel subunit was isolated using a 548 bp EcoRI-NcoI restriction endonuclease fragment from the 5'-end of clone 1.205 (nt 2432 to nt 2979 SEQ ID No. 49) to rescreen the TT cell cDNA library under high stringency conditions.
5 Briefly, DNA encoding the amino terminus of human α_{1H} calcium containing inserts of >3.5 kb was incubated with the purified restriction fragment and hybridized at 42 °C and washed under high stringency
10 conditions as described above.

One recombinant, clone 1.305, was identified that contains a 3,530 nucleotide insert that shares at its 3' end approximately 1.1 kb of sequence identity with the 5'-end of clone 1.205 (~nt 2432 to nt 3530 SEQ ID No. 49) and also contains 2.4 kb of sequence upstream of the
15 EcoRI site located at the 5'-end of clone 1.205 (nt 2433 to 2438 SEQ ID No. 49). This sequence encodes the ATG initiation codon (nt 249 to nt 251 SEQ ID No. 12) and 1,094 amino acids of the amino terminus of the α_{1H} subunit as well as 248 bp of 5'-untranslated sequence, including a consensus ribosome binding site (nt 244 to nt 248 of SEQ ID No. 49).

20 Two other recombinants were also identified (SEQ ID NOs. 13 and 14) that share approximately 1.1 kb of sequence identity with the 3'-end of clone 1.305 but differ in the length of the DNA sequence corresponding to the extended intracellular loop located between transmembrane Domains I and II.

25 **3. Construction of a full-length $\alpha_{1H.1}$ -encoding DNA clone**

Portions of these partial cDNA clones can be ligated to generate a full-length α_{1H} cDNA using common restriction endonuclease sites shared amongst the α_{1H} -encoding fragments. A full-length α_{1H} encoding clone was constructed by 1) combining the DNA encoding the 5'-end of α_{1H} present

-85-

- in clone 1.305 with clone 1.205 using a common EcoRI site (nt 2433 to 2438 SEQ ID No. 49); and 2) the resulting clone, which encodes the amino terminus of α_{1H} was combined with the carboxyl terminal sequences of α_{1H} encoded in clone 1.203 using the common EcoRV
- 5 restriction endonuclease site shared between clone 1.205 and 1.203 (nt 4517-4522 of SEQ ID NO. 12). The resulting full-length human α_{1H} calcium channel subunit is 2,353 amino acid residues in length (SEQ ID NO. 12). The expression construct was assembled in pCDNA1 (Invitrogen, San Diego, CA) and included a consensus ribosome binding
- 10 site (RBS) followed by the full-length α_{1H} coding sequence (see, for a description of pcDNA1-based vectors containing the RBS, see, e.g., in International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097, U.S. Patent No. 5,851,824, and U.S. Patent No. 5,846,756). The resulting construct was designated
- 15 pcDNA1 α_{1H} RBS.

EXAMPLE 2: Cloning of human calcium channel α_{1H-2} subunit

- T-type channel currents are heterogeneous among different cell types, with varying biophysical and pharmacological profiles, and as shown in this and the following examples can result from expression of
- 20 different α_1 subunit subtypes in different cells.

A. Cloning of α_{1H-2}

- As described above, PCR Primers-1 and -2, chosen based on an alignment of the human α_{1A} - α_{1E} sequences in the central cytoplasmic loop II/III region and Primer-3 (GA(A/G)ATGATGATGAA(A/G)GT SEQ ID NO. 10) was chosen after considering α_1 -related *C. elegans* sequences in
- 25 cosmid C54D2 aligned with the human α_1 -encoding nucleic acid sequences.

The α_1 -related encoding nucleic acids were amplified in two steps from TT cellular poly(A) + RNA, using Primers-1 and -2 first in a

-86-

degenerate amplification reaction followed by Primer-3 and Primer-2 in a nested PCR amplification. This resulted in amplification of a 340 nucleotide fragment that encodes a portion of the α_{1H} subunit. This amplification product was used as a probe to screen the library to isolate
5 nucleic acid clones encoding a full-length α_{1H} subunit.

Using a primer base on the α_{1H-1} sequence and RT-PCR on various tissues, transcripts with an in-frame deletion relative to α_{1H-1} were identified and isolated from the TT cell library. Fragments spanning this deletion were isolated and, when lined up matched the α_{1H-1} sequence
10 except for a 957 base pair deletion. A full-length clone, designated α_{1H-2} (see SEQ ID NO. 16), was constructed from among these fragments, and inserted in the pcDNA1 with the RBS as for α_{1H-1} . α_{1H-2} transcripts were identified in all tissues examined.

Nucleic acid encoding α_{1H-2} results from an alternately spliced RNA
15 and has a 957 nucleotide in-frame deletion relative to α_{1H-1} , as detected in the PCR products from numerous tissues and cells, including TT cellular cDNA,, amygdala cDNA, caudate nucleus cDNA, putamen cDNA, heart cDNA, kidney cDNA and liver cDNA. PCR primers were: (i) 5'-primer corresponding to the sense strand of α_{1H-1} at nucleotide 1373 through
20 1393; (ii) 3'-primer corresponding to the antisense strand of α_{1H-1} at nucleotide 2657 through 2680.

SEQ ID Nos. 12 and 15 show the nucleotide sequence of α_{1H-1} . The coding sequence for α_{1H-1} begins at nucleotide 249 and ends at 7310. (SEQ ID Nos. 12 and 15 differ in minor respects,
25 e.g., amino acid 2230 (bases 6983-6985) is Asp (GAC) in the SEQ ID No. 15 and Glu (GAA) in SEQ ID No. 12).

-87-

SEQ ID No. 16 shows the nucleotide sequence of the α_{1H-2} splice variant. The coding sequence for α^{1H-2} begins at 249 and ends at 6353.

B. Summary

Nucleic acid clones encoding full length α_{1H} T-type channel subtype were isolated from TT cells. Although similar in overall nucleotide sequence topography to other previously cloned HVA α_1 subunits, the α_{1H} subunit contained several unusual features, including a large II-III domain loop, absence of the common α_1 interaction domain, and altered ion selectivity properties. Two isoforms of α_{1H} designated α_{1H-1} , and α_{1H-2} were identified. The first α_{1H-1} is the larger of the two, and the second α_{1H-2} is the smaller of the two containing a 957 nucleotide deletion in the II-III loop relative to α_{1H-1} . The nucleotide sequence of α_{1H-1} is set forth in SEQ ID No. 12 and No. 15 and that of α_{1H-2} is set forth in SEQ ID NO. 16. α_{1H-2} contains a 957 nucleotide deletion relative to α_{1H-1} which results in a loss of 319 amino acids (amino acids 470-788 of α_{1H-1}) from within the intracellular loop between domains II and III. The splice variant deletion was identified by PCR in all cells and tissues examined. These include TT-cells, amygdala, caudate nucleus, putamen, heart, kidney and liver cells. In the brain expression is primarily in the amygdala, caudate nucleus and putamen. Liver, kidney and heart have high levels. The coding sequence for α_{1H-1} begins at nucleotide 249 and ends at nucleotide 7310 while the coding sequence for α_{1H-2} begins at nucleotide 249 and ends at nucleotide 6353.

Polyclonal antiserum was raised to the putative II-III intracellular loop domain of the α_{1H} subunit. Following transient expression in HEK293 cells a protein of the appropriate size was detected by SDS-PAGE and Western blotting. Functional characterization of human α_{1H} channels is provided in EXAMPLE 3.

-88-

EXAMPLE 3: Biophysical and Pharmacological properties of channels containing α_{1H-1} and α_{1H-2} subunits

A. Materials and Methods

Materials and methods for biophysical and pharmacology study of calcium channel subunits are described in this EXAMPLE and EXAMPLE 4 below with reference to previously cloned subunits. Such methods or other similar methods known to those of skill in the art have been used to study these properties of human α_{1H-1} subunits as described in this Example.

- 10 **Electrophysiology:** HEK293 cells were transiently transfected with 6 μ g pcDNA1 α_{1H} RBS using a standard Ca^{2+} phosphate procedure (see, e.g., EXAMPLE below, see, also Williams *et al.* (1992) *Neuron*, 8:71-84, for transfection procedure). pCMVCD4, a human CD expression plasmid, was included in the transfections as a marker to permit the identification
15 of transfected cells. Prior to recording, cells were washed with mammalian Ringer's solution, incubated for approximately 10 min in a solution containing a 1/1000 dilution of M-450 CD4 Dynabeads (Dynal Inc., Lake Success, NY) and rewashed with mammalian Ringer's solution to remove excess beads. Functional expression of α_{1H} channels in
20 transfected cells was evaluated 24-48 hours following transfection using the whole-cell patch clamp technique. All recordings were performed on single cells at room temperature (19-24°C). Whole-cell currents were recorded using an Axopatch-200A (Axon Instruments, Foster City, CA) or anEPC-9 (HEKA elektronik, Lambrecht, Germany) patch clamp amplifier,
25 low-pass filtered at 1 kHz (-3 dB, 8-pole Bessel filter) and digitized at a rate of 10 kHz, unless otherwise stated. Pipettes were manufactured

-89-

from borosilicate glass (TW150, WPI, Sarasota, FL), coated with Sylgard (Dow Corning Midland, MI), and had a resistance of 1.1-2.0 MΩ when filled with internal solution. Series resistance was 2-5 MΩ and 70-90% series resistance compensation was generally used. The pipette solution
5 contained (in mM): 135 CsCl, 10 EGTA, 1 MgCl₂, 10 HEPES (pH 7.3, adjusted with Cs-OH). The external solution contained (in mM): 15 BaCl₂ or CaCl₂, 150 Choline C1, 1 MgCl₂, 5 TEA-OH and 10 HEPES (pH 7.3, adjusted with HC1). Single channel recordings were obtained using the cell-attached configuration of the patch-clamp technique. The pipette
10 solution contained (in mM): 110 BaCl₂, 10 HEPES (pH 7.3, adjusted with TEA-OH). The membrane potential of individual HEK293 cells was set to zero with a solution containing (in mM): 140 K-aspartate, 5 EGTA, and 10 HEPES (pH 7.3). Membrane potentials in the single channel recordings were not corrected for liquid junction potential offset (+12 mV). Linear
15 leak and residual capacitive currents were on-line subtracted using a P/4 protocol (whole-cell recording) or scaled single-channel sweeps with no activity (single-channel recordings).

Drugs: Mibepradil (Ro 40-5967) was a gift from F. Hoffman-LaRoche. Nimodipine and (-)BayK-8644 were obtained from Research
20 Biochemicals (Natick, MA). The peptide toxins ω -CgTx GVIA (conotoxin) and ω -CmTx MVIIC (conotoxin) were obtained from Bachem (Torrance, A). All remaining compounds were obtained from Sigma. Stock solutions were prepared in dimethyl sulfoxide (amiloride, nimodipine), ethanol ((-)-BayK-8644) or water (verapamil, mibepradil, ethosuximide, ω -CmTx GVIA
25 and ω -CmTx MVIIC) and stored at 4°C. Drugs were prepared fresh on each experimental day from stock solutions and applied via peristaltic pump at a flow rate of <0.5 ml/min. The maximal solvent concentration in the final test solution was <0.1%. At these concentrations these solvents ha no effect on α_{1H} -mediated currents.

-90-

- Xenopus oocyte studies:** Xenopus laevis frogs were purchased from Nasco (Fort Atkinson, Wisconsin). Oocytes were incubated in Ca^{2+} -free solution containing 88 mM NaCl, 1 mM KCl, 0.82 mM MgSO_4 , 2.4 mM NaHCO_3 , 10 mM Hepes and 1.5 mg/ml collagenase A (Worthington, Freehold NJ; Type 4, 1.5 hr and subsequently Sigma, St. Louis, MO, Type 1A, 0.5 hr.). Following collagenase treatment, oocytes were transferred to frog Ringer's solution that contained 88mM nACl, 1mM KCl, 0.91 mM CaCl_2 , 0.82 mM MgSO_4 , 0.33 mM $\text{Ca}(\text{NO}_3)_2$, 2.4 mM NaHCO_3 and 10 mM Hepes. Under these conditions, manual removal of the follicle cell layer was not required. Oocytes were injected with 50 ng ($1\mu\text{g}/\text{ml}$) of *in vitro* transcripts encoding the $\alpha_{1\text{H}}$ subunit and incubated for 3-5 days at 19°C prior to recording. The incubation medium was frog Ringer's solution containing penicillin/streptomycin (Sigma; 10 ml/L), gentamicin (Sigma; 1 ml/L and 5% heat-inactivated horse serum (Gibco, Gaithersburg, MD). Microelectrodes were pulled on a horizontal puller (Model P80, Sutter Instruments, Novato, CA); filled with 3 M KCl; and selected for resistances in the range of 0.5-2.0 M Ω . Data were recorded using a GeneClamp 500; digitized at 1-5 KHz; and stored on magnetic disks for analysis offline using pClamp or Axograph software (Axon Instruments). Ba^{2+} or Ca^{2+} currents were recorded in a solution containing 36 mM TEA-OH, 2.5 mM KOH, 75 mM mannitol, 10 mM HEPES and 15 mM $\text{Ba}(\text{OH})_2$ or $\text{Ca}(\text{OH})_2$, respectively at pH 7.3. Currents were leak-subtracted using the P/6 protocol. To block Ca^{2+} -activated chloride currents, niflumic acid ($300\mu\text{M}$) was included in experiments where the relative permeability of $\alpha_{1\text{H}}$ channels to Ba^{2+} or Ca^{2+} was measured. All values are reported as mean \pm S.D. unless stated otherwise. Drugs (above) were applied via a gravity-fed perfusion system. At the concentrations used herein, solvents had no effect on $\alpha_{1\text{H}}$ -mediated currents.

-91-

B. Electrophysiology

1. Current-Voltage Properties

The rapid inactivation of $\alpha_{1H.1}$ Ca^{2+} channels was strongly voltage-dependent. The current decay was best described with an exponential function with time constants ranging from 42.2 ± 7.8 to 8.8 ± 3.8 ms at membrane potentials between -50 and +30 mV ($n = 6$; data not shown). Activation kinetics of $\alpha_{1H.1}$ Ca^{2+} channels were also voltage-dependent with time constants ranging from 9.9 ± 4.7 to 0.9 ± 0.3 ms for membrane potentials between -50 and +30 mV ($n = 8$; data not shown). $\alpha_{1H.1}$ Ca^{2+} channels inactivated completely during the 150-ms depolarization. Recovery from inactivation occurred within a period of ~3 s with a fast component ($\tau = 37 \pm 9$ ms; $16.5 \pm 4.6\%$ of all channels) and a slow component ($\tau = 37 \pm 61$ ms; $78 \pm 8.5\%$ of all channels; $n = 3$; data not shown). To confirm the biophysical properties of recombinant α_{1H} channels observed in whole-cell recordings from HEK293 cells, the functional expression of α_{1H} in *Xenopus* oocytes was tested. Substantial currents (<1 μA) after injection of α_{1H} transcripts alone was observed.

The current-voltage relationship for Ba^{2+} or Ca^{2+} from traces determined. Following transient transfection of HEK293 cells with a DNA encoding the $\alpha_{1H.1}$ subunit, Ba^{2+} currents that were rapidly activating and inactivating were observed. Ba^{2+} currents (15 mM) elicited by step depolarizations to various test potentials from a holding potential of -90-mV were measured. Currents were activated at a test potential of -50 mV, peaked between -20 and -10 mV, and reversed at a membrane potential more positive than +60 mV. Similar results were obtained with Ca^{2+} (15 mM) as the charge carrier.

-92-

2. Voltage-Dependence of Activation and Inactivation

FIGURE 1 shows the voltage-dependence of activation (m_∞) and steady-state inactivation (h) of human α_{1H} calcium channels expressed transiently in HEK cells. Voltage-dependence of activation (m_∞) was determined from tail current analysis. Tail currents were normalized with respect to the maximum peak tail current obtained at +60 mV and were plotted (open symbols, mean \pm SEM; n = 11) vs. test potential. Data were fitted by the sum of two Boltzman function $m_\infty = F_A * [1 + \exp(-(V_{test} - V_{1/2,A})/k_A)] + F_B * [1 + \exp(-(V_{test} - V_{1/2,B})/k_B)]^{-1}$, $F_A = 0.67$, $V_{1/2,A} = -$ 5 21.5 mV, $k_A = 7.5$, $F_B = 0.33$, $V_{1/2,B} = 25.5$ mV, $k_B = 14.7$. Steady-state inactivation (h_∞) was determined from a holding potential of -100 mV by a test pulse to -20 mV (p1), followed by a 20 second prepulse from -100 mV to -10 mV in 5 mV decrements (pHold) preceding a second test pulse to -20 mV (p2). Normalized current amplitudes were plotted (closed 10 symbols, mean \pm SEM; n = 9) vs. holding potential. Data were fitted by a Boltzman function $h_\infty = [1 + \exp((V_{hold} - V_{1/2})/k)]^{-1}$, $V_{1/2} = -63.9$ mV, $k = 3.9$ mV.

15

3. Tail Current Deactivation

Tail current deactivation profiles for $\alpha_{1H,1}$ calcium channels in 20 transiently transfected HEK cells were studied. One hallmark of LVA channels is their slow rate of deactivation, which is reflected in a slow decay of tail currents. The time constant of this decay is ~10-fold slower for LVA channels (2-12 ms) than for HVA channels <300 μ s. A slow decay of $\alpha_{1H,1}$ mediated tail currents over a period of ~15 ms was 25 observed. In contrast to the monoexponential decay of the tail currents reported for many native T-type Ca^{2+} channels, tail currents from $\alpha_{1H,1}$ channels showed a biexponential decay. At a test potential of -20 mV,

-93-

the decay rate of the slow component, comprising $88.1 \pm 33.8\%$ of the total current, was 2.1 ± 1.06 ms ($n = 6$), which is similar to those observed in native T-type Ca^{2+} channels. The decay rate of the faster component was 0.64 ± 0.21 ms ($n = 6$). Slow decay of α_{1H-1} -mediated tail currents were observed over a period of 15 ms.

The voltage dependence of activation of α_{1H-1} containing Ca^{2+} channels was determined from tail-current analysis. Normalized tail-current amplitudes were plotted as a function of test potential and revealed a biphasic activation curve that was well fitted by the sum of two Boltzmann functions (Figure 1). The potentials for half-maximal activation of the individual Boltzmann terms were as follows: $V_{1/2,A}$: -25.1 ± 3.0 mV; and $V_{1/2,B}$: $+25.5 \pm 3.9.9$ mV ($n = 11$). A value similar to $V_{1/2,A}$ has been reported previously for voltage dependence of activation of T-type Ca^{2+} channels in the human TT cell line (-27 mV). The value of the second Boltzmann term $V_{1/2,B}$ is somewhat similar to that reported for HVA Ca^{2+} channels. Using a similar protocol, tail currents of HVA Ca^{2+} channels decay with time constants of $< 300 \mu\text{s}$, whereas with α_{1H} the most prominent at test potentials close to $V_{1/2,B}$. The availability of α_{1H} containing Ca^{2+} channels for opening was dependent on the membrane potential as shown in FIGURE 1. The potential for half-maximal steady-state inactivation ($V_{1/2}$) was -63.2 ± 2.0 mV ($n = 9$).

4. Kinetics of Activation and Inactivation of α_{1H} Channels

FIGURE 2 shows the kinetics of activation (FIGURE 2A) and inactivation (FIGURE 2B) of human α_{1H} calcium channels. Kinetics of activation and inactivation were determined from current traces by fitting an exponential function to rising (FIGURE 2A) or declining (FIGURE 2B) phase of the current. The voltage-dependence for activation and inactivation follows approximately an exponential function.

-94-

5. Recovery from Inactivation

Recovery of α_{1H} channels expressed transiently in HEK293 cells from inactivation induced by using a double pulse protocol using depolarizing pulses to -20mV was evaluated. The fraction of recovered 5 channels was plotted vs. interpulse interval and the data point were fitted by a bi-exponential function in the form $I = A_0 + A_1 \exp(-t/\tau_1) + A_2 \exp(-t/\tau_2)$. $\tau_1: 35$ ms, $A_1: 0.165$, $\tau_2: 337$ ms, $A_2: 0.788$.

6. Single-Channel Recording from Human α_{1H} calcium channels

Single-channel properties of $\alpha_{1H}Ca^{2+}$ channels in HEK293 cells were 10 determined in cell-attached recordings with 110 mM Ba²⁺ as the charge carrier. Single-channel recordings at a test potential of -30 mV from a patch that contains at least three α_{1H} showed that channel openings occurred in bursts and were clustered mainly in the first third of the 100-ms depolarizing pulse, especially with stronger depolarizations.

15 Occasionally, channel activity was spread throughout the entire sweep. The time course of the ensemble-averaged current recorded at -30mV in 110 mM Ba²⁺ was similar to the α_{1H} whole-cell Ba²⁺ current recorded at -40 mV in 15 mM Ba²⁺. The currents were compared at different potentials to compensate for the shift in the activation curve to more 20 positive potentials due to the increase in divalent concentration. The unitary current-voltage relationship yielded a unitary slope conductance of 9.06 \pm 0.22 pS ($n = 4$).

C. Biophysical Characterization of Human α_{1H} calcium channels in *Xenopus* Oocytes

25

1. Overview

Cloned human α_{1H} calcium channels were characterized further by transient expression of α_{1H-1} mRNA in *Xenopus* oocytes. Injection of α_{1H-1} mRNA alone resulted in expression of large currents, i.e., typically $> 1\mu A$ 30 when recording in 15 mM Ba²⁺. The α_{1H} channels were activated at

-95-

approximately -50 mV with peak responses between -30 mV and -40 mV, which is consistent with low voltage activated channels. Permeability of the α_{1H} channels to Ca^{2+} was slightly greater than to Ba^{2+} . In contrast with high voltage channel, the α_{1H} channels activated slowly ($\tau = 5.7 \pm 5$ ms at the peak of the I-V curve, 3.3 ± 0.5 ms at -20mV) and inactivated rapidly ($\tau = 13.4 \pm 1.9$ ms at the peak of I-V curve, 12.2 ± 1.5 ms at -20 mV). The α_{1H} channels expressed in oocytes were sensitive to steady-state inactivation at relatively negative membrane potentials ($V_{1/2} = -64.5 \pm 1.0$ mV) and recovered quickly from inactivation (τ of recovery ≈ 330 ms). These values are very similar to those obtained from α_{1H} channels expressed in HEK293 cells. The Ba^{2+} currents through α_{1H} channels in oocytes were sensitive to blocking by Ni^{2+} and Cd^{2+} with IC₅₀ values of $6.3\mu\text{M}$ and $8.3\mu\text{M}$, respectively. Of the antagonists tested, only amiloride ($\text{IC}_{50} \approx 16\mu\text{M}$) and mibefradil ($\text{IC}_{50} \approx 2\mu\text{M}$) markedly inhibited α_{1H} -mediated Ba^{2+} currents through α_{1H} channels expressed in oocytes. Taken together the results indicate that α_{1H} represents a low-voltage activated calcium channel subunit.

2. Activation and Inactivation Properties of α_{1H} Channel Ba^{2+} Currents

20 Current-voltage relationships for Ba^{2+} (15 mM) currents were recorded from single oocytes injected with mRNA encoding the human α_{1H} subunit. Ba^{2+} currents were activated at a membrane potential of about -50 mV and peaked at -30 mV. The relative inactivation rates of human α_{1H} channels were investigated in different oocyte preparations and compared with inactivation rates of $\alpha 1A-2\alpha 2b\delta\beta 4a$ channels; $\alpha 1B-1\alpha 2b\delta\beta 3a$ channels; and, $\alpha 1E-3\alpha 2b\delta\beta 1b$ channels. Ba^{2+} currents were elicited using a voltage command in the range of -120 mV to -30 mV for α_{1H} channels, or -90 mV to 0 mV or + 10 mV for the other respective α_{1A} , α_{1B} and α_{1E} containing channels. The results presented show the

-96-

relatively electro-negative activation range of α_{1H} channels in comparison with the high-voltage activated $\alpha 1A-2\alpha 2b\delta\beta 4a$, $\alpha 1B-1\alpha 2b\delta\beta 3a$ and, $\alpha 1E-3\alpha 2b\delta\beta 1b$ calcium channels.

5 **3. Permeability, Inactivation and Biophysical Properties of Human α_{1H} Expressed in *Xenopus* oocytes**

Permeability and inactivation properties of human α_{1H} channels were investigated in oocytes by studying Ba^{2+} and Ca^{2+} currents. The results show that Ba^{2+} currents were not significantly larger than Ca^{2+} currents in oocytes expressing the α_{1H} subunit. Results presented in 10 show normalized steady-state inactivation curves for α_{1H} -mediated Ba^{2+} currents, where $V1/2$ was calculated to be equal to a value of -64.5 ± 1.0 mV. A double pulse protocol, i.e., with increasing time intervals between pulses, was used to examine the recovery of α_{1H} channels from 15 inactivation. The results of relative recovery of channels plotted against the interpulse interval (ms) and demonstrated that α_{1H} channel currents recovered quickly from inactivation, with an average time constant of 330 ms ($n = 5$).

15 **4. Cadmium, Nickel, Amiloride and Mibepradil Antagonize human α_{1H} Channel Ba^{2+} Currents**

20 Cd^{2+} was found to antagonize low-threshold human α_{1H} currents in oocytes in a concentration dependent manner. By plotting the inhibition of Cd^{2+} as the percentage of the control Ba^{2+} current achieved at different concentration of Cd^{2+} , an IC_{50} of $10.3\mu M$ as calculated. Ni^{2+} was also found to antagonize low-threshold human α_{1H} channels in 25 oocyte, and also in a concentration dependent manner. The inhibition of Ba^{2+} currents produced by different concentrations of Ni^{2+} ($n = 4$ experiments; $n_H = 0.84$) was tested. The calculated IC_{50} for Ni^{2+} was $6.3\mu M$. Antagonism by Ni^{2+} and Ba^{2+} were largely reversible.

-97-

In addition, each of Amiloride and Mibefradil blocked low-threshold Ba^{2+} currents in oocytes in a concentration-dependent manner giving a calculated IC_{50} of $161\mu\text{M}$ for Amiloride; mean of 7 experiments, $n_H=0.62$) and mean of $2.1\mu\text{M}$ for Mibefradil; mean of 4 experiments, $n_H=0.71$).

5 These results demonstrate that incorporation of an α_{1H} subunit into functional calcium channels in the membranes of cells, conveys the electrophysiologic and biophysical properties of low-voltage activated, particularly T-type, calcium channels upon those channels. The α_{1H} -containing channels were activated rapidly at relatively negative
10 membrane potentials (i.e., $V_{1/2}=64.5\text{ mV}$), and were also inactivated rapidly (i.e., $\tau=12.2\text{ ms}$ at -20mV). Peak channel open activity was observed at a membrane potential of -30mV . These channels also exhibited approximately equal permeability for Ca^{2+} and Ba^{2+} .

15 Pharmacologic properties of α_{1H} containing channels were also consistent with those of other low-threshold calcium channels. They are blocked by Ni^{2+} ($\text{IC}_{50}=6.3\mu\text{M}$), Cd^{2+} ($\text{IC}_{50}=10.3\mu\text{M}$), Amiloride ($\text{IC}_{50}=16.1\mu\text{M}$) and Mibefradil ($\text{IC}_{50}=2.1\mu\text{M}$).

D. Comparison of calcium channels containing human α_{1H} subunits expressed in HEK293 Cells with those expressed in *Xenopus* oocytes
20

TABLE 4 summarizes the biophysical properties of: (i) human $\alpha_{1H.1}$ -containing calcium channels expressed in HEK293 cells, (ii) human $\alpha_{1H.1}$ -containing channels expressed in *Xenopus* oocytes, and (iv) native T-type calcium channels expressed in various tissues.

-98-

TABLE 4
Biophysical properties of α_{1H} -containing Ca^{2+} channels

Properties:	α_{1H} HEK293	α_{1H} <i>Xenopus</i> Oocytes	Native T-type ^b
5 Relative conductance conductance [pS]	$\text{Ba}^{2+} \equiv \text{Ca}^{2+}$ 9.06 ± 0.22	$\text{Ba}^{2+} \equiv \text{Ca}^{2+}$ n.d.	$\text{Ba}^{2+} \equiv \text{Ca}^{2+}$ 5-9
10 Activation kinetics, τ [ms] $V_{1/2}$ [mV]	2.8 ± 0.5^c -25.1 ± 3.9 25.5 ± 9.9	3.3 ± 0.5^c n.d.	2 to 8 -60 to -45
15 Inactivation kinetics, τ [ms] $V_{1/2}$ [mV]	16.9 ± 5.3^c -63.2 ± 2.0 0.64 ± 0.21	23.3 ± 1.5^c -64.5 ± 1.0 n.d.	10 to 30 -100 to -50 2 to 12
15 Tail deactivation τ [ms]	2.1 ± 1.06		

b Huguenard (1996) Annual Rev. Physiol. **58**:329-348; *c* determined at -20 mV test potential; n.d. not determined

20 E. Properties of calcium channels containing α_{1H-2} subunits

Summary Discussion

The biophysical properties of α_{1H-2} , revealed a shift in the $V_{1/2}$ of isochronic inactivation (20 seconds) to -73 mV compared to a $V_{1/2}$ of -62.5 mV for α_{1H-1} . The $V_{1/2}$ of α_{1H-2} , thus exhibits a range closer to $V_{1/2}$ values reported for certain native T-type calcium channels (Huguenard (1996) Annual Rev. Physiol. **58**:329-348). For example, under similar recording conditions the $V_{1/2}$ of isochronic inactivation for T-channels in rat dorsal horn neurons (DHN) is reported to be -82 mV, while the $V_{1/2}$ recorded in rat dorsal lateral geniculate neurons (LGN) is -64 mV. In addition, the $V_{1/2}$ of α_{1H-2} more closely approximates the $V_{1/2}$ in native rat DHN compared to the value for α_{1H-1} , which, instead, comes closer to the value recorded for T-type calcium channels in LGN. Thus, the observed differences the amino acid sequence of the α_{1H-1} and α_{1H-2} subunits appears linked to differences in tissue distribution of these two different forms of the α_{1H} channel. These results also provide basis for

-99-

understanding the observed different broad ranges of values that have been reported for the $V_{1/2}$ inactivation of T-type calcium channels (-100 to -50 mV) in different tissues (see, e.g., Huguenard (1996) Annual Rev. Physiol. 58:329-348).

5 F. Summary of Biophysical Properties of Human α_{1H} Containing calcium channels

TABLE 5 summarizes the biophysical properties of calcium channels containing the human α_{1H} subunits.

TABLE 5

10 Comparison of biophysical parameters of α_{1H} subunits transiently expressed in HEK293 cells using 15 mM Ba²⁺ as the charge carrier:

	Parameter	α_{1H-1}	α_{1H-2}	Statistical significance
15 Current voltage relationship	max current at x [mV]	-10	-20	p < 0.05
Isochronic inactivation (20 seconds)	$V_{1/2}$ [mV]	-62.5	-73	p < 0.05
	Slope	-3.45	-3.82	no (0.279)
Steady-state activation	$V_{1/2,A}$ [mV] Slope _A Fraction _A $V_{1/2,B}$ [mV] Slope _B	-23.7 8.03 0.617 23.1 10.9	-33.8 5.51 0.519 10.7 11.6	p < 0.05 p < 0.05 no (0.133) p < 0.05 no (0.742)

20 α_{1H-1} corresponds to the wild type form of the subunit; α_{1H-2} to the splice variant form;

25 Steady-state activation from Boltzman fit in the form: $m\infty = \text{Fraction}_A * [1 + \exp(-(\text{V}_{test} - V_{1/2,A})/\text{Slope}_A)]^{-1} + (1 - \text{Fraction}_A) * [1 + \exp(-(\text{V}_{test} - V_{1/2,B})/\text{Slope}_B)]^{-1}$; Isochronic inactivation (or steady-state inactivation) from Boltzman fit in the form: $h\infty = [1 + \exp((\text{V}_{test} - V_{1/2})/\text{Slope})]^{-1}$

G. Pharmacologic Profile of Human α_{1H} calcium channels

The sensitivity of $\alpha_{1H}\text{Ca}^{2+}$ channels expressed in HEK293 cells to several agents known to act on VGCCs (Table below) was tested. α_{1H} -mediated currents were 16-fold more sensitive to Ni²⁺ ($\text{IC}_{50} = 6.6 \mu\text{M}$) than to Cd²⁺ ($\text{IC}_{50} = 104 \mu\text{M}$). Currents were also inhibited by the T-type

-100-

channel antagonists amiloride ($IC_{50} = 167\mu M$) and mibepradil ($51.0 \pm 10.0\%$ at $1\mu M$; $n=5$). In contrast, the T-type channel antagonist ethosuximide produced little inhibition of α_{1H} -mediated currents ($7.2 \pm 1.8\%$ inhibition at $300\mu M$; $n = 5$). The calcium channel inhibitor
5 verapamil, the L-type antagonist nimodipine, and the L-type agonist (-)-
Bay K 8644 had little effect on α_{1H} channels at a concentration of $1\mu M$. A higher concentration ($10\mu M$) of nimodipine or (-)-Bay K 8644 produced a marked inhibition ($43.7 \pm 4.1\%$, $n = 4$, and $18.1 \pm 9.1\%$, $n = 5$, respectively). The peptide toxins ω -CgTx GVIA and ω -CmTx MVIIC at a
10 concentration of $1\mu M$ provided little or no inhibition of α_{1H} -mediated currents.

Pharmacological studies reveal the following rank order of potency for inhibition of α_{1H-1} -containing channels: ni^{2+} ($IC_{50}: 6.6\mu M$) \approx Mibepradil (51% at $1\mu M$) $>$ Cd^{2+} ($IC_{50}: 104\mu M$) $>$ Amiloride ($IC_{50}: 167\mu M$) $>>$ Ethosuximide (7% at $300\mu M$). Nimodipine, Verapamil, ω -CgTx GVIA and ω -CmTx MVIIC had little effect (0-17%) at a concentration of $1\mu M$. These findings demonstrate that α_{1H} -containing calcium channels have properties corresponding to native LVA, or T-type calcium channels.
15

Table 6 summarizes the pharmacological profile of human α_{1H} containing calcium channels expressed in HEK293 cells. With the exception of ω -CmTx MVIIC, in all cases the charge carrier was 15 mM Ba^{2+} . In the case of ω -CmTx MVIIC the charge carrier for was 2 mM Ba^{2+} because ω -CmTx MVIIC was a more effective inhibitor at lower
20 divalent concentrations. Values for % block are mean \pm SD(n). IC_{50} values were calculated from sigmoidal curve fitting data (Prism, Graphpad Inc.) for data points from 3 to 6 determinations.
25

-101-

TABLE 6
Pharmacology of α_{1H} Ca²⁺ Channels Expressed in HEK293 Cells

	Compound	Concentration	% Inhibition of Control Response or IC ₅₀
5	Cd ²⁺	range	104 μM
	Ni ²⁺	range	6.6 μM
	Amiloride	range	167 μM
	Mibepradil	1 μM	51.0 ± 10.0%(5)
	Ethosuximide	300 μM	7.2 ± 1.8%(5)
10	Verapamil		
	Nimodipine	1 μM	17.2 ± 1.3%(3)
	(-)BayK-8644	1 μM	3.4 ± 1.1%(4)
	(-)BayK-8644	10 μM	43.7 ± 4.1%(4)
15	(-)BayK-8644	1 μM	0.4 ± 0.8%(3)
	ω -CgTx	10 μM	18.1 ± 9.1%(5)
	GVIA	1 μM	0%(3)
	ω -CmTx		
20	MVIIC	1 μM	8.6 ± 11.5%(3)

EXAMPLE 4: RECOMBINANT EXPRESSION OF HUMAN NEURONAL CALCIUM CHANNEL SUBUNIT-ENCODING cDNA AND RNA TRANSCRIPTS IN MAMMALIAN CELLS

The methods and assays described in this example, may be employed using the nucleic encoding an α_{1H} subunit in place of the α_1 subunits exemplified below. Of particular interest are cells that express the α_{1H} subunit alone, as homomers, monomers or multimers, or in combination with selected α_2 subunits.

A. Recombinant Expression of the Human Neuronal Calcium Channel α_2 subunit cDNA in DG44 Cells

1. Stable transfection of DG44 cells

DG44 cells (dhfr^r Chinese hamster ovary cells; see, e.g., Urlaub, G. et al. (1986) *Som. Cell Molec. Genet.* 12:555-566) obtained from Lawrence Chasin at Columbia University were stably transfected by 35CaPO_4 precipitation methods (Wigler et al. (1979) *Proc. Natl. Acad. Sci. USA* 76:1373-1376) with pSV2dhfr vector containing the human neuronal calcium channel α_2 -subunit cDNA for polycistronic

-102-

expression/selection in transfected cells. Transfectants were grown on 10% DMEM medium without hypoxanthine or thymidine in order to select cells that had incorporated the expression vector. Twelve transfectant cell lines were established as indicated by their ability to survive on this
5 medium.

2. Analysis of α_2 subunit cDNA expression in transfected DG44 cells

Total RNA was extracted according to the method of Birnboim ((1988) *Nuc. Acids Res.* 16:1487-1497) from four of the DG44 cell lines
10 that had been stably transfected with pSV2dhfr containing the human neuronal calcium channel α_2 subunit cDNA. RNA (~15 μ g per lane) was separated on a 1% agarose formaldehyde gel, transferred to nitrocellulose and hybridized to the random-primed human neuronal calcium channel α_2 cDNA (hybridization: 50% formamide, 5 x SSPE, 5 x Denhardt's, 42° C.;
15 wash :0.2 x SSPE, 0.1% SDS, 65° C.). Northern blot analysis of total RNA from four of the DG44 cell lines that had been stably transfected with pSV2dhfr containing the human neuronal calcium channel α_2 subunit cDNA revealed that one of the four cell lines contained hybridizing mRNA the size expected for the transcript of the α_2 subunit cDNA (5000 nt
20 based on the size of the cDNA) when grown in the presence of 10 mM sodium butyrate for two days. Butyrate nonspecifically induces transcription and is often used for inducing the SV40 early promoter.
(Gorman, C. and Howard, B. (1983) *Nucleic Acids Res.* 11:1631). This cell line, 44 α_2 -9, also produced mRNA species smaller (several species)
25 and larger (6800 nt) than the size expected for the transcript of the α_2 cDNA (5000 nt) that hybridized to the α_2 cDNA-based probe. The 5000- and 6800-nt transcripts produced by this transfectant should contain the entire α_2 subunit coding sequence and therefore should yield a full-length α_2 subunit protein. A weakly hybridizing 8000-nucleotide transcript was

-103-

present in untransfected and transfected DG44 cells. Apparently, DG44 cells transcribe a calcium channel α_2 subunit or similar gene at low levels. The level of expression of this endogenous α_2 subunit transcript did not appear to be affected by exposing the cells to butyrate before isolation of
5 RNA for northern analysis.

Total protein was extracted from three of the DG44 cell lines that had been stably transfected with pSV2dhfr containing the human neuronal calcium channel α_2 subunit cDNA. Approximately 10^7 cells were sonicated in 300 μ l of a solution containing 50 mM HEPES, 1 mM EDTA,
10 1 mM PMSF. An equal volume of 2x loading dye (Laemmli, U.K. (1970). *Nature* 227:680) was added to the samples and the protein was subjected to electrophoresis on an 8% polyacrylamide gel and then electrotransferred to nitrocellulose. The nitrocellulose was incubated with polyclonal guinea pig antisera (1:200 dilution) directed against the rabbit
15 skeletal muscle calcium channel α_2 subunit (obtained from K. Campbell, University of Iowa) followed by incubation with [125 I]-protein A. The blot was exposed to X-ray film at -70° C. Reduced samples of protein from the transfected cells as well as from untransfected DG44 cells contained immunoreactive protein of the size expected for the α_2 subunit of the
20 human neuronal calcium channel (130-150 kDa). The level of this immunoreactive protein was higher in 44 α_2 -9 cells that had been grown in the presence of 10 mM sodium butyrate than in 44 α_2 -9 cells that were grown in the absence of sodium butyrate. These data correlate well with those obtained in northern analyses of total RNA from 44 α_2 -9 and
25 untransfected DG44 cells. Cell line 44 α_2 -9 also produced a 110 kD immunoreactive protein that may be either a product of proteolytic degradation of the full-length α_2 subunit or a product of translation of one of the short r (<5000 nt) mRNA produced in this cell line that hybridized to the α_2 subunit cDNA probe.

-104-

B. Expression of DNA encoding human neuronal calcium channel α_1 , α_2 and β_1 subunits in HEK cells

- Human embryonic kidney cells (HEK 293 cells) were transiently and
- 5 stably transfected with human neuronal DNA encoding calcium channel subunits. Individual transfectants were analyzed electrophysiologically for the presence of voltage-activated barium currents and functional recombinant voltage-dependent calcium channels were analyzed.

1. Transfection of HEK 293 cells

- 10 Separate expression vectors containing DNA encoding human neuronal calcium channel α_{1D} , α_2 and β_1 subunits, plasmids pVDCCIII(A), pHBCaCH α_2 A, and pHBCaCH β_{1a} RBS(A), respectively, were constructed as described in International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097. These three vectors
- 15 were used to transiently co-transfect HEK 293 cells. For stable transfection of HEK 293 cells, vector pHBCaCH β_{1b} RBS(A) was used in place of pHBCaCH β_{1a} RBS(A) to introduce the DNA encoding the β_1 subunit into the cells along with pVDCCIII(A) and pHBCaCH α_2 A.

a. Transient transfection

- 20 Expression vectors pVDCCIII(A), pHBCaCH α_2 A and pHBCaCH β_{1a} RBS(A) were used in two sets of transient transfections of HEK 293 cells (ATCC Accession No. CRL1573). In one transfection procedure, HEK 293 cells were transiently cotransfected with the α_1 subunit cDNA expression plasmid, the α_2 subunit cDNA expression
- 25 plasmid, the β_1 subunit cDNA expression plasmid and plasmid pCMV β gal (Clontech Laboratories, Palo Alto, CA). Plasmid pCMV β gal contains the lacZ gene (encoding *E. coli* β -galactosidase) fused to the cytomegalovirus (CMV) promoter and was included in this transfection as a marker gene for monitoring the efficiency of transfection. In the other transfection
- 30 procedure, HEK 293 cells were transiently co-transfected with the α_1 ,

-105-

subunit cDNA expression plasmid pVDCCIII(A) and pCMV β gal. In both transfections, 2-4 x 10⁶ HEK 293 cells in a 10-cm tissue culture plate were transiently co-transfected with 5 μ g of each of the plasmids included in the experiment according to standard CaPO₄ precipitation

- 5 transfection procedures (Wigler *et al.* (1979) *Proc. Natl. Acad. Sci. USA* 76:1373-1376). The transfectants were analyzed for β -galactosidase expression by direct staining of the product of a reaction involving β -galactosidase and the X-gal substrate (Jones, J.R. (1986) *EMBO* 5:3133-3142) and by measurement of β -galactosidase activity (Miller, J.H. (1972)
- 10 Experiments in Molecular Genetics, pp. 352-355, Cold Spring Harbor Press). To evaluate subunit cDNA expression in these transfectants, the cells were analyzed for subunit transcript production (northern analysis), subunit protein production (immunoblot analysis of cell lysates) and functional calcium channel expression (electrophysiological analysis).

15 b. Stable transfection

- HEK 293 cells were transfected using the calcium phosphate transfection procedure (*Current Protocols in Molecular Biology*, Vol. 1, Wiley Inter-Science, Supplement 14, Unit 9.1.1-9.1.9 (1990)). Ten-cm plates, each containing one-to-two million HEK 293 cells, were
- 20 transfected with 1 ml of DNA/calcium phosphate precipitate containing 5 μ g pVDCCIII(A), 5 μ g pHBCaCH α ₂A, 5 μ g pHBCaCH β _{1b}RBS(A), 5 μ g pCMVBgal and 1 μ g pSV2neo (as a selectable marker). After 10-20 days of growth in media containing 500 μ g G418, colonies had formed and were isolated using cloning cylinders.

25 2. Analysis of HEK 293 cells transiently transfected with DNA encoding human neuronal calcium channel subunits

a. Analysis of β -galactosidase expression

- Transient transfectants were assayed for β -galactosidase expression by β -galactosidase activity assays (Miller, J.H., (1972)

-106-

Experiments in Molecular Genetics, pp. 352-355, Cold Spring Harbor Press) of cell lysates (prepared as described in International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097) and staining of fixed cells (Jones, J.R. (1986) 5 *EMBO 5*:3133-3142). The results of these assays indicated that approximately 30% of the HEK 293 cells had been transfected.

b. Northern analysis

PolyA + RNA was isolated using the Invitrogen Fast Trak Kit (Invitrogen, San Diego, CA) from HEK 293 cells transiently transfected 10 with DNA encoding each of the α_1 , α_2 and β_1 subunits and the *lacZ* gene or the α_1 subunit and the *lacZ* gene. The RNA was subjected to electrophoresis on an agarose gel and transferred to nitrocellulose. The nitrocellulose was then hybridized with one or more of the following radiolabeled probes: the *lacZ* gene, human neuronal calcium channel α_{1D} 15 subunit-encoding cDNA, human neuronal calcium channel α_2 subunit-encoding cDNA or human neuronal calcium channel β_1 subunit-encoding cDNA. Two transcripts that hybridized with the α_1 subunit-encoding cDNA were detected in HEK 293 cells transfected with the DNA encoding the α_1 , α_2 , and β_1 subunits and the *lacZ* gene as well as in HEK 293 cells 20 transfected with the α_1 subunit cDNA and the *lacZ* gene. One mRNA species was the size expected for the transcript of the α_1 subunit cDNA (8000 nucleotides). The second RNA species was smaller (4000 nucleotides) than the size expected for this transcript. RNA of the size expected for the transcript of the *lacZ* gene was detected in cells 25 transfected with the α_1 , α_2 and β_1 subunit-encoding cDNA and the *lacZ* gene and in cells transfected with the α_1 subunit cDNA and the *lacZ* gene by hybridization to the *lacZ* gene sequence.

RNA from cells transfected with the α_1 , α_2 and β_1 subunit-encoding cDNA and the *lacZ* gene was also hybridized with the α_2 and β_1 subunit

-107-

cDNA probes. Two mRNA species hybridized to the α_2 subunit cDNA probe. One species was the size expected for the transcript of the α_2 subunit cDNA (4000 nucleotides). The other species was larger (6000 nucleotides) than the expected size of this transcript. Multiple RNA species in the cells co-transfected with α_1 , α_2 and β_1 subunit-encoding cDNA and the *lacZ* gene hybridized to the β_1 subunit cDNA probe. Multiple β subunit transcripts of varying sizes were produced since the β subunit cDNA expression vector contains two potential polyA⁺ addition sites.

10 c. Electrophysiological analysis

Individual transiently transfected HEK 293 cells were assayed for the presence of voltage-dependent barium currents using the whole-cell variant of the patch clamp technique (Hamill et al. (1981). *Pflugers Arch.* 391:85-100). HEK 293 cells transiently transfected with pCMV β gal only were assayed for barium currents as a negative control in these experiments. The cells were placed in a bathing solution that contained barium ions to serve as the current carrier. Choline chloride, instead of NaCl or KCl, was used as the major salt component of the bath solution to eliminate currents through sodium and potassium channels. The bathing solution contained 1 mM MgCl₂ and was buffered at pH 7.3 with 10 mM HEPES (pH adjusted with sodium or tetraethylammonium hydroxide). Patch pipettes were filled with a solution containing 135 mM CsCl, 1 mM MgCl₂, 10 mM glucose, 10 mM EGTA, 4 mM ATP and 10 mM HEPES (pH adjusted to 7.3 with tetraethylammonium hydroxide). Cesium and tetraethylammonium ions block most types of potassium channels. Pipettes were coated with Sylgard (Dow-Corning, Midland, MI) and had resistances of 1-4 megohm. Currents were measured through a 500 megohm headstage resistor with the Axopatch IC (Axon Instruments, Foster City, CA) amplifier, interfaced with a Labmaster (Scientific

-108-

Solutions, Solon, OH) data acquisition board in an IBM-compatible PC. PClamp (Axon Instruments) was used to generate voltage commands and acquire data. Data were analyzed with pClamp or Quattro Professional (Borland International, Scotts Valley, CA) programs.

- 5 To apply drugs, "puffer" pipettes positioned within several micrometers of the cell under study were used to apply solutions by pressure application. The drugs used for pharmacological characterization were dissolved in a solution identical to the bathing solution. Samples of a 10 mM stock solution of Bay K 8644 (RBI, Natick, MA), which was
10 prepared in DMSO, were diluted to a final concentration of 1 μ M in 15 mM Ba²⁺-containing bath solution before they were applied.

Twenty-one negative control HEK 293 cells (transiently transfected with the *lacZ* gene expression vector pCMV β gal only) were analyzed by the whole-cell variant of the patch clamp method for recording currents.
15 Only one cell displayed a discernable inward barium current; this current was not affected by the presence of 1 μ M Bay K 8644. In addition, application of Bay K 8644 to four cells that did not display Ba²⁺ currents did not result in the appearance of any currents.

- Two days after transient transfection of HEK 293 cells with α_1 , α_2
20 and β_1 subunit-encoding cDNA and the *lacZ* gene, individual transfectants were assayed for voltage-dependent barium currents. The currents in nine transfectants were recorded. Because the efficiency of transfection of one cell can vary from the efficiency of transfection of another cell, the degree of expression of heterologous proteins in individual transfectants
25 varies and some cells do not incorporate or express the foreign DNA. Inward barium currents were detected in two of these nine transfectants. In these assays, the holding potential of the membrane was -90 mV. The membrane was polarized in a series of voltage steps to different test potentials and the current in the presence and absence of 1 μ M Bay K

-109-

8644 was recorded. The inward barium current was significantly enhanced in magnitude by the addition of Bay K 8644. The largest inward barium current (~ 160 pA) was recorded when the membrane was depolarized to 0 mV in the presence of 1 μ M Bay K 8644. A comparison 5 of the I-V curves, generated by plotting the largest current recorded after each depolarization versus the depolarization voltage, corresponding to recordings conducted in the absence and presence of Bay K 8644 illustrated the enhancement of the voltage-activated current in the presence of Bay K 8644.

10 Pronounced tail currents were detected in the tracings of currents generated in the presence of Bay K 8644 in HEK 293 cells transfected with α_1 , α_2 and β_1 subunit-encoding cDNA and the *lacZ* gene, indicating that the recombinant calcium channels responsible for the voltage-activated barium currents recorded in this transfected appear to be DHP-15 sensitive.

The second of the two transfected cells that displayed inward barium currents expressed a ~ 50 pA current when the membrane was depolarized from -90 mV. This current was nearly completely blocked by 200 μ M cadmium, an established calcium channel blocker.

20 Ten cells that were transiently transfected with the DNA encoding the α_1 subunit and the *lacZ* gene were analyzed by whole-cell patch clamp methods two days after transfection. One of these cells displayed a 30 pA inward barium current. This current amplified 2-fold in the presence of 1 μ M Bay K 8644. Furthermore, small tail currents were detected in 25 the presence of Bay K 8644. These data indicate that expression of the human neuronal calcium channel α_{1D} subunit-encoding cDNA in HEK 293 yields a functional DHP-sensitive calcium channel.

-110-

3. Analysis of HEK 293 cells stably transfected with DNA encoding human neuronal calcium channel subunits

Individual stably transfected HEK 293 cells were assayed electrophysiologically for the presence of voltage-dependent barium currents as described for electrophysiological analysis of transiently transfected HEK 293 cells (International PCT application No. 5 PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097). In an effort to maximize calcium channel activity via cyclic-AMP-dependent kinase-mediated phosphorylation (Pelzer, et al. (1990) 10 *Rev. Physiol. Biochem. Pharmacol.* 114:107-207), cAMP (Na salt, 250 μ M) was added to the pipet solution and forskolin (10 μ M) was added to the bath solution in some of the recordings. Qualitatively similar results were obtained whether these compounds were present or not.

Barium currents were recorded from stably transfected cells in the absence and presence of Bay K 8644 (1 μ M). When the cell was depolarized to -10 mV from a holding potential of -90 mV in the absence of Bay K 8644, a current of approximately 35pA with a rapidly deactivating tail current was recorded. During application of Bay K 8644, an identical depolarizing protocol elicited a current of approximately 75 pA, accompanied by an augmented and prolonged tail current. The peak magnitude of currents recorded from this same cell as a function of a series of depolarizing voltages were assessed. The responses in the presence of Bay K 8644 not only increased, but the entire current-voltage relation shifted about -10 mV. Thus, three typical hallmarks of Bay K 20 8644 action, namely increased current magnitude, prolonged tail currents, and negatively shifted activation voltage, were observed, clearly indicating the expression of a DHP-sensitive calcium channel in these 25 stably transfected cells. No such effects of Bay K 8644 were observed in untransfected HEK 293 cells, either with or without cAMP or forskolin.

-111-

C. Use of pCMV-based vectors and pcDNA1-based vectors for expression of DNA encoding human neuronal calcium channel subunits

1. Preparation of constructs

- 5 Additional expression vectors were constructed using pCMV. The full-length α_{1D} cDNA from pVDCCIII(A) (see International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097), the full-length α_2 cDNA, contained on a 3600 bp EcoRI fragment from HBCaCH α_2 (International PCT application No.

10 PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097) and a full-length β_1 subunit cDNA from pHBCaCH β_1 RBS(A) (see International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097) were separately subcloned into plasmid pCMV β gal. Plasmid pCMV β gal was digested with

15 *NotI* to remove the *lacZ* gene. The remaining vector portion of the plasmid, referred to as pCMV, was blunt-ended at the *NotI* sites. The full-length α_2 -encoding DNA and β_1 -encoding DNA, contained on separate EcoRI fragments, were isolated, blunt-ended and separately ligated to the blunt-ended vector fragment of pCMV locating the DNA between the

20 CMV promoter and SV40 polyadenylation sites in pCMV. To ligate the α_{1D} -encoding cDNA with pCMV, the restriction sites in the polylinkers immediately 5' of the CMV promoter and immediately 3' of the SV40 polyadenylation site were removed from pCMV. A polylinker was added at the *NotI* site. The polylinker had the following sequence of restriction

25 enzyme recognition sites:

The diagram shows a horizontal DNA sequence with various restriction enzyme sites indicated by vertical lines. From left to right, the sites are: *Eco*RI, *Sal*I, *Pst*I, *Eco*RV, *Hind*III, *Xba*I, and *GT*. Below the sequence, labels indicate the presence of a CG dinucleotide at the first site and a CACCGG sequence at the last site. An arrow points to the *Not*I site, which is located between the *Pst*I and *Eco*RV sites. The label "Destroys *Not*" is placed below the sequence, indicating that the *Not*I site is destroyed by the *Pst*I or *Eco*RV enzymes.

-112-

The α_{1D} -encoding DNA, isolated as a *Bam*H/*Xba*I fragment from pVDCCIII(A), was then ligated to *Xba*I/*Sal*I-digested pCMV to place it between the CMV promoter and SV40 polyadenylation site.

Plasmid pCMV contains the CMV promoter as does pcDNA1, but 5 differs from pcDNA1 in the location of splice donor/splice acceptor sites relative to the inserted subunit-encoding DNA. After inserting the subunit-encoding DNA into pCMV, the splice donor/splice acceptor sites are located 3' of the CMV promoter and 5' of the subunit-encoding DNA start codon. After inserting the subunit-encoding DNA into pcDNA1, the 10 splice donor/splice acceptor sites are located 3' of the subunit cDNA stop codon.

2. Transfection of HEK 293 cells

HEK 293 cells were transiently co-transfected with the α_{1D} , α_2 and β_1 subunit-encoding DNA in pCMV or with the α_{1D} , α_2 and β subunit-encoding DNA in pcDNA1 (vectors pVDCCIII(A), pHBCaCH α_2 A and pHBCaCH β_1 bRBS(A), respectively (see, International PCT application No. 15 PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097). Plasmid pCMV β gal was included in each transfection as a measure of transfection efficiency. The results of β -galactosidase assays 20 of the transfected (International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097), indicated that HEK 293 cells were transfected equally efficiently with pCMV- and pcDNA1-based plasmids. The pcDNA1-based plasmids, however, are presently preferred for expression of calcium channel receptors.

25 D. Expression in *Xenopus laevis* oocytes of RNA encoding human neuronal calcium channel subunits

Various combinations of the transcripts of DNA encoding the human neuronal α_{1D} , α_2 and β_1 subunits prepared *in vitro* were injected

-113-

into *Xenopus laevis* oocytes. Those injected with combinations that included α_{1D} exhibited voltage-activated barium currents.

1. Preparation of transcripts

Transcripts encoding the human neuronal calcium channel α_{1D} , α_2 and β_1 subunits were synthesized according to the instructions of the mCAP mRNA CAPPING KIT (Stratagene, La Jolla, CA catalog #200350). As described in International PCT application No. PCT/US94/09230, see, also allowed U.S. application Serial No. 08/149,097, plasmids pVDCC III.RBS(A), containing pcDNA1 and the α_{1D} cDNA that begins with a ribosome binding site and the eighth ATG codon of the coding sequence plasmid pHBCaCH α_1A containing pcDNA1 and an α_2 subunit cDNA, and plasmid pHBCaCH β_1b RBS(A) containing pcDNA1 and the β_1 DNA lacking intron sequence and containing a ribosome binding site were linearized by restriction digestion. The α_{1D} cDNA- and α_2 subunit-encoding plasmids were digested with *Xhol*, and the β_1 subunit- encoding plasmid was digested with *EcoRV*. The DNA insert was transcribed with T7 RNA polymerase.

2. Injection of oocytes

Xenopus laevis oocytes were isolated and defolliculated by collagenase treatment and maintained in 100 mM NaCl, 2 mM KC1, 1.8 mM CaC1₂, 1 mM MgCl₂, 5 mM HEPES, pH 7.6, 20 μ g/ml ampicillin and 25 μ g/ml streptomycin at 19-25°C for 2 to 5 days after injection and prior to recording. For each transcript that was injected into the oocyte, 6 ng of the specific mRNA was injected per cell in a total volume of 50 nl.

25 3. Intracellular voltage recordings

Injected oocytes were examined for voltage-dependent barium currents using two-electrode voltage clamp methods (Dascal, N. (1987) *CRC Crit. Rev. Biochem.* 22:317). The pClamp (Axon Instruments) software package was used in conjunction with a Labmaster 125 kHz

-114-

data acquisition interface to generate voltage commands and to acquire and analyze data. Quattro Professional was also used in this analysis.

Current signals were digitized at 1-5 kHz, and filtered appropriately. The bath solution contained of the following: 40 mM BaCl₂, 36 mM

- 5 tetraethylammonium chloride (TEA-Cl), 2 mM KCl, 5 mM 4-aminopyridine, 0.15 mM niflumic acid, 5 mM HEPES, pH 7.6.

a. **Electrophysiological analysis of oocytes injected with transcripts encoding the human neuronal calcium channel α_1 , α_2 and β_1 -subunits**

- 10 Uninjected oocytes were examined by two-electrode voltage clamp methods and a very small (25 nA) endogenous inward Ba²⁺ current was detected in only one of seven analyzed cells.

Oocytes coinjected with α_{1D} , α_2 and β_1 subunit transcripts expressed sustained inward barium currents upon depolarization of the membrane from a holding potential of -90 mV or -50 mV (154 ± 129 nA, n = 21). These currents typically showed little inactivation when test pulses ranging from 140 to 700 msec. were administered. Depolarization to a series of voltages revealed currents that first appeared at approximately -30 mV and peaked at approximately 0 mV.

- 20 Application of the DHP Bay K 8644 increased the magnitude of the currents, prolonged the tail currents present upon repolarization of the cell and induced a hyperpolarizing shift in current activation. Bay K 8644 was prepared fresh from a stock solution in DMSO and introduced as a 10x concentrate directly into the 60 µl bath while the perfusion pump was turned off. The DMSO concentration of the final diluted drug solutions in contact with the cell never exceeded 0.1%. Control experiments showed that 0.1% DMSO had no effect on membrane currents.

Application of the DHP antagonist nifedipine (stock solution prepared in DMSO and applied to the cell as described for application of 30 Bay K 8644) blocked a substantial fraction (91 ± 6%, n = 7) of the

-115-

inward barium current in oocytes co-injected with transcripts of the α_{1D} , α_2 and β_1 subunits. A residual inactivating component of the inward barium current typically remained after nifedipine application. The inward barium current was blocked completely by 50 μM Cd^{2+} , but only approximately

5 15% by 100 μM Ni^{2+} .

The effect of ω -CgTX-GVIA on the inward barium currents in oocytes co-injected with transcripts of the α_{1D} , α_2 , and β_1 subunits was investigated. ω -CgTX-GVIA (Bachem, Inc., Torrance CA) was prepared in the 15 mM BaCl_2 bath solution plus 0.1% cytochrome C (Sigma) to serve 10 as a carrier protein. Control experiments showed that cytochrome C had no effect on currents. A series of voltage pulses from a -90 mV holding potential to 0 mV were recorded at 20 msec. intervals. To reduce the inhibition of ω CgTX binding by divalent cations, recordings were made in 15 mM BaCl_2 , 73.5 mM tetraethylammonium chloride, and the remaining 15 ingredients identical to the 40 mM Ba^{2+} recording solution. Bay K 8644 was applied to the cell prior to addition to ω CgTX in order to determine the effect of ω CgTX on the DHP-sensitive current component that was distinguished by the prolonged tail currents. The inward barium current was blocked weakly (54 \pm 29%, n = 7) and reversibly by relatively high 20 concentrations (10-15 μM) of ω CgTX. The test currents and the accompanying tail currents were blocked progressively within two to three minutes after application of ω CgTX, but both recovered partially as the ω CgTX was flushed from the bath.

25

b. Analysis of oocytes injected with transcripts encoding the human neuronal calcium channel α_{1D} or transcripts encoding an α_{1D} and other subunits

The contribution of the α_2 and β_1 subunits to the inward barium current in oocytes injected with transcripts encoding the α_{1D} , α_2 and β_1 subunits was assessed by expression of the α_{1D} subunit alone or in

-116-

combination with either the β_1 subunit or the α_2 subunit. In oocytes injected with only the transcript of a α_{1D} cDNA, no Ba^{2+} currents were detected ($n=3$). In oocytes injected with transcripts of α_{1D} and β_1 , encoding DNA, small (108 ± 39 nA) Ba^{2+} currents were detected upon 5 depolarization of the membrane from a holding potential of -90 mV that resembled the currents observed in cells injected with transcripts of α_{1D} , α_2 and β_1 encoding DNA, although the magnitude of the current was less. In two of the four oocytes injected with transcripts of the α_{1D} -encoding 10 and β_1 -encoding DNA, the Ba^{2+} currents exhibited a sensitivity to Bay K 8644 that was similar to the Bay K 8644 sensitivity of Ba^{2+} currents expressed in oocytes injected with transcripts encoding the α_{1D} α_1 -, α_2 - and β_1 subunits.

Three of five oocytes injected with transcripts encoding the α_{1D} and α_2 subunits exhibited very small Ba^{2+} currents (15-30 nA) upon 15 depolarization of the membrane from a holding potential of -90 mV. These barium currents showed little or no response to Bay K 8644.

c. Analysis of oocytes injected with transcripts encoding the human neuronal calcium channel α_2 and/or β_1 subunit

To evaluate the contribution of the α_{1D} α_1 -subunit to the inward 20 barium currents detected in oocytes co-injected with transcripts encoding the α_{1D} , α_2 and β_1 subunits, oocytes injected with transcripts encoding the human neuronal calcium channel α_2 and/or β_1 subunits were assayed for barium currents. Oocytes injected with transcripts encoding the α_2 25 subunit displayed no detectable inward barium currents ($n=5$). Oocytes injected with transcripts encoding a β_1 subunit displayed measurable (54 ± 23 nA, $n=5$) inward barium currents upon depolarization and oocytes injected with transcripts encoding the α_2 and β_1 subunits displayed inward barium currents that were approximately 50% larger (80 ± 61 nA,

-117-

$n = 18$) than those detected in oocytes injected with transcripts of the β_1 -encoding DNA only.

The inward barium currents in oocytes injected with transcripts encoding the β_1 subunit or α_2 and β_1 subunits typically were first observed 5 when the membrane was depolarized to -30 mV from a holding potential of -90 mV and peaked when the membrane was depolarized to 10 to 20 mV. Macroscopically, the currents in oocytes injected with transcripts encoding the α_2 and β_1 subunits or with transcripts encoding the β_1 subunit were indistinguishable. In contrast to the currents in oocytes co-10 injected with transcripts of α_{1D} , α_2 and β_1 subunit encoding DNA, these currents showed a significant inactivation during the test pulse and a strong sensitivity to the holding potential. The inward barium currents in oocytes co-injected with transcripts encoding the α_2 and β_1 subunits usually inactivated to 10-60% of the peak magnitude during a 140-msec 15 pulse and were significantly more sensitive to holding potential than those in oocytes co-injected with transcripts encoding the α_{1D} , α_2 and β_1 subunits. Changing the holding potential of the membranes of oocytes co-injected with transcripts encoding the α_2 and β_1 subunits from -90 to -50 mV resulted in an approximately 81% ($n = 11$) reduction in the 20 magnitude of the inward barium current of these cells. In contrast, the inward barium current measured in oocytes co-injected with transcripts encoding the α_{1D} , α_2 and β_1 subunits were reduced approximately 24% ($n = 11$) when the holding potential was changed from -90 to -50 mV.

The inward barium currents detected in oocytes injected with 25 transcripts encoding the α_2 and β_1 subunits were pharmacologically distinct from those observed in oocytes co-injected with transcripts encoding the α_{1D} , α_2 and β_1 subunits. Oocytes injected with transcripts encoding the α_2 and β_1 subunits displayed inward barium currents that were insensitive to Bay K 8644 ($n = 11$). Nifedipine sensitivity was

-118-

- difficult to measure because of the holding potential sensitivity of nifedipine and the current observed in oocytes injected with transcripts encoding the α_2 and β_1 subunits. Nevertheless, two oocytes that were co-injected with transcripts encoding the α_2 and β_1 subunits displayed
- 5 measurable (25 to 45 nA) inward barium currents that were insensitive to nifedipine (5 to 10 μ M), when depolarized from a holding potential of -50 mV. The inward barium currents in oocytes injected with transcripts encoding the α_2 and β_1 subunits showed the same sensitivity to heavy metals as the currents detected in oocytes injected with transcripts
- 10 encoding the α_{1D} , α_2 and β_1 subunits.

The inward barium current detected in oocytes injected with transcripts encoding the human neuronal α_2 and β_1 subunits has pharmacological and biophysical properties that resemble calcium currents in uninjected *Xenopus* oocytes. Because the amino acids of this human

15 neuronal calcium channel β_1 subunit lack hydrophobic segments capable of forming transmembrane domains. It is unlikely that recombinant β_1 subunits alone form an ion channel, but rather that an endogenous α_1 subunit exists in oocytes and that the activity mediated by such an α_1 subunit is enhanced by expression of a human neuronal β_1 subunit.

20

While the subject matter of the invention has been described with some specificity, modifications apparent to those with ordinary skill in the art may be made without departing from the scope of the invention. Since such modifications will be apparent to those of skill in the art, it is

25 intended that this invention be limited only by the scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid fragment that encodes a low-voltage activated subunit of an animal calcium channel.
2. The nucleic acid of claim 1, wherein the subunit is an α_{1H} -
5 subunit.
3. The nucleic acid of claim 2, wherein the calcium channel is a mammalian calcium channel.
4. The isolated nucleic acid fragment of claim 2, comprising a sequence of nucleotides that encodes the subunit, wherein the sequence
10 of nucleotides encoding the subunit is selected from among:
 - (a) a sequence of nucleotides that encodes a calcium channel subunit and comprises the coding portion of the sequence of nucleotides set forth in any of SEQ ID Nos. 12-16;
 - (b) a sequence of nucleotides that encodes an α_{1H} -subunit and
15 hybridizes under conditions of high stringency to DNA that is complementary to an mRNA transcript present in a mammalian cell that encodes an α_{1H} -subunit;
 - (c) a sequence of nucleotides that encodes the subunit that comprises a sequence of amino acids encoded by any of
20 SEQ ID Nos. 12-16; and
 - (d) a sequence of nucleotides that is degenerate with any of (a), (b) or (c).
5. The molecule of claim 2, wherein the subunit is an α_{1H-1} subunit or an α_{1H-2} subunit.
- 25 6. A eukaryotic cell, comprising heterologous nucleic acid that encodes an α_1 -subunit, wherein the α_1 -subunit is encoded by the nucleic acid of any of claims 1-5.

7 The cell of claim 6, further comprising heterologous nucleic acid that encodes a $\alpha_2\delta$ -subunit of a calcium channel.

8. The eukaryotic cell of claim 6 or claim 7 that has a functional heterologous calcium channel that contains at least one subunit encoded
5 by the heterologous nucleic acid.

9. The eukaryotic cell of any of claims 6-8 selected from the group consisting of HEK 293 cells, Chinese hamster ovary cells, African green monkey cells, and mouse L cells.

10. A eukaryotic cell with a functional, heterologous calcium channel, produced by a process comprising:

introducing into the cell heterologous nucleic acid that encodes at least one subunit of a calcium channel, wherein the subunit is encoded by the nucleic acid of any of claims 1-5.

11. The eukaryotic cell of claim 10 that is an amphibian oöcyte.
15 12. The eukaryotic cell of claim 8 or claim 10, wherein the heterologous calcium channel comprises a plurality of α_{1H} -subunits.

13 The eukaryotic cell of claim 12, wherein the α_{1H} -subunits comprise a homomer.

14. The eukaryotic cell of any of claims 10-13, further
20 comprising an $\alpha_2\delta$ -subunit of a calcium channel.

15. The eukaryotic cell of claim 10, wherein the heterologous nucleic acid encodes a T-type calcium channel.

16. The eukaryotic cell of claim 8 with a functional, heterologous calcium channel, produced by a process comprising:

25 introducing into the cell RNA that encodes an α_{1H} subunit of a calcium chann I and optionally introducing into th cell nucleic acid that encodes a β , $\alpha_2\delta$ and/or γ -subunit of a calcium channel, wher in:

the heterologous calcium channel contains at least one subunit encoded by the heterologous nucleic acid; and

the only heterologous ion channels are calcium channels.

17. The eukaryotic cell of claim 8 with a functional, heterologous 5 calcium channel, produced by a process comprising:

introducing into the cell DNA that encodes an α_{1H} subunit of a calcium channel and optionally introducing into the cell nucleic acid that encodes a β , $\alpha_2\delta$ and/or γ -subunit of a calcium channel, wherein:

the heterologous calcium channel contains at least one subunit 10 encoded by the heterologous nucleic acid.

18. The eukaryotic cell of claim 17 selected from the group consisting of HEK 293 cells, Chinese hamster ovary cells, African green monkey cells, mouse L cells and amphibian oocytes.

19. The eukaryotic cell of claim 16 selected from the group 15 consisting of amphibian oocytes.

20. The eukaryotic cell of any of claims 6-19, wherein the α_{1H} -subunit is an α_{1H-1} subunit or an α_{1H-2} subunit.

21. The eukaryotic cell of claim 20, wherein the α_{1H} subunit is a human calcium channel subunit.

20 22. A method for identifying a compound that modulates the activity of a calcium channel that contains an α_{1H} subunit, comprising; suspending the eukaryotic cell of any of claims 8-21 in a solution containing the compound and a calcium channel selective ion:

depolarizing the cell membrane of the cell; and

25 detecting the current or ions flowing into the cell,

wherein:

the heterologous calcium channel includes at least one calcium channel subunit encoded by DNA or RNA that is heterologous to the cell,

the current that is detected is different from that produced by depolarizing the same or a substantially identical cell in the presence of the same calcium channel selective ion but in the absence of the compound.

5 23. The method of claim 22, wherein prior to the depolarization step the cell is maintained at a holding potential which substantially inactivates calcium channels that are endogenous to the cell.

24. The method of claim 23, wherein:

the cell is an amphibian oocyte;
10 the heterologous subunits are encoded by nucleic acid injected into the oocyte; and
 the heterologous subunits include an α_{1H} -subunit.

25. The method of claim 24, wherein the subunits encoded by the nucleic acid further comprise a $\alpha_2\delta$ -subunit.

15 26. The method of any of claims 22-25, wherein the cell is an HEK cell and the heterologous subunit is encoded by heterologous nucleic acid.

27. The method of any of claims 22-26, wherein the α_{1H} -subunit is an $\alpha_{1H.1}$ -subunit or an $\alpha_{1H.2}$ -subunit.

20 28. The method of claim 22, wherein:
 the heterologous calcium channel includes at least one calcium channel subunit encoded by DNA or RNA that is heterologous to the cell;
 at least one subunit is an α_{1H} -subunit;
 the current that is detected is different from that produced by
25 depolarizing the same or a substantially identical cell in the presence of the same calcium channel selective ion but in the absence of the compound.

29. A substantially pure α_1 -subunit encoded by the nucleic acid molecule of any of claims 1-5.

30. An RNA or DNA probe of at least 16 bases in length, comprising at least 16 substantially contiguous nucleic acid bases from 5 the sequence of nucleotides of claim 1 that encodes an α_{1H} -subunit of a calcium channel.

31. The probe of claim 28 that contains at least 30 nucleic acid bases that encode the subunit of a calcium channel.

32. A method for identifying nucleic acids that encode a α_{1H} 10 subunit of a calcium channel subunit, comprising hybridizing under conditions of at least low stringency a probe of claim 28 to a library of nucleic acid fragments;, and selecting hybridizing fragments.

33. The method of claim 30, wherein hybridization is effected under conditions of high stringency.

34. A method for identifying cells or tissues that express a 15 calcium channel subunit-encoding nucleic acid, comprising hybridizing under conditions of at least low stringency a probe of claim 30 or claim 31 with mRNA expressed in the cells or tissues or cDNA produced from the mRNA, and thereby identifying cells or tissue that express mRNA that 20 encodes the subunit.

35. The method of claim 32, wherein hybridization is effected under conditions of high stringency.

36. A method for producing a subunit of a calcium channel, comprising introducing the nucleic acid molecule of any of claims 1-5 into 25 a host cell, under conditions whereby the encoded subunit is expressed.

37. The method of claim 35, wherein the cell is a eukaryotic cell.

38. A eukaryotic cell, comprising a heterologous calcium channel encoded by nucleic acid encoding an α -subunit of a calcium channel, wherein the heterologous calcium channel is a low voltage activated channel or a T-type channel.

5 39. The eukaryotic cell of any of claims 6-21 and 38, wherein the α -subunit comprises the sequence of amino acids set forth in any of SEQ ID Nos. 12-16.

40. An isolated nucleic acid molecule, comprising the sequence of amino acids encoded by nucleotides 1506 to 2627 of SEQ ID No. 12.

10 41. The isolated nucleic acid molecule of claim 40, comprising the sequence of nucleotides set forth in nucleotides 1506 to 2627 of SEQ ID No. 12.

42. The nucleic acid of any of claims 1-5, 40 and 41 that is RNA.

15 43. The nucleic acid of any of claims 1-5, 40 and 41 that is DNA.

44. The cell of claim 8, further comprising nucleic acid that encodes a reporter gene construct containing a reporter gene in operative linkage with one or more transcriptional control elements that is regulated 20 by a calcium channel.

45. A method for identifying compounds that modulate the activity of a low-voltage activated calcium channel, the method comprising:

25 comparing the difference in the amount of transcription of a the reporter gene in the cell of claim 44 in the presence of the compound with the amount of transcription in the absence of the compound, or with the amount of transcription in the absence of the heterologous calcium channel, whereby compounds that

modulate the activity of the heterologous calcium channel in the cell are identified.

46. The nucleic acid molecule of any of claims 1-5, 40 and 41, wherein the calcium channel is a human calcium channel.

5 47. A screening assay for identifying a compound that modulates the activity of a low-voltage activated (LVA) calcium channel comprising the steps of:

contacting the test compound with a cell that expresses a LVA calcium channel; and

10 measuring the activity of the LVA channel in the cell before and after the addition of the test compound or in comparable cell that does not express the LVA channel; and

15 determining that the test compound modulates the activity of the low-voltage calcium channel if the measurement after compound addition is different from the measurement before the compound addition or if the measurement in presence of the receptor is different from the measurement in the absence of the receptor.

20 48. The method of claim 47, wherein the LVA channel is produced by introducing the a nucleic acid that encodes the LVA into the cell under conditions whereby the encoded LVA is expressed.

49. The method of claim 47 or claim 48, wherein the LVA is a T-type channel.

50. The method of any of claims 47-49, wherein the LVA comprises an α_{1H} -subunit of a calcium channel.

25 51. The method of any of claims 47-50, wherein the cell expresses a low-voltage calcium channel having a relative conductance of Ba^{2+} of about 5 pS to about 9 pS, an activation time of about 2 to about 8 milliseconds, a kinetics of activation $V_{1/2}$ value of about -60 millivolts to

about 26 millivolts, an inactivation time of about 10 to about 30 milliseconds, a kinetics of inactivation $V_{1/2}$ value of about -100 millivolts to about -500 millivolts, and a tail deactivation time of about 2 to about 12 milliseconds.

5 52. The screening method of any of claims 47-51, wherein the isolated nucleic acid molecule comprises a sequence of nucleotides encoding an α_{1H} -subunit of a calcium channel.

53. A compound identified by the method of any of claims 45 and 47-52.

10 54. A method of identifying compounds for treatment of LVA-type calcium channel mediated disorders, comprising identifying compounds that modulate the activity of LVA-type channels in cells that express channels containing a subunit encoded by the nucleic acid of any of claims 1-5, 40 and 41.

15 55. Compounds identified by the method of 54.

56. The method of claim 54, wherein the channels are produced by introduction of the nucleic acid of any of claims 1-5, 40 and 41 into cells under conditions whereby channels that contain the encoded subunit are expressed.

20 57. The method of claim 54 or claim 56, wherein the disorder is selected from among, neurological, endocrinological, cardiovascular, urological, hepatic, respiratory, and vascular disorders.


FIGURE 1**Steady-state activation and inactivation**




FIGURE 2A**Kinetics of activation****FIGURE 2B****Kinetics of inactivation****SUBSTITUTE SHEET (RULE 26)**

FIGURE 3
Features of the α_{1H} Subunit



Tail current deactivation




FIGURE 4B





FIGURE 4C



SUBSTITUTE SHEET (RULE 26)

(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92007

(ii) TITLE OF INVENTION: CALCIUM CHANNEL COMPOSITIONS AND METHODS

(iii) NUMBER OF SEQUENCES: 16

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Heller Ehrman White & McAuliffe
(B) STREET: 4250 Executive Square, 7th Floor
(C) CITY: La Jolla
(D) STATE: California
(E) COUNTRY: US
(F) ZIP: 92037

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 1.5 and Patentin 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 09/188,932
(B) FILING DATE: 10-NOV-1998
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Seidman, Stephanie L.
(B) REGISTRATION NUMBER: 33,779
(C) REFERENCE/DOCKET NUMBER: 24735-9815PC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (619) 450-8400
(B) TELEFAX: (619) 450-8499

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: SIBIA Neurosciences, Inc.
(B) STREET: 505 Coast Boulevard South, Suite 300
(C) CITY: La Jolla
(D) STATE: California
(E) COUNTRY: US
(F) POSTAL CODE (ZIP): 92037-4641

(i) INVENTOR/APPLICANT:

(A) NAME: Mark E. Williams
(B) STREET: 946 Jasmine Court
(C) CITY: Carlsbad
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92009

(i) INVENTOR/APPLICANT:

(A) NAME: Kenneth A. Stauderman
(B) STREET: 3615 Lotus Dr.
(C) CITY: San Diego
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92106

(i) INVENTOR/APPLICANT:

(A) NAME: Michael M. Harpold
(B) STREET: 1462 Encina Road
(C) CITY: Sante Fe
(D) STATE: New Mexico
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 87505-4726

(i) INVENTOR/APPLICANT:

(A) NAME: Michael Hans
(B) STREET: 2635 Clemente Terrace
(C) CITY: San Diego
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92122

(i) INVENTOR/APPLICANT:

(A) NAME: Arturo Urrutia
(B) STREET: 778 Beech Avenue
(C) CITY: Chula Vista
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 91910

(i) INVENTOR/APPLICANT:

(A) NAME: Mark S. Washburn
(B) STREET: 1535 Kings Cross Drive
(C) CITY: Cardiff
(D) STATE: California

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TYCCCTTGAA GAGCTGNACC CC

22

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGTGCACGTC ACGCTAG

17

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATTCTAGCG TGACGTGCAC G

21

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ACNGTGTTYC AGATCCTGAC

2

(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATCCTGACNG GNGARGACTG GAA

23

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TYCCCTTGAA GAGCTGNACN GC

22

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TYCCCTTGA AGAGCTGNAC CCC

22

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AACTGYATYA CCCTGGC

17

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATYACCCTGG CNATGGAGCG

20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GARATGATGA TGAARGT

17

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 342 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGAGATGAT	GGTGAAAGTG	GTGGCCCTGG	GGCTGCTGTC	CGGCGAGCAC	GCCTACCTGC	60
AGAGCAGCTG	GAACCTGCTG	GATGGGCTGC	TGGTGCTGGT	GTCCCTGGTG	GACATTGTCG	120
TGGCCATGGC	CTCGGCTGGT	GGCGCCAAGA	TCCTGGGTGT	TCTGCGCGTG	CTGCGTCTGC	180
TGCGGACCT	GCGGCCTCTG	AGGGTCATCA	GCCGGGGCCC	GGGCCTCAAG	CTGGTGGTGG	240
AGACGCTGAT	ATCATCACTC	AGGCCATTG	GGAACATCGT	CCTCATCTGC	TGCGCCTTCT	300
TCATCATTTC	TGGCATTTC	GGGGTTTCAGC	TCTTCAAGGG			340

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7898 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 249...7307

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGAGGCCGCC	GCCGTCGCCT	CCGCCGGGCG	AGCCGGAGCC	GGAGTCGAGC	CGCGGCCGGG	60
AGCCGGCGG	GCTGGGGACG	CGGGCCGGGG	GCGGAGGCGC	TGGGGGCCGG	GGCCGGGGCC	120
GGGGGCCGGAG	GCGCTGGGGG	CCGGGGCCGG	GGCCGGGCCGC	CGAGCGGGGT	CCGCGGTGAC	180
CGCGCCGCC	GGGCGATGCC	CGCGGGGACG	CCGCCGGCCA	GCAGAGCGAG	GTGCTGCCGG	240
CCGCCACC	ATG ACC GAG GGC	GCA CGG GCC	GAC GAG GTC	CGG GTG CCC		290
	Met Thr Glu Gly	Ala Arg Ala	Asp Glu Val	Arg Val Pro		
1	5		10			
CTG GGC GCG CCG CCC CCT GGC CCT GCG GCG TTG GTG GGG GCG TCC CCG						338
Leu Gly Ala Pro Pro Pro Gly Pro Ala Ala Leu Val Gly Ala Ser Pro						
15	20		25			30

GAG AGC CCC GGG GCG CCG GGA CGC GAG GCG GAG CGG GGG TCC GAG CTC Glu Ser Pro Gly Ala Pro Gly Arg Glu Ala Glu Arg Gly Ser Glu Leu 35 40 45	386
GGC GTG TCA CCC TCC GAG AGC CCG GCG GCC GAG CGC GGC GCG GAG CTG Gly Val Ser Pro Ser Glu Ser Pro Ala Ala Glu Arg Gly Ala Glu Leu 50 55 60	434
GGT GCC GAC GAG GAG CAG CGC GTC CCG TAC CCG GCC TTG GCG GCC ACG Gly Ala Asp Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr 65 70 75	482
GTC TTC TTC TGC CTC GGT CAG ACC ACG CGG CCG CGC AGC TGG TGC CTC Val Phe Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu 80 85 90	530
CGG CTG GTC TGC AAC CCA TGG TTC GAG CAC GTG AGC ATG CTG GTA ATC Arg Leu Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile 95 100 105 110	578
ATG CTC AAC TGC GTG ACC CTG GGC ATG TTC CGG CCC TGT GAG GAC GTT Met Leu Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val 115 120 125	626
GAG TGC GGC TCC GAG CGC TGC AAC ATC CTG GAG GCC TTT GAC GCC TTC Glu Cys Gly Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe 130 135 140	674
ATT TTC GCC TTT TTT GCG GTG GAG ATG GTC ATC AAG ATG GTG GCC TTG Ile Phe Ala Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu 145 150 155	722
GGG CTG TTC GGG CAG AAG TGT TAC CTG GGT GAC ACG TGG AAC AGG CTG Gly Leu Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu 160 165 170	770
GAT TTC TTC ATC GTC GTG GCG GGC ATG ATG GAG TAC TCG TTG GAC GGA Asp Phe Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly 175 180 185 190	818
CAC AAC GTG AGC CTC TCG GCT ATC AGG ACC GTG CGG GTG CTG CGG CCC His Asn Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro 195 200 205	866
CTC CGC GCC ATC AAC CGC GTG CCT AGC ATG CGG ATC CTG GTC ACT CTG Leu Arg Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu 210 215 220	914
CTG CTG GAT ACG CTG CCC ATG CTC GGG AAC GTC CTT CTG CTG TGC TTC Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe 225 230 235	962
TTC GTC TTC TTC ATT TTC GGC ATC GTT GGC GTC CAG CTC TGG GCT GGC Phe Val Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly 240 245 250	1010
CTC CTG CGG AAC CGC TGC TTC CTG GAC AGT GCC TTT GTC AGG AAC AAC Leu Leu Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn	1058

255	260	265	270	
AAC CTG ACC TTC CTG CGG CCG TAC TAC CAG ACG GAG GAG GGC GAG GAG				1106
Asn Leu Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu				
275	280	285		
AAC CCG TTC ATC TGC TCC TCA CGC CGA GAC AAC GGC ATG CAG AAG TGC				1154
Asn Pro Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys				
290	295	300		
TCG CAC ATC CCC GGC CGC CGC GAG CTG CGC ATG CCC TGC ACC CTG GGC				1202
Ser His Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly				
305	310	315		
TGG GAG GCC TAC ACG CAG CCG CAG GCC GAG GGG GTG GGC GCT GCA CGC				1250
Trp Glu Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg				
320	325	330		
AAC GCC TGC ATC AAC TGG AAC CAG TAC TAC AAC GTG TGC CGC TCG GGT				1298
Asn Ala Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly				
335	340	345	350	
GAC TCC AAC CCC CAC AAC GGT GCC ATC AAC TTC GAC AAC ATC GGC TAC				1346
Asp Ser Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr				
355	360	365		
GCC TGG ATT GCC ATC TTC CAG GTG ATC ACG CTG GAA GGC TGG GTG GAC				1394
Ala Trp Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp				
370	375	380		
ATC ATG TAC TAC GTC ATG GAC GCC CAC TCA TTC TAC AAC TTC ATC TAT				1442
Ile Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr				
385	390	395		
TTC ATC CTG CTC ATC ATC GTG GGC TCC TTC TTC ATG ATC AAC CTG TGC				1490
Phe Ile Leu Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys				
400	405	410		
CTG GTG GTG ATT GCC ACG CAG TTC TCG GAG ACG AAG CAG CGG GAG AGT				1538
Leu Val Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser				
415	420	425	430	
CAG CTG ATG CGG GAG CAG CGG GCA CGC CAC CTG TCC AAC GAC AGC ACG				1586
Gln Leu Met Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr				
435	440	445		
CTG GCC AGC TTC TCC GAG CCT GGC AGC TGC TAC GAA GAG CTG CTG AAG				1634
Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Leu Leu Lys				
450	455	460		
TAC GTG GGC CAC ATA TTC CGC AAG GTC AAG CGG CGC AGC TTG CGC CTC				1682
Tyr Val Gly His Ile Phe Arg Lys Val Lys Arg Arg Ser Leu Arg Leu				
465	470	475		
TAC GCC CGC TGG CAG AGC CGC TGG CGC AAG AAG GTG GAC CCC AGT GCT				1730
Tyr Ala Arg Trp Gln Ser Arg Trp Arg Lys Lys Val Asp Pro Ser Ala				
480	485	490		

GTG CAA GGC CAG GGT CCC GGG CAC CGC CAG CGC CGG GCA GGC AGG CAC Val Gln Gly Gln Gly Pro Gly His Arg Gln Arg Arg Ala Gly Arg His 495 500 505 510	1778
ACA GCC TCG GTG CAC CAC CTG GTC TAC CAC CAC CAT CAC CAC CAC CAC Thr Ala Ser Val His His Leu Val Tyr His His His His His His His 515 520 525	1826
CAC CAC TAC CAT TTC AGC CAT GGC AGC CCC CGC AGG CCC GGC CCC GAG His His Tyr His Phe Ser His Gly Ser Pro Arg Arg Pro Gly Pro Glu 530 535 540	1874
CCA GGC GCC TGC GAC ACC AGG CTG GTC CGA GCT GGC GCG CCC CCC TCG Pro Gly Ala Cys Asp Thr Arg Leu Val Arg Ala Gly Ala Pro Pro Ser 545 550 555	1922
CCA CCT TCC CCA GGC CGC GGA CCC CCC GAC GCA GAG TCT GTG CAC AGC Pro Pro Ser Pro Gly Arg Gly Pro Pro Asp Ala Glu Ser Val His Ser 560 565 570	1970
ATC TAC CAT GCC GAC TGC CAC ATA GAG GGG CCG CAG GAG AGG GCC CGG Ile Tyr His Ala Asp Cys His Ile Glu Gly Pro Gln Glu Arg Ala Arg 575 580 585 590	2018
GTG GCA CAT GCC GCA ACT GCC GCT GCC AGC CTC AGG CTG GCC ACA Val Ala His Ala Ala Ala Thr Ala Ala Ser Leu Arg Leu Ala Thr 595 600 605	2066
GGG CTG GGC ACC ATG AAC TAC CCC ACG ATC CTG CCC TCA GGG GTG GGC Gly Leu Gly Thr Met Asn Tyr Pro Thr Ile Leu Pro Ser Gly Val Gly 610 615 620	2114
AGC GGC AAA GGC AGC ACC AGC CCC GGA CCC AAG GGG AAG TGG GCC GGT Ser Gly Lys Gly Ser Thr Ser Pro Gly Pro Lys Gly Lys Trp Ala Gly 625 630 635	2162
GGA CCG CCA GGC ACC GGG GGG CAC GGC CCG TTG AGC TTG AAC AGC CCT Gly Pro Pro Gly Thr Gly Gly His Gly Pro Leu Ser Leu Asn Ser Pro 640 645 650	2210
GAT CCC TAC GAG AAG ATC CCG CAT GTG GTC GGG GAG CAT GGA CTG GGC Asp Pro Tyr Glu Lys Ile Pro His Val Val Gly Glu His Gly Leu Gly 655 660 665 670	2258
CAG GCC CCT GGC CAT CTG TCG GGC CTC AGT GTG CCC TGC CCC CTG CCC Gln Ala Pro Gly His Leu Ser Gly Leu Ser Val Pro Cys Pro Leu Pro 675 680 685	2306
AGC CCC CCA GCG GGC ACA CTG ACC TGT GAG CTG AAG AGC TGC CCG TAC Ser Pro Pro Ala Gly Thr Leu Thr Cys Glu Leu Lys Ser Cys Pro Tyr 690 695 700	2354
TGC ACC CGT GCC CTG GAG GAC CCG GAG GGT GAG CTC AGC GGC TCG GAA Cys Thr Arg Ala Leu Glu Asp Pro Glu Gly Glu Leu Ser Gly Ser Glu 705 710 715	2402
AGT GGA GAC TCA GAT GGC CGT GGC GTC TAT GAA TTC ACG CAG GAC GTC Ser Gly Asp Ser Asp Gly Arg Gly Val Tyr Glu Phe Thr Gln Asp Val	2450

720	725	730	
CGG CAC GGT GAC CGC TGG GAC CCC ACG CGA CCA CCC CGT GCG ACG GAC Arg His Gly Asp Arg Trp Asp Pro Thr Arg Pro Pro Arg Ala Thr Asp			2498
735	740	745	750
ACA CCA GGC CCA GGC CCA GGC AGC CCC CAG CGG CGG GCA CAG CAG AGG Thr Pro Gly Pro Gly Ser Pro Gln Arg Arg Ala Gln Gln Arg			2546
755	760	765	
GCA GCC CCG GGC GAG CCA GGC TGG ATG GGC CGC CTC TGG GTT ACC TTC Ala Ala Pro Gly Glu Pro Gly Trp Met Gly Arg Leu Trp Val Thr Phe			2594
770	775	780	
AGC GGC AAG CTG CGC CGC ATC GTG GAC AGC AAG TAC TTC AGC CGT GGC Ser Gly Lys Leu Arg Arg Ile Val Asp Ser Lys Tyr Phe Ser Arg Gly			2642
785	790	795	
ATC ATG ATG GCC ATC CTT GTC AAC ACG CTG AGC ATG GGC GTG GAG TAC Ile Met Met Ala Ile Leu Val Asn Thr Leu Ser Met Gly Val Glu Tyr			2690
800	805	810	
CAT GAG CAG CCC GAG GAG CTG ACT AAT GCT CTG GAG ATC AGC AAC ATC His Glu Gln Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile			2738
815	820	825	830
GTG TTC ACC AGC ATG TTT GCC CTG GAG ATG CTG CTG AAG CTG CTG GCC Val Phe Thr Ser Met Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Ala			2786
835	840	845	
TGC GGC CCT CTG GGC TAC ATC CGG AAC CCG TAC AAC ATC TTC GAC GGC Cys Gly Pro Leu Gly Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp Gly			2834
850	855	860	
ATC ATC GTG GTC ATC AGC GTC TGG GAG ATC GTG GGG CAG GCG GAC GGT Ile Ile Val Val Ile Ser Val Trp Glu Ile Val Gly Gln Ala Asp Gly			2882
865	870	875	
GGC TTG TCT GTG CTG CGC ACC TTC CGG CTG CTG CGT GTG CTG AAG CTG Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg Val Leu Lys Leu			2930
880	885	890	
GTG CGC TTT CTG CCA GCC CTG CGG CGC CAG CTC GTG GTG CTG GTG AAG Val Arg Phe Leu Pro Ala Leu Arg Arg Gln Leu Val Val Leu Val Lys			2978
895	900	905	910
ACC ATG GAC AAC GTG GCT ACC TTC TGC ACG CTG CTC ATG CTC TTC ATT Thr Met Asp Asn Val Ala Thr Phe Cys Thr Leu Leu Met Leu Phe Ile			3026
915	920	925	
TTC ATC TTC AGC ATC CTG GGC ATG CAC CTT TTC GGC TGC AAG TTC AGC Phe Ile Phe Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ser			3074
930	935	940	
CTG AAG ACA GAC ACC GGA GAC ACC GTG CCT GAC AGG AAG AAC TTC GAC Leu Lys Thr Asp Thr Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp			3122
945	950	955	

TCC CTG CTG TGG GCC ATC GTC ACC GTG TTC CAG ATC CTG ACC CAG GAG Ser Leu Leu Trp Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu 960 965 970	3170
GAC TGG AAC GTG GTC CTG TAC AAC GGC ATG GCC TCC ACC TCC TCC TGG Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp 975 980 985 990	3218
GCC GCC CTC TAC TTC GTG GCC CTC ATG ACC TTC GGC AAC TAT GTG CTC Ala Ala Leu Tyr Phe Val Ala Leu Met Thr Phe Gly Asn Tyr Val Leu 995 1000 1005	3266
TTC AAC CTG CTG GTG GCC ATC CTC GTG GAG GGC TTC CAG GCG GAG GGC Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly 1010 1015 1020	3314
GAT GCC AAC AGA TCC GAC ACG GAC GAG GAC AAG ACG TCG GTC CAC TTC Asp Ala Asn Arg Ser Asp Thr Asp Glu Asp Lys Thr Ser Val His Phe 1025 1030 1035	3362
GAG GAG GAC TTC CAC AAG CTC AGA GAA CTC CAG ACC ACA GAG CTG AAG Glu Glu Asp Phe His Lys Leu Arg Glu Leu Gln Thr Thr Glu Leu Lys 1040 1045 1050	3410
ATG TGT TCC CTG GCC GTG ACC CCC AAC GGG CAC CTG GAG GGA CGA GGC Met Cys Ser Leu Ala Val Thr Pro Asn Gly His Leu Glu Gly Arg Gly 1055 1060 1065 1070	3458
AGC CTG TCC CCT CCC CTC ATC ATG TGC ACA GCT GCC ACG CCC ATG CCT Ser Leu Ser Pro Pro Leu Ile Met Cys Thr Ala Ala Thr Pro Met Pro 1075 1080 1085	3506
ACC CCC AAG AGC TCA CCA TTC CTG GAT GCA GCC CCC AGC CTC CCA GAC Thr Pro Lys Ser Ser Pro Phe Leu Asp Ala Ala Pro Ser Leu Pro Asp 1090 1095 1100	3554
TCT CGG CGT GGC AGC AGC TCC GGG GAC CCG CCA CTG GGA GAC CAG Ser Arg Arg Gly Ser Ser Ser Gly Asp Pro Pro Leu Gly Asp Gln 1105 1110 1115	3602
AAG CCT CCG GCC AGC CTC CGA AGT TCT CCC TGT GCC CCC TGG GGC CCC Lys Pro Pro Ala Ser Leu Arg Ser Ser Pro Cys Ala Pro Trp Gly Pro 1120 1125 1130	3650
AGT GGC GCC TGG AGC AGC CGG CGC TCC AGC TGG AGC AGC CTG GGC CGT Ser Gly Ala Trp Ser Ser Arg Arg Ser Ser Trp Ser Ser Leu Gly Arg 1135 1140 1145 1150	3698
GCC CCC AGC CTC AAG CGC CGC GGC CAG TGT GGG GAA CGT GAG TCC CTG Ala Pro Ser Leu Lys Arg Arg Gly Gln Cys Gly Glu Arg Glu Ser Leu 1155 1160 1165	3746
CTG TCT GGC GAG GGC AAG GGC AGC ACC GAC GAC GAA GCT GAG GAC GGC Leu Ser Gly Glu Gly Lys Gly Ser Thr Asp Asp Glu Ala Glu Asp Gly 1170 1175 1180	3794
AGG GCC GCG CCC GGG CCC CGT GCC ACC CCA CTG CGG CGG GCC GAG TCC Arg Ala Ala Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg Ala Glu Ser	3842

1185	1190	1195		
CTG GAC CCA CGG CCC CTG CGG CCG GCC GCC CTC CCG CCT ACC AAG TGC Leu Asp Pro Arg Pro Leu Arg Pro Ala Ala Leu Pro Pro Thr Lys Cys 1200	1205	1210	3890	
CGC GAT CGC GAC GGG CAG GTG GTG GCC CTG CCC AGC GAC TTC TTC CTG Arg Asp Arg Asp Gly Gln Val Val Ala Leu Pro Ser Asp Phe Phe Leu 1215	1220	1225	1230	3938
CGC ATC GAC AGC CAC CGT GAG GAT GCA GCC GAG CTT GAC GAC GAC TCG Arg Ile Asp Ser His Arg Glu Asp Ala Ala Glu Leu Asp Asp Asp Ser 1235	1240	1245	3986	
GAG GAC AGC TGC TGC CTC CGC CTG CAT AAA GTG CTG GAG CCC TAC AAG Glu Asp Ser Cys Cys Leu Arg Leu His Lys Val Leu Glu Pro Tyr Lys 1250	1255	1260	4034	
CCC CAG TGG TGC CGG AGC CGC GAG GCC TGG GCC CTC TAC CTC TTC TCC Pro Gln Trp Cys Arg Ser Arg Glu Ala Trp Ala Leu Tyr Leu Phe Ser 1265	1270	1275	4082	
CCA CAG AAC CGG TTC CGC GTC TCC TGC CAG AAG GTC ATC ACA CAC AAG Pro Gln Asn Arg Phe Arg Val Ser Cys Gln Lys Val Ile Thr His Lys 1280	1285	1290	4130	
ATG TTT GAT CAC GTG GTC CTC GTC TTC ATC TTC CTC AAC TGC GTC ACC Met Phe Asp His Val Val Leu Val Phe Ile Phe Leu Asn Cys Val Thr 1295	1300	1305	1310	4178
ATC GCC CTG GAG AGG CCT GAC ATT GAC CCC GGC AGC ACC GAG CGG GTC Ile Ala Leu Glu Arg Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg Val 1315	1320	1325	4226	
TTC CTC AGC GTC TCC AAT TAC ATC TTC ACG GCC ATC TTC GTG GCG GAG Phe Leu Ser Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala Glu 1330	1335	1340	4274	
ATG ATG GTG AAG GTG GTG GCC CTG GGG CTG CTG TCC GGC GAG CAC GCC Met Met Val Lys Val Val Ala Leu Gly Leu Leu Ser Gly Glu His Ala 1345	1350	1355	4322	
TAC CTG CAG AGC AGC TGG AAC CTG CTG GAT GGG CTG CTG GTG CTG GTG Tyr Leu Gln Ser Ser Trp Asn Leu Leu Asp Gly Leu Leu Val Leu Val 1360	1365	1370	4370	
TCC CTG GTG GAC ATT GTC GTG GCC ATG GCC TCG GCT GGT GGC GCC AAG Ser Leu Val Asp Ile Val Val Ala Met Ala Ser Ala Gly Gly Ala Lys 1375	1380	1385	1390	4418
ATC CTG GGT GTT CTG CGC GTG CTG CGT CTG CTG CGG ACC CTG CGG CCT Ile Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro 1395	1400	1405	4466	
CTA AGG GTC ATC AGC CGG GCC CCG GGC CTC AAG CTG GTG GTG GAG ACG Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu Thr 1410	1415	1420	4514	

CTG ATA TCG TCG CTC AGG CCC ATT GGG AAC ATC GTC CTC ATC TGC TGC Leu Ile Ser Ser Leu Arg Pro Ile Gly Asn Ile Val Leu Ile Cys Cys 1425 1430 1435	4562
GCC TTC TTC ATC ATT TTT GGC ATC TTG GGT GTG CAG CTC TTC AAA GGG Ala Phe Phe Ile Ile Phe Gly Ile Leu Gly Val Gln Leu Phe Lys Gly 1440 1445 1450	4610
AAG TTC TAC TAC TGC GAG GGC CCC GAC ACC AGG AAC ATC TCC ACC AAG Lys Phe Tyr Tyr Cys Glu Gly Pro Asp Thr Arg Asn Ile Ser Thr Lys 1455 1460 1465 1470	4658
GCA CAG TGC CGG GCC GCC CAC TAC CGC TGG GTG CGA CGC AAG TAC AAC Ala Gln Cys Arg Ala Ala His Tyr Arg Trp Val Arg Arg Lys Tyr Asn 1475 1480 1485	4706
TTC GAC AAC CTG GGC CAG GCC CTG ATG TCG CTG TTC GTG CTG TCA TCC Phe Asp Asn Leu Gly Gln Ala Leu Met Ser Leu Phe Val Leu Ser Ser 1490 1495 1500	4754
AAG GAT GGA TGG GTG AAC ATC ATG TAC GAC GGG CTG GAT GCC GTG GGT Lys Asp Gly Trp Val Asn Ile Met Tyr Asp Gly Leu Asp Ala Val Gly 1505 1510 1515	4802
GTC GAC CAG CAG CCT GTG CAG AAC CAC AAC CCC TGG ATG CTG CTG TAC Val Asp Gln Gln Pro Val Gln Asn His Asn Pro Trp Met Leu Leu Tyr 1520 1525 1530	4850
TTC ATC TCC TTC CTG CTC ATC GTC AGC TTC TTC GTG CTC AAC ATG TTC Phe Ile Ser Phe Leu Leu Ile Val Ser Phe Phe Val Leu Asn Met Phe 1535 1540 1545 1550	4898
GTG GGC GTC GTG GTC GAG AAC TTC CAC AAG TGC CGG CAG CAC CAG GAG Val Gly Val Val Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu 1555 1560 1565	4946
GCG GAG GAG GCG CGG CGG CGA GAG GAG AAG CGG CTG CGG CGC CTA GAG Ala Glu Ala Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu 1570 1575 1580	4994
AGG AGG CGC AGG AGC ACT TTC CCC AGC CCA GAG GCC CAG CGC CGG CCC Arg Arg Arg Arg Ser Thr Phe Pro Ser Pro Glu Ala Gln Arg Arg Pro 1585 1590 1595	5042
TAC TAT GCC GAC TAC TCG CCC ACG CGC CGC TCC ATT CAC TCG CTG TGC Tyr Tyr Ala Asp Tyr Ser Pro Thr Arg Arg Ser Ile His Ser Leu Cys 1600 1605 1610	5090
ACC AGC CAC TAT CTC GAC CTC TTC ATC ACC TTC ATC ATC TGT GTC AAC Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile Cys Val Asn 1615 1620 1625 1630	5138
GTC ATC ACC ATG TCC ATG GAG CAC TAT AAC CAA CCC AAG TCG CTG GAC Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys Ser Leu Asp 1635 1640 1645	5186
GAG GCC CTC AAG TAC TGC AAC TAC GTC TTC ACC ATC GTG TTT GTC TTC Glu Ala Leu Lys Tyr Cys Asn Tyr Val Phe Thr Ile Val Phe Val Phe	5234

	1650	1655	1660	
GAG GCT GCA CTG AAG CTG GTA GCA TTT GGG TTC CGT CCG TTC TTC AAG Glu Ala Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Arg Phe Phe Lys	1665	1670	1675	5282
GAC AGG TGG AAC CAG CTG GAC CTG GCC ATC GTG CTG CTG TCA CTC ATG Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Leu Met	1680	1685	1690	5330
GGC ATC ACG CTG GAG GAG ATA GAG ATG AGC GCC GCG CTG CCC ATC AAC Gly Ile Thr Leu Glu Glu Ile Glu Met Ser Ala Ala Leu Pro Ile Asn	1695	1700	1705	5378
CCC ACC ATC ATC CGC ATC ATG CGC GTG CTT CGC ATT GCC CGT GTG CTG Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu	1715	1720	1725	5426
AAG CTG CTG AAG ATG GCT ACG GGC ATG CGC GCC CTG CTG GAC ACT GTG Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr Val	1730	1735	1740	5474
GTG CAA GCT CTC CCC CAG GTG GGG AAC CTG GGC CTT CTT TTC ATG CTC Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met Leu	1745	1750	1755	5522
CTG TTT TTT ATC TAT GCT GCG CTG GGA GTG GAG CTG TTC GGG AGG CTG Leu Phe Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly Arg Leu	1760	1765	1770	5570
GAG TGC AGT GAA GAC AAC CCC TGC GAG GGC CTG AGC AGG CAC GCC ACC Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg His Ala Thr	1775	1780	1785	5618
TTC AGC AAC TTC GGC ATG GCC TTC CTC ACG CTG TTC CGC GTG TCC ACG Phe Ser Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser Thr	1795	1800	1805	5666
GGG GAC AAC TGG AAC GGG ATC ATG AAG GAC ACG CTG CGC GAG TGC TCC Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Glu Cys Ser	1810	1815	1820	5714
CGT GAG GAC AAG CAC TGC CTG AGC TAC CTG CCG GCC CTG TCG CCC GTC Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu Ser Pro Val	1825	1830	1835	5762
TAC TTC GTG ACC TTC GTG CTG GTG GCC CAG TTC GTG CTG GTG AAC GTG Tyr Phe Val Thr Phe Val Leu Val Ala Gln Phe Val Leu Val Asn Val	1840	1845	1850	5810
GTG GTG GCC GTG CTC ATG AAG CAC CTG GAG GAG AGC AAC AAG GAG GCA Val Val Ala Val Leu Met Lys His Leu Glu Ser Asn Lys Glu Ala	1855	1860	1865	5858
CGG GAG GAT GCG GAG CTG GAC GCC GAG ATC GAG CTG GAG ATG GCG CAG Arg Glu Asp Ala Glu Leu Asp Ala Glu Ile Glu Leu Glu Met Ala Gln	1875	1880	1885	5906

GGC CCC GGG AGT GCA CGC CGG GTG GAC GCG GAC AGG CCT CCC TTG CCC Gly Pro Gly Ser Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu Pro 1890 1895 1900	5954
CAG GAG AGT CCG GGC GCC AGG GAT GCC CCA AAC CTG GTT GCA CGC AAG Gln Glu Ser Pro Gly Ala Arg Asp Ala Pro Asn Leu Val Ala Arg Lys 1905 1910 1915	6002
GTG TCC GTG TCC AGG ATG CTC TCG CTG CCC AAC GAC AGC TAC ATG TTC Val Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met Phe 1920 1925 1930	6050
AGG CCC GTG GTG CCT GCC TCG GCG CCC CAC CCC CGC CCG CTG CAG GAG Arg Pro Val Val Pro Ala Ser Ala Pro His Pro Arg Pro Leu Gln Glu 1935 1940 1945 1950	6098
GTG GAG ATG GAG ACC TAT GGG GCC GGC ACC CCC TTG GGC TCC GTT GCC Val Glu Met Glu Thr Tyr Gly Ala Gly Thr Pro Leu Gly Ser Val Ala 1955 1960 1965	6146
TCT GTG CAC TCT CCG CCC GCA GAG TCC TGT GCC TCC CTC CAG ATC CCA Ser Val His Ser Pro Pro Ala Glu Ser Cys Ala Ser Leu Gln Ile Pro 1970 1975 1980	6194
CTG GCT GTG TCG TCC CCA GCC AGG AGC GGC GAG CCC CTC CAC GCC CTG Leu Ala Val Ser Ser Pro Ala Arg Ser Gly Glu Pro Leu His Ala Leu 1985 1990 1995	6242
TCC CCT CGG GGC ACA GCC CGC TCC CCC AGT CTC AGC CGG CTG CTC TGC Ser Pro Arg Gly Thr Ala Arg Ser Pro Ser Leu Ser Arg Leu Leu Cys 2000 2005 2010	6290
AGA CAG GAG GCT GTG CAC ACC GAT TCC TTG GAA GGG AAG ATT GAC AGC Arg Gln Glu Ala Val His Thr Asp Ser Leu Glu Gly Lys Ile Asp Ser 2015 2020 2025 2030	6338
CCT AGG GAC ACC CTG GAT CCT GCA GAG CCT GGT GAG AAA ACC CCG GTG Pro Arg Asp Thr Leu Asp Pro Ala Glu Pro Gly Glu Lys Thr Pro Val 2035 2040 2045	6386
AGG CCG GTG ACC CAG GGG GGC TCC CTG CAG TCC CCA CCA CGC TCC CCA Arg Pro Val Thr Gln Gly Ser Leu Gln Ser Pro Pro Arg Ser Pro 2050 2055 2060	6434
CGG CCC GCC AGC GTC CGC ACT CGT AAG CAT ACC TTC GGA CAG CAC TGC Arg Pro Ala Ser Val Arg Thr Arg Lys His Thr Phe Gly Gln His Cys 2065 2070 2075	6482
GTC TCC AGC CGG CCG GCG GCC CCA GGC GGA GAG GAG GCC GAG GGC TCG Val Ser Ser Arg Pro Ala Ala Pro Gly Gly Glu Ala Glu Ala Ser 2080 2085 2090	6530
GAC CCA GCC GAC GAG GAG GTC AGC CAC ATC ACC AGC TCC GCC TGC CCC Asp Pro Ala Asp Glu Glu Val Ser His Ile Thr Ser Ser Ala Cys Pro 2095 2100 2105 2110	6578
TGG CAG CCC ACA GCC GAG CCC CAT GGC CCC GAA GGC TCC TCT CCG GTG GCC Trp Gln Pro Thr Ala Glu Pro His Gly Pro Glu Ala Ser Pro Val Ala	6626

2115	2120	2125		
Gly Gly Glu Arg Asp Leu Arg Arg Leu Tyr Ser Val Asp Ala Gln Gly 2130	2135	2140	6674	
TTC CTG GAC AAG CCG GGC CGG GCA GAC GAG CAG TGG CGG CCC TCG GCG Phe Leu Asp Lys Pro Gly Arg Ala Asp Glu Gln Trp Arg Pro Ser Ala 2145	2150	2155	6722	
GAG CTG GGC AGC GGG GAG CCT GGG GAG GCG AAG GCC TGG GGC CCT GAG Glu Leu Gly Ser Gly Glu Pro Gly Glu Ala Lys Ala Trp Gly Pro Glu 2160	2165	2170	6770	
GCC GAG CCC GCT CTG GGT GCG CGC AGA AAG AAG ATG AGC CCC CCC Ala Glu Pro Ala Leu Gly Ala Arg Arg Lys Lys Met Ser Pro Pro 2175	2180	2185	2190	6818
TGC ATC TCG GTG GAA CCC CCT GCG GAG GAC GAG GGC TCT GCG CGG CCC Cys Ile Ser Val Glu Pro Pro Ala Glu Asp Glu Gly Ser Ala Arg Pro 2195	2200	2205	6866	
TCC GCG GCA GAG GGC GGC AGC ACC ACA CTG AGG CGC AGG ACC CCG TCC Ser Ala Ala Glu Gly Ser Thr Thr Leu Arg Arg Arg Thr Pro Ser 2210	2215	2220	6914	
TGT GAG GCC ACG CCT CAC AGG GAA TCC CTG GAG CCC ACA GAG GGC TCA Cys Glu Ala Thr Pro His Arg Glu Ser Leu Glu Pro Thr Glu Gly Ser 2225	2230	2235	6962	
GGC GCC GGG GGG GAC CCT GCA GCC AAG GGG GAG CGC TGG GGC CAG GCC Gly Ala Gly Gly Asp Pro Ala Ala Lys Gly Glu Arg Trp Gly Gln Ala 2240	2245	2250	7010	
TCC TGC CGG GCT GAG CAC CTG ACC GTC CCC AGC TTT GCC TTT GAG CCG Ser Cys Arg Ala Glu His Leu Thr Val Pro Ser Phe Ala Phe Glu Pro 2255	2260	2265	2270	7058
CTG GAC CTC GGG GTC CCC AGT GGA GAC CCT TTT TTG GAC GGT AGC CAC Leu Asp Leu Gly Val Pro Ser Gly Asp Pro Phe Leu Asp Gly Ser His 2275	2280	2285	7106	
AGT GTG ACC CCA GAA TCC AGA GCT TCC TCT TCA GGG GCC ATA GTG CCC Ser Val Thr Pro Glu Ser Arg Ala Ser Ser Ser Gly Ala Ile Val Pro 2290	2295	2300	7154	
CTG GAA CCC CCA GAA TCA GAG CCT CCC ATG CCC GTC GGT GAC CCC CCA Leu Glu Pro Pro Glu Ser Glu Pro Pro Met Pro Val Gly Asp Pro Pro 2305	2310	2315	7202	
GAG AAG AGG CGG GGG CTG TAC CTC ACA GTC CCC CAG TGT CCT CTG GAG Glu Lys Arg Arg Gly Leu Tyr Leu Thr Val Pro Gln Cys Pro Leu Glu 2320	2325	2330	7250	
AAA CCA GGG TCC CCC TCA GCC ACC CCT GCC CCA GGG GGT GGT GCA GAT Lys Pro Gly Ser Pro Ser Ala Thr Pro Ala Pro Gly Gly Gly Ala Asp 2335	2340	2345	2350	7298

GAC CCC GTG TAGCTGGGG CTTGGTGCCG CCCACGGCTT TGGCCCTGGG GTCTGGGGC
 7357
 Asp Pro Val

CCCGCTGGGG	TGGAGGCCA	GGCAGAACCC	TGCATGGACC	CTGACTTGGG	TCCCCTCGTG	7417
AGCAGAAAGG	CCCCGGGAGG	ATGACGGCCC	AGGCCCTGGT	TCTCTGCCA	GCAGAGCAGG	7477
AGTAGCTGCC	GGGGCCCACG	AGCCTCCATC	CGTTCTGGTT	CGGGTTTCTC	CGAGTTTGC	7537
TACCAGCCGA	GGCTGTGCGG	GCAACTGGGT	CAGCCTCCCG	TCAGGAGAGA	AGCCGCGTCT	7597
GTGGGACGAA	GACCGGGCAC	CCGCCAGAGA	GGGGAAAGGTA	CCAGGTTGCG	TCCCTTCAGG	7657
CCCCCGCTTG	TTACAGGACA	CTCGCTGGGG	GCCCTGTGCC	CTTGCCTGGCG	GCAGGTTGCA	7717
GCCACCGCGG	CCCAATGTCA	CCTTCACTCA	CAGTCTGAGT	TCTTGTCCGC	CTGTCACGCC	7777
CTCACCAACCC	TCCCCCTCCA	GCCACCACCC	TTTCCGTTCC	GCTCGGGCCT	TCCCAGAACG	7837
GTCCTGTGAC	TCTGGGAGAG	GTGACACCTC	ACTAAGGGGC	CGACCCCATG	GAGTAACGCG	7897
C						7898

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1669 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTGCGGCTCC	GAGCGCTGCA	ACATCTTGG	GCCCTTTGAC	GCCTTCATT	TCGCCTTTT	60
TGCGGTGGAG	ATGGTCATCA	AGATGGTGGC	CTTGGGGCTG	TTCGGGCAGA	AGTGTACCT	120
GGGTGACACG	TGGAACAGGC	TGGATTCTT	CATCGTCGTG	GCAGGCATGA	TGGAGTACTC	180
GTGGGACGGA	CACAAACGTGA	GCCTCTCGGC	TATCAGGACC	GTGCGGGTGC	TGCGGCCCT	240
CCGCGCCATC	AACCGCGTGC	CTAGCATGCG	GATCCTGGTC	ACTCTGCTGC	TGGATACGCT	300
GCCCAGCTC	GGGAACGTCC	TTCTGCTGTG	CTTCTTCGTG	TTCTTCATT	TGGCATCGT	360
TGGCGTCCAG	CTCTGGGCTG	GCCTCTCGCG	GAACCGCTGC	TTCCTGGACA	GTGCCTTGT	420
CAGGAACAAAC	AACCTGACCT	TCCTGCAGCC	GTACTACCAG	ACGGAGGAGG	GCGAGGAGAA	480
CCCGTTCATC	TGCTCCTCAC	GCCGAGACAA	CGGCATGCG	AAGTGTCTGC	ACATCCCCGG	540
CCGCGCGCAG	CTGCGCATGC	CCTGCACCCCT	GGGCTGGGAG	GCCTACACGC	AGCCGCAGGC	600
CGAGGGGGTG	GGCGCTGCAC	GCAACGCGCTG	CATCAACTGG	AACCAGTACT	ACAACGTGTG	660
CCGCTCGGGT	GACTCCAACC	CCCACAAACGG	TGCCATCAAC	TTCGACAACA	TGGCTACGC	720
CTGGATTGCC	ATCTTCCAGG	TGATCACGCT	GGAAGGCTGG	GTGGACATCA	TGTACTACGT	780
CATGGACGCC	CACTCATTCT	ACAACTTCAT	CTATTTCATC	CTGCTCATCA	TCGTGGGCTC	840
CTTCTTCATG	ATCAACCTGT	GCCTGGTGGT	GATTGCCACG	CAGTCTCGG	AGACGAAGCA	900
GGGGGAGAGT	CAGCTGATGC	GGGAGCAGCG	GGCACGCCAC	CTGTCCAACG	ACAGCACGCT	960
GGCCAGCTTC	TCCGAGCCTG	GCAGCTGCTA	CGAAGAGCTG	CCCGTACTGC	ACCCGTGCC	1020
TGGAGGACCC	GGAGGGTGAG	CTCAGCGGCT	CGGAAAGTGG	AGACTCAGAT	GGCCGTGGCG	1080
TCTATGAATT	CACCGCAGGAC	GTCCGGCAGC	GTGACCGCTG	GGACCCACG	CGACCACCCC	1140
GGGCGAGCCA	GGCTGGATGG	GCCGCCCTCG	GGTTACCTTC	AGCGGCAAGC	TGCGCCGCAT	1200
CGTGGACAGC	AAGTACTTCA	GCCGTGGCAT	CATGATGGCC	ATCCTTGTCA	ACACGCTGAG	1260
CATGGGGCTG	GAGTACCATG	AGCAGCCGA	GGAGCTGACT	AATGCTCTGG	AGATCAGCAA	1320
CATCGTGTTC	ACCAGCATGT	TTGCCCTGGA	GATGCTGCTG	AAGCTGCTGG	CCTGCGGCC	1380
TCTGGGCTAC	ATCCGGAACC	CGTACAACAT	CTTCGACGGC	ATCATCGTGG	TCATCAGCGT	1440
CTGGGAGATC	GTGGGGCAGG	CGGACGGTGG	CTTGTCTGTG	CTGCGCACCT	TCCGGCTGCT	1500
CGGTGTGCTG	AAGCTGGTGC	GCTTCTGCC	AGCCCTGCCG	CGCCAGCTCG	TGGTGTGCTGGT	1560

GAAGACCATG GACAACGTGG CTACCTTCTG CACGCTGCTC ATGCTCTCA TTTTCATCTT 1620
 CAGCATCCTG GGATGCACC TTTTCGGCTG GCAAGTTCAAG CCTGAAGAA 1669

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1413 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ACGGGCTCGA	GGCTCGCTCG	CTGCCTCACCC	GGTCCCCGGC	CCGGCGCCCCG	CGCCCCGGCG	60
CCCGCGCCCC	GGCCTCACCC	GTCCGCTCAG	CGGCCCTCCAC	GCCGCGCCGA	GGCCGCGGCC	120
GTCGCCTCCG	CCGGGCGAGC	CGGAGCCGG	GTCGAGCCGC	GGCCGGGAGC	CGGGCGGGCT	180
GGGGACGCGG	GCCGGGGCG	GAGGCGCTGG	GGGCCGGGG	CGGGGCCGGG	CGCCGAGCGG	240
GGTCCGCGGT	GACCGCGCCG	CCCAGGGCGAT	GCCCGCGGGG	ACGCCGCGG	CCAGCAGAGC	300
GAGGCATGCG	GATCCTGGTC	ACTCTGCTG	TGGATAACGCT	GCCCAGTGC	GGGAACGTCC	360
TTCTGCTGTG	CTTCTCGTC	TTCTTCATT	TCGGCATCGT	TGGCGTCCAG	CTCTGGCTG	420
GCCTCCCTCG	AAACCGCTG	TTCCCTGACA	GTGCCCTTTGT	CAGGAACAAAC	AACCTGACCT	480
TCCTGCGGGC	GTACTACCAG	ACGGAGGAGG	GCGAGGAGAA	CCCGTTCATC	TGCTCCTCAC	540
GCCGAGACAA	CGGCATGCG	AAGTGCTCG	ACATCCCCGG	CCGCCGCGAG	CTGCGCATGC	600
CCTGCACCCCT	GGGCTGGGAG	GCCTACACGC	AGCCGCAGGG	CGAGGGGGTG	GGCGCTGCAC	660
GCAACGCCCTG	CATCAACTGG	AACCAGTACT	ACAAACGTGTG	CCGCTCGGGT	GACTCCAACC	720
CCCACAACGG	TGCCATCAAC	TTCGACAAAC	TCGGCTACGC	CTGGATTGCC	ATCTTCCAGG	780
TGATCACGCT	GGAAAGGCTGG	GTGGACATCA	TGTACTACGT	CATGGACGCC	CACTCATCT	840
ACAACATTCA	CTATTTCATC	CTGCTCATCA	TCTGGGGCTC	CTTCTTCATG	ATCAAACCTGT	900
GCCTGGTGGT	GATTGCCACG	CAGTCTCGG	AGACGAAGCA	GCGGGAGAGT	CAGCTGATGC	960
GGGAGCAGCG	GGCACGCCAC	CTGTCCAACG	ACAGCACGCT	GGCCAGCTTC	TCCGAGCCTG	1020
GCAGCTGCTA	CGAACAGACTG	CTGAAGACTG	GGCCAGGCC	CTGGCCATCT	GTCGGGCCTC	1080
AGTGTGCCCT	GCCCCCTGCC	CAGCCCCCA	GGGGGCACAC	TGACCTGTGA	GCTGAAGAGC	1140
TGCCCCGTACT	GCACCCGTGC	CCTGGAGGAC	CCGGAGGGTG	AGCTCAGCGG	CTCGGAAAGT	1200
GGAGACTCAG	ATGGCCGTGG	CGTCTATGAA	TTCACGCAGG	ACGTCCGGCA	CGGTGACCGC	1260
TGGGACCCA	CGCGACCACC	CCGTGCGACG	GACACACCAG	GCCCAAGGCC	AGGCAGCCCC	1320
CAGCGGCGGG	CACAGCAGAG	GGCAGCCCCG	GGCGAGCCAG	GCTGGATGGG	CCGCCTCTGG	1380
GTTACTTCAG	CGGCAAGCTG	CGCGCATCGT	GGA			1413

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7898 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 249...7307
 (D) OTHER INFORMATION: α_{1H-1}

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15

cgaggccgccc	gccgtcgccct	ccggccggggcg	agccggagcc	ggagtcgagc	cgccggccggg	60
agccggggcg	gctggggacg	ccggccgggg	gcggaggcgc	tggggccgg	ggccggggcc	120
ggggggcgag	gcgtgggg	ccggggccgg	ggccggggcgc	cgagcggggt	ccgcgggtgac	180
cgcggccccc	ggcgatgcc	cgcggggacg	ccgcccccca	gcagagcag	tgctgcgg	240
ccgcccacc	atg acc gag ggc gca cgg gcc gac gag gtc cgg gtg ccc	290				
Met Thr Gly Ala Arg Ala Ala Asp Glu Val Arg Val Pro						
1	5	10				
ctg ggc gcg ccg ccc cct ggc cct gcg gcg ttg gtg ggg gcg tcc ccg	338					
Leu Gly Ala Pro Pro Pro Gly Pro Ala Ala Leu Val Gly Ala Ser Pro						
15	20	25	30			
gag agc ccc ggg gcg ccg gga cgc gag gcg gag cgg ggg tcc gag ctc	386					
Glu Ser Pro Gly Ala Pro Gly Arg Glu Ala Glu Arg Gly Ser Glu Leu						
35	40	45				
ggc gtg tca ccc tcc gag agc ccg gcg gcc gag cgc ggc gcg gag ctg	434					
Gly Val Ser Pro Ser Glu Ser Pro Ala Ala Glu Arg Gly Ala Glu Leu						
50	55	60				
ggt gcc gac gag gag cag cgc gtc ccg tac ccg gcc ttg gcg gcc acg	482					
Gly Ala Asp Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr						
65	70	75				
gtc ttc ttc tgc ctc ggt cag acc acg cgg ccg cgc agc tgg tgc ctc	530					
Val Phe Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu						
80	85	90				
cgg ctg gtc tgc aac cca tgg ttc gag cac gtg agc atg ctg gta atc	578					
Arg Leu Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile						
95	100	105				
atg ctc aac tgc gtg acc ctg ggc atg ttc cgg ccc tgt gag gac gtt	626					
Met Leu Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val						
110	115	120	125			
gag tgc ggc tcc gag cgc tgc aac atc ctg gag gcc ttt gac gcc ttc	674					
Glu Cys Gly Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe						
130	135	140				
att ttc gcc ttt ttt gcg gtg gag atg gtc atc aag atg gtg gcc ttg	722					
Ile Phe Ala Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu						
145	150	155				
ggg ctg ttc ggg cag aag tgt tac ctg ggt gac acg tgg aac agg ctg	770					
Gly Leu Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu						
160	165	170				

gat ttc ttc atc gtc gtg gcg ggc atg atg gag tac tcg ttg gac gga	818
Asp Phe Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly	
175 180 185 190	
cac aac gtg agc ctc tcg gct atc agg acc gtg cgg gtg ctg cgg ccc	866
His Asn Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro	
195 200 205	
ctc cgc gcc atc aac cgc gtg cct agc atg cgg atc ctg gtc act ctg	914
Leu Arg Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu	
210 215 220	
ctg ctg gat acg ctg ccc atg ctc ggg aac gtc ctt ctg ctg tgc ttc	962
Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe	
225 230 235	
tcc gtc ttc ttc att ttc ggc atc gtt ggc gtc cag ctc tgg gct ggc	1010
Phe Val Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly	
240 245 250	
ctc ctg cgg aac cgc tgc ttc ctg gac agt gcc ttt gtc agg aac aac	1058
Leu Leu Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn	
255 260 265 270	
aac ctg acc ttc ctg cgg tac tac cag acg gag gag ggc gag gag	1106
Asn Leu Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu	
275 280 285	
aac ccg ttc atc tgc tcc tca cgc cga gac aac ggc atg cag aag tgc	1154
Asn Pro Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys	
290 295 300	
tcg cac atc ccc ggc cgc cgc gag ctg cgc atg ccc tgc acc ctg ggc	1202
Ser His Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly	
305 310 315	
tgg gag gcc tac acg cag ccg cag gcc gag ggg gtg ggc gct gca cgc	1250
Trp Glu Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg	
320 325 330	
aac gcc tgc atc aac tgg aac cag tac tac aac gtg tgc cgc tcg ggt	1298
Asn Ala Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly	
335 340 345 350	
gac tcc aac ccc cac aac ggt gcc atc aac ttc gac aac atc ggc tac	1346
Asp Ser Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr	
355 360 365	
gcc tgg att gcc atc ttc cag gtg atc acg ctg gaa ggc tgg gtg gac	1394
Ala Trp Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp	
370 375 380	
atc atg tac tac gtc atg gac gcc cac tca ttc tac aac ttc atc tat	1442
Ile Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr	
385 390 395	
ttc atc ctg ctc atc atc gtg ggc tcc ttc ttc atg atc aac ctg tgc	1490

Phe Ile Leu Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys			
400	405	410	
ctg gtg gtg att gcc acg cag ttc tcg gag acg aag cag cgg gag agt		1538	
Leu Val Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser			
415	420	425	
cag ctg atg cgg gag cag cgg gca cgc cac ctg tcc aac gac agc acg		1586	
Gln Leu Met Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr			
430	435	440	
ctg gcc agc ttc tcc gag cct ggc agc tgc tac gaa gag ctg ctg aag		1634	
Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys			
445	450	455	460
tac gtg ggc cac ata ttc cgc aag gtc aag cgg cgc agc ttg cgc ctc		1682	
Tyr Val Gly His Ile Phe Arg Lys Val Lys Arg Arg Ser Leu Arg Leu			
465	470	475	
tac gcc cgc tgg cag agc cgc tgg cgc aag aag gtg gac ccc agt gct		1730	
Tyr Ala Arg Trp Gln Ser Arg Trp Arg Lys Lys Val Asp Pro Ser Ala			
480	485	490	
gtg caa ggc cag ggt ccc ggg cac cgc cag cgc cgg gca ggc agg cac		1778	
Val Gln Gly Gln Gly Pro Gly His Arg Gln Arg Arg Ala Gly Arg His			
495	500	505	510
aca gcc tcg gtg cac cac ctg gtc tac cac cac cat cac cac cac		1826	
Thr Ala Ser Val His His Leu Val Tyr His His His His His His His			
515	520	525	
cac cac tac cat ttc agc cat ggc agc ccc cgc agg ccc ggc ccc gag		1874	
His His Tyr His Phe Ser His Gly Ser Pro Arg Arg Pro Gly Pro Glu			
530	535	540	
cca ggc gcc tgc gac acc agg ctg gtc cga gct ggc gcg ccc ccc tcg		1922	
Pro Gly Ala Cys Asp Thr Arg Leu Val Arg Ala Gly Ala Pro Pro Ser			
545	550	555	
cca cct tcc cca ggc cgc gga ccc ccc gac gca gag tct gtg cac agc		1970	
Pro Pro Ser Pro Gly Arg Gly Pro Pro Asp Ala Glu Ser Val His Ser			
560	565	570	
atc tac cat gcc gac tgc cac ata gag ggg ccg cag gag agg gcc cgg		2018	
Ile Tyr His Ala Asp Cys His Ile Glu Gly Pro Gln Glu Arg Ala Arg			
575	580	585	590
gtg gca cat gcc gca gcc act gcc gct gcc agc ctc agg ctg gcc aca		2066	
Val Ala His Ala Ala Ala Thr Ala Ala Ser Leu Arg Leu Ala Thr			
595	600	605	
ggg ctg ggc acc atg aac tac ccc acg atc ctg ccc tca ggg gtg ggc		2114	
Gly Leu Gly Thr Met Asn Tyr Pro Thr Ile Leu Pro Ser Gly Val Gly			
610	615	620	
agc ggc aaa ggc agc acc agc ccc gga ccc aag ggg aag tgg gcc ggt		2162	
Ser Gly Lys Gly Ser Thr Ser Pro Gly Pro Lys Gly Lys Trp Ala Gly			
625	630	635	

gga ccg cca ggc acc ggg ggg cac ggc ccg ttg agc ttg aac agc agc cct Gly Pro Pro Gly Thr Gly Gly His Gly Pro Leu Ser Leu Asn Ser Pro 640 645 650	2210
gat ccc tac gag aag atc ccg cat gtg gtc ggg gag cat gga ctg ggc Asp Pro Tyr Glu Lys Ile Pro His Val Val Gly Glu His Gly Leu Gly 655 660 665 670	2258
cag gcc cct ggc cat ctg tcg ggc ctc agt gtg ccc tgc ccc ctg ccc Gln Ala Pro Gly His Leu Ser Gly Leu Ser Val Pro Cys Pro Leu Pro 675 680 685	2306
agc ccc cca gcg ggc aca ctg acc tgt gag ctg aag agc tgc ccg tac Ser Pro Pro Ala Gly Thr Leu Thr Cys Glu Leu Lys Ser Cys Pro Tyr 690 695 700	2354
tgc acc cgt gcc ctg gag gac ccg gag ggt gag ctc agc ggc tcg gaa Cys Thr Arg Ala Leu Glu Asp Pro Glu Gly Glu Leu Ser Gly Ser Glu 705 710 715	2402
agt gga gac tca gat ggc cgt ggc gtc tat gaa ttc acg cag gac gtc Ser Gly Asp Ser Asp Gly Arg Gly Val Tyr Glu Phe Thr Gln Asp Val 720 725 730	2450
cgg cac ggt gac cgc tgg gac ccc acg cga cca ccc cgt gcg acg gac Arg His Gly Asp Arg Trp Asp Pro Thr Arg Pro Pro Arg Ala Thr Asp 735 740 745 750	2498
aca cca ggc cca ggc cca ggc agc ccc cag cgg cgg gca cag cag agg Thr Pro Gly Pro Gly Ser Pro Gln Arg Arg Ala Gln Gln Arg 755 760 765	2546
gca gcc ccg ggc gag cca ggc tgg atg ggc cgc ctc tgg gtt acc ttc Ala Ala Pro Gly Glu Pro Gly Trp Met Gly Arg Leu Trp Val Thr Phe 770 775 780	2594
agc ggc aag ctg cgc cgc atc gtg gac agc aag tac ttc agc cgt ggc Ser Gly Lys Leu Arg Arg Ile Val Asp Ser Lys Tyr Phe Ser Arg Gly 785 790 795	2642
atc atg atg gcc atc ctt gtc aac acg ctg agc atg ggc gtg gag tac Ile Met Met Ala Ile Leu Val Asn Thr Leu Ser Met Gly Val Glu Tyr 800 805 810	2690
cat gag cag ccc gag gag ctg act aat gct ctg gag atc agc aac atc His Glu Gln Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile 815 820 825 830	2738
gtg ttc acc agc atg ttt gcc ctg gag atg ctg ctg aag ctg ctg gcc Val Phe Thr Ser Met Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Ala 835 840 845	2786
tgc ggc cct ctg ggc tac atc cgg aac ccg tac aac atc ttc gac ggc Cys Gly Pro Leu Gly Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp Gly	2834

850	855	860	
atc atc gtg gtc atc agc gtc tgg gag atc gtg ggg cag gcg gac ggt Ile Ile Val Val Ile Ser Val Trp Glu Ile Val Gly Gln Ala Asp Gly 865	870	875	2882
ggc ttg tct gtg ctg cgc acc ttc cgg ctg ctg cgt gtg ctg aag ctg Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg Val Leu Lys Leu 880	885	890	2930
gtg cgc ttt ctg cca gcc ctg cgg cgc cag ctc gtg gtg ctg gtg aag Val Arg Phe Leu Pro Ala Leu Arg Arg Gln Leu Val Val Leu Val Lys 895	900	905	2978
acc atg gac aac gtg gct acc ttc tgc acg ctg ctc atg ctc ttc att Thr Met Asp Asn Val Ala Thr Phe Cys Thr Leu Leu Met Leu Phe Ile 915	920	925	3026
ttc atc ttc agc atc ctg ggc atg cac ctt ttc ggc tgc aag ttc agc Phe Ile Phe Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ser 930	935	940	3074
ctg aag aca gac acc gga gac acc gtg cct gac agg aag aac ttc gac Leu Lys Thr Asp Thr Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp 945	950	955	3122
tcc ctg ctg tgg gcc atc gtc acc gtg ttc cag atc ctg acc cag gag Ser Leu Leu Trp Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu 960	965	970	3170
gac tgg aac gtg gtc ctg tac aac ggc atg gcc tcc acc tcc tcc tgg Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp 975	980	985	3218
gcc gcc ctc tac ttc gtg gcc ctc atg acc ttc ggc aac tat gtg ctc Ala Ala Leu Tyr Phe Val Ala Leu Met Thr Phe Gly Asn Tyr Val Leu 995	1000	1005	3266
ttc aac ctg ctg gtg gcc atc ctc gtg gag ggc ttc cag gcg gag ggc Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly 1010	1015	1020	3314
gat gcc aac aga tcc gac acg gac gag aag acg tcg gtc cac ttc Asp Ala Asn Arg Ser Asp Thr Asp Glu Asp Lys Thr Ser Val His Phe 1025	1030	1035	3362
gag gag gac ttc cac aag ctc aga gaa ctc cag acc aca gag ctg aag Glu Glu Asp Phe His Lys Leu Arg Glu Leu Gln Thr Thr Glu Leu Lys 1040	1045	1050	3410
atg tgt tcc ctg gcc gtg acc ccc aac ggg cac ctg gag gga cga ggc Met Cys Ser Leu Ala Val Thr Pro Asn Gly His Leu Glu Gly Arg Gly 1055	1060	1065	3458
agc ctg tcc cct ccc ctc atc atg tgc aca gct gcc acg ccc atg cct Ser Leu Ser Pro Pro Leu Ile Met Cys Thr Ala Ala Thr Pro Met Pro			3506

1075	1080	1085	
acc ccc aag agc tca cca ttc ctg gat Thr Pro Lys Ser Ser Pro Phe Leu Asp Ala Ala Pro Ser Leu Pro Asp 1090	1095	1100	3554
tct cgg cgt ggc agc agc tcc ggg gac ccg cca ctg gga gac cag Ser Arg Arg Gly Ser Ser Ser Gly Asp Pro Pro Leu Gly Asp Gln 1105	1110	1115	3602
aag cct ccg gcc agc ctc cga agt tct ccc tgt gcc ccc tgg ggc ccc Lys Pro Pro Ala Ser Leu Arg Ser Ser Pro Cys Ala Pro Trp Gly Pro 1120	1125	1130	3650
agt ggc gcc tgg agc agc cgg cgc tcc agc tgg agc agc ctg ggc cgt Ser Gly Ala Trp Ser Ser Arg Arg Ser Ser Trp Ser Ser Leu Gly Arg 1135	1140	1145	3698
gcc ccc agc ctc aag cgc cgc ggc cag tgt ggg gaa cgt gag tcc ctg Ala Pro Ser Leu Lys Arg Arg Gly Gln Cys Gly Glu Arg Glu Ser Leu 1155	1160	1165	3746
ctg tct ggc gag ggc aag ggc agc acc gac gac gaa gct gag gac ggc Leu Ser Gly Glu Gly Lys Gly Ser Thr Asp Asp Glu Ala Glu Asp Gly 1170	1175	1180	3794
agg gcc gcg ccc ggg ccc cgt gcc acc cca ctg cgg cgg gcc gag tcc Arg Ala Ala Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg Ala Glu Ser 1185	1190	1195	3842
ctg gac cca cgg ccc ctg cgg ccc gcc ccc ctc ccc cct acc aag tgc Leu Asp Pro Arg Pro Leu Arg Pro Ala Ala Leu Pro Pro Thr Lys Cys 1200	1205	1210	3890
cgc gat cgc gac ggg cag gtg gtg gcc ctg ccc agc gac ttc ttc ctg Arg Asp Arg Asp Gly Gln Val Val Ala Leu Pro Ser Asp Phe Phe Leu 1215	1220	1225	3938
cgc atc gac agc cac cgt gag gat gca gcc gag ctt gac gac gac tcg Arg Ile Asp Ser His Arg Glu Asp Ala Ala Glu Leu Asp Asp Asp Ser 1235	1240	1245	3986
gag gac agc tgc tgc ctc cgc ctg cat aaa gtg ctg gag ccc tac aag Glu Asp Ser Cys Cys Leu Arg Leu His Lys Val Leu Glu Pro Tyr Lys 1250	1255	1260	4034
ccc cag tgg tgc cgg agc cgc gag gcc tgg gcc ctc tac ctc ttc tcc Pro Gln Trp Cys Arg Ser Arg Glu Ala Trp Ala Leu Tyr Leu Phe Ser 1265	1270	1275	4082
cca cag aac cgg ttc cgc gtc tcc tgc cag aag gtc atc aca cac aag Pro Gln Asn Arg Phe Arg Val Ser Cys Gln Lys Val Ile Thr His Lys 1280	1285	1290	4130
atg ttt gat cac gtg gtc ctc gtc ttc atc ttc ctc aac tgc gtc acc Met Phe Asp His Val Val Leu Val Phe Ile Phe Leu Asn Cys Val Thr 1295	1300	1305	4178
		1310	

atc gcc ctg gag agg cct gac att gac ccc ggc agc acc gag cggttc	4226
Ile Ala Leu Glu Arg Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg Val	
1315 1320 1325	
ttc ctc agc gtc tcc aat tac atc ttc acg gcc atc ttc gtggcg gag	4274
Phe Leu Ser Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala Glu	
1330 1335 1340	
atg atg gtg aag gtg gtg gcc ctg ggg ctg ctg tcc ggc gag cac gcc	4322
Met Met Val Lys Val Val Ala Leu Gly Leu Leu Ser Gly Glu His Ala	
1345 1350 1355	
tac ctg cag agc agc tgg aac ctg ctg gat ggg ctg ctg gtg ctg gtg	4370
Tyr Leu Gln Ser Ser Trp Asn Leu Leu Asp Gly Leu Leu Val Leu Val	
1360 1365 1370	
tcc ctg gtg gac att gtc gtg gcc atg gcc tcg gct ggt ggc gcc aag	4418
Ser Leu Val Asp Ile Val Val Ala Met Ala Ser Ala Gly Gly Ala Lys	
1375 1380 1385 1390	
atc ctg ggt gtt ctg cgc gtg ctg cgt ctg ctg cgg acc ctg cgg cct	4466
Ile Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro	
1395 1400 1405	
cta agg gtc atc agc cgg gcc ccg ggc ctc aag ctg gtg gtg gag acg	4514
Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu Thr	
1410 1415 1420	
ctg ata tcg tcg ctc agg ccc att ggg aac atc gtc ctc atc tgc tgc	4562
Leu Ile Ser Ser Leu Arg Pro Ile Gly Asn Ile Val Leu Ile Cys Cys	
1425 1430 1435	
gcc ttc ttc atc att ttt ggc atc ttg ggt gtg cag ctc ttc aaa ggg	4610
Ala Phe Phe Ile Ile Phe Gly Ile Leu Gly Val Gln Leu Phe Lys Gly	
1440 1445 1450	
aag ttc tac tac tgc gag ggc ccc gac acc agg aac atc tcc acc aag	4658
Lys Phe Tyr Tyr Cys Glu Gly Pro Asp Thr Arg Asn Ile Ser Thr Lys	
1455 1460 1465 1470	
gca cag tgc cgg gcc gcc cac tac cgc tgg gtg cga cgc aag tac aac	4706
Ala Gln Cys Arg Ala Ala His Tyr Arg Trp Val Arg Arg Lys Tyr Asn	
1475 1480 1485	
ttc gac aac ctg ggc cag gcc ctg atg tcg ctg ttc gtg ctg tca tcc	4754
Phe Asp Asn Leu Gly Gln Ala Leu Met Ser Leu Phe Val Leu Ser Ser	
1490 1495 1500	
aag gat gga tgg gtg aac atc atg tac gac ggg ctg gat gcc gtg ggt	4802
Lys Asp Gly Trp Val Asn Ile Met Tyr Asp Gly Leu Asp Ala Val Gly	
1505 1510 1515	
gtc gac cag cag cct gtg cag aac cac aac ccc tgg atg ctg ctg tac	4850
Val Asp Gln Gln Pro Val Gln Asn His Asn Pro Trp Met Leu Leu Tyr	
1520 1525 1530	

ttc atc tcc ttc ctg ctc atc gtc agc ttc ttc gtg ctc aac atg ttc Phe Ile Ser Phe Leu Leu Ile Val Ser Phe Phe Val Leu Asn Met Phe	1535	1540	1545	1550	4898
gtg ggc gtc gtg gtc gag aac ttc cac aag tgc cgg cag cac cag gag Val Gly Val Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu	1555		1560	1565	4946
gcg gag gag gcg cggtt cga gag gag aag cgg ctg cgg cgc cta gag Ala Glu Ala Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu	1570	1575		1580	4994
agg agg cgc agg agc act ttc ccc agc cca gag gcc cag cgc cgg ccc Arg Arg Arg Arg Ser Thr Phe Pro Ser Pro Glu Ala Gln Arg Arg Pro	1585	1590		1595	5042
tac tat gcc gac tac tcg ccc acg cgc cgc tcc att cac tcg ctg tgc Tyr Tyr Ala Asp Tyr Ser Pro Thr Arg Arg Ser Ile His Ser Leu Cys	1600	1605		1610	5090
acc agc cac tat ctc gac ctc ttc atc acc ttc atc atc tgt gtc aac Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile Cys Val Asn	1615	1620	1625		5138
gtc atc acc atg tcc atg gag cac tat aac caa ccc aag tcg ctg gac Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys Ser Leu Asp	1635		1640	1645	5186
gag gcc ctc aag tac tgc aac tac gtc ttc acc atc gtg ttt gtc ttc Glu Ala Leu Lys Tyr Cys Asn Tyr Val Phe Thr Ile Val Phe Val Phe	1650	1655		1660	5234
gag gct gca ctg aag ctg gta gca ttt ggg ttc cgt cgg ttc ttc aag Glu Ala Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Phe Phe Lys	1665	1670		1675	5282
gac agg tgg aac cag ctg gac ctg gcc atc gtg ctg ctg tca ctc atg Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Leu Met	1680	1685		1690	5330
ggc atc acg ctg gag gag ata gag atg agc gcc gcg ctg ccc atc aac Gly Ile Thr Leu Glu Ile Glu Met Ser Ala Ala Leu Pro Ile Asn	1695	1700	1705		5378
ccc acc atc atc cgc atc atg cgc gtg ctt cgc att gcc cgt gtg ctg Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu	1715		1720	1725	5426
aag ctg ctg aag atg gct acg ggc atg cgc gcc ctg ctg gac act gtg Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr Val	1730	1735		1740	5474
gtg caa gct ctc ccc cag gtg ggg aac ctg ggc ctt ctt ttc atg ctc Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met Leu	1745	1750		1755	5522

ctg ttt ttt atc tat gct gcg ctg gga gtg gag ctg ttc ggg agg ctg Leu Phe Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly Arg Leu 1760 1765 1770	5570
gag tgc agt gaa gac aac ccc tgc gag ggc ctg agc agg cac gcc acc Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg His Ala Thr 1775 1780 1785 1790	5618
ttc agc aac ttc ggc atg gcc ttc ctc acg ctg ttc cgc gtg tcc acg Phe Ser Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser Thr 1795 1800 1805	5666
ggg gac aac tgg aac ggg atc atg aag gac acg ctg cgc gag tgc tcc Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Glu Cys Ser 1810 1815 1820	5714
cgt gag gac ag cac tgc ctg agc tac ctg ccg gcc ctg tcg ccc gtc Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu Ser Pro Val 1825 1830 1835	5762
tac ttc gtg acc ttc gtg ctg gtg gcc cag ttc gtg ctg gtg aac gtg Tyr Phe Val Thr Phe Val Leu Val Ala Gln Phe Val Leu Val Asn Val 1840 1845 1850	5810
gtg gtg gcc gtg ctc atg aag cac ctg gag gag agc aac aag gag gca Val Val Ala Val Leu Met Lys His Leu Glu Glu Ser Asn Lys Glu Ala 1855 1860 1865 1870	5858
cgg gag gat gcg gag ctg gac gcc gag atc gag ctg gag atg gcg cag Arg Glu Asp Ala Glu Leu Asp Ala Glu Ile Glu Leu Glu Met Ala Gln 1875 1880 1885	5906
ggc ccc ggg agt gca cgc cgg gtg gac gcg gac agg cct ccc ttg ccc Gly Pro Gly Ser Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu Pro 1890 1895 1900	5954
cag gag agt ccg ggc gcc agg gat gcc cca aac ctg gtt gca cgc aag Gln Glu Ser Pro Gly Ala Arg Asp Ala Pro Asn Leu Val Ala Arg Lys 1905 1910 1915	6002
gtg tcc gtg tcc agg atg ctc tcg ctg ccc aac gac agc tac atg ttc Val Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met Phe 1920 1925 1930	6050
agg ccc gtg gtg cct gcc tcg gcg ccc cac ccc cgc ccc ctg cag gag Arg Pro Val Val Pro Ala Ser Ala Pro His Pro Arg Pro Leu Gln Glu 1935 1940 1945 1950	6098
gtg gag atg gag acc tat ggg gcc ggc acc ccc ttg ggc tcc gtt gcc Val Glu Met Glu Thr Tyr Gly Ala Gly Thr Pro Leu Gly Ser Val Ala 1955 1960 1965	6146
tct gtg cac tct ccg ccc gca gag tcc tgt gcc tcc ctc cag atc cca Ser Val His Ser Pro Pro Ala Glu Ser Cys Ala Ser Leu Gln Ile Pro 1970 1975 1980	6194
ctg gct gtg tcg tcc cca gcc agg agc ggc gag ccc ctc cac gcc ctg	6242

Leu Ala Val Ser Ser Pro Ala Arg Ser Gly Glu Pro Leu His Ala Leu
 1985 1990 1995

tcc cct cg ^g aca gcc cgc tcc ccc agt ctc agc cg ^g ctg ctc tgc	6290
Ser Pro Arg Gly Thr Ala Arg Ser Pro Ser Leu Ser Arg Leu Leu Cys	
2000 2005 2010	
aga cag gag gct gtg cac acc gat tcc ttg gaa ggg aag att gac agc	6338
Arg Gln Glu Ala Val His Thr Asp Ser Leu Glu Gly Lys Ile Asp Ser	
2015 2020 2025 2030	
cct agg gac acc ctg gat cct gca gag cct ggt gag aaa acc ccg gtg	6386
Pro Arg Asp Thr Leu Asp Pro Ala Glu Pro Gly Glu Lys Thr Pro Val	
2035 2040 2045	
agg ccg gtg acc cag ggg ggc tcc ctg cag tcc cca cca cgc tcc cca	6434
Arg Pro Val Thr Gln Gly Gly Ser Leu Gln Ser Pro Pro Arg Ser Pro	
2050 2055 2060	
cg ^g ccc gcc agc gtc cgc act cgt aag cat acc ttc gga cag cac tgc	6482
Arg Pro Ala Ser Val Arg Thr Arg Lys His Thr Phe Gly Gln His Cys	
2065 2070 2075	
gtc tcc agc cg ^g ccg ggc gcc cca ggc gga gag gag gcc gag ggc tcg	6530
Val Ser Ser Arg Pro Ala Ala Pro Gly Gly Glu Ala Glu Ala Ser	
2080 2085 2090	
gac cca gcc gac gag gag gtc agc cac atc acc agc tcc gcc tgc ccc	6578
Asp Pro Ala Asp Glu Glu Val Ser His Ile Thr Ser Ser Ala Cys Pro	
2095 2100 2105 2110	
tgg cag ccc aca gcc gag ccc cat gg ^g ccc gaa gcc tct ccg gtg gcc	6626
Trp Gln Pro Thr Ala Glu Pro His Gly Pro Glu Ala Ser Pro Val Ala	
2115 2120 2125	
ggc ggc gag cg ^g gac ctg cgc agg ctc tac agc gtg gac gct cag ggc	6674
Gly Gly Glu Arg Asp Leu Arg Arg Leu Tyr Ser Val Asp Ala Gln Gly	
2130 2135 2140	
tcc ctg gac aag ccg ggc cg ^g gca gac gag cag tgg ccg ccc tcg gcg	6722
Phe Leu Asp Lys Pro Gly Arg Ala Asp Glu Gln Trp Arg Pro Ser Ala	
2145 2150 2155	
gag ctg ggc agc ggg gag cct ggg gag ggc aag gcc tgg ggc cct gag	6770
Glu Leu Gly Ser Gly Glu Pro Gly Glu Ala Lys Ala Trp Gly Pro Glu	
2160 2165 2170	
gcc gag ccc gct ctg ggt ggc cgc aga aag aag aag atg agc ccc ccc	6818
Ala Glu Pro Ala Leu Gly Ala Arg Arg Lys Lys Lys Met Ser Pro Pro	
2175 2180 2185 2190	
tgc atc tcg gtg gaa ccc cct ggc gag gac gag ggc tct gcg cg ^g ccc	6866
Cys Ile Ser Val Glu Pro Pro Ala Glu Asp Glu Gly Ser Ala Arg Pro	
2195 2200 2205	
tcc gcg gca gag ggc ggc agc acc aca ctg agg cgc agg acc ccg tcc	6914
Ser Ala Ala Glu Gly Gly Ser Thr Thr Leu Arg Arg Arg Thr Pro Ser	
2210 2215 2220	

tgt gag gcc acg cct cac agg gac tcc ctg gag ccc aca gag ggc tca	6962
Cys Glu Ala Thr Pro His Arg Asp Ser Leu Glu Pro Thr Glu Gly Ser	
2225 2230 2235	
ggc gcc ggg ggg gac cct gca gcc aag ggg gag cgc tgg ggc cag gcc	7010
Gly Ala Gly Gly Asp Pro Ala Ala Lys Gly Glu Arg Trp Gly Gln Ala	
2240 2245 2250	
tcc tgc cgg gct gag cac ctg acc gtc ccc agc ttt gcc ttt gag ccg	7058
Ser Cys Arg Ala Glu His Leu Thr Val Pro Ser Phe Ala Phe Glu Pro	
2255 2260 2265 2270	
ctg gac ctc ggg gtc ccc agt gga gac cct ttc ttg gac ggt agc cac	7106
Leu Asp Leu Gly Val Pro Ser Gly Asp Pro Phe Leu Asp Gly Ser His	
2275 2280 2285	
agt gtg acc cca gaa tcc aga gct tcc tct tca ggg gcc ata gtg ccc	7154
Ser Val Thr Pro Glu Ser Arg Ala Ser Ser Gly Ala Ile Val Pro	
2290 2295 2300	
ctg gaa ccc cca gaa tca gag cct ccc atg ccc gtc ggt gac ccc cca	7202
Leu Glu Pro Pro Glu Ser Glu Pro Pro Met Pro Val Gly Asp Pro Pro	
2305 2310 2315	
gag aag agg cgg ggg ctg tac ctc aca gtc ccc cag tgt cct ctg gag	7250
Glu Lys Arg Arg Gly Leu Tyr Leu Thr Val Pro Gln Cys Pro Leu Glu	
2320 2325 2330	
aaa cca ggg tcc ccc tca gcc acc cct gcc cca ggg ggt ggt gca gat	7298
Lys Pro Gly Ser Pro Ser Ala Thr Pro Ala Pro Gly Gly Ala Asp	
2335 2340 2345 2350	
gac ccc gtg tag ctcggggctt ggtgccgccc acggctttgg ccctggggtc	7350
Asp Pro Val	
tggggcccccc gctggggtgg aggcccaggc agaaccctgc atggaccctg acttgggtcc	7410
cgtcgtagc agaaaggccc ggggaggatg acggcccagg ccctggttct ctgcccagcg	7470
aaggcaggagt agctgccggg ccccacgagc ctccatccgt tctggttcgg gtttctccga	7530
gtttgtcac cagcccgaggc tggcgccca actgggtcag cctcccgta ggagagaagc	7590
cgcgctgtg ggacgaagac cgggcacccg ccagagaggg gaaggtacca gtttgctcc	7650
tttcaggccc cgcttgtta caggacactc gctggggcc ctgtgccctt gccggcggca	7710
ggttgcagcc accgcggccc aatgtcacct tcactcacag tctgagttct tgccgcctg	7770
tcacgcctc accacccctcc cttccagcc accaccctt ccgtccgct cgggccttcc	7830
cagaagcgtc ctgtgactct gggagaggtg acacctaact aaggggccga ccccatggag	7890
taacgcgc	7898

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6941 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:
 (vi) ORIGINAL SOURCE:
 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence
 (B) LOCATION: 249... 6353
 (D) OTHER INFORMATION: α_{1H-2}

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16

cgaggccgccc	gccgtcgccct	ccggccggggcg	agccggagcc	ggagtcgagc	cgcggccggg	60
agccggggcg	gctggggacg	ccccgggggg	gcggaggcgc	tggggggccgg	ggccggggcc	120
ggggggcgag	gcgctggggg	ccggggggccgg	ggccggggcgc	cgagcgggggt	ccgcgggtgac	180
cgcggccccc	gggcgatgcc	cgccggggacg	ccgcggggcca	gcagagcggag	gtgctggccgg	240
ccgccacc	atg acc gag ggc gca cgg gcc gac gag gtc cgg gtg ccc	290				
Met Thr Glu Gly Ala Arg Ala Ala Asp Glu Val Arg Val Pro						
1	5	10				
ctg ggc gcg ccc cct ggc cct gcg gcg ttg gtg ggg gcg tcc ccg	338					
Leu Gly Ala Pro Pro Pro Gly Pro Ala Ala Leu Val Gly Ala Ser Pro						
15	20	25				30
gag agc ccc ggg gcg ccg gga cgc gag gcg gag cgg ggg tcc gag ctc	386					
Glu Ser Pro Gly Ala Pro Gly Arg Glu Ala Glu Arg Gly Ser Glu Leu						
35	40	45				
ggc gtg tca ccc tcc gag agc ccg gcg gcc gag cgc ggc gcg gag ctg	434					
Gly Val Ser Pro Ser Glu Ser Pro Ala Ala Glu Arg Gly Ala Glu Leu						
50	55	60				
ggt gcc gac gag gag cag cgc gtc ccg tac ccg gcc ttg gcg gcc acg	482					
Gly Ala Asp Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr						
65	70	75				
gtc ttc ttc tgc ctc ggt cag acc acg ccg ccg cgc agc tgg tgc ctc	530					
Val Phe Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu						
80	85	90				
cgg ctg gtc tgc aac cca tgg ttc gag cac gtg agc atg ctg gta atc	578					
Arg Leu Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile						
95	100	105				110
atg ctc aac tgc gtg acc ctg ggc atg ttc ccg ccc tgt gag gac gtt	626					
Met Leu Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val						
115	120	125				
gag tgc ggc tcc gag cgc tgc aac atc ctg gag gcc ttt gac gcc ttc	674					
Glu Cys Gly Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe						
130	135	140				
att ttc gcc ttt ttt gcg gtg gag atg gtc atc aag atg gtg gcc ttg	722					
Ile Phe Ala Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu						
145	150	155				
ggg ctg ttc ggg cag aag tgt tac ctg ggt gac acg tgg aac agg ctg	770					

Gly Leu Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu			
160	165	170	
gat ttc ttc atc gtc gtg gcg ggc atg atg gag tac tcg ttg gac gga			818
Asp Phe Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly			
175	180	185	190
cac aac gtg agc ctc tcg gct atc agg acc gtg cggttg ctg cgg ccc			866
His Asn Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro			
195	200	205	
ctc cgc gcc atc aac cgc gtg cct agc atg cggtatc ctg gtc act ctg			914
Leu Arg Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu			
210	215	220	
ctg ctg gat acg ctg ccc atg ctc ggg aac gtc ctt ctg ctg tgc ttc			962
Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe			
225	230	235	
tcc gtc ttc att ttc ggc atc gtt ggc gtc cag ctc tgg gct ggc			1010
Phe Val Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly			
240	245	250	
ctc ctg cgg aac cgc tgc ttc ctg gac agt gcc ttt gtc agg aac aac			1058
Leu Leu Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn			
255	260	265	270
aac ctg acc ttc ctg cgg ccg tac tac cag acg gag gag ggc gag gag			1106
Asn Leu Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu			
275	280	285	
aac ccg ttc atc tgc tcc tca cgc cga gac aac ggc atg cag aag tgc			1154
Asn Pro Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys			
290	295	300	
tcg cac atc ccc ggc cgc cgc gag ctg cgc atg ccc tgc acc ctg ggc			1202
Ser His Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly			
305	310	315	
tgg gag gcc tac acg cag ccg cag gcc gag ggg gtg ggc gct gca cgc			1250
Trp Glu Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg			
320	325	330	
aac gcc tgc atc aac tgg aac cag tac tac aac gtg tgc cgc tcg ggt			1298
Asn Ala Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly			
335	340	345	350
gac tcc aac ccc cac aac ggt gcc atc aac ttc gac aac atc ggc tac			1346
Asp Ser Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr			
355	360	365	
gcc tgg att gcc atc ttc cag gtg atc acg ctg gaa ggc tgg gtg gac			1394
Ala Trp Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp			
370	375	380	
atc atg tac tac gtc atg gac gcc cac tca ttc tac aac ttc atc tat			1442
Ile Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr			
385	390	395	

ttc atc ctg ctc atc atc gtg ggc tcc ttc atg atc aac ctg tgc Phe Ile Leu Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys	1490
400 405 410	
ctg gtg gtg att gcc acg cag ttc tcg gag acg aag cag cg ^g gag agt Leu Val Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser	1538
415 420 425 430	
cag ctg atg cgg gag cag cgg gca cgc cac ctg tcc aac gac agc acg Gln Leu Met Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr	1586
435 440 445	
ctg gcc agc ttc tcc gag cct ggc agc tgc tac gaa gag ctg ctg aag Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys	1634
450 455 460	
tac gtg ggc cac ata ttc cgc atc gtg gac agc aag tac ttc agc cgt Tyr Val Gly His Ile Phe Arg Ile Val Asp Ser Lys Tyr Phe Ser Arg	1682
465 470 475	
ggc atc atg atg gcc atc ctt gtc aac acg ctg agc atg ggc gtg gag Gly Ile Met Met Ala Ile Leu Val Asn Thr Leu Ser Met Gly Val Glu	1730
480 485 490	
tac cat gag cag ccc gag gag ctg act aat gct ctg gag atc agc aac Tyr His Glu Gln Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn	1778
495 500 505 510	
atc gtg ttc acc agc atg ttt gcc ctg gag atg ctg ctg aag ctg ctg Ile Val Phe Thr Ser Met Phe Ala Leu Glu Met Leu Leu Lys Leu Leu	1826
515 520 525	
gcc tgc ggc cct ctg ggc tac atc cgg aac ccg tac aac atc ttc gac Ala Cys Gly Pro Leu Gly Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp	1874
530 535 540	
ggc atc atc gtg gtc atc agc gtc tgg gag atc gtg ggg cag gc ^g gac Gly Ile Ile Val Val Ile Ser Val Trp Glu Ile Val Gly Gln Ala Asp	1922
545 550 555	
ggt ggc ttg tct gtg ctg cgc acc ttc cgg ctg ctg cgt gtg ctg aag Gly Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg Val Leu Lys	1970
560 565 570	
ctg gtg cgc ttt ctg cca gcc ctg cgg cgc cag ctc gtg gtg ctg gtg Leu Val Arg Phe Leu Pro Ala Leu Arg Arg Gln Leu Val Val Leu Val	2018
575 580 585 590	
aag acc atg gac aac gtg gct acc ttc tgc acg ctg ctc atg ctc ttc Lys Thr Met Asp Asn Val Ala Thr Phe Cys Thr Leu Leu Met Leu Phe	2066
595 600 605	
att ttc atc ttc agc atc ctg ggc atg cac ctt ttc ggc tgc aag ttc Ile Phe Ile Phe Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe	2114
610 615 620	
agc ctg aag aca gac acc gga gac acc gtg cct gac agg aag aac ttc	2162

Ser	Leu	Lys	Thr	Asp	Thr	Gly	Asp	Thr	Val	Pro	Asp	Arg	Lys	Asn	Phe	
625						630						635				
gac	tcc	ctg	ctg	tgg	gcc	atc	gtc	acc	gtg	ttc	cag	atc	ctg	acc	cag	2210
Asp	Ser	Leu	Leu	Trp	Ala	Ile	Val	Thr	Val	Phe	Gln	Ile	Leu	Thr	Gln	
640				645							650					
gag	gac	tgg	aac	gtg	gtc	ctg	tac	aac	ggc	atg	gcc	tcc	acc	tcc	tcc	2258
Glu	Asp	Trp	Asn	Val	Val	Leu	Tyr	Asn	Gly	Met	Ala	Ser	Thr	Ser	Ser	
655				660					665					670		
tgg	gcc	gcc	ctc	tac	ttc	gtg	gcc	ctc	atg	acc	ttc	ggc	aac	tat	gtg	2306
Trp	Ala	Ala	Leu	Tyr	Phe	Val	Ala	Leu	Met	Thr	Phe	Gly	Asn	Tyr	Val	
675					680								685			
ctc	ttc	aac	ctg	ctg	gtg	gcc	atc	ctc	gtg	gag	ggc	tcc	cag	gcg	gag	2354
Leu	Phe	Asn	Leu	Leu	Val	Ala	Ile	Leu	Val	Glu	Gly	Phe	Gln	Ala	Glu	
690					695								700			
ggc	gat	gcc	aac	aga	tcc	gac	acg	gac	gag	gac	aag	acg	tcg	gtc	cac	2402
Gly	Asp	Ala	Asn	Arg	Ser	Asp	Thr	Asp	Glu	Asp	Lys	Thr	Ser	Val	His	
705					710						715					
tcc	gag	gag	gac	ttc	cac	aag	ctc	aga	gaa	ctc	cag	acc	aca	gag	ctg	2450
Phe	Glu	Glu	Asp	Phe	His	Lys	Leu	Arg	Glu	Leu	Gln	Thr	Thr	Glu	Leu	
720					725						730					
aag	atg	tgt	tcc	ctg	gcc	gtg	acc	ccc	aat	ggg	cac	ctg	gag	gga	cga	2498
Lys	Met	Cys	Ser	Leu	Ala	Val	Thr	Pro	Asn	Gly	His	Leu	Glu	Gly	Arg	
735					740					745				750		
ggc	agc	ctg	tcc	cct	ccc	ctc	atc	atg	tgc	aca	gct	gcc	acg	ccc	atg	2546
Gly	Ser	Leu	Ser	Pro	Pro	Leu	Ile	Met	Cys	Thr	Ala	Ala	Thr	Pro	Met	
755					760								765			
cct	acc	ccc	aag	agc	tca	cca	ttc	ctg	gat	gca	gcc	ccc	agc	ctc	cca	2594
Pro	Thr	Pro	Ser	Ser	Pro	Phe	Leu	Asp	Ala	Ala	Pro	Ser	Leu	Pro		
770					775						780					
gac	tct	cg	gt	gg	gc	ag	tc	gg	gac	cc	cc	ct	gg	gac	2642	
Asp	Ser	Arg	Arg	Gly	Ser	Ser	Ser	Ser	Gly	Asp	Pro	Pro	Leu	Gly	Asp	
785					790					795						
cag	aag	cct	ccg	gcc	agc	ctc	cg	agt	tct	ccc	tgt	gcc	ccc	tgg	ggc	2690
Gln	Lys	Pro	Pro	Ala	Ser	Leu	Arg	Ser	Ser	Pro	Cys	Ala	Pro	Trp	Gly	
800					805						810					
ccc	agt	ggc	gcc	tgg	agc	agc	cg	cg	tcc	agc	tgg	agc	agc	ctg	ggc	2738
Pro	Ser	Gly	Ala	Trp	Ser	Ser	Arg	Arg	Ser	Ser	Trp	Ser	Ser	Leu	Gly	
815					820					825				830		
cgt	gcc	ccc	agc	ctc	aag	cg	cg	gg	cag	tgt	ggg	gaa	cgt	gag	tcc	2786
Arg	Ala	Pro	Ser	Leu	Lys	Arg	Arg	Gly	Gln	Cys	Gly	Glu	Arg	Glu	Ser	
835						840							845			
ctg	ctg	tct	ggc	gag	ggc	aag	ggc	agc	acc	gac	gac	gaa	gct	gag	gac	2834
Leu	Leu	Ser	Gly	Glu	Gly	Lys	Gly	Ser	Thr	Asp	Asp	Glu	Ala	Glu	Asp	
850						855							860			

ggc agg gcc gcg ccc ggg ccc cgt gcc acc cca ctg cgg cgg gcc gag	2882
Gly Arg Ala Ala Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg Ala Glu	
865 870 875	
tcc ctg gac cca cg ^g ccc ctg cgg cc ^g gcc ctc cc ^g cct acc aag	2930
Ser Leu Asp Pro Arg Pro Leu Arg Pro Ala Ala Leu Pro Pro Thr Lys	
880 885 890	
tgc cgc gat cgc gac ggg cag gtg gtg gcc ctg ccc agc gac ttc ttc	2978
Cys Arg Asp Arg Asp Gly Gln Val Val Ala Leu Pro Ser Asp Phe Phe	
895 900 905 910	
ctg cgc atc gac agc cac cgt gag gat gca gcc gag ctt gac gac gac	3026
Leu Arg Ile Asp Ser His Arg Glu Asp Ala Ala Glu Leu Asp Asp Asp	
915 920 925	
tgc gag gac agc tgc tgc ctc cgc ctg cat aaa gtg ctg gag ccc tac	3074
Ser Glu Asp Ser Cys Cys Leu Arg Leu His Lys Val Leu Glu Pro Tyr	
930 935 940	
aag ccc cag tgg tgc cgg agc cgc gag gcc tgg gcc ctc tac ctc ttc	3122
Lys Pro Gln Trp Cys Arg Ser Arg Glu Ala Trp Ala Leu Tyr Leu Phe	
945 950 955	
tcc cca cag aac cgg ttc cgc gtc tcc tgc cag aag gtc atc aca cac	3170
Ser Pro Gln Asn Arg Phe Arg Val Ser Cys Gln Lys Val Ile Thr His	
960 965 970	
aag atg ttt gat cac gtg gtc ctc gtc ttc atc ttc ctc aac tgc gtc	3218
Lys Met Phe Asp His Val Val Leu Val Phe Ile Phe Leu Asn Cys Val	
975 980 985 990	
acc atc gcc ctg gag agg cct gac att gac ccc ggc agc acc gag cgg	3266
Thr Ile Ala Leu Glu Arg Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg	
995 1000 1005	
gtc ttc ctc agc gtc tcc aat tac atc ttc acg gcc atc ttc gtg gcg	3314
Val Phe Leu Ser Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala	
1010 1015 1020	
gag atg atg gtg aag gtg gtg gcc ctg ggg ctg ctg tcc ggc gag cac	3362
Glu Met Met Val Lys Val Val Ala Leu Gly Leu Leu Ser Gly Glu His	
1025 1030 1035	
gcc tac ctg cag agc agc tgg aac ctg ctg gat ggg ctg ctg gtg ctg	3410
Ala Tyr Leu Gln Ser Ser Trp Asn Leu Leu Asp Gly Leu Leu Val Leu	
1040 1045 1050	
gtg tcc ctg gtg gac att gtc gtg gcc atg gcc tcg gct ggt ggc gcc	3458
Val Ser Leu Val Asp Ile Val Val Ala Met Ala Ser Ala Gly Gly Ala	
1055 1060 1065 1070	
aag atc ctg ggt gtt ctg cgc gtg cgt ctg ctg cgg acc ctg cgg	3506
Lys Ile Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg	
1075 1080 1085	
cct cta agg gtc atc agc cgg gcc ccg ggc ctc aag ctg gtg gtg gag	3554

Pro Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu			
1090	1095	1100	
acg ctg ata tcg tcg ctc agg ccc att ggg aac atc gtc ctc atc tgc	3602		
Thr Leu Ile Ser Ser Leu Arg Pro Ile Gly Asn Ile Val Leu Ile Cys			
1105	1110	1115	
tgc gcc ttc ttc atc att ttt ggc atc ttg ggt gtg cag ctc ttc aaa	3650		
Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu Gly Val Gln Leu Phe Lys			
1120	1125	1130	
ggg aag ttc tac tac tgc gag ggc ccc gac acc agg aac atc tcc acc	3698		
Gly Lys Phe Tyr Tyr Cys Glu Gly Pro Asp Thr Arg Asn Ile Ser Thr			
1135	1140	1145	1150
aag gca cag tgc cgg gcc gcc cac tac cgc tgg gtg cga cgc aag tac	3746		
Lys Ala Gln Cys Arg Ala Ala His Tyr Arg Trp Val Arg Arg Lys Tyr			
1155	1160	1165	
aac ttc gac aac ctg ggc cag gcc ctg atg tcg ctg ttc gtg ctg tca	3794		
Asn Phe Asp Asn Leu Gly Gln Ala Leu Met Ser Leu Phe Val Leu Ser			
1170	1175	1180	
tcc aag gat gga tgg gtg aac atc atg tac gac ggg ctg gat gcc gtg	3842		
Ser Lys Asp Gly Trp Val Asn Ile Met Tyr Asp Gly Leu Asp Ala Val			
1185	1190	1195	
ggt gtc gac cag cag cct gtg cag aac cac aac ccc tgg atg ctg ctg	3890		
Gly Val Asp Gln Gln Pro Val Gln Asn His Asn Pro Trp Met Leu Leu			
1200	1205	1210	
tac ttc atc tcc ttc ctg ctc atc gtc agc ttc ttc gtg ctc aac atg	3938		
Tyr Phe Ile Ser Phe Leu Leu Ile Val Ser Phe Phe Val Leu Asn Met			
1215	1220	1225	1230
ttc gtg ggc gtc gtg gtc gag aac ttc cac aag tgc cgg cag cac cag	3986		
Phe Val Gly Val Val Glu Asn Phe His Lys Cys Arg Gln His Gln			
1235	1240	1245	
gag gcg gag gag gcg cgg cgg cga gag gag aag cgg ctg cgg cgc cta	4034		
Glu Ala Glu Ala Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu			
1250	1255	1260	
gag agg agg cgc agg agc act ttc ccc agc cca gag gcc cag cgc cgg	4082		
Glu Arg Arg Arg Ser Thr Phe Pro Ser Pro Glu Ala Gln Arg Arg			
1265	1270	1275	
ccc tac tat gcc gac tac tcg ccc acg cgc cgc tcc att cac tcg ctg	4130		
Pro Tyr Tyr Ala Asp Tyr Ser Pro Thr Arg Arg Ser Ile His Ser Leu			
1280	1285	1290	
tgc acc agc cac tat ctc gac ctc ttc atc acc ttc atc atc tgt gtc	4178		
Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile Cys Val			
1295	1300	1305	1310
aac gtc atc acc atg tcc atg gag cac tat aac caa ccc aag tcg ctg	4226		
Asn Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys Ser Leu			
1315	1320	1325	

Ala Arg Glu Asp Ala Glu Leu Asp Ala Glu Ile Glu Leu Glu Met Ala			
1555	1560	1565	
cag ggc ccc ggg agt gca cgc cgg gtg gac gcg gac agg cct ccc ttg		4994	
Gln Gly Pro Gly Ser Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu			
1570	1575	1580	
ccc cag gag agt ccg ggc gcc agg gat gcc cca aac ctg gtt gca cgc		5042	
Pro Gln Glu Ser Pro Gly Ala Arg Asp Ala Pro Asn Leu Val Ala Arg			
1585	1590	1595	
aag gtg tcc gtg tcc agg atg ctc tcg ctg ccc aac gac agc tac atg		5090	
Lys Val Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met			
1600	1605	1610	
ttc agg ccc gtg gtg cct gcc tcg gcg ccc cac ccc cgc ccg ctg cag		5138	
Phe Arg Pro Val Val Pro Ala Ser Ala Pro His Pro Arg Pro Leu Gln			
1615	1620	1625	1630
gag gtg gag atg gag acc tat ggg gcc ggc acc ccc ttg ggc tcc gtt		5186	
Glu Val Glu Met Glu Thr Tyr Gly Ala Gly Thr Pro Leu Gly Ser Val			
1635	1640	1645	
gcc tct gtg cac tct ccg ccc gca gag tcc tgt gcc tcc ctc cag atc		5234	
Ala Ser Val His Ser Pro Pro Ala Glu Ser Cys Ala Ser Leu Gln Ile			
1650	1655	1660	
cca ctg gct gtg tcg tcc cca gcc agg agc ggc gag ccc ctc cac gcc		5282	
Pro Leu Ala Val Ser Ser Pro Ala Arg Ser Gly Glu Pro Leu His Ala			
1665	1670	1675	
ctg tcc cct cgg ggc aca gcc cgc tcc ccc agt ctc agc cgg ctg ctc		5330	
Leu Ser Pro Arg Gly Thr Ala Arg Ser Pro Ser Leu Ser Arg Leu Leu			
1680	1685	1690	
tgc aga cag gag gct gtg cac acc gat tcc ttg gaa ggg aag att gac		5378	
Cys Arg Gln Glu Ala Val His Thr Asp Ser Leu Glu Gly Lys Ile Asp			
1695	1700	1705	1710
agc cct agg gac acc ctg gat cct gca gag cct ggt gag aaa acc ccg		5426	
Ser Pro Arg Asp Thr Leu Asp Pro Ala Glu Pro Gly Glu Lys Thr Pro			
1715	1720	1725	
gtg agg ccg gtg acc cag ggg ggc tcc ctg cag tcc cca cca cgc tcc		5474	
Val Arg Pro Val Thr Gln Gly Gly Ser Leu Gln Ser Pro Pro Arg Ser			
1730	1735	1740	
cca cgg ccc gcc agc gtc cgc act cgt aag cat acc ttc gga cag cac		5522	
Pro Arg Pro Ala Ser Val Arg Thr Arg Lys His Thr Phe Gly Gln His			
1745	1750	1755	
tgc gtc tcc agc cgg ccg gcg gcc cca ggc gga gag gag gcc gag gcc		5570	
Cys Val Ser Ser Arg Pro Ala Ala Pro Gly Gly Glu Glu Ala Glu Ala			
1760	1765	1770	
tcg gac cca gcc gac gag gag gtc agc cac atc acc agc tcc gcc tgc		5618	
Ser Asp Pro Ala Asp Glu Glu Val Ser His Ile Thr Ser Ser Ala Cys			
1775	1780	1785	1790

ccc tgg cag ccc aca gcc gag ccc cat ggc ccc gaa gcc tct ccg gtg Pro Trp Gln Pro Thr Ala Glu Pro His Gly Pro Glu Ala Ser Pro Val 1795 1800 1805	5666
gcc ggc ggc gag cgg gac ctg cgc agg ctc tac agc gtg gac gct cag Ala Gly Gly Glu Arg Asp Leu Arg Arg Leu Tyr Ser Val Asp Ala Gln 1810 1815 1820	5714
ggc ttc ctg gac aag ccc ggg gca gac gag cag tgg cgg ccc tcg Gly Phe Leu Asp Lys Pro Gly Arg Ala Asp Glu Gln Trp Arg Pro Ser 1825 1830 1835	5762
gcg gag ctg ggc agc ggg gag cct ggg gag gcg aag gcc tgg ggc cct Ala Glu Leu Gly Ser Gly Glu Pro Gly Glu Ala Lys Ala Trp Gly Pro 1840 1845 1850	5810
gag gcc gag ccc gct ctg ggt gcg cgc aga aag aag aag atg agc ccc Glu Ala Glu Pro Ala Leu Gly Ala Arg Arg Lys Lys Met Ser Pro 1855 1860 1865 1870	5858
ccc tgc atc tcg gtg gaa ccc cct gcg gag gac gag ggc tct gcg cgg Pro Cys Ile Ser Val Glu Pro Pro Ala Glu Asp Glu Gly Ser Ala Arg 1875 1880 1885	5906
ccc tcc gcg gca gag ggc ggc agc acc aca ctg agg cgc agg acc ccc Pro Ser Ala Ala Glu Gly Ser Thr Thr Leu Arg Arg Arg Thr Pro 1890 1895 1900	5954
tcc tgt gag gcc acg cct cac agg gac tcc ctg gag ccc aca gag ggc Ser Cys Glu Ala Thr Pro His Arg Asp Ser Leu Glu Pro Thr Glu Gly 1905 1910 1915	6002
tca ggc gcc ggg ggg gac cct gca gcc aag ggg gag cgc tgg ggc cag Ser Gly Ala Gly Gly Asp Pro Ala Ala Lys Gly Glu Arg Trp Gly Gln 1920 1925 1930	6050
gcc tcc tgc cgg gct gag cac ctg acc gtc ccc agc ttt gcc ttt gag Ala Ser Cys Arg Ala Glu His Leu Thr Val Pro Ser Phe Ala Phe Glu 1935 1940 1945 1950	6098
ccg ctg gac ctc ggg gtc ccc agt gga gac cct ttc ttg gac ggt agc Pro Leu Asp Leu Gly Val Pro Ser Gly Asp Pro Phe Leu Asp Gly Ser 1955 1960 1965	6146
cac agt gtg acc cca gaa tcc aga gct tcc tct tca ggg gcc ata gtg His Ser Val Thr Pro Glu Ser Arg Ala Ser Ser Ser Gly Ala Ile Val 1970 1975 1980	6194
ccc ctg gaa ccc cca gaa tca gag cct ccc atg ccc gtc ggt gac ccc Pro Leu Glu Pro Pro Glu Ser Glu Pro Pro Met Pro Val Gly Asp Pro 1985 1990 1995	6242
cca gag aag agg cgg ggg ctg tac ctc aca gtc ccc cag tgt cct ctg Pro Glu Lys Arg Arg Gly Leu Tyr Leu Thr Val Pro Gln Cys Pro Leu 2000 2005 2010	6290
gag aaa cca ggg tcc ccc tca gcc acc cct gcc cca ggg ggt ggt gca	6338

Glu Lys Pro Gly Ser Pro Ser Ala Thr Pro Ala Pro Gly Gly Ala
2015 2020 2025 2030 2035

gat gac ccc gtg tag ctcggggctt ggtgccgccc acggctttgg ccctggggtc 6393
Asp Asp Pro Val

tggggggcccc gctggggtgg aggcccaggc agaaccctgc atggaccctg acttgggtcc 6453
cgtcgtgagc agaaaggccc ggggaggatg acggcccagg ccctgggtct ctgcccagcg 6513
aaggcaggagt agctgccggg cccccacgagc ctccatccgt tctgggtcgg gtttctccga 6573
gttttgcata cagccgaggc tgcggca actgggtcag cctccgtca ggagagaagc 6633
cgcgtctgtg ggacgaagac cgggcacccg ccagagaggg gaaggtacca ggttgcgtcc 6693
tttcaggccc cgcggttgtta caggacactc gctgggggccc ctgtgccctt gccggcggca 6753
ggttgcagcc accgcggccc aatgtcacct tcactcacag tctgagttct tgtccgcctg 6813
tcacgccttc accaccctcc cttccagcc accacccttt ccgttccgct cgggccttcc 6873
cagaagcgtc ctgtgactct gggagaggtg acacctaact aaggggcccga ccccatggag 6933
taacgcgc 6941

THIS PAGE BLANK (USPTO)


FIGURE 1**Steady-state activation and inactivation**




FIGURE 2A**Kinetics of activation****FIGURE 2B****Kinetics of inactivation****SUBSTITUTE SHEET (RULE 26)**

FIGURE 3
Features of the α_{1H} Subunit



SUBSTITUTE SHEET (RULE 26)

Tail current deactivation




FIGURE 4B





FIGURE 4C



SUBSTITUTE SHEET (RULE 26)

(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92007

(ii) TITLE OF INVENTION: CALCIUM CHANNEL COMPOSITIONS AND METHODS

(iii) NUMBER OF SEQUENCES: 16

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Heller Ehrman White & McAuliffe
(B) STREET: 4250 Executive Square, 7th Floor
(C) CITY: La Jolla
(D) STATE: California
(E) COUNTRY: US
(F) ZIP: 92037

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 1.5 and Patentin 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-1998
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 09/188,932
(B) FILING DATE: 10-NOV-1998
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Seidman, Stephanie L.
(B) REGISTRATION NUMBER: 33,779
(C) REFERENCE/DOCKET NUMBER: 24735-9815PC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (619) 450-8400
(B) TELEFAX: (619) 450-8499

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

(A) NAME: SIBIA Neurosciences, Inc.
(B) STREET: 505 Coast Boulevard South, Suite 300
(C) CITY: La Jolla
(D) STATE: California
(E) COUNTRY: US
(F) POSTAL CODE (ZIP): 92037-4641

(1) INVENTOR/APPLICANT:

(A) NAME: Mark E. Williams
(B) STREET: 946 Jasmine Court
(C) CITY: Carlsbad
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92009

(i) INVENTOR/APPLICANT:

(A) NAME: Kenneth A. Stauderman
(B) STREET: 3615 Lotus Dr.
(C) CITY: San Diego
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92106

(i) INVENTOR/APPLICANT:

(A) NAME: Michael M. Harpold
(B) STREET: 1462 Encina Road
(C) CITY: Santa Fe
(D) STATE: New Mexico
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 87505-4726

(i) INVENTOR/APPLICANT:

(A) NAME: Michael Heng
(B) STREET: 2635 Clemente Terrace
(C) CITY: San Diego
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 92122

(i) INVENTOR/APPLICANT:

(A) NAME: Arturo Urrutia
(B) STREET: 778 Beech Avenue
(C) CITY: Chula Vista
(D) STATE: California
(E) COUNTRY: USA
(F) POSTAL CODE (ZIP): 91910

(i) INVENTOR/APPLICANT:

(A) NAME: Mark S. Washburn
(B) STREET: 1535 Kings Cross Drive
(C) CITY: Cardiff
(D) STATE: California

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TYCCCTTGAA GAGCTGNACC CC

22

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGTGCACGTC ACGCTAG

17

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AATTCTAGCG TGACGGCGAC G

21

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ACNGTGTTYC AGATCCTGAC

2

(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

ATCCCTGAENG GMGARGACTG GAA

23

(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TYCCCTTGAA GAGCTGNAEN GC

22

(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

TYCCCTTGA AGAGCTGNAC CCC

22

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AACTGATYATYA CCCTGGC

17

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATYACCCCTGG CNATGGAGCG

20

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GARATGATGTA TGAARGT

17

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 342 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GGGAGATGAT	GGTGAAAGTG	CTGCCCTCTGG	GGCTGCTGTC	CGGGGAGGCAC	GCCTACCTGC	60
AGGCCAGCTG	GAACCTGCTG	GATGGGCTGTC	TGGTACTGAT	GTCCCTGGTG	GACATTGTCG	120
TGGCCATGCC	CTCGGCTGCT	GGCOCCLANGA	TCTGGGTGT	TCTGGCGTC	CTGCCTCTGC	180
TGEEGACCT	GGGGCCTCTG	AGGGTCATCA	OCCGGGGCCCC	GGGCTCTAAG	CTGGTGGTGG	240
AGACGGCTGAT	ATCATCACTC	AGGGCCATTG	GGAACATCGT	CCTCATCTGC	TGCGCCTTCT	300
TCATCATTTT	TGGCATTTCAGC	GGGGTTTCAGC	TCTTCAGGG			340

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7898 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 249...7307

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CGAGGGCGGCC	CCCGTCGCGCT	CGGCCCGGGCG	AGCCCGGAGCC	GGAGTCGAGC	CGCGGGCGGGG	60
AGCCCGGGCGG	GCTGGGGACG	CGGGCGGGCGG	GGGGAGGCGC	TGGGGCGCGG	GGCCGGGGGGCC	120
GGGGGGGGAG	CGCGCTGGGGG	CGGGGGCGGG	GGCOCGGGCGC	CGAGCGGGGT	CGCGGGGTGAC	180
GGCGCCGGCCC	GGGCGATGCC	GGCGGGGGACG	CGCGCGGGCCA	GCAGAGGGAG	CTGCTGCCGG	240
CGCGCCACC	ATG ACC GAG CGC GCA CGG GCC CCC GAC GAG GTC CGG GTG CCC					290
Met Thr Glu Gly Ala Arg Ala Asp Glu Val Arg Val Pro						
1	5	10				
CTG GGC GCG CCG CCC CCT GGC CCT GCG GCG TTG GTG GGG GCG TCC CCG						338
Leu Gly Ala Pro Pro Pro Gly Pro Ala Ala Leu Val Gly Ala Ser Pro						
15	20	25				30

GAG AGC CCC GGG GCG CCG GGA CGC GAG GCG GAG CGG GGG TCC GAG CTC Glu Ser Pro Gly Ala Pro Gly Arg Glu Ala Glu Arg Gly Ser Glu Leu 35 40 45	386
GGC GTG TCA CCC TCC GAG AGC CGG GCG GCC GAG CGC GGC GCG GAG CTG Gly Val Ser Pro Ser Glu Ser Pro Ala Ala Glu Arg Gly Ala Glu Leu 50 55 60	434
GGT GCC GAC GAG GAG CGG CGC GTC CCG TAC CCG GCC TTG GCG GCC ACG Gly Ala Asp Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr 65 70 75	482
GTC TTC TTC TGC CTC GGT CAG ACC ACG CGG CCG CCC AGC TGG TGC CTC Val Phe Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu 80 85 90	530
CGG CTG GTC AAC CCA TGG TTC GAG CAC GTG AGC ATG CTG GTA ATC Arg Leu Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile 95 100 105 110	578
ATG CTC AAC TGC GTG ACC CTG GGC ATG TTC CGG CCC TGT GAG GAC GTT Met Leu Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val 115 120 125	626
GAG TGC GGC TCC GAG CGC TGC AAC ATC CTG GAG GCC TTT GAC GCC TTC Glu Cys Gly Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe 130 135 140	674
ATT TTC GCC TTT TTT GCG GTG GAG ATG GTC ATC AAG ATG GTG GCC TTG Ile Phe Ala Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu 145 150 155	722
CGG CTG TTC GGG CAG AAG TGT TAC CTG GGT GAC ACG TGG AAC AGG CTG Gly Leu Phe Gly Gln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu 160 165 170	770
GAT TTC TTC ATC GTC GTC GCG GGC ATG ATG GAG TAC TCG TTG GAC GGA Asp Phe Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly 175 180 185 190	818
CAC AAC GTG AGC CTC TCG GCT ATC AGG ACC GTG CGG GTG CTG CGG CCC His Asn Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro 195 200 205	866
CTC CGC GCG ATC AAC CGC GTG CCT AGC ATG CGG ATC CTG GTC ACT CTG Leu Arg Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu 210 215 220	914
CTG CTG GAT AGC CTG CCC ATG CTC GGG AAC GTC CTT CTC CTG TGC TTG Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe 225 230 235	962
TTC GTC TTC TTC ATT TTC GGC ATC GTT GGC GTC CAG CTC TGG GCT GGC Phe Val Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly 240 245 250	1010
CTC CTG CGG AAC CGC TGC TTC CTG GAC AGT GCC TTT GTC AGG AAC AAC Leu Leu Arg Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn	1058

255	260	265	270	
AAC CTG ACC TTC CTG CGG CCG TAC TAC	CAG ACG GAG GAG GGC GAG GAG			1106
Arg Leu Thr Phe Leu Arg Pro Tyr Tyr	Gln Thr Glu Glu Gly Glu Glu			
275	280		285	
AAC CCG TTC ATC TGC TCC TCA CGC CGA GAC AAC GGC ATG CAG AAG TGC				1154
Asn Pro Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys				
290	295		300	
TGG CAC ATC CCC GGC CGC CGC GAG CTG CGC ATG CCC TGC ACC CTG GGC				1202
Ser His Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly				
305	310		315	
TGG GAG GCC TAC ACG CAG CCG CAG GCC GAG GGG GTG GGC GCT GCA CGC				1250
Trp Glu Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg				
320	325		330	
AAC CCC TGC ATC AAC TGG AAC CAG TAC TAC AAC GTG TGC CGC TCG GGT				1298
Asn Ala Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly				
335	340		350	
GAC TCC AAC CCC CAC AAC GGT GCC ATC AAC TTC GAC AAC ATC GGC TAC				1346
Asp Ser Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr				
355	360		365	
GCC TGG ATT GCC ATC TTC CAG GTG ATC ACG CTG GAA GGC TGG GTG GAC				1394
Ala Trp Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp				
370	375		380	
ATC ATG TAC TAC GTC ATG GAC GCC CAC TCA TTC TAC AAC TTC ATC TAT				1442
Ile Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr				
385	390		395	
TTC ATC CTG CTC ATC ATC GTG GGC TCC TTC TTC ATG ATC AAC CTC TGC				1490
Phe Ile Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys				
400	405		410	
CTG GTG GTG ATT GCC ACG CAG TTC TCG QAG ACG AAG CAG CGG GAG AGT				1538
Leu Val Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser				
415	420		425	
CAG CTG ATG CGG GAG CAG CGG GCA CGC CAC CTG TCC AAC GAC AGC ACG				1586
Gln Leu Met Arg Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr				
435	440		445	
CTG GCC AGC TTC TCC GAG CCT GGC AGC TGC TAC GAA GAG CTG CTG AAG				1634
Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys				
450	455		460	
TAC GTG GGC CAC ATA TTC CGC AAG GTG AAG CGG CGC AGC TTG CGC CTC				1682
Tyr Val Gly His Ile Phe Arg Lys Val Lys Arg Arg Ser Leu Arg Leu				
465	470		475	
TAC GCC CGC TGG CAG AGC CGC TGG CGC AAG AAG GTG GAC CCC AGT GCT				1730
Tyr Ala Arg Trp Gln Ser Arg Trp Arg Lys Lys Val Asp Pro Ser Ala				
480	485		490	

GTG CAA GGC CAG GGT CCC GGG CAC CGC CAG CGC CGG GCA GGC AGG CAC Val Gln Gly Gln Gly Pro Gly His Arg Gln Arg Arg Ala Gly Arg His 495 500 505 510	1776
ACA GCC TCG GTG CAC CAC CTG CTC TAC CAC CAC CAT CAC CAC CAC CAC Thr Ala Ser Val His His Leu Val Tyr His His His His His His His 515 520 525	1826
CAC CAC TAC CAT TTC AGC CAT GGC ACG CCC CGC AGG CCC GGC CCC GAG His His Tyr His Phe Ser His Gly Ser Pro Arg Arg Pro Gly Pro Glu 530 535 540	1874
CCA GGC CCC TGC GAC ACC AGG CTG GTC CGA GCT GGC GCG CCC CCC TCG Pro Gly Ala Cys Asp Thr Arg Leu Val Arg Ala Gly Ala Pro Pro Ser 545 550 555	1922
CCA CCT TCC CCA GGC CGC GGA CCC CCC GAC GCA GAG TCT GTG CAC AGC Pro Pro Ser Pro Gly Arg Gly Pro Pro Asp Ala Glu Ser Val His Ser 560 565 570	1970
ATC TAC CAT GCC GAC TGC CAC ATA GAG GGG CCG CAG GAG AGG GCC CGG Ile Tyr His Ala Asp Cys His Ile Glu Gly Pro Gln Glu Arg Ala Arg 575 580 585 590	2010
GTC GCA CAT GCC GCA GCC ACT GCC GCT GCC AGC CTC AGG CTG GCC ACA Val Ala His Ala Ala Ala Thr Ala Ala Ser Leu Arg Leu Ala Thr 595 600 605	2066
GGG CTG GGC ACC ATG AAC TAC CCA ACG ATC CTG CCC TCA GGG GTG GGC Gly Leu Gly Thr Met Asn Tyr Pro Thr Ile Leu Pro Ser Gly Val Gly 610 615 620	2114
AGC GGC AAA GGC AGC ACC AGC CCC GGA CCC AAG GGG AAG TGG GCC GGT Ser Gly Lys Gly Ser Thr Ser Pro Gly Pro Lys Gly Lys Trp Ala Gly 625 630 635	2162
GGA CCG CCA GGC ACC GGG GGG CAC CGC CGC TTG AGC TTG AAC AGC CCT Gly Pro Pro Gly Thr Gly His Gly Pro Leu Ser Leu Asn Ser Pro 640 645 650	2210
GAT CCC TAC GAG AAG ATC CCG CAT CTG GTC GGG GAG CAT GGA CTG GGC Asp Pro Tyr Glu Lys Ile Pro His Val Val Gly Glu His Gly Leu Gly 655 660 665 670	225B
CAG GCC CCT GGC CAT CTG TCG GGC CTC AGT GTG CCC TGC CCC CTG CCC Gln Ala Pro Gly His Leu Ser Gly Leu Ser Val Pro Cys Pro Leu Pro 675 680 685	2306
AGC CCC CCA GCG GGC ACA CTG ACC TGT GAG CTG AAG AGC TGC CCG TAC Ser Pro Pro Ala Gly Thr Leu Thr Cys Glu Leu Lys Ser Cys Pro Tyr 690 695 700	2354
TGC ACC CGT GCC CTG GAG GAC CCG GAG GGT GAG CTC AGC GGC TCG GAA Cys Thr Arg Ala Leu Glu Asp Pro Glu Gly Glu Leu Ser Gly Ser Glu 705 710 715	2402
AQT GGA GAC TCA GAT GGC CGT GGC GTC TAT GAA TTC AGC CAG GAC GTC Ser Gly Asp Ser Asp Gly Arg Gly Val Tyr Glu Phe Thr Gln Asp Val	2450

720	725	730	
CGG CAC GAC CGC TGG GAC CCC ACG CGA CCA CCC CGT GCG ACG GAC Arg His Gly Asp Arg Trp Asp Pro Thr Arg Pro Pro Arg Ala Thr Asp 735 740 745 750			2498
ACA CCA GGC CCA GGC CCC AGC CCC CAG CGG GCA CAG CRG AGG Thr Pro Gly Pro Gly Ser Pro Gln Arg Arg Ala Gln Gln Arg 755 760 765			2546
GCA GCC CCG GGC GAG CCA GGC TGG ATG GGC CGC CTC TGG GTT ACC TTC Ala Ala Pro Gly Glu Pro Gly Trp Met Gly Arg Leu Trp Val Thr Phe 770 775 780			2594
AGC GGC AAG CTG CGC CGC ATC GTG GAC AGC ARG TAC TTK AGC CGT GGC Ser Gly Lys Leu Arg Arg Ile Val Asp Ser Lys Tyr Phe Ser Arg Gly 785 790 795			2642
ATC ATG ATG GCC ATC CTT GTC AAC ACG CTG AGC ATG GGC GTG GAG TAC Ile Met Met Ala Ile Leu Val Asn Thr Leu Ser Met Gly Val Glu Tyr 800 805 810			2690
CAT GAG CAG CCC GAG GAG CTG ACT AAT GCT CTG GAG ATC AGC AAC ATC His Glu Gln Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile 815 820 825 830			2738
GTG TTC ACC AGC ATG TTT GCC CTG GAG ATG CTG CTG AAG CTG CTG GCC Val Phe Thr Ser Met Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Ala 835 840 845			2786
TGC GGC CCT CTG CGC TAC ATC CGG AAC CCG TAC AAC ATC TTC GAC GGC Cys Gly Pro Leu Gly Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp Gly 850 855 860			2834
ATC ATC GTG GTC ATC AGC GTC TGG GAG ATC GTG GGC CAG GCG GAC GGT Ile Ile Val Val Ile Ser Val Trp Glu Ile Val Gly Gln Ala Asp Gly 865 870 875			2882
GGC TTG TCT GTG CTG CGC ACC TTC CGG CTG CTG CGT GTG CTG AAG CTG Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg Val Leu Lys Leu 880 885 890			2930
GTC CGC TTT CTG CCA GCC CTG CGG CGC CAG CTC GTG GTG CTG GTG AAG Val Arg Phe Leu Pro Ala Leu Arg Arg Gln Leu Val Leu Val Lys 895 900 905 910			2978
ACC ATG GAC AAC GTG GCT ACC TTC TGC ACG CTG CTC ATG CTC TTC ATT Thr Met Asp Asn Val Ala Thr Phe Cys Thr Leu Leu Met Leu Phe Ile 915 920 925			3026
TTC ATC TTC AGC ATC CTG GGC ATG CAC CTT TTC GGC TGC AAG TTC AGC Phe Ile Phe Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ser 930 935 940			3074
CTG AAG ACA GAC ACC GGA GAC ACC GTG CCT GAC AGG AAG AAC TTC GAC Leu Lys Thr Asp Thr Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp 945 950 955			3122

TCC CTG CTG TGG GCC ATC GTC ACC GTG TTC CAG ATC CTG ACC CAG CAG Ser Leu Leu Trp Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu 960 965 970	3170
GAC TGG AAC GTG GTC CTG TAC AAC GGC ATG GCC TCC ACC TCC TCC TGG Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp 975 980 985 990	3238
GCC GCC CTC TAC TTC GTG GCC CTC ATG ACC TTC GGC AAC TAT GTG CTC Ala Ala Leu Tyr Phe Val Ala Leu Met Thr Phe Gly Asn Tyr Val Leu 995 1000 1005	3266
TTC AAC CTG CTG GTG GCC ATC CTC GTG CAG GGC TTC CAG GCG GAG GGC Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly 1010 1015 1020	3314
GAT GCC AAC AGA TCC GAC ACG GAC GAG GAC AAG ACG TCG GTG CAC TTC Asp Ala Asn Arg Ser Asp Thr Asp Glu Asp Lys Thr Ser Val His Phe 1025 1030 1035	3362
GAG GAG GAC TTC CAC AAG CTC AGA GAA CTC CAG ACC ACA GAG CTG AAG Glu Glu Asp Phe His Lys Leu Arg Glu Leu Gln Thr Thr Glu Leu Lys 1040 1045 1050	3410
ATG TGT TCC CTG GCC GTG ACC CCC AAC GGG CAC CTG GAG GGA CGA CGC Met Cys Ser Leu Ala Val Thr Pro Asn Gly His Leu Glu Gly Arg Gly 1055 1060 1065 1070	3458
AGC CTG TCC CCT CCC CTC ATC ATG TGC ACA GCT GCC ACG CCC ATG CCT Ser Leu Ser Pro Pro Leu Ile Met Cys Thr Ala Ala Thr Pro Met Pro 1075 1080 1085	3506
ACC CCC AAG AGC TCA CCA TTC CTG GAT GCA GCC CCC AGC CTC CCA GAC Thr Pro Lys Ser Ser Pro Phe Leu Asp Ala Ala Pro Ser Leu Pro Asp 1090 1095 1100	3554
TCT CGG CGT GGC AGC AGC TCC GGG GAC CCG CCA CTG GGA GAC CAG Ser Arg Arg Gly Ser Ser Ser Gly Asp Pro Pro Leu Gly Asp Gln 1105 1110 1115	3602
AAG CCT CGG GCC AGC CTC CGA AGT TCT CCT TGT GCC CCC TGG GGC CCC Lys Pro Pro Ala Ser Leu Arg Ser Ser Pro Cys Ala Pro Trp Gly Pro 1120 1125 1130	3650
AGT GGC CCC TGG AGC AGC CGG CGC TCC AGC TGG AGC AGC CTG GGC CGT Ser Gly Ala Trp Ser Ser Arg Arg Ser Ser Trp Ser Ser Leu Gly Arg 1135 1140 1145 1150	3698
GCC CCC AGC CTC AAC CGC CGC GGC CAG TGT GGG GAA CGT GAG GAC GGC Ala Pro Ser Leu Lys Arg Arg Gly Gln Cys Gly Glu Arg Glu Ser Leu 1155 1160 1165	3746
CTG TCT GGC GAG GGC AAG GGC AGC ACC GAC GAC GAA GCT GAG GAC GGC Leu Ser Gly Glu Gly Lys Ser Thr Asp Asp Glu Ala Glu Asp Gly 1170 1175 1180	3794
AGG GCC GCG CCC GGG CCC CGT GCC ACC CCA CTG CGG CGG CCC GAG TCC Arg Ala Ala Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg Ala Glu Ser	3842

1185	1190	1195		
CTG GAC CCA CGG CCC CTG CGG CCG GCC GCC CTC CCG CCT ACC AAG TGC Leu Asp Pro Arg Pro Leu Arg Pro Ala Ala Leu Pro Pro Thr Lys Cys 1200	1205	1210	3890	
CGC GAT CGC GAC CGG CAG GTG GTG GCC CTG CCC AGC GAC TTC TTC CTG Arg Asp Arg Asp Gly Gln Val Val Ala Leu Pro Ser Asp Phe Phe Leu 1215	1220	1225	1230	3938
CGC ATC GAC AGC CAC CGT GAG GAT GCA GCC GAG CTT AAC GAC GAC TCG Arg Ile Asp Ser His Arg Glu Asp Ala Ala Glu Leu Asp Asp Asp Ser 1235	1240	1245	3986	
GAG GAC AGC TGC TGC CTC CGC CTG CAT AAA GTG CTG GAG CCC TAC AAG Glu Asp Ser Cys Cys Leu Arg Leu His Lys Val Leu Glu Pro Tyr Lys 1250	1255	1260	4034	
CCC CAG TGG TGC CGG AGC CGC GAG GCC TGG GCC CTC TAC CTC TTC TCC Pro Gln Trp Cys Arg Ser Arg Glu Ala Trp Ala Leu Tyr Leu Phe Ser 1265	1270	1275	4082	
CCA CAQ AAC CGG TTC CGC GTC TCC TGC CAG AAG GTC ATC ACA CAC AAG Pro Gln Asn Arg Phe Arg Val Ser Cys Gln Lys Val Ile Thr His Lys 1280	1285	1290	4130	
ATG TTT GAT CAC GTG GTC CTC GTC TTC ATC TTC CTC AAC TGC GTC ACC Met Phe Asp His Val Val Leu Val Phe Ile Phe Leu Asn Cys Val Thr 1295	1300	1305	1310	4178
ATC GCC CTG GAG AGG CCT GAC ATT GAC CCC GGC AGC ACC GAG CGG GTC Ile Ala Leu Glu Arg Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg Val 1315	1320	1325	4226	
TTC CTC AGC GTC TCC AAT TAC ATC TTC ACG GCC ATC TTC GTG GCG GAG Phe Leu Ser Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala Glu 1330	1335	1340	4274	
ATG ATG GTG AAG GTG GTG GCC CTG GGG CTG CTG TCC GCC GAG CAC GCC Met Met Val Lys Val Val Ala Leu Gly Leu Leu Ser Gly Glu His Ala 1345	1350	1355	4322	
TAC CTC CAG AGC AGC TGG AAC CTG CTG GAT GGG CTG CTG GTG CTG GTG Tyr Leu Gln Ser Ser Trp Asn Leu Leu Asp Gly Leu Leu Val Leu Val 1360	1365	1370	4370	
TCC CTG GTG GAC ATT GTC GTG GCC ATG GCC TCG GCT GGT GGC GCC AAG Ser Leu Val Asp Ile Val Val Ala Met Ala Ser Ala Gly Gly Ala Lys 1375	1380	1385	1390	4418
ATC CTG CCT CTG CGC GTG CTG CGT CTG CTG CGG ACC CTC CGG CCT Ile Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg Pro 1395	1400	1405	4466	
CTA AGG GTC ATC AGC CGG GCC CCG GGC CTC AAG CTG STG GTG GAG ACG Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu Thr 1410	1415	1420	4514	

CTG ATA TCG TCG CTC ACG CCC ATT GGG AAC ATC GTC CTC ATC TGC TGC Leu Ile Ser Ser Leu Arg Pro Ile Gly Asn Ile Val Leu Ile Cys Cys 1425 1430 1435	4562
GCC TTC TTC ATC ATT TTT GGC ATC TTG GGT GTG CAG CTC TTC AAA GGG Ala Phe Phe Ile Ile Phe Gly Ile Leu Gly Val Glu Leu Phe Lys Gly 1440 1445 1450	4610
AAG TTC TAC TAC TGC GAG GGC CCC GAC ACC AGG AAC ATC TCC ACC AAG Lys Phe Tyr Tyr Cys Glu Gly Pro Asp Thr Arg Asn Ile Ser Thr Lys 1455 1460 1465 1470	4658
GCA CAG TGC CGG GCC CCC CAC TAC CGC TGG GTG CGA CGC AAG TAC AAC Ala Glu Cys Arg Ala Ala His Tyr Arg Trp Val Arg Arg Lys Tyr Asn 1475 1480 1485	4706
TTC GAC AAC CTG GGC CAG GCC CTG ATG TCG CTG TTC GTG CTG TCA TCC Phe Asp Asn Leu Gly Glu Ala Leu Met Ser Leu Phe Val Leu Ser Ser 1490 1495 1500	4754
AAG GAT GGA TGG GTG AAC ATC ATG TAC GAC GGG CTC GAT GCC GTG GGT Lys Asp Gly Trp Val Asn Ile Met Tyr Asp Gly Leu Asp Ala Val Gly 1505 1510 1515	4802
GTC GAC CAG CAG CCT GTG CAG AAC CTC AAC CCC TGG ATG CTC CTG TAC Val Asp Glu Glu Pro Val Glu Asn His Asn Pro Trp Met Leu Leu Tyr 1520 1525 1530	4850
TTC ATC TCC TTC CTG CTC ATC GTC AGC TTC TTC GTG CTC AAC ATG TTC Phe Ile Ser Phe Leu Ile Val Ser Phe Phe Val Leu Asn Met Phe 1535 1540 1545 1550	4898
GTG GGC GTC GTG GTC GAG AAC TTC CAC AAG TGC CGG CAG CAC CAG GAG Val Gly Val Val Val Glu Asn Phe His Lys Cys Arg Glu His Glu Glu 1555 1560 1565	4946
GCG GAG GAG GCG CGG CGG CGA GAG GAG AAG CGG CTC CGG CGC CTA GAG Ala Glu Ala Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu 1570 1575 1580	4994
AGG AGG CGC AGG AGC ACT TTC CCC AGC CCA GAG GCC CAG CGC CGG CCC Arg Arg Arg Arg Ser Thr Phe Pro Ser Pro Glu Ala Glu Arg Arg Pro 1585 1590 1595	5042
TAC TAT GCC GAC TAC TCG CCC ACG CGC CGC TCC ATT CAC TCG CTG TGC Tyr Tyr Ala Asp Tyr Ser Pro Thr Arg Arg Ser Ile His Ser Leu Cys 1600 1605 1610	5090
ACC AGC CAC TAT CTC GAC CTC TTC ATC ACC TTC ATC ATC TGT GTC AAC Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile Cys Val Asn 1615 1620 1625 1630	5138
GTC ATC ACC ATG TCC ATG GAG CAC TAT AAC CAA CCC AAG TCG CTG GAC Val Ile Thr Met Ser Met Glu His Tyr Asn Glu Pro Lys Ser Leu Asp 1635 1640 1645	5186
GAG GCC CTC AAG TAC TGC AAC TAC GTC TJC ACC ATC GTG TTT GTC TTC Glu Ala Leu Lys Tyr Cys Asn Tyr Val Phe Thr Ile Val Phe Val Phe	5234

1650	1655	1660	
GAG GCT GCA CTG AAG CTG GIA GCA TTT GGG TTC CGT CGG TTC TTC AAG Glu Ala Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Arg Phe Phe Lys 1665 1670 1675			5282
GAC AGG TGG AAC CAG CTG GAC CTG GCC ATC GTG CTG CTG TCA CTC ATG Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Leu Met 1680 1685 1690			5330
GCC ATC ACG CTG GAG GAG ATA GAG ATG AGC GCC GCG CTC CCC ATC AAC Gly Ile Thr Leu Glu Glu Ile Glu Met Ser Ala Ala Leu Pro Ile Asn 1695 1700 1705 1710			5378
CCC ACC ATC ATC CGC ATC ATG CGC GTG CTT CGC ATT GCC CGT GTG CTG Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu 1715 1720 1725			5426
AAG CTG CTG AAG ATG GCT ACG GGC ATG CGC GCC CTG CTG GAC ACT GTG Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr Val 1730 1735 1740			5474
GTG CAA GCT CTC CCC CAG GTG GGG AAC CTG GGC CTT CTT TTC ATG CTC Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met Leu 1745 1750 1755			5522
CTG TTT TTT ATC TAT GCT GCG CTG GGA GTG GAG CTG TTC GGG AGG CTG Leu Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly Arg Leu 1760 1765 1770			5570
GAG TCC AGT GAA GAC AAC CCC TGC GAG GGC CTG AGC AGG CRC GCC ACC Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg His Ala Thr 1775 1780 1785 1790			5618
TTC AGC AAC TTC GGC ATG GCC TTC CTC ACG CTG TTC CGC GTG TCC ACG Phe Ser Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser Thr 1795 1800 1805			5666
GGG GAC AAC TGG AAC GGG ATC ATG AAG GAC ACG CTG CGC GAG TGC TCC Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Glu Cys Ser 1810 1815 1820			5714
CGT GAG GAC AAG CAC TGC AGC TAC CTG CCG GCC CTG TCG CCC GTC Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu Ser Pro Val 1825 1830 1835			5762
TAC TTC GTG ACC TTC GTG CTG GTG GCC CAG TTC GTG CTG GTG AAC GTG Tyr Phe Val Thr Phe Val Leu Val Ala Gln Phe Val Leu Val Asn Val 1840 1845 1850			5810
GTG GTG GCC GTG CTC ATG AAG CAC CTG GAG GAG AGC AAC AAG GAG GCA Val Val Ala Val Leu Met Lys His Leu Glu Glu Ser Asn Lys Glu Ala 1855 1860 1865 1870			5858
CGG QAG GAT GCG GAG CTG GAC GCC GAG ATC GAG CTG GAG ATG GCG CAG Arg Glu Asp Ala Glu Leu Asp Ala Glu Ile Glu Leu Glu Met Ala Gln 1875 1880 1885			5906

GCG CCC GGG AGT GCA CGC CGG GTG GAC GCG GAC AGG CCT CCC TTG CCC Gly Pro Gly Ser Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu Pro 1890 1895 1900	5954
CAG GAG ATG CCG GGC GCC AGG GAT GCC CCA AAC CTG GTT GCA CGC AAG Gln Glu Ser Pro Gly Ala Arg Asp Ala Pro Asn Leu Val Ala Arg Lys 1905 1910 1915	6002
GTC TCC GTG TCC AGG ATG CTC TCG CTG CCC AAC GAC AGC TAC ATG TTC Val Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met Phe 1920 1925 1930	6050
AEG CCC GTG GTG CCT GCC TCC GCG CCC CAC CCC CGC CCG CTG CAG GNG Arg Pro Val Val Pro Ala Ser Ala Pro His Pro Arg Pro Leu Gln Glu 1935 1940 1945 1950	6098
GTG GAG ATG GAG ACC TAT GGG GCC GGC ACC CCC TTG GGC TCC GTT GCC Val Glu Met Glu Thr Tyr Gly Ala Gly Thr Pro Leu Gly Ser Val Ala 1955 1960 1965	6146
TCT GTG CAC TCT CCG CCC GCA GNG TCC TGT GCC TCC CTC CAG ATC CCA Ser Val His Ser Pro Pro Ala Glu Ser Cys Ala Ser Leu Gln Ile Pro 1970 1975 1980	6194
CTG GCT GTG TCG TCC CCA GCC AEG AGC GGC GAG CCC CTC CAC GCC CTG Leu Ala Val Ser Ser Pro Ala Arg Ser Gly Glu Pro Leu His Ala Leu 1985 1990 1995	6242
TCC CCT CGG GCC ACA GCC CGC TCC CCC AGT CTC AGC CGG CTG CTC TGC Ser Pro Arg Gly Thr Ala Arg Ser Pro Ser Leu Ser Arg Leu Leu Cys 2000 2005 2010	6290
AGA CAG GAG GCT GTG CAC ACC GAT TCC TTG GAA GGG AAG ATT GAC AGC Arg Gln Glu Ala Val His Thr Asp Ser Leu Glu Gly Lys Ile Asp Ser 2015 2020 2025 2030	6336
CCT AGG GAC ACC CTG GAT CCT GCA GAG CCT GGT GAG AAA ACC CGG GTG Pro Arg Asp Thr Leu Asp Pro Ala Glu Pro Gly Glu Lys Thr Pro Val 2035 2040 2045	6386
AGG CCC GTG ACC CAG GGG GGC TCC CTG CAG TCC CCA CCA CGC TCC CCA Arg Pro Val Thr Gln Gly Gly Ser Leu Gln Ser Pro Pro Arg Ser Pro 2050 2055 2060	6434
CGG CCC GGC AGC GTC CGC ACT CGT AAG CAT ACC TTC GGA CAG CAC TGC Arg Pro Ala Ser Val Arg Thr Arg Lys His Thr Phe Gly Gln His Cys 2065 2070 2075	6482
GTC TCC AGC CGG CGG GGG GCC CCA GGC GGA GAG GAG GCC EAG GCC TCG Val Ser Ser Arg Pro Ala Ala Pro Gly Gly Glu Glu Ala Glu Ala Ser 2080 2085 2090	6530
GAC CCA GCC GAC GAG GAG GTC AGC CAC ATC ACC AGC TCC GCC TGC CCC Asp Pro Ala Asp Glu Glu Val Ser His Ile Thr Ser Ser Ala Cys Pro 2095 2100 2105 2110	6578
TGG CAG CCC ACA GCC GAG CCC CAT GGC CCC GAA GCC TCT CCG GTG GCC Trp Gln Pro Thr Ala Glu Pro His Gly Pro Glu Ala Ser Pro Val Ala	6626

2115	2120	2125	
GGC GGC GAG CGG GAC CTG CGC AGG CTC TAC AGC GTG GAC GCT CAG GGC Gly Gly Glu Arg Asp Leu Arg Arg Leu Tyr Ser Val Asp Ala Gln Gly 2130	2135	2140	6674
TTC CTG GAC AAG CCG GGC CGG GCA GAC GAG CAG TGG CGG CCC TCG GCG Phe Leu Asp Lys Pro Gly Arg Ala Asp Glu Gln Thr Arg Pro Ser Ala 2145	2150	2155	6722
CAG CTG GGC AGC GGG GAG CCT GGG GAG GCG AAG GCC TGG GGC CCT GAG Glu Leu Gly Ser Gly Glu Pro Gly Glu Ala Lys Ala Thr Gly Pro Glu 2160	2165	2170	6770
GCC GAG CCC GCT CTG GGT GCG CGC AGA AAG AAG ATG AGC CCC CCC Ala Gln Pro Ala Leu Gly Ala Arg Arg Lys Lys Lys Met Ser Pro Pro 2175	2180	2185	6818
TGC ATC TCG GTG GAA CCC CCT GCG GAG GAC GAG GGC TCT GCG CGG CCC Cys Ile Ser Val Glu Pro Pro Ala Glu Asp Glu Gly Ser Ala Arg Pro 2195	2200	2205	6866
TCC GCG GCA GAG GGC GGC AGC ACC ACA CTG AGG CGC AGG ACC CGG TCC Ser Ala Ala Glu Gly Ser Thr Thr Leu Arg Arg Arg Thr Pro Ser 2210	2215	2220	6914
TGT GAG CCC ACG CCT CAC AGG GAA TCC CTG GAG CCC ACA GAG GGC TCA Cys Glu Ala Thr Pro His Arg Glu Ser Leu Glu Pro Thr Glu Gly Ser 2225	2230	2235	6962
GGC GCC GGG GGG GAC CCT GCA GCC RAG GGG GAG CGC TGG GGC CGG GGC Gly Ala Gly Gly Asp Pro Ala Ala Lys Gly Glu Arg Trp Gly Gln Ala 2240	2245	2250	7010
TCC TGC CGG GCT GAG CAC CTG ACC GTC CCC AGC TTT GCC TTT GAG CGG Ser Cys Arg Ala Glu His Leu Thr Val Pro Ser Phe Ala Phe Glu Pro 2255	2260	2265	7058
CTG GAC CTC GGG GTC CCC AGT GGA GAC CCT TTT TTG GAC GGT AGC CAC Leu Asp Leu Gly Val Pro Ser Gly Asp Pro Phe Leu Asp Gly Ser His 2275	2280	2285	7106
AGT GTG ACC CCA GAA TCC AGA GCT TCC TCT TCA GGG GCC ATA GTG CCC Ser Val Thr Pro Glu Ser Arg Ala Ser Ser Gly Ala Ile Val Pro 2290	2295	2300	7154
CTG GAA CCC CCA GAA TCA GAG CCT CCC ATG CCC GTC GGT GAC CCC CCA Leu Glu Pro Pro Glu Ser Glu Pro Pro Met Pro Val Gly Asp Pro Pro 2305	2310	2315	7202
GAG AAG AGG CGG CGG CTG TAC CTC ACA GTC CCC CAG TGT CCT CTG GAG Glu Lys Arg Arg Gly Leu Tyr Leu Thr Val Pro Gln Cys Pro Leu Glu 2320	2325	2330	7250
AAA CCA GGG TCC CCC TCA GCC ACC CCT GCC CCA GGG GGT GGT GCA GAT Lys Pro Gly Ser Pro Ser Ala Thr Pro Ala Pro Gly Gly Gly Ala Asp 2335	2340	2345	7298
		2350	

GAC CCC GTG TAGCTCGGG CTTGGTGCCG CCACGGCTT TGGCCCTGGG GTCCTGGGGC
 7357
 Asp Pro Val

CCCCGTGGGG	TGGAGGGCCA	GGCACAAACCC	TGCATGEACC	CTGACTTGGG	TCCCCTCGTG	7617
AGCAGAARAGG	CCCCTGGAGG	ATGACGGGCC	AGGCCCCTGGT	TCTCTGCCA	CGCAAGCAGG	7477
AGTAGCTGCC	GGGGCCCCAAG	AGCCTCCATC	CCTCTGGGT	CGGGTTTCTC	CGAGTTTTGC	7537
TACCAAGCCGA	GGCTGTGGCG	GCACACTGGGT	CAGCCTCCCG	TCAGGAGAGA	AGCCGCGTCT	7597
GTUUGGACGAA	GACCCGGGCAAC	CGGCCAGAGA	GGGGAAAGGTA	CCAGGTTGGCG	TCCTTTUAGG	7657
CCCCCGCTTG	TTACAGGACA	CTCGCTGGGG	GCCCTGTGCC	CTTACCGGGCG	GCAGGTTGCA	7717
GCCACCGCGG	CCCRATGTCA	CCTTCACTCA	CAGTCTGAGT	TCTTGTCOGC	CTGTCACGCC	7777
CTCACCAACCC	TCCCCCTCCA	GGCACCCACCC	TTTCCGTTCC	GCTCGGGCCT	TCCCAGAAGC	7837
GTCCTGTGAC	TCTGGGAGAG	GTGACACCTC	ACTAAGGGGC	CGACCCCCATG	GAGTAACCGG	7897
C						7898

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1669 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTCCGGCTCC	GACCGCTGCA	ACATCCTGGA	GGCCTTTCAC	GCCTCATTT	TCGCCCTTTT	60
TGCGGTGCGAG	ATGGTCATCA	AGATGGTGGC	CTTGGGCCCTG	TTCCGGGCAGA	AGTGTAACT	120
GGGTGACACC	TGGAACAGGGC	TOGATTTCCTT	CATCGTCTGTG	GGGGGCGATGA	TGGAGTACTC	180
GTTEGGACGGA	CACRAACGTA	GGCTCTCGGC	WATCAGGACC	GTGCGGGTGC	TGCGGCCCT	240
CCGGCGCCATC	AACCGCGTGC	CTAGCATACTG	GATCCTGGTC	ACTCTOCTGC	TGGATAACCT	300
GCCCATGCTC	GGGAAAGTCC	TTCTGCTGTG	CTTCTTCGTG	TTCTTCATTT	TGGGCATCGT	360
TGGCGTCCAG	CTCTGGGCTG	GGCTCTGCG	GAACCGCTGC	TTCCCTGGACA	TCGCCCTTGT	420
CAGGAACAAAC	AACCTGTGACT	TCCTGGGGCC	GTACTAACAG	ACGGAGGGAGG	GGGAGGAGAA	480
CCCGTTCACTC	TGCTCTCTAC	GGCGAGACAA	GGCCATGCGAG	AAAGTGTCTGC	ACATCCCCGG	540
CCGGCGCGGAG	CTCGCGCATGC	CCTGCACCCCT	GGGCTGGGAG	GCCTACACGC	AGCCGCGAGGC	600
CGAGGGGGTG	GGCGCTECAC	GAACAGCTG	CATCAACTGG	AACCAGTACT	ACAAACGTGT	660
CGCGCTGGGT	GACTCCAAAC	CCCACAAAGG	TGCCATCAAC	TTCGACACAA	TCGGCTACGC	720
CTGGATTGCG	ATCTTCCAGG	TGATCTGGCT	GGAAAGGCTGG	GTGGACATCA	TGTACTACGT	780
CATGGACGCC	CACTCATTCCT	ACAACCTTCAT	CTATTTTCATC	CTGCTCATCA	TCGTGGGCTC	840
CTTCTTCATG	ATCAACCTGT	GGCTGGTGGT	GATTGCCACG	CACTTCTCGG	AGACGAAGCA	900
GC3GGAGAGT	CAGCTGATGC	GGGAGCAGCG	GGCACGECAC	CTGTCACACG	ACAGCACGCT	960
GGCCACBCTTC	TCCGAGCCTG	CGAGCTGCTA	CGAAGAGCTG	CCCCTACTGC	ACCCCTGCCC	1020
TGCGGGACCC	GGAGGGGTGAG	CTCAGCGCT	CGGAAAGSTGG	AGACTCAGAT	GGCCGTTGGCG	1080
TCTATGAATT	CACCGCAGGAC	GTCCGGCAGC	GGGACCCGCTG	GGACCCCCACG	CGACCAACCCC	1140
GGGGGGAGGCCA	GGCTGGATGG	GGCGCCCTCTG	GGTTACCTTC	AGCGGCGAGC	TGCGGCCCAT	1200
CGTGERACAGC	AAGTACTTC	GGCGTGGCAT	CATGATGCC	ATCTTGTCA	ACACGCTGAG	1260
CATGGGGCGTG	GAGTACCATC	AGCAGCCCGA	GGAGCTGACT	ATGCTCTCG	AGATCAGCAA	1320
CATCGTGTTC	ACCAAGCATGT	TTGCCCTGGA	GATGCTCTG	AAAGCTGCTGG	CCTGCGGCC	1380
TCTGGGGCTAC	ATCCGGAAAC	CGTACAAACAT	CTTGGACGGC	ATCATCCTGG	TCATCAGCGT	1440
CTGGGGAGATC	GTGGGGCAGG	CGGACGGGTGG	CTTGTCTGTG	CTGGGCCACCT	TCCGGCTGCT	1500
GGGTGTGCTG	AAGCTGGTGC	GCTTCTGCCC	AGCCCTGCGG	CGCCAGCTCG	GGGTGTGCTG	1560

GAAGACCCTTG GACAAACGTGG CTACCTTCTG CACCGCTGCTC ATGCTCTTC A TTTTCATCTT 1620
 CAGGCATCCCTG CCACATGCACC TTTTCGGCTG GCAAGTTCTG CCTGAAAGAA 1669

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1413 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

ACGGGCTCTGA	GGCTCGCTCG	CTGCCCTCACCC	GGTCCCCGGGC	CCGGGGGGGGG	CGCCCCGGCGC	60
CCGGGGGGCCC	GGCCCTCACCC	GTCGGCTCAG	CGGGCTCCAC	CCCGGGGGCGA	GGGGGGGGCCC	120
GTCGGCTCAG	CGGGGGGGAGC	CGGAGCCCGA	GTCGAGCCGC	GGCCGGGGAGC	CGGGGGGGCT	180
CGGGGAGCGCG	GCCCGGGGGG	GAGGCGCTGG	GGGGCGGGGC	CGGGGGGGGG	CGGGGGGGGG	240
GTCGGGGGGT	GACGGGGGGCC	CCCGGGCGAT	GCCDGCGGGGG	ACGGGGCGGG	CGAGCAGAGC	300
GAGGGCATGCG	GATGCTGGTC	ACTCTGCTGC	TGGATACGGT	GCCCATGCTC	GGGAACGGTCC	360
TTCTGCTGTC	CTTCTTCGTC	TTCTTCATT	TCGGCATCGT	TGGGGTOCAG	CTCTGGGCTG	420
GCCTCTGCG	GAACGGCTGC	TTCCTGGACA	GTGCCCTTTGT	CAGGAAACAA	AACCTGACCT	480
TCTCTGGGCC	GTACTAACAG	ACGGGAGGAGG	GGGAAGGAGAA	CCCCTTCATC	TGCTCTTCAC	540
CCGGAGAGACAA	CGGCGATGCG	AAAGTCTCGC	ACATCCCCCG	CCGGGGGGGAG	CTGCCTCATGC	600
CCTGCACCT	GGGGCTGGGAG	GGCTACACGC	AGCCGGAGGC	CGAGGGGGGTG	GGCGCTGCAC	660
GCAACGGCTG	CATCGAACTGG	AAACCGTACT	ACAAACGTGTG	CCGCTCGGGT	GACTCCAACC	720
CCACACAAACG	TGCCATCAC	TTCGACAAACA	TGGGCTACGC	CTGGAATGGC	ATCTTCCAGG	780
TGATCACGCT	GGAAAGGGCTGG	GTGGGACATCA	TGTAATACGT	CATGACGCC	CACTCATCT	840
ACAAACTTCAF	CTTATTCATC	CTGCTCATCA	TGTTGGGCTC	CTTCTTCATG	ATCAAACCTGT	900
GGCTGGTGGT	GATTGCCAGC	CAGTTCTCGG	AGACCGAAGCA	GGGGGGAGGT	CGCTGATGC	960
GGGAGGAGCG	GGCAACCGCC	CTETCCAAAG	ACPGCAAGCT	GGCCAGGCTTC	TCCGAGGCTG	1020
CGAGCTGCTA	CGAAAGAGCTG	CTGAAAGACTG	GGCCAGGGCCC	CTGGCCATCT	GTGGGGGCTC	1080
AGTGTGCCCC	GCCCCCTGEC	CGGCCCCCCC	GGGGCCACAC	TGACCTGTGA	GCTGAAGAGC	1140
TGCCCGTACT	GCACCCGTGC	CCTGGAGGGAC	CCGGAGGGTG	AGCTCAGCGG	CTCGGAAAGT	1200
CGAGACTCA	ATGGCCGTGG	CGTCTATGAA	TTCACCGCAGG	ACGTCCGGCA	CGGTGACCGC	1260
TGGGACCCCA	CGGGACCCACC	CGGTGCGACG	GACACACCG	GCCCAAGGCC	AGGCAGGCC	1320
CAGCGGGCGG	CACAGCAGAG	GGCAAGCCCCG	GGCGAGGCCAG	GCTGGATGGG	CCGGCTCTGG	1380
GTTACTTCAG	CGGCAAGCTG	CGCGSCATCGT	GGA			1413

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7892 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 249...7307
 (D) OTHER INFORMATION: $\alpha_{1\beta-1}$

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15

cgaggccggcc	gcgcgtcgcc	ccgcctggggcg	agccggagcc	ggagtcgagc	cgccggccgg	60										
agccggggcg	gctggggacg	ccggccgggg	ggggggggcg	tggggggccgg	ggccggggcc	120										
ggggggggag	gcgcgtgggg	ccggggccgg	ggccggggcg	cgagccgggt	ccgcgggtgac	180										
cgcgcggccc	ggggcgatggcc	cgccggggacg	ccggccggccca	gcagagccgg	gtgcgtgggg	240										
cgcgcacc atg acc gag ggc gca cgg gcc gac gag gtc cgg gtg ccc						290										
Met	Thr	Glu	Gly	Ala	Arg	Ala	Asp	Glu	Val	Arg	Val	Pro				
1	5	10														
ctg	ggc	gag	ccc	acc	cct	ggc	cct	gag	gag	ggg	tcc	ccc	338			
Leu	Gly	Ala	Pro	Pro	Pro	Gly	Pro	Ala	Leu	Gly	Ala	Ser	Pro			
15	20	25										30				
gag	agc	ccc	ggg	gag	ccg	ggc	gag	ggg	tcc	gag	ctc		386			
Glu	Ser	Pro	Gly	Ala	Pro	Gly	Arg	Glu	Ala	Glu	Arg	Gly	Ser	Glu	Leu	
35	40	45														
ggc	gtg	tca	ccc	tcc	gag	agc	ccg	gag	ccg	ggc	gag	ctg		434		
Gly	Val	Ser	Pro	Ser	Glu	Ser	Pro	Ala	Ala	Glu	Arg	Gly	Ala	Glu	Leu	
50	55	60														
ggc	gtc	gtc	acc	tcc	gag	agc	ccg	gag	ccg	ggc	gag	ctg		482		
Gly	Val	Ser	Pro	Ser	Glu	Ser	Pro	Ala	Ala	Glu	Arg	Gly	Ala	Glu	Leu	
65	70	75														
gtc	tcc	tcc	tcc	gtt	cag	acc	ccg	egg	ccg	ccg	ggc	ttc		530		
Val	Phe	Phe	Cys	Leu	Gly	Gln	Thr	Thr	Arg	Pro	Arg	Ser	Trp	Cys	Leu	
80	85	90														
egg	ctg	gtc	aac	cca	tgg	tcc	gag	cac	gtg	agc	atg	ctg	gtc	atc	578	
Arg	Leu	Val	Cys	Asn	Pro	Trp	Phe	Glu	His	Val	Ser	Met	Leu	Val	Ile	
95	100	105														
atg	ctc	aac	tgc	gtg	acc	ctg	ggc	atg	tcc	egg	ccc	tgt	gag	gac	626	
Met	Leu	Asn	Cys	Val	Thr	Leu	Gly	Met	Phe	Arg	Pro	Cys	Glu	Asp	Val	
110	115	120											125			
gag	tgc	ggc	tcc	gag	ccg	tgc	aac	atc	ctg	gag	gcc	ttt	gac	gcc	ttc	674
Glu	Cys	Gly	Ser	Glu	Arg	Cys	Asn	Ile	Leu	Glu	Ala	Phe	Asp	Ala	Phe	
130	135	140														
att	tcc	gcc	ttt	ttt	ggc	gtg	gag	atg	gtc	atc	aag	atg	gtg	gcc	ttt	722
Ile	Phe	Ala	Phe	Ala	Val	Glu	Met	Val	Ile	Lys	Met	Val	Ala	Ile		
145	150	155														
ggg	ctg	tcc	ggg	cag	aag	tgt	tac	ctg	ggt	gac	scg	tgg	aac	agg	ctt	770
Gly	Leu	Phe	Gly	Gln	Lys	Cys	Tyr	Leu	Gly	Asp	Thr	Trp	Asn	Arg	Leu	
160	165	170														

gat ttc ttc atc gtc gtg gcg ggc atg atg gag tac tcc ttg gac gga Asp Phe Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly 175 180 185 190	810
cac aac gtg aac ctc tcc gct atc agg acc gtg cgg gtg ctg cgg ccc His Asn Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro 195 200 205	866
ctc cgc gcc atc zac cgc gtg cct aac atg cgg atc ctg gtc act ctg Leu Arg Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu 210 215 220	914
ctg ctg gat aac ctg ccc atc ctc ggg aac gtc ctt ctg ctg tgc ttc Leu Leu Asp Thr Leu Pro Met Leu Gly Asn Val Leu Leu Leu Cys Phe 225 230 235	962
tcc gtc ttc att ttc ggc atc gtt ggc gtc cag ctc tgg gct ggc Phe Val Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly 240 245 250	1010
ctc ctg cgg aac cgc tgc ttc ctg gac aac gtc ttt gtc agg aac aac Leu Leu Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn 255 260 265 270	1058
aac ctg acc ttc ctg cgg ccc tac tac cag acg gag gag ggc gag gag Asn Leu Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu 275 280 285	1106
aac ccg ttc atc tgc tcc tca cgc cga gac zac ggc atg cag aag tgc Asn Pro Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys 290 295 300	1154
tcc cac atc ccc ggc cgc cgc gag ctg cgc atg ccc tgc acc ctg ggt Ser His Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly 305 310 315	1202
tgg gag gec tac acg cag ccc cag gec gag ggg gtg ggc gct gca cgc Trp Glu Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg 320 325 330	1250
aac gcc tgc atc aac tgg aac cag tac tac aac gtc tgc cgc tcc ggt Asn Ala Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly 335 340 345 350	1298
gac tcc aec ccc cac aac ggt gcc atc aac ttc gac aac atc ggc tac Asp Ser Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asn Ile Gly Tyr 355 360 365	1346
gcc tgg att gcc atc ttc cag gtg atc acg ctg gaa ggc tgg gtg gac Ala Trp Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp 370 375 380	1394
atc atg tac tac gtc atg gac gcc ccc tca ttc tac aac ttc atc tat Ile Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr 385 390 395	1442
ttc atc ctg ctc atc atc gtg ggc tcc ttc ttc atg atc aac ctg tgc	1490

Phe Ile Leu Leu Ile Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys			
400	405	410	
ctg gtg atg gcc acg cag ttc tcc tcc ggg gag acg aag cag cgg ggg agt	1538		
Leu Val Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser			
615	620	625	
cag ctg atg cgg ggg cag cgg gca cgc cac ctg tcc sac gac agc acg	1586		
Gln Leu Met Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr			
430	435	440	
ctg gcc agc ttc tcc gag cct ggc agc tgc tac gaa gag ctg ctg aag	1634		
Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys			
665	450	455	460
tac gtg ggc cac ata ttc cgc aag gtc aag cgg cgc agc ttg cgc ctc	1682		
Tyr Val Gly His Ile Phe Arg Lys Val Lys Arg Arg Ser Leu Arg Leu			
465	470	475	
tac gcc cgc tgg cgg agc cgc tgg cgc aag aag stg gac ccc agt get	1730		
Tyr Ala Arg Trp Gln Ser Arg Trp Arg Lys Lys Val Asp Pro Ser Ala			
480	485	490	
gtg cca ggc cag ggt ccc ggg cac cgc cag cgc cgg gca ggc agg cac	1778		
Val Gln Gly Gln Gly Pro Gly His Arg Gln Arg Arg Ala Gly Arg His			
495	500	505	510
aca gcc tcg gtg ccc cac ctg gtc tac cac cac cat cac cac cac cac	1826		
Thr Ala Ser Val His His Leu Val Tyr His His His His His His His			
515	520	525	
cac cac tac cat ttc agc cat ggc agc ccc cgc agg ccc ggc ccc gag	1874		
His His Tyr His Phe Ser His Gly Ser Pro Arg Arg Pro Gly Pro Glu			
530	535	540	
cca ggc gcc tgc gag acc egg ctc gtc cga gct ggc gcg ccc ccc tcc	1922		
Pro Gly Ala Cys Asp Thr Arg Leu Val Arg Ala Pro Pro Ser			
545	550	555	
cca ccc tcc cca ggc cgc gga ccc ccc gac gca gag tcc tcc ccc agc	1970		
Pro Pro Ser Pro Gly Arg Gly Pro Pro Asp Ala Glu Ser Val His Ser			
560	565	570	
atc tac cat gcc gac tgc car ata gag ggg ccc cag gag egg gcc cgg	2018		
Ile Tyr His Ala Asp Cys His Ile Glu Gly Pro Gln Glu Arg Ala Arg			
575	580	585	590
gtg gca cat gcc gca gcc act gcc gct gcc agc ctc agg ctc gcc aca	2066		
Val Ala His Ala Ala Ala Thr Ala Ala Ser Leu Arg Leu Ala Thr			
595	600	605	
ggg ctg ggc acc aeg aac tac ccc acg atc ctg ccc tcc ggg gtc ggc	2110		
Gly Leu Gly Thr Met Asn Tyr Pro Thr Ile Leu Pro Ser Gly Val Gly			
610	615	620	
agg ggc aas ggc agc acc aeg ccc gga ccc aag cgg aag tgg gcc egt	2162		
Ser Gly Lys Gly Ser Thr Ser Pro Gly Pro Lys Gly Lys Trp Ala Gly			
625	630	635	

gga ccg cca ggc acc ggg ggg ccc ggc ccg ttg agc ttg aac aac agc oct Gly Pro Pro Gly Thr Gly Gly His Gly Pro Leu Ser Leu Asn Ser Pro 640 645 650	2210
gat ccc tac gag aag atc ccc cat gtg ctc ggg gag cat gga ctg ggc Asp Pro Tyr Glu Lys Ile Pro His Val Val Gly Glu His Gly Leu Gly 655 660 665 670	2258
cag gcc cct ggc cat ctg tcg ggc ctc agt gtg ccc tgc ccc ctg ccc Gln Ala Pro Gly His Leu Ser Gly Leu Ser Val Pro Cys Pro Leu Pro 675 680 685	2306
aga ccc cca gcg ggc aca ctc acc tgt gag ctg aag aac tgc ccc tcc tac Ser Pro Pro Ala Gly Thr Leu Thr Cys Glu Leu Lys Ser Cys Pro Tyr 690 695 700	2354
tgc acc cgt gcc ctg gag gac ccg gag ggt gag ctc agc ggc tcc gaa Cys Thr Arg Ala Leu Glu Asp Pro Glu Gly Glu Leu Ser Gly Ser Glu 705 710 715	2402
agt gga gac tca gat ggc cgt ggc gtc tat gaa ttc aca cag gac gtc Ser Gly Asp Ser Asp Gly Arg Gly Val Tyr Glu Phe Thr Gln Asp Val 720 725 730	2450
cgg cac ggt gac cgc tgg gac ccc acg cga cca ccc cgt gcg aca gac Arg His Gly Asp Arg Trp Asp Pro Thr Arg Pro Pro Arg Ala Thr Asp 735 740 745 750	2498
aca cca ggc ccc ggc cca ggc aca ccc cag cgg cgg gca cag cag agg Thr Pro Gly Pro Gly Ser Pro Gln Arg Arg Ala Gln Gln Arg 755 760 765	2546
gca gcc ccc ggc gag cca ggc tgg atg ggc cgc ctc tgg gtt acc ttc Ala Ala Pro Gly Glu Pro Gly Trp Met Gly Arg Leu Trp Val Thr Phe 770 775 780	2594
aac ggc aag ctg cgc cgc atc gtg gac agc aag tac ttc agc cgt ggc Ser Gly Lys Leu Arg Arg Ile Val Asp Ser Lys Tyr Phe Ser Arg Gly 785 790 795	2642
atc atg atg gcc atc ctt gtc aac acg ctg agc atg ggc gtg gag tac Ile Met Met Ala Ile Leu Val Asn Thr Leu Ser Met Gly Val Glu Tyr 800 805 810	2690
cat gag cag ccc gag gag ctg act aat gct ctg gag atc agc aac atc His Glu Gln Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn Ile 815 820 825 830	2738
gtg ttc acc aac atg ttt gcc ctg gag atg ctg ctg aag ctg ctg gac Val Phe Thr Ser Met Phe Ala Leu Glu Met Leu Leu Lys Leu Leu Ala 835 840 845	2786
tgc ggc ccc ctg ggc tac atc cgg aac ccc tac aac acc ttc gac ggc Cys Gly Pro Leu Gly Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp Gly	2834

850	855	860	
atc atc stg stc atc aac gtc tgg gag atc gtc ggg cag gca gac ggt Ile Ile Val Val Ile Ser Val Trp Glu Ile Val Gly Gln Ala Asp Gly 865 870 875			2862
ggc ttg tct gtg ctg cgc acc ttc tgg ctg ctg cgt gtg ctg aag ctg Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg Val Leu Lys Leu 880 885 890			2930
gtg cgc ttt ctg cca gcc ctg cgg cgc cag ctc gtg gtg ctg gtg aag Val Arg Phe Leu Pro Ala Leu Arg Arg Gln Leu Val Val Leu Val Lys 895 900 905 910			2978
acc atg gac rac gtc gct acc ttc tgc acg ctg ctc atg otc ttc att Thr Met Asp Asn Val Ala Thr Phe Cys Thr Leu Leu Met Leu Phe Ile 915 920 925			3026
tcc atc ttc aac atc ctg ggc atg cac ctt ttc ggc tgc aag ttc agc Phe Ile Phe Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe Ser 930 935 940			3074
ctg aag aca gac acc gga gac acc gtg oct gac aag aag aac ttc gac Leu Lys Thr Asp Thr Gly Asp Thr Val Pro Asp Arg Lys Asn Phe Asp 945 950 955			3122
tcc ctg ctg tgg gcc atc gtc acc gtg ttc cag atc ctg acc cag gag Ser Leu Leu Trp Ala Ile Val Thr Val Phe Gln Ile Leu Thr Gln Glu 960 965 970			3170
gac tgg aac gtc ctg tec aac ggc atg gac tcc acc tcc tcc tgg Asp Trp Asn Val Val Leu Tyr Asn Gly Met Ala Ser Thr Ser Ser Trp 975 980 985 990			3218
gcc gcc ctc tae ttc gtg gcc ctc atg acc ttc ggc aac tat gtg ctc Ala Ala Leu Tyr Phe Val Ala Leu Met Thr Phe Gly Asn Tyr Val Leu 995 1000 1005			3266
tcc aac ctg ctg gtg gcc atc ctc gtg gag ggc ttc cag gca gag ggc Phe Asn Leu Leu Val Ala Ile Leu Val Glu Gly Phe Gln Ala Glu Gly 1010 1015 1020			3314
aat gcc aac aga tcc gac aac gac gag gag aac aac tcc gtc cac ttc Asp Ala Asn Arg Ser Asp Thr Asp Glu Asp Lys Thr Ser Val His Phe 1025 1030 1035			3362
gag gag gac ttc cac sag ctc aga gaa ctc cag acc aca gag ctg aag Glu Glu Asp Phe His Lys Leu Arg Glu Leu Gln Thr Thr Glu Leu Lys 1040 1045 1050			3410
atg tgt tcc ctg gcc gtg acc ccc aac ggg cac ctg gag gga cga ggc Met Cys Ser Leu Ala Val Thr Pro Asn Gly His Leu Glu Gly Arg Gly 1055 1060 1065 1070			3456
agc ctg tcc cct ccc ctc atc atg tgc aca gct gcc aac ccc atg cct Ser Leu Ser Pro Pro Leu Ile Met Cys Thr Ala Ala Thr Pro Met Pro			3506

1075	1080	1085	
acc ccc aag agc tca cca ttc ctg gat	gca gcc ccc agc ctc cca gac		3554
Thr Pro Lys Ser Ser Pro Phe Leu Asp Ala Ala Pro Ser Leu Pro Asp			
1090	1095	1100	
tct cgg cgt ggc agc agc tcc ggg gac ccc ctg gga gac cag			3602
Ser Arg Arg Gly Ser Ser Ser Gly Asp Pro Pro Leu Gly Asp Gln			
1105	1110	1115	
aag cct ccc gcc agc ctc cga agt tct ccc tgt gcc ccc tgg ggc ccc			3650
Lys Pro Pro Ala Ser Leu Arg Ser Ser Pro Cys Ala Pro Trp Gly Pro			
1120	1125	1130	
agt ggc gcc tgg agc agc cgg cgc tcc agc tgg agc agc ctg ggc cgt			3698
Ser Gly Ala Trp Ser Ser Arg Arg Ser Ser Trp Ser Ser Leu Gly Arg			
1135	1140	1145	1150
gcc ccc agc ctc aag cgc cgc ggc cag tgt ggg gaa cgt gag tcc ctg			3746
Ala Pro Ser Leu Lys Arg Arg Gly Gln Cys Gly Glu Arg Glu Ser Leu			
1155	1160	1165	
ctg tct ggc gag ggc aag ggc agc acc gac gac gaa gct gag gac ggc			3794
Leu Ser Gly Glu Gly Lys Gly Ser Thr Asp Asp Glu Ala Glu Asp Gly			
1170	1175	1180	
agg gcc gcc ccc ggg ccc cgt gcc acc ccc tcc cgg cgg gcc gag tcc			3842
Arg Ala Ala Pro Gly Pro Arg Ala Thr Pro Leu Arg Ala Glu Ser			
1185	1190	1195	
ctg gac cca cgg ccc ctg cgg ccc gcc gcc ccc ccc acc aag tcc			3890
Leu Asp Pro Arg Pro Leu Arg Pro Ala Ala Leu Pro Pro Thr Lys Cys			
1200	1205	1210	
cgc gat cgc gac ggg cag tgc gtc gcc ctg ccc agc gac ttc ttc tcc			3938
Arg Asp Arg Asp Gly Gln Val Val Ala Leu Pro Ser Asp Phe Phe Leu			
1215	1220	1225	1230
cgc atc gac agc cac cgt gag gat gca gcc gag ctt gac gac gac tcc			3986
Arg Ile Asp Ser His Arg Glu Asp Ala Ala Glu Leu Asp Asp Ser			
1235	1240	1245	
gag gac agc tgc tcc cgc ctg cat aac gtg ctg gag ccc tac aag			4034
Glu Asp Ser Cys Cys Leu Arg Leu His Lys Val Leu Glu Pro Tyr Lys			
1250	1255	1260	
ccc cag tgg tgc cgg agc cgc gag gtc tgg gcc ctc tac ctc ttc tcc			4082
Pro Gln Trp Cys Arg Ser Arg Glu Ala Trp Ala Leu Tyr Leu Phe Ser			
1265	1270	1275	
cca cag aac cgg ttc cgc gtc tcc tgc cag aag gtc atc aca cac aag			4130
Pro Gln Asn Arg Phe Arg Val Ser Cys Gln Lys Val Ile Thr His Lys			
1280	1285	1290	
atg ttt gat cac tgc gtc ctc gtc ttc atc ttc ctc aac tgc gtc acc			4178
Met Phe Asp His Val Val Leu Val Phe Ile Phe Leu Asn Cys Val Thr			
1295	1300	1305	1310

atc gcc ctg gag agg cct gac att gac ccc ggc agc acc gag cgg gtc Ile Ala Leu Glu Arg Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg Val 1315 1320 1325	4226
tcc ctc agc gtc tcc sat tac atc ttc acg gcc atc ttc gtg gcs gag Phe Leu Ser Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala Glu 1330 1335 1340	4274
atg atg gts aag gtg gts gcc ctg ggg ctg tcc ggc gag cac gcc Met Met Lys Val Val Ala Leu Gly Leu Leu Ser Gly Glu His Ala 1345 1350 1355	4322
tac ctg cag agt agc tgg aac ctg ctg gat ggg ctg ctg gts ctg gtg Tyr Leu Gln Ser Ser Trp Asn Leu Leu Asp Gly Leu Leu Val Leu Val 1360 1365 1370	4370
tcc ctg gtc gac att gtc gtc gcc atg gcc tcc gct ggt ggc gcc aag Ser Leu Val Asp Ile Val Val Ala Met Ala Ser Ala Gly Gly Ala Lys 1375 1380 1385 1390	4418
atc ctg ggt gtt ctg cgc gtc ctg cgt ctg ctg cgg acc ctg egg oct Ile Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr Ile Arg Pro 1395 1400 1405	4466
cta agg gtc atc agc cgg gcc ccg ggc ctc aag ctg gtc gtc gag acg Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu Thr 1410 1415 1420	4514
ctg ata tcg tcg ctc agg ccc att ggg aac atc gtc ctc att tgc tgc Leu Ile Ser Ser Leu Arg Pro Ile Gly Asn Ile Val Leu Ile Cys Cys 1425 1430 1435	4562
gcc ttc ttc atc att ttt ggc atc ttg ggt gtc cay ctc ttc aaa ggg Ala Phe Ile Ile Phe Gly Ile Leu Gly Val Gln Leu Phe Lys Gly 1440 1445 1450	4610
aag ttc tac tac tgc gag ggc ccc gac acc agg aac atc tcc acc aag Lys Phe Tyr Tyr Cys Glu Gly Pro Asp Thr Arg Asn Ile Ser Thr Lys 1455 1460 1465 1470	4658
gca cag tgc cgg gcc gcc rac tac cgc tgg gtc cga cgc aag tac aac Ala Gln Cys Arg Ala Ala His Tyr Arg Trp Val Arg Arg Lys Tyr Asn 1475 1480 1485	4706
tcc gac aac ctg ggc cag gcc ctg atg tgg ctg ttc gtg ctg tca tcc Phe Asp Asn Leu Gly Gln Ala Leu Met Ser Leu Phe Val Leu Ser Ser 1490 1495 1500	4754
aag gat gga tgg gtc aac atc atg tac gac ggg ctg gat gcc gtc ggt Lys Asp Gly Trp Val Asn Ile Met Tyr Asp Gly Leu Asp Ala Val Gly 1505 1510 1515	4802
gtc gac cag cag cct gtc cag aac cac aac ccc tgg atg ctg ctg tac Val Asp Gln Gln Pro Val Gln Asn His Asn Pro Trp Met Leu Leu Tyr 1520 1525 1530	4850

ttc atc tcc ttc ctg ctc atc gag ttc ttc ggc ctc aac atg ttc Phe Ile Ser Phe Leu Leu Ile Val Ser Phe Phe Val Leu Asn Met Phe	1535	1540	1545	1550	1898
gtg ggc gtc gtg gtc gag aac ttc cac aag tgc egg cay cac cag gag Val Gly Val Val Glu Asn Phe His Lys Cys Arg Gln His Gln Glu	1555		1560	1565	4946
gcg gag gag cog cog cog ega gag gag ega cog ctg egg cgc cta gag Ala Glu Ala Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu Glu	1570		1575	1580	4994
agg agg cgc agg agg act ttc ccc age cca gag gcc cag cgc egg ccc Arg Arg Arg Arg Ser Thr Phe Pro Ser Pro Glu Ala Gln Arg Arg Pro	1585		1590	1595	5042
tac tat gcc gac tac tcc ccc aeg cgc egc tcc att cac tcg ctg tgc Tyr Tyr Ala Asp Tyr Ser Pro Thr Arg Arg Ser Ile His Ser Leu Cys	1600	1605		1610	5090
acc agc cac tat ctc gac ctc ttc atc sec ttc atc atc tgt gtc aac Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile Cys Val Asn	1615	1620	1625	1630	5138
gtc atc acc atg tcc atg gag gag cad tat aac caa ccc aag tcg ctg gac Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys Ser Leu Asp	1635		1640	1645	5186
gag gcc ctc aag tac tgc aac tac gtc ttc acc atc gtg ttt gtc ttc Glu Ala Leu Lys Tyr Asn Tyr Val Phe Thr Ile Val Phe Val Phe	1650		1655	1660	5234
gag qct gca ctg aag ctg gta gca ttt ggg ttc cgt cgg ttc ttc aag Glu Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Arg Phe Phe Lys	1665		1670	1675	5282
gac agg tgc aac cag ctg gac ctg gcc atc gtg ctg ctg tca ctc atg Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Leu Met	1680	1685		1690	5330
ggc atc acg ctg gag gag ata gag atg ago gtc gcg ctg ccc atc aac Gly Ile Thr Leu Glu Glu Ile Glu Met Ser Ala Ala Leu Pro Ile Asn	1695	1700	1705	1710	5378
ccc acc atc atc cgc atc atg cgc gtg ctt cgc att gcc cgt gtg ctg Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val Leu	1715		1720	1725	5426
aag ctg ctg aag atg got acg ggc atg cgc ggc ctg ctg gac act gtg Lys Leu Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr Val	1730		1735	1740	5474
gtg caa gct ctc ccc cag ctg ggg aac ctg ggc ctt ctt ttc atg ctc Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met Leu	1745		1750	1755	5522

ctg ttt rtt atc tat gct gcg ctg gga gtg gag ctg ttc ggg agg ctg Leu Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly Arg Leu 1760 1765 1770	5570
gag tgc agt gaa gac aac ccc tgc gag ggc ctg agc agg cac gcc acc Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg His Ala Thr 1775 1780 1785 1790	5618
tte agc aac ttc ggc atg gct ttc ctc acg ctg ttc cgc gtg tcc acg Phe Ser Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser Thr 1795 1800 1805	5666
ggg gag aac tgg aac ggg atc atg aag gac acg ctg cgc gag tgc tcc Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Glu Cys Ser 1810 1815 1820	5714
cgt gag gag ag cac tgc ctg agc tac ctg ccc gac ctg tcc ccc gtc Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu Ser Pro Val 1825 1830 1835	5762
tac ttc gtg acc ttc gtg ctg gtg gcc cag ttc gtg ctg gtg aac gtg Tyr Phe Val Thr Phe Val Leu Val Ala Gln Phe Val Leu Val Asn Val 1840 1845 1850	5810
gtg gtg gcc gtg ctc atg aag cac ctg gag gag agc aac aag gag gca Val Val Ala Val Leu Met Lys His Leu Glu Ser Asn Lys Glu Ala 1855 1860 1865 1870	5858
cgg ggg gat gca gag ctg gag gac gac gag atc gag ctg gag atg scg cag Arg Glu Asp Ala Glu Leu Asp Ala Glu Ile Glu Leu Glu Met Ala Gln 1875 1880 1885	5906
gcc ccc ggg agt gca cgc cgg gtg gag gac agg cct ccc ttg ccc Gly Pro Oly Ser Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu Pro 1890 1895 1900	5954
cag gag agt ccc ggc agg gat gca cca aac ctg gtt gca cgc aag Gln Glu Ser Pro Gly Ala Arg Asp Ala Pro Asn Leu Val Ala Arg Lys 1905 1910 1915	6002
gtg tcc gtg tcc agg atg ctc tcg ctg ccc aac gac agc tac atg ttc Val Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met Phe 1920 1925 1930	6050
agg ccc gtg gtg cct gcc tcg gcg ccc cac ccc cgc ccc ctg cag gag Arg Pro Val Val Pro Ala Ser Ala Pro His Pro Arg Pro Leu Gln Glu 1935 1940 1945 1950	6098
gtg gag atg gag acc tat ggg gcc ggc acc ccc ttg ggc tcc gtt gcc Val Glu Met Glu Thr Tyr Oly Ala Gly Thr Pro Leu Gly Ser Val Ala 1955 1960 1965	6146
tct gtg ccc tcc ccc gca gag tcc tgt gcc tcc ctc cag atc cca Ser Val His Ser Pro Pro Ala Glu Ser Cys Ala Ser Leu Gln Ile Pro 1970 1975 1980	6194
ctg gct gtg tcc tcc cca gcc agg agc ggc gag ccc ctc cac gcc ctg	6242

Leu Ala Val Ser Ser Pro Ala Arg Ser Gly Glu Pro Leu His Ala Leu
 1985 1990 1995

tcc cct ccg ggc aca gcc cgc tcc ccc agt ctc agc egg ctg ctc tgc Ser Pro Arg Gly Thr Ala Arg Ser Pro Ser Leu Ser Arg Leu Leu Cys 2000 2005 2010	6290
aga cag gag gct gtg ccc acc gat tcc ttg gaa ggg aag att gar agc Arg Gln Glu Ala Val His Thr Asp Ser Leu Glu Gly Lys Ile Asp Ser 2015 2020 2025 2030	6336
cct agg gag acc ctg gat cct gca gag ctt gat gag aaa acc ccg gtg Pro Arg Asp Thr Leu Asp Pro Ala Glu Pro Gly Glu Lys Thr Pro Val 2035 2040 2045	6386
agg ccg gtg acc cag ggg ggc tcc ctg cag tcc cca cca cgc tcc cca Arg Pro Val Thr Gln Gly Gly Ser Leu Gln Ser Pro Pro Arg Ser Pro 2050 2055 2060	6434
cgg ccc gcc agt gtc cgc act cgt aag cat acc ttc gga cag cac tgc Arg Pro Ala Ser Val Arg Thr Arg Lys His Thr Phe Gly Gln His Cys 2065 2070 2075	6482
gtc tcc zgc cgg ccc ggc ggc cca ggc gga gag gag gac gag gac tcg Val Ser Ser Arg Pro Ala Ala Pro Gly Gly Glu Ala Glu Ala Ser 2080 2085 2090	6530
gac cca gcc gag gag gtc arg cac atc acc agc tcc gcc tgc ccc Asp Pro Ala Asp Glu Glu Val Ser His Ile Thr Ser Ser Ala Cys Pro 2095 2100 2105 2110	6578
tgg cag ccc aca gcc gag ccc cat ggc ccc gag gcc tct ccc gtg gcc Trp Gln Pro Thr Ala Glu Pro His Gly Pro Glu Ala Ser Pro Val Ala 2115 2120 2125	6626
ggc ggc gag cgg gac tgg cgc egg ctc tac arg gtg gag get cag ggc Gly Glu Arg Asp Leu Arg Arg Leu Tyr Ser Val Asp Ala Gln Gly 2130 2135 2140	6674
tcc tgg gag aag ccc ggc cgg gca gag gag cag tgg egg ccc tcg ccc Phe Leu Asp Lys Pro Gly Arg Ala Asp Glu Gln Trp Arg Pro Ser Ala 2145 2150 2155	6722
gag ctg ggc agc ggg gag cct ggg gag ggc aag gcc tgg ggc cct gag Glu Leu Gly Ser Gly Glu Pro Gly Glu Ala Lys Ala Trp Gly Pro Glu 2160 2165 2170	6770
gcc gag ccc gct ctg ggt gcg cgc aga aag aag aag atg agc ccc ccc Ala Glu Pro Ala Leu Gly Ala Arg Arg Lys Lys Met Ser Pro Pro 2175 2180 2185 2190	6810
tgc att tcc tgg gaa ccc cct gcg gag gac gag ggc tct gcg cgg ccc Cys Ile Ser Val Glu Pro Pro Ala Glu Asp Glu Gly Ser Ala Arg Pro 2195 2200 2205	6866
tcc gcg gca gag ggc ggc agc acc aca ctg agg cgc agg acc ccc tcc Ser Ala Ala Glu Gly Gly Ser Thr Thr Leu Arg Arg Arg Thr Pro Ser 2210 2215 2220	6914

tgt gag gcc acg cct cac egg gac tcc ctg gag ccc aca gag ggc tca Cys Glu Ala Thr Pro His Arg Asp Ser Leu Glu Pro Thr Glu Gly Ser 2325	2230	2235	6962
ggc gcc ggg ggg gac cct gca gcc aag ggg gag cgc tgg ggc cag gcc Gly Ala Gly Gly Asp Pro Ala Ala Lys Gly Glu Arg Trp Gly Gln Ala 2240	2245	2250	7010
tcc tgc cgg gct gag cac ctg acc gtc ccc agc ttt gcc ttt gag ccg Ser Cys Arg Ala Glu His Leu Thr Val Pro Ser Phe Ale Phe Glu Pro 2255	2260	2265	7058
ctg gac ctc ggg gtc ccc ayt gga gac cct ttc ttg gac ggt agc cac Leu Asp Leu Gly Val Pro Ser Gly Asp Pro Phe Leu Asp Gly Ser His 2275	2280	2285	7106
agt gtg acc cca gaa tcc aga gct tcc tca ggg gcc ata gtg ccc Ser Val Thr Pro Glu Ser Arg Ala Ser Ser Gly Ala Ile Val Pro 2290	2295	2300	7154
ctg gaa ccc cca gaa tca gag cct ccc atg ccc gtc ggt gac ccc cca Leu Glu Pro Pro Glu Ser Glu Pro Pro Met Pro Val Gly Asp Pro Pro 2305	2310	2315	7202
gag aag agg cgg ggg ctg tac ctc aca gtc ccc cag tgt crt ctg gag Glu Lys Arg Arg Gly Leu Tyr Leu Thr Val Pro Gln Cys Pro Leu Glu 2320	2325	2330	7250
aaa cca ggg tcc acc tca gcc acc cct gcc cca ggg ggt ggt gca gat Lys Pro Gly Ser Pro Ser Ala Thr Pro Ala Pro Gly Gly Gly Ala Asp 2335	2340	2345	7298
gac ccc gtg tag ctgggggtt agtggcgccc aacgggtttgg ccctggggtc Asp Pro Val			7350
tggggggcccd gctgggggtgg aggccccaggc acaaaccctgc atggacccttg acttgggttc cgtegtgago aaaaaggccc ggggaggatg acggcccccgg ccctgggttc ctggccatcg aaggcaggagt agctggcggg ccccaacggc ctccatccgt tctgggttgg gttttcccg gttttgcatac cagcccgaggc tggcgccggca actgggtttag cctcccggtca ggagagaago cgggtctgtg ggacgaaagac cggccacccgg ccagagaggg gaaggtaatac ggttgcgtcc tttccggccc cggcggtta caggacactc gctggggggcc ctgtgcctt gccgggggtca ggtgtgcagcc acceggggcc aatgtcacct taacttacag tctgagttct tgcccgctg tcacggccctc accaccctcc ctttccagcc accacccttt ccgttccogct cgggccttcc cagaaggcgtc ctgtgtactt gggagagggtg acacccactt aaaaaaaaaa ccccatggag taaccatcg			7410

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6941 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(iii) MOLECULE TYPE: cDNA

(113) HYPOTHETICAL: NO

(iv) ANTI SENSE: NO

(v) FRAGMENT TYPE:
 (vi) ORIGINAL SOURCE:
 (ix) FEATURE:

(A) NAME/KEY: Coding Sequence
 (B) LOCATION: 249... 6353
 (D) OTHER INFORMATION: $\alpha_{18.2}$

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16

cgaggccgccc	gcctgtggcct	cggccgggggg	aggccggggcc	ggagtcggcgc	cgcggccgggg	60
aggccgggggg	actggggggacg	cggggccgggg	gggggggggg	ggccggggggcc	ggccggggggcc	120
ggggggccgggg	gggggggggggg	ccggggggccgg	ggccgggggg	cgccgggggt	cggccgtgac	180
ccggccggccc	ggggggatggcc	cggggggggcc	ggccggggccaa	gcagagccaa	gtgtgtgggg	240
ccggccacc	atg acc gag ggc gca cgg	gcc gca gag gtc	cgg gtg ccc	290		
	Met Thr Glu Gly Ala Arg Ala Asp	Glu Val Arg Val Pro				
1	5	10				
ctg ggc gcg ccc cct	ggc cct gcg gcg ttg	gtg ggg gcg tcc	cgg 330			
Leu Gly Ala Pro Pro Pro	Gly Pro Ala Ala Leu Val Gly Ala Ser Pro					
15	20	25	30			
gag agc ccc ggg gcg ccc gga cgc gag gcg ggg cgg ggg tcc	gag ctc 386					
Glu Ser Pro Gly Ala Pro Gly Glu Ala Glu Arg Gly Ser Glu Leu						
35	40	45				
ggc gtc tca ccc tcc gag agc ctc gcg gcc gag cgc ggc gcg gag ctg	434					
Gly Val Ser Pro Ser Glu Ser Pro Ala Ala Glu Arg Gly Ala Glu Leu						
50	55	60				
ggt gcc gac gag gag cag cgc gtc ccg tac ccg gcc ttg gcg gcc acg	482					
Gly Ala Asp Glu Glu Gln Arg Val Pro Tyr Pro Ala Leu Ala Ala Thr						
65	70	75				
gtc ttc ttc tgc ctc ggt cag acc acg cgg ccc acg tgg tgc ctc	530					
Val Phe Phe Cys Leu Gly Gln Thr Thr Arg Pro Arg Ser Trp Cys Leu						
80	85	90				
ccg ctg gtc tgc aac cca tgg ttc gac cac gtg agc atg ctg gta atc	578					
Arg Leu Val Cys Asn Pro Trp Phe Glu His Val Ser Met Leu Val Ile						
95	100	105	110			
atg ctc aac tgc gtg acc ctc ggc atg ttc cgg ccc tgt gag gac gtt	626					
Met Leu Asn Cys Val Thr Leu Gly Met Phe Arg Pro Cys Glu Asp Val						
115	120	125				
gag tgc ggc tcc gag ggc tgc aac atc ctc gag gcc ttg gac gcc ttc	674					
Glu Cys Gly Ser Glu Arg Cys Asn Ile Leu Glu Ala Phe Asp Ala Phe						
130	135	140				
att ttc gcc ttt ttt gcg stg gag atg gtc atc aag atg gtg gcc ttg	722					
Ile Phe Ala Phe Ala Val Glu Met Val Ile Lys Met Val Ala Leu						
145	150	155				
ggg ctg etc ggg cag aag tgt tac ctc ggt gac acg tgg aac agg ctg	770					

Gly Leu Phe Gly Cln Lys Cys Tyr Leu Gly Asp Thr Trp Asn Arg Leu
 160 165 170

gat ttc ttc atc gtc gtg gcg ggc atg atg gag tac tcc ttc gac gga 816
 Asp Phe Phe Ile Val Val Ala Gly Met Met Glu Tyr Ser Leu Asp Gly
 175 180 185 190

cac aac gtg aac ctc tcc gct atc agg acc gtg cgg ctg ctg cgg ccc 866
 His Asn Val Ser Leu Ser Ala Ile Arg Thr Val Arg Val Leu Arg Pro
 195 200 205

ctc cgc gcc atc aac cgc gtg cct agc atg cgg atc ctg gtc act ctg 914
 Leu Arg Ala Ile Asn Arg Val Pro Ser Met Arg Ile Leu Val Thr Leu
 210 215 220

ctg ctg gat acg ctg ccc atg ctc ggg aac gtc ctt ctg ctg tgc ttc 962
 Leu Leu Asp Thr Leu Phe Met Leu Gly Asn Val Leu Leu Leu Cys Phe
 225 230 235

ttc gtc ttc att ttc ggc atc gtt ggc gtc cag ctc tgg gct ggc 1010
 Phe Val Phe Phe Ile Phe Gly Ile Val Gly Val Gln Leu Trp Ala Gly
 240 245 250

ctc ctg cgg aac cgc tgc ttc ctg gac aat gac ttt gtc agg aac aac 1058
 Leu Leu Arg Asn Arg Cys Phe Leu Asp Ser Ala Phe Val Arg Asn Asn
 255 260 265 270

aac ctg acc ttc ctg cgg ccc tac tac cag acg gag gag ggc gag gag 1106
 Asn Leu Thr Phe Leu Arg Pro Tyr Tyr Gln Thr Glu Glu Gly Glu Glu
 275 280 285

aac ccg ttc atc tgc tcc tca cgc cgg gac aac ggc atg cag aag tgc 1154
 Asn Pro Phe Ile Cys Ser Ser Arg Arg Asp Asn Gly Met Gln Lys Cys
 290 295 300

tcg cat atc tcc ggc cgc cgc gag ctg cgc atg ccc tgc aac ctg ggc 1202
 Ser His Ile Pro Gly Arg Arg Glu Leu Arg Met Pro Cys Thr Leu Gly
 305 310 315

tgg gag acc tac acg cag ccc cag gtc gag ggg gtc ggc gct gca cgc 1250
 Trp Glu Ala Tyr Thr Gln Pro Gln Ala Glu Gly Val Gly Ala Ala Arg
 320 325 330

aac gcc tgc atc aac tgg aac cag tac tac aac gtc tgc cgc tcc ggt 1298
 Asn Ala Cys Ile Asn Trp Asn Gln Tyr Tyr Asn Val Cys Arg Ser Gly
 335 340 345 350

gac tcc aac ccc cac aac ggt gcc atc aac ttc gac aac atc ggc tac 1346
 Asp Ser Asn Pro His Asn Gly Ala Ile Asn Phe Asp Asp Ile Gly Tyr
 355 360 365

gcc tgg att gcc atc ttc cag gtg atc acg ctg gaa ggc tgg gtg gac 1394
 Ala Trp Ile Ala Ile Phe Gln Val Ile Thr Leu Glu Gly Trp Val Asp
 370 375 380

atc atg tac tac gtc atg gac gcc cac tca ttc tac aac ttc atc tat 1442
 Ile Met Tyr Tyr Val Met Asp Ala His Ser Phe Tyr Asn Phe Ile Tyr
 385 390 395

tcc atc ctg ctc atc atc gtg ggc tcc ttc atg atc aac ctg tgc Phe Ile Leu Leu Ile Val Gly Ser Phe Phe Met Ile Asn Leu Cys 400 405 410	1490
ctg gtg gtg att gcc acg cag ttc tog gag acg aag cag cgg gag agt Leu Val Val Ile Ala Thr Gln Phe Ser Glu Thr Lys Gln Arg Glu Ser 415 420 425 430	1538
cag ctg atg cgg gag cag cgg gca cgc cac ctg tcc aac gac ago acg Gln Leu Met Arg Glu Gln Arg Ala Arg His Leu Ser Asn Asp Ser Thr 435 440 445	1586
ctg gcc agc ttc tcc gag cct ggc agc tgc tac gaa gag ctg ctg aag Leu Ala Ser Phe Ser Glu Pro Gly Ser Cys Tyr Glu Glu Leu Leu Lys 450 455 460	1634
tar gtg ggc cac ata ttc cgc atc gtg gag aac aag tac ttc agc cgt Tyr Val Gly His Ile Phe Arg Ile Val Asp Ser Lys Tyr Phe Ser Arg 465 470 475	1682
ggc atc atg atg gcc atc ctt gtc sac acg ctg agc atg ggc gtg gag Gly Ile Met Met Ala Ile Leu Val Asn Thz Leu Ser Met Gly Val Glu 480 485 490	1730
tac cst gag cag ccc gag gag ctg act aat got ctg gag atc agc aac Tyr His Glu Gln Pro Glu Glu Leu Thr Asn Ala Leu Glu Ile Ser Asn 495 500 505 510	1776
atc gtg ttc acc agc atg ttt gcc ctg gag atg ctg ctg aag ctg ctg Ile Val Phe Thr Ser Met Phe Ala Leu Glu Met Leu Leu Lys Leu Leu 515 520 525	1826
gcc tgc ggc cct ctg ggc tac atc cgg sac cgg tac aac atc ttc gac Ala Cys Gly Pro Leu Gly Tyr Ile Arg Asn Pro Tyr Asn Ile Phe Asp 530 535 540	1874
ggc atc atc gtg gtc atc agc gtc tgg gag att atg ggg cag gcg gac Gly Ile Ile Val Val Ile Ser Val Trp Glu Ile Val Gly Gln Ala Asp 545 550 555	1922
ggt ggc ttg tct gtg ctg cgc acc ttc cgg ctg ctg cgt gtg ctg aag Gly Gly Leu Ser Val Leu Arg Thr Phe Arg Leu Leu Arg Val Leu Lys 560 565 570	1970
ctg gtg cgc ttt ctg cca gcc ctg cgg cgc cag ctc gtg gtg ctg gtg Leu Val Arg Phe Leu Pro Ala Leu Arg Arg Gln Leu Val Val Leu Val 575 580 585 590	2018
aag acc atg gac aac gtg gct acc ttc tgc acg ctg ctc atg ctc ttc Lys Thr Met Asp Asn Val Ala Thr Phe Cys Thr Leu Leu Met Leu Phe 595 600 605	2066
att ttc atc ttc agc atc ctg ggc atg cac ctt ttc ggc tgc aag ttc Ile Phe Ile Phe Ser Ile Leu Gly Met His Leu Phe Gly Cys Lys Phe 610 615 620	2114
agc ctg aag aca gac acc gga gac acc gtg cct gac agg aag aac ttc	2162

Ser	Leu	Lys	Thr	Asp	Thr	Gly	Asp	Thr	Val	Pro	Asp	Arg	Lys	Asn	Phe	
625																
gac	tcc	ctg	ctg	tgg	gcc	atc	gtc	acc	gtg	tcc	cag	atc	ctg	acc	cag	2210
Asp	Ser	Leu	Leu	Trp	Ala	Ile	Val	Thr	Val	Phe	Gln	Ile	Leu	Thr	Gln	
640																
645											650					
gag	gac	tgg	aac	gtg	gtc	ctg	tac	aac	ggc	atg	gcc	tcc	acc	tcc	tcc	2258
Glu	Asp	Trp	Asn	Val	Val	Leu	Tyr	Asn	Gly	Met	Ala	Ser	Thr	Ser	Ser	
655											665					
660															670	
tgg	gcc	gcc	ctc	tac	ttc	gtg	gcc	ctc	atg	acc	tcc	ggc	aac	tat	gtg	2306
Trp	Ala	Ala	Leu	Tyr	Phe	Val	Ala	Leu	Met	Thr	Phe	Gly	Asn	Tyr	Val	
675											680				685	
etc	ttc	aac	ctg	ctg	gtg	gcc	atc	ctc	gtg	gag	ggc	tcc	cag	ggg	gag	2354
Leu	Phe	Asn	Leu	Leu	Val	Ala	Ile	Leu	Val	Glu	Gly	Phe	Gln	Ala	Glu	
690										695					700	
ggc	gat	gcc	aac	aga	tcc	gac	atc	gac	gag	gac	aag	atc	tcg	gtc	cac	2402
Gly	Asp	Ala	Asn	Arg	Ser	Asp	Thr	Asp	Glu	Asp	Lys	Thr	Ser	Val	His	
705										710					715	
ttc	gag	gag	gac	tcc	cac	aag	ctc	aga	gaa	ctc	cag	acc	aca	gag	ctg	2450
Phe	Glu	Glu	Asp	Phe	His	Lys	Leu	Arg	Glu	Leu	Gln	Thr	Thr	Glu	Leu	
720										725					730	
aag	atg	tgt	tcc	ctg	gcc	gtg	acc	ccc	aac	ggg	cac	ctg	gag	gga	cga	2490
Lys	Met	Cys	Ser	Leu	Ala	Val	Thr	Pro	Asn	Gly	His	Leu	Glu	Gly	Arg	
735										740					750	
ggc	agc	ctg	tcc	cct	ccc	ctc	atc	atg	tgc	aca	gtt	gcc	acc	atg	2546	
Gly	Ser	Leu	Ser	Pro	Pro	Leu	Ile	Met	Cys	Thr	Ala	Ala	Thr	Pro	Met	
755										760					765	
cct	acc	ccc	aag	agc	tca	cca	tcc	ctg	gat	gtt	gcc	ccc	ago	ctc	cca	2594
Pro	Thr	Pro	Lys	Ser	Ser	Pro	Phe	Leu	Asp	Ala	Ala	Pro	Ser	Leu	Pro	
770										775					780	
gac	tct	ccg	cgt	ggc	agc	agc	agc	tcc	ggg	gac	ccg	oca	ctg	gga	gac	2642
Asp	Ser	Arg	Arg	Gly	Ser	Ser	Ser	Ser	Gly	Asp	Pro	Pro	Leu	Gly	Asp	
785										790					795	
cag	aag	cct	ccg	gcc	agg	ctc	cga	agt	tct	ccc	tgt	gcc	ccc	tgg	ggc	2690
Gln	Lys	Pro	Pro	Ala	Ser	Leu	Arg	Ser	Ser	Pro	Cys	Ala	Pro	Trp	Gly	
800										805					810	
ccc	agt	ggc	gcc	tgg	agc	agc	agg	ggc	tcc	agc	tgg	agc	agc	ctg	ggc	2738
Pro	Ser	Gly	Ala	Trp	Ser	Ser	Arg	Arg	Ser	Ser	Trp	Ser	Ser	Leu	Gly	
815										820					830	
cgt	gcc	ccc	ago	ctc	aag	cgc	cgc	ggc	cag	tgt	ggg	saa	cgt	gag	tcc	2786
Arg	Ala	Pro	Ser	Leu	Lys	Arg	Arg	Gly	Gln	Cys	Gly	Glu	Arg	Glu	Ser	
835										840					845	
ctg	tct	ggc	gag	ggc	aag	ggc	agg	acc	gac	gac	gca	gtt	gag	gac		2834
Leu	Leu	Ser	Gly	Glu	Gly	Lys	Gly	Ser	Thr	Asp	Asp	Olu	Ala	Glu	Asp	
850										855					860	

ggc agg gac gac ccc ggg ccc cgt gcc acc cca ctg cgg cgg gcc gag Gly Arg Ala Ala Pro Gly Pro Arg Ala Thr Pro Leu Arg Arg Ala Glu 865 870 875	2882
tcc ctg gac cca cgg ccc ctg cgg ccc gcc gcc ctc ccc aag aag Ser Leu Asp Pro Arg Pro Leu Arg Pro Ala Ala Leu Pro Pro Thr Lys 880 885 890	2930
tgc cgc gat cgc gac ggg cag gtg gtg gcc ctg ccc agc gac ttc ttc Cys Arg Asp Arg Asp Gly Cln Val Val Ala Leu Pro Ser Asp Phe Phe 895 900 905 910	2978
ctg cgc atc gac agc cac cgt gag gat gca gcc gag ctt gac gac gac Leu Arg Ile Asp Ser His Arg Glu Asp Ala Ala Glu Leu Asp Asp Asp 915 920 925	3026
tcc gag gac agc tcc tcc atc cgc ctg cat aaa gtg ctg gag ccc tac Ser Glu Asp Ser Cys Leu Arg Leu His Lys Val Leu Glu Pro Tyr 930 935 940	3074
aat ccc cag tgg tgc cgg agc cgc gag gcc tgg gcc ctc tac atc ttc Lys Pro Gln Trp Cys Arg Ser Arg Glu Ala Trp Ala Leu Tyr Leu Phe 945 950 955	3122
tcc cca cag aac cgg ttc cgc gtc tcc tgc cag aag gtc atc aca oac Ser Pro Gln Asn Arg Phe Arg Val Ser Cys Gln Lys Val Ile Thr His 960 965 970	3170
aag atg ttt gat cac gtg gtc atc gtc ttc atc ttc atc aac tcc gtc Lys Met Phe Asp His Val Val Phe Ile Phe Leu Asn Cys Val 975 980 985 990	3218
acc atc gcc ctg gag agg cct gac ccc ggc agc acc gag cgg Thr Ile Ala Leu Glu Arg Pro Asp Ile Asp Pro Gly Ser Thr Glu Arg 995 1000 1005	3266
gtc ttc ctc aco gtc tcc aat tac atc ttc acg gcc atc ttc gtg gcy Val Phe Leu Ser Val Ser Asn Tyr Ile Phe Thr Ala Ile Phe Val Ala 1010 1015 1020	3314
gag atg atg gtg aag gtg gtg gcc ctg ggg ctg ctg tcc ggc gag cac Glu Met Met Val Lys Val Val Ala Leu Gly Leu Leu Ser Gly Glu His 1025 1030 1035	3362
gcc tac ctg cag aac agc tgg aac ctg ctg gat ggg ctg ctg gtg ctg Ala Tyr Leu Gln Ser Ser Trp Asp Leu Leu Asp Gly Leu Leu Val Leu 1040 1045 1050	3410
gtg tcc ctg gtg gac att gtc gtg gcc atg gcc tcc gct ggt ggc gcc Val Ser Leu Val Asp Ile Val Val Ala Met Ala Ser Ala Gly Gly Ala 1055 1060 1065 1070	3458
aag atc ctg ggt gtt ctg cgc gtg cgt ctg ctg cgg acc ctg cgg Lys Ile Leu Gly Val Leu Arg Val Leu Arg Leu Leu Arg Thr Leu Arg 1075 1080 1085	3506
cct cta egg gtc atc agc egg gcc ccg ggc atc aag ctg gtg gtg gag	3554

Pro Leu Arg Val Ile Ser Arg Ala Pro Gly Leu Lys Leu Val Val Glu			
1090	1095	1100	
acg ctg atc tcg tcc atc agg ccc att ggg aac atc gtc ctc atc tgc	3602		
Thr Leu Ile Ser Ser Leu Arg Pro Ile Gly Asn Ile Val Leu Ile Cys			
1105	1110	1115	
tgc gcc ttc tcc atc att rtt ggc atc ttg ggt gtg cag rtc ttc aaa	3650		
Cys Ala Phe Phe Ile Ile Phe Gly Ile Leu Gly Val Gln Leu Phe Lys			
1120	1125	1130	
ggg aag ttc tac tac tgc gag ggc ccc gac acc agg aac atc tcc acc	3698		
Gly Lys Phe Tyr Tyr Cys Glu Gly Pro Asp Thr Arg Asn Ile Ser Thr			
1135	1140	1145	1150
aag gca cag tgc cgg gcc cac tac cgc tgg gtg cga cgc aag tac	3746		
Lys Ala Gln Cys Arg Ala Ala His Tyr Arg Trp Val Arg Arg Lys Tyr			
1155	1160	1165	
aac ttc gac sac ctg ggc cag gcc ctg atg tcc atg ttc gtg ctg tca	3794		
Asn Phe Asp Asn Leu Gly Gln Ala Leu Met Ser Leu Phe Val Leu Ser			
1170	1175	1180	
tcc aag gat gga tgg gtg aac atc atg tac gac ggg ctg gat gcc gtg	3842		
Ser Lys Asp Gly Trp Val Asn Ile Met Tyr Asp Gly Leu Asp Ala Val			
1185	1190	1195	
ggc gtc gac cag cag cct gtg cag aac cac aac ccc tgg atg ctg ctg	3890		
Gly Val Asp Gln Gln Pro Val Gln Asn His Asn Pro Trp Met Leu Leu			
1200	1205	1210	
tac ttc atc tcc ttc ctg ctc atc gtc agc ttc ttc gtg ctc aac atg	3938		
Tyr Phe Ile Ser Phe Leu Leu Ile Val Ser Phe Val Leu Asn Met			
1215	1220	1225	1230
tcc gtg ggc gtc gtg gtc gag aac ttc cac aag tcc cgg cag cac cag	3986		
Phe Val Gly Val Val Val Glu Asn Phe His Lys Cys Arg Gln His Gln			
1235	1240	1245	
gag gcg gag gag gcg cgg cgg cga gag gag aag cgg ctg cgg cgc cta	4034		
Glu Ala Glu Ala Arg Arg Arg Glu Glu Lys Arg Leu Arg Arg Leu			
1250	1255	1260	
gag agg agg cgc agg agc act ttc ccc agc cca ggg ggc cag cgc cgg	4082		
Glu Arg Arg Arg Ser Thr Phe Pro Ser Pro Glu Ala Gln Arg Arg			
1265	1270	1275	
ccc tac tat gcc gac tac tcc gcc acc cgc cgc tcc att cac tcc ctg	4130		
Pro Tyr Tyr Ala Asp Tyr Ser Pro Thr Arg Arg Ser Ile His Ser Leu			
1280	1285	1290	
tgc acc agc cac tat ctc gac ctc ttc atc acc ttc atc atc tgt gtc	4178		
Cys Thr Ser His Tyr Leu Asp Leu Phe Ile Thr Phe Ile Ile Cys Val			
1295	1300	1305	1310
aac gtc atc acc atg tcc atg gag cac tat aac caa ccc ag tcc ctg	4226		
Asn Val Ile Thr Met Ser Met Glu His Tyr Asn Gln Pro Lys Ser Leu			
1315	1320	1325	

gac gag gcc ctc aag tac tgc aac tac gtc ttc acc atc gtg ttt gtc Asp Glu Ala Leu Lys Tyr Cys Asn Tyr Val Phe Thr Ile Val Phe Val 1330 1335 1340	4274
ttc gag gct gca ctg aag ctg gta gca ttt ggg ttc cgt cgg ttc ttc Phe Glu Ala Ala Leu Lys Leu Val Ala Phe Gly Phe Arg Arg Phe Phe 1345 1350 1355	4322
aag gag aac tgg aac cag ctg gac ctg gcc atc gtg ctg ctg tca ctc Lys Asp Arg Trp Asn Gln Leu Asp Leu Ala Ile Val Leu Leu Ser Leu 1360 1365 1370	4370
atg ggc atc acg ctg gag gag Ata gag atg agc gtc gcg ccc atc Met Gly Ile Thr Leu Glu Glu Ile Glu Met Ser Ala Ala Leu Pro Ile 1375 1380 1385 1390	4410
aac ccc acc atc atc cgc atc atg cgc gtg ctt cgc att gcc cgt gtg Asn Pro Thr Ile Ile Arg Ile Met Arg Val Leu Arg Ile Ala Arg Val 1395 1400 1405	4456
ctg aag ctg ctg aag atg gct aca ggc atg cgc gca ctg ctg gac act Leu Lys Leu Lys Met Ala Thr Gly Met Arg Ala Leu Leu Asp Thr 1410 1415 1420	4514
gtg gtg cas gct ctc ccc cag gtg ggg aac ctg ggc ctt ctt ttc atg Val Val Gln Ala Leu Pro Gln Val Gly Asn Leu Gly Leu Leu Phe Met 1425 1430 1435	4562
ctc ctg ttt atc tat gct gcg ctg gga gtg gas ctg ttc ggg agg Leu Leu Phe Phe Ile Tyr Ala Ala Leu Gly Val Glu Leu Phe Gly Arg 1440 1445 1450	4610
ctg gag tgc agt gaa gac aac ccc tgc gag ggc ctg agc agg ccc gcr Leu Glu Cys Ser Glu Asp Asn Pro Cys Glu Gly Leu Ser Arg His Ala 1455 1460 1465 1470	4658
acc ttc aac aac ttc ggc atg gcc ttc ctc acg ctg ttc cgc gtg toc Thr Phe Ser Asn Phe Gly Met Ala Phe Leu Thr Leu Phe Arg Val Ser 1475 1480 1485	4706
acg ggg gac aac tgg aac ggg atc atg aag gac acg ctg cgc gag tgc Thr Gly Asp Asn Trp Asn Gly Ile Met Lys Asp Thr Leu Arg Glu Cys 1490 1495 1500	4754
tcc cgt gag gac aag cac tgc ctg aac tac ctg ccc gcc ctg ctg tcc Ser Arg Glu Asp Lys His Cys Leu Ser Tyr Leu Pro Ala Leu Ser Pro 1505 1510 1515	4802
gtc tac ttc gtc acc ttc gtg ctg gtg gcc cag ttc stg ctg gtg aac Val Tyr Phe Val Thr Phe Val Leu Val Ala Gln Phe Val Leu Val Asn 1520 1525 1530	4850
stg gtg gtg gcc gtg ctc atg aag ctc ctg gag gag agc aac agc gag Val Val Val Ala Val Leu Met Lys His Leu Glu Ser Asn Lys Glu 1535 1540 1545 1550	4898
gra cgg gag gat gcg gag ctg gac gcc gag atc gag ctg gag atg gcg	4946

Ala Arg Glu Asp Ala Glu Leu Asp Ala Glu Ile Glu Leu Glu Met Ala			
1555	1560	1565	
cag ggc ccc gag agt gca cgc cgg stg gac gcg gac agg cct ccc ttg			4994
Gln Gly Pro Gly Ser Ala Arg Arg Val Asp Ala Asp Arg Pro Pro Leu			
1570	1575	1580	
ccc cag gag agt ccg ggc gcc agg gat gcc cca aac ctg ttg gca cgc			5043
Pro Gln Glu Ser Pro Gly Ala Arg Asp Ala Pro Asn Leu Val Ala Arg			
1585	1590	1595	
aag gtg tcc gtg tcc agg atg ctc tgg ctg ccc aac gac agc tac atg			5090
Lys Val Ser Val Ser Arg Met Leu Ser Leu Pro Asn Asp Ser Tyr Met			
1600	1605	1610	
tcc agg ccc gtg gtg cct gcc tgg gcg ccc cac ccc cgc ccc cgg ctg cag			5138
Phe Arg Pro Val Val Pro Ala Ser Ala Pro His Pro Arg Pro Leu Gln			
1615	1620	1625	1630
gag gtg gag atg gag acc tat ggg gcc ggc acc ccc tgg ggc tcc gtt			5186
Glu Val Glu Met Glu Thr Tyr Gly Ala Gly Thr Pro Leu Gly Ser Val			
1635	1640	1645	
gcc tcc gtg cac tct ccc gca gag tcc tgt gcc tcc ctc ccc atc			5234
Ala Ser Val His Ser Pro Pro Ala Glu Ser Cys Ala Ser Leu Gln Ile			
1650	1655	1660	
cca ctg ctc gtg tcc cca gcc agg aac ggc gag ccc ctc ccc ccc			5283
Pro Leu Ala Val Ser Ser Pro Ala Arg Ser Gly Glu Pro Leu His Ala			
1665	1670	1675	
ctg tcc cct cgg ggc aca gcc tcc ccc agt ctc aac cgg ctg ctc			5330
Leu Ser Pro Arg Gly Thr Ala Arg Ser Pro Ser Leu Ser Arg Leu Leu			
1680	1685	1690	
tgc aca cag gag gtc gtg cac aac gat tcc ttg gaa ggg aag att gac			5378
Cys Arg Gln Glu Ala Val His Thr Asp Ser Leu Glu Gly Lys Ile Asp			
1695	1700	1705	1710
agg ccc agg gac acc ctg gat ccc gca gag ccc ggt gag aac acc ccc			5426
Ser Pro Arg Asp Thr Leu Asp Pro Ala Glu Pro Gly Glu Lys Thr Pro			
1715	1720	1725	
gtg agg ccc gtg acc cag ggg ggc tcc ctg cag ccc cca cca ccc tcc			5474
Val Arg Pro Val Thr Gln Gly Gly Ser Leu Gln Ser Pro Pro Arg Ser			
1730	1735	1740	
cca cgg ccc gcc agc gtc cgc act cgt aag cat acc tcc gga cag cac			5522
Pro Arg Pro Ala Ser Val Arg Thr Arg Lys His Thr Phe Gly Gln His			
1745	1750	1755	
tgc gtc tcc aca cgg ccc ggc cca ggc gga gag gag gac gac gac			5570
Cys Val Ser Ser Arg Pro Ala Ala Pro Gly Gly Glu Glu Ala Glu Ala			
1760	1765	1770	
tcc gac cca gcc gac gag gag gtc aac ccc acc acc aac tcc gcc tcc			5618
Ser Asp Pro Ala Asp Glu Glu Val Ser His Ile Thr Ser Ser Ala Cys			
1775	1780	1785	1790

ccc tgg cag ccc aca gac gag ccc cat ggc ccc gaa gec tct ccg gtg Pro Trp Gln Pro Thr Ala Glu Pro His Gly Pro Glu Ala Ser Pro Val 1795 1800 1805	5666
gcc ggc ggc gag cgg gac ctg cgc egg ctc tac agc gtg gac gct cag Ala Gly Gly Glu Arg Asp Leu Arg Arg Leu Tyr Ser Val Asp Ala Gln 1810 1815 1820	5714
ggc ttc ctg gac aag ccc cgg gca gac gag cag tgg cgg ccc tcc Gly Phe Leu Asp Lys Pro Gly Arg Ala Asp Glu Gln Trp Arg Pro Ser 1825 1830 1835	5762
gag gag ctg ggc aac ggg gag cct ggg gag gog aag gcc tgg ggc cct Ala Glu Leu Gly Ser Gly Glu Pro Gly Ala Lys Ala Trp Gly Pro 1840 1845 1850	5810
gag gcc gag ccc gct ctg ggt gcg cgc aga aag aag aag atg agc ccc Glu Ala Glu Pro Ala Leu Gly Ala Arg Arg Lys Lys Met Ser Pro 1855 1860 1865 1870	5858
ccc tcc atc tcg gtg gaa ccc cct gcg gag sac gag ggc tct gcg cgg Pro Cys Ile Ser Val Glu Pro Pro Ala Glu Asp Glu Gly Ser Ala Arg 1875 1880 1885	5906
ccc tcc gcg gca gag ggc ggc aac acc aca ctg agg cgc agg acc ccc Pro Ser Ala Ala Glu Gly Ser Thr Thr Leu Arg Arg Arg Thr Pro 1890 1895 1900	5954
tcc tgt gag gcc acg cct cac agg gag tac ctg gag ccc aca gag ggc Ser Cys Glu Ala Thr Pro His Arg Asp Ser Leu Glu Pro Thr Glu Gly 1905 1910 1915	6002
tca ggc gcc ggg ggg gac cct gca gcc aag ggg gag cgc tgg ggc cag Ser Gly Ala Gly Cys Asp Pro Ala Ala Lys Gly Glu Arg Trp Gly Gln 1920 1925 1930	6050
gcc tcc tcc cgg gct gag cac ctg acc gtc ccc aac ttt gcc ttt gag Ala Ser Cys Arg Ala Glu His Leu Thr Val Pro Ser Phe Ala Phe Glu 1935 1940 1945 1950	6098
ccg ctg gac ctc ggg gtc ccc aat gga gac cct ttc ttg gac ggt agc Pro Leu Asp Leu Gly Val Pro Ser Gly Asp Pro Phe Leu Asp Gly Ser 1955 1960 1965	6146
cac agt gtg acc cca gaa tcc aga gct tcc tct tca ggg gcc ata gtg His Ser Val Thr Pro Glu Ser Arg Ala Ser Ser Ser Gly Ala Ile Val 1970 1975 1980	6194
ccc ctg gaa ccc cca gaa tca gag cct ccc atg ccc gtc ggt gac ccc Pro Leu Glu Pro Pro Glu Ser Glu Pro Pro Met Pro Val Gly Asp Pro 1985 1990 1995	6242
cca gag aag agg cgg ggg ctg tac ctc aca gtc ccc cag tgt cct ctg Pro Glu Lys Arg Arg Gly Leu Tyr Leu Thr Val Pro Gln Cys Pro Leu 2000 2005 2010	6290
gag aac cca ggg tcc ccc tca gcc acc cct gcc cca ggg ggt ggt gca	6338

Glu Lys Pro Gly Ser Pro Ser Ala Thr Pro Ala Pro Gly Gly Ala
2015 2020 2025 2030 2035

gat gac ccc gtc tag ctgggggtt ggtgcgcggcc acggcttgg ccctgggtc 6393
Asp Asp Pro Val
2035

tggggggccc gctgggggtgg aggccccaggc agaaccctgc atggaccctg acttgggtcc 6453
cgtcgtgagc agaaaggccc gggggggatg acggccccagg ccctggttct ctggccagcg 6513
aaggcggagt agctgcgggg ccccacgago ctccatccgt tctggttogg gtttctccga 6573
tttttgcac cagcccgaggc tggccgggca actgggtcag ctccccgtca ggagagaagc 6633
cgggtctgtg ggaacgaaagac ggggcaccccg ccagagaggg gaaggtacca ggttgcgtcc 6693
tttcaggccc cgggttgtta caggacactc gctgggggcctt ctgtggccctt gccccggcca 6753
ggttgcagcc accggggccc aatgtcacct tcactcacag tctgagttct tggccggccctg 6813
ccacgcgcctc accacccctcc cttccaaaggc accaccccttc cggttccgtt cgggccttcc 6873
cagaaggcgtc ctgtgactct ggggggggtg acacccact aaggggccga ccctatggag 6933
taacgcgc 6941


THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A3	(11) International Publication Number:	WO 99/28342	
C12N 15/12, C07K 14/705, 16/28, C12N 5/10, G01N 33/68		(43) International Publication Date:	10 June 1999 (10.06.99)	
(21) International Application Number:	PCT/US98/25671			
(22) International Filing Date:	3 December 1998 (03.12.98)		HANS, Michael [DE/US]; 2635 San Clemente Terrace, San Diego, CA 92122 (US). URRUTIA, Arturo [US/US]; 778 Beech Avenue, Chula Vista, CA 91910 (US). WASHBURN, Mark, S. [US/US]; 1535 Kings Cross Drive, Cardiff, CA 92007 (US).	
(30) Priority Data:	08/984,709 09/188,932	3 December 1997 (03.12.97) 10 November 1998 (10.11.98)	US US	(74) Agent: SEIDMAN, Stephanie, L.; Heller Ehrman White & McAuliffe, Suite 700, 4250 Executive Square, La Jolla, CA 92037 (US).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications				(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
US Filed on	08/984,709 (CON) 3 December 1997 (03.12.97)			
US Filed on	09/188,932 (CON) 10 November 1998 (10.11.98)			
(71) Applicant (for all designated States except US):	SIBIA NEUROSCIENCES, INC. [US/US]; Suite 300, 505 Coast Boulevard South, La Jolla, CA 92037-4641 (US).			
(72) Inventors; and			Published	
(75) Inventors/Applicants (for US only):	WILLIAMS, Mark [US/US]; 946 Jasmine Court, Carlsbad, CA 92009 (US). STAUDERMAN, Kenneth [US/US]; 3615 Lotus Drive, San Diego, CA 92106 (US). HARPOLD, Michael [US/US]; 1462 Encina Road, Santa Fe, NM 87505-4726 (US).		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
			(88) Date of publication of the international search report: 26 August 1999 (26.08.99)	

(54) Title: LOW-VOLTAGE ACTIVATED CALCIUM CHANNEL COMPOSITIONS AND METHODS

Steady-state activation and inactivation

(57) Abstract

Isolated nucleic acid encoding low voltage activated calcium channel subunits, including subunits encoded by nucleic acid that arises as splice variants of primary transcripts, is provided. Cells and vectors containing the nucleic acid and methods for identifying compounds that modulate the activity of calcium channels that contain these subunits are also provided.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/25671

A. CLASSIFICATION OF SUBJECT MATTER	IPC 6 C12N15/12 C07K14/705 C07K16/28 C12N5/10 G01N33/68
-------------------------------------	---

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 04144 A (NEUREX CORP) 9 February 1995 see abstract; claims 1-10 ----	1, 6, 8, 10, 15, 29-38, 47
X	NOONEY JM (REPRINT) ET AL: "Identifying neuronal non-L Ca ²⁺ channels - more than stamp collecting?" TRENDS IN PHARMACOLOGICAL SCIENCES, 10-1997, 18, 363-371, XP002093637 see page 369, right-hand column - page 370, right-hand column ---- -/-	1, 6

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

21 June 1999

06/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

Int'l. Application No.

PCT/US 98/25671

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ERTEL S I ET AL: "Low-voltage-activated T-type Cachannels" TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 18, no. 2, February 1997, page 37-42 XP004055849 see page 39, left-hand column, paragraph 4 - page 40, middle column, paragraph 1; table 1 ---	1,6
X	DZHURA IO ET AL: "Characterization of hypothalamic low-voltage-activated Ca channels based on their functional expression in Xenopus oocytes." NEUROSCIENCE, FEB 1996, 70 (3) P729-38, XP002093638 UNITED STATES see the whole document ---	1,6
A	WO 93 04083 A (SALK INST BIOTECH IND) 4 March 1993 see abstract; claims 1-39 ---	1-16, 36-44
P,X	CRIBBS LL ET AL: "Cloning and characterization of alpha1H from human heart, a member of the T-type Ca ²⁺ channel gene family." CIRC RES, JUL 13 1998, 83 (1) P103-9, XP002093640 UNITED STATES see the whole document ---	1-16, 36-44
T	WILLIAMS ME ET AL: "Structure and functional characterization of a novel human low-voltage activated calcium channel." J NEUROCHEM, FEB 1999, 72 (2) P791-9, XP002106656 UNITED STATES see the whole document -----	1-16, 36-44

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Application No

PCT/US 98/25671

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9504144	A	09-02-1995	EP	0778890 A	18-06-1997
			JP	9501051 T	04-02-1997
WO 9304083	A	04-03-1993	US	5429921 A	04-07-1995
			AU	677571 B	01-05-1997
			AU	2495792 A	16-03-1993
			CA	2113203 A	04-03-1993
			EP	0598840 A	01-06-1994
			JP	6509717 T	02-11-1994
			US	5874236 A	23-02-1999
			US	5846757 A	08-12-1998
			US	5851824 A	22-12-1998
			US	5876958 A	02-03-1999
			US	5792846 A	11-08-1998

THIS PAGE BLANK (USPTO)